What happens when the moment a company finally succeeds is the moment it becomes most likely to be destroyed? Most founders assume the market rewards the better product and protects what they built. The legal reality runs the other way. The dominant theory of the corporation treats a company as a financial instrument designed to enrich its shareholders, and treats everything else as optional.

That theory has a name, shareholder primacy, and nobody voted for it. It hardened in courtrooms and boardrooms about forty years ago. Founders sign it into their own charter on day one without reading the line, and by the time the gap between the mission statement and the legal purpose becomes visible, the exit has been engineered.

Eric Ries, founder of the Long-Term Stock Exchange and author of The Lean Startup, explains how corporate purpose disappeared out of the legal documents and what can be put back in its place. He shows why protection alone makes an extractive company worse, why independent directors are not neutral, and why a mission guardian belongs above the board rather than inside it.

Beginning with the pattern he watched destroy company after company, the conversation becomes a practical guide to governance: the three-legged stool of 19th century corporate law, what actually killed Sears, why Novo Nordisk, Patagonia, IKEA and Grundfos outlive their competitors, and how the Public Benefit Corporation restores something far older than it looks. It ends on the question neither of us could fully answer. If a guardian protects the mission, who guards the guardian?

WHAT LISTENERS CAN EXPECT TO LEARN

Why shareholder primacy is a recent legal theory rather than a permanent feature of capitalism
How the phrase "any lawful act or activity" removed purpose from corporate charters, and what quietly replaced it
Why structure protects an ethos but cannot create one, and what has to be real before the protection is added
How industrial foundations, purpose trusts and public benefit corporations keep a mission alive across generations
Why independent directors have incentives of their own, and what to look for in a board instead

BEST QUOTES

(00:04:10) "A company is just a financial instrument, designed to enrich itself and its shareholders." — Eric Ries
(00:14:12) "If you go to your local park, you'll find trees older than shareholder primacy." — Eric Ries
(00:25:28) "Somebody took over Sears and managed to extract for himself $1.5 billion, at a time when the company lost $11 billion." — Eric Ries
(00:40:09) "Who would you rather die than betray?" — Eric Ries
(00:48:12) "Being a leader is much more like being a mother than a slave owner. We birth these things. We do not own them." — Eric Ries

TIMESTAMPS

(00:00:00) Why Good Companies Go Bad After Success

(00:02:43) What Made Eric Ries Write Incorruptible

(00:04:10) A Company Is Just a Financial Instrument

(00:07:03) The Pill You Swallow and the Shareholder Calculation

(00:15:48) The Three-Legged Stool of Corporate Law

(00:19:31) How "Any Lawful Act or Activity" Erased Purpose

(00:25:28) What Actually Happened to Sears

(00:30:38) Stainless Steel for Organizations That Last

(00:34:39) Why Foundation-Owned Companies Outlive the Rest

(00:37:59) The Public Benefit Corporation Explained

(00:44:40) Why Every Company Needs a Mission Guardian

(00:50:22) Why Independent Directors Are Not Neutral

(00:53:11) Who Guards the Mission Guardian

(00:56:18) What AI Changes for Governance

(00:59:58) Closing Thoughts

Eric's book, Incorruptible: https://amzn.to/3S4n4BN

If you'd like to keep talking about these topics, you're welcome to join Eric's free Incorruptible community here: https://community.incorruptible.co/

Follow Beginner's Mind for long-form conversations on leadership, capital, technology, and the people shaping what comes next. Ranked in the global top 10% of all podcasts, named #1 Deep Tech Podcast in 2025, and #8 Deep Tech Podcast in 2026

Send us Fan Mail

Join Christian Soschner for expert coaching.
50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.

Support the show

Join the Podcast Newsletter: Link

View Details

What happens when the instinct to help a struggling company is exactly what prevents the strongest companies from succeeding? Venture capital forces investors to make decisions that can feel deeply uncomfortable: stop rescuing the weakest, concentrate scarce capital behind the most promising, and accept that most investments will fail.

Deep tech intensifies this conflict. Investors must commit capital while the technology remains unproven, customers are still uncertain and the eventual exit may be more than a decade away. The wrong team, an inflated valuation or a fund timeline that does not fit the technology can destroy an otherwise promising company.

Joško Bobanović, Partner at Sofinnova, explains how experienced investors make these decisions without ever receiving complete information. He reveals why people matter more than patents, why founders must start selling before they have a product and why investors should support management from the back seat—without trying to drive the company themselves.

Beginning with a destructive storm Joško predicted but could not prevent, the conversation develops into a practical guide to risk, patience and capital allocation. It also confronts Europe’s central deep-tech challenge: the continent produces exceptional science, but without sufficient scale-up capital, specialist investors and corporate buyers, much of the value will be created elsewhere.

WHAT LISTENERS CAN EXPECT TO LEARN

Why successful venture investing requires resisting the instinct to rescue struggling portfolio companies
How investors make consequential decisions with partial information—and recognize when it is time to stop researching
Why the team, storytelling and customer conversations can matter more than exceptional technology alone
How inflated valuations, ten-year fund structures and limited exit opportunities affect deep-tech companies
What Europe must change to scale its best companies instead of watching them industrialize elsewhere

BEST QUOTES

(00:20:04) “The nature of venture capital decisions is very counter to human instincts.” — Joško Bobanović
(00:41:05) “Investment in a startup is like a marriage that is predetermined with a divorce at some point in time in the future.” — Joško Bobanović
(00:54:25) “Nothing validates what you’re doing better than cash.” — Joško Bobanović
(00:57:35) “A B team will probably destroy exceptional technology, but an A team will make a success even of average technology.” — Joško Bobanović
(01:56:22) “Otherwise we become a museum. And I don’t think we want to be a museum.” — Joško Bobanović

TIMESTAMPS

(00:00:00) Why Venture Capital Fights Human Instinct
(00:03:08) The Storm Joško Predicted but Could Not Stop
(00:09:11) How the Early Internet Changed Access to Opportunity
(00:16:49) If You Do Not Play, You Cannot Win
(00:20:04) Why Investors Must Resist the Rescue Instinct
(00:29:33) Scientists Must Learn to Decide with Partial Information
(00:35:58) Can Founders Make Themselves Replaceable?
(00:41:05) A Marriage with a Predetermined Divorce
(00:47:45) Why Storytelling Is a Critical Deep-Tech Skill
(00:52:03) Start Selling from Day One
(00:57:03) Why Venture Capital Is a People Business
(01:00:11) Investors Belong in the Back Seat
(01:10:50) Better Decisions Require Broader Comparisons
(01:18:00) When a Higher Valuation Becomes Dangerous
(01:27:15) Why Every Venture Investment Needs 10× Potential
(01:37:29) Deep Tech’s Missing Exit Opportunities
(01:45:05) Why VCs See IPOs as a Necessary Evil
(01:52:49) Europe’s Scientific Strength and Scale-Up Weakness
(02:05:01) What Europe Gets Wrong About Failure
(02:13:13) Get Involved Instead of Complaining from the Sidelines

Follow Beginner's Mind for long-form conversations on leadership, capital, technology, and the people shaping what comes next.

Ranked in the global top 10% of all podcasts, named #1 Deep Tech Podcast in 2025, and #8 Deep Tech Podcast in 2026

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

How can a company have the right numbers and still reach the wrong strategic conclusion?

In 2017, Volkswagen’s chief executive mocked Tesla as one of the “world champions of big announcements.” At the time, Volkswagen sold roughly eleven million cars a year, while Tesla sold fewer than eighty thousand. The facts supported the criticism, but the conclusion missed the change already underway.

That moment explains why Elon Musk remains worth studying.

Most public discussion focuses on his personality, political views, wealth, or communication style. This episode takes a different approach and examines the methods that allowed him to enter industries dominated by governments and large corporations, pursue ideas that initially appeared uneconomic, and force entire markets to reconsider what could be built.

The starting point is Eric Jorgenson’s The Book of Elon, which brings together more than two decades of Musk’s interviews, speeches, podcasts, and public writing. Jorgenson has already done the first stage of the work by reducing a vast archive to the statements that best explain how Musk thinks about purpose, engineering, talent, production, and company building.

Because the book is itself a quote summary, I treated it as raw material rather than as a conventional biography.

I selected seven recurring principles and tested them against more than 25 years of my own company-building experience. That includes six years in public-market M&A and two decades building biopharma and medtech companies from Series A toward IPO across more than seven company journeys. I also draw on several Musk biographies, years of long-form podcast interviews, and his public writing on X.

The result is not another biography, and it is not an argument that every founder should copy Elon Musk.

It is a practical framework for founders, CEOs, board members, investors, scientists, and senior executives who build or finance hard companies.

The central question is straightforward:

What can you copy from Elon Musk without copying the personality?

The episode examines why utility matters more than glory, why important companies often have to build before market permission arrives, and how first-principles thinking exposes opportunities that remain hidden when an industry accepts precedent as fact. It also explains why strong teams delete complexity before they automate it, why positive-sum founders enlarge markets instead of fighting over a fixed share, and why talent density matters more than headcount.

The final principle brings everything together. A prototype may attract attention and capital, but the company only creates lasting value when it can produce, learn, improve, and scale faster than its competitors.

This distinction matters in life sciences and deep tech, where strong science can still fail during translation. A molecule may work while manufacturing, clinical execution, reimbursement, financing, or commercialization remain underdeveloped. The same problem appears in industrial technology, energy, AI, and robotics, where an impressive demonstration can conceal a production system that will never support scale.

Three statements from the book frame the discussion:

“How many people you helped, and how much. That’s the total utility.”“The most common mistake of smart engineers is to optimize a thing that should not exist.”“What really matters is the machine that builds the machines, the factory.”

Taken together, the seven principles form a founder test.

For investors, they provide a structured way to assess mission, judgment, cost discipline, team quality, and the ability to scale. For company builders, they offer practical questions that belong in financing discussions, board meetings, and leadership offsites.

Are you building something useful enough to change customer behavior?

Does the team reason from fundamental constraints, or does it repeat the industry’s assumptions?

Are you simplifying the company, or automating bureaucracy?

Can the organization turn promising technology into a repeatable system that produces real customer value?

Whatever your opinion of Elon Musk, dismissing the method because you dislike the man can become an expensive mistake. The personality remains optional, while the principles deserve serious examination.

Choose one of the seven and bring it into your next board meeting.

Chapters

(00:00) Introduction: Why the market keeps underestimating Elon Musk
(03:31) The Big Idea
(08:13) Eric Jorgenson and why he is the right author
(10:47) Lesson 1: Build for Utility, Not Glory
(16:39) Lesson 2: Missionary Courage Beats Market Permission
(21:28) Lesson 3: First Principles Reveal Hidden Upside
(25:59) Lesson 4: The Algorithm: Delete Before You Optimize
(31:09) Lesson 5: Grow the Pie: Reject Zero-Sum Thinking
(35:57) Lesson 6: Talent Density Is the Company
(40:54) Lesson 7: Production and Speed Are the Real Moat
(45:46) The Seven Practical Takeaways
(51:55) Personal Reflection, Critique, and Closing

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

Private companies are staying private longer, and that changes who gets liquidity, when, and why.

Founders, employees, and early investors can wait a decade or more for an IPO or acquisition. Meanwhile, venture funds face growing pressure to return capital, and many of Europe's best companies struggle to access the growth capital needed to scale.

In this conversation, Christian Soschner speaks with Alberto Chalon, Co-Founder of Giano Capital, about the rise of single-asset secondary investments and why they have become an important part of the European innovation ecosystem.

Topics include:

• What secondary transactions are and why they matter

• Why many companies now stay private far longer than before

• How founders, employees, and early investors can access liquidity before an exit

• The differences between venture capital, private equity, and late-stage secondary investing

• Europe's challenge with risk capital, fragmentation, and scaling companies

• Lessons from investments such as Revolut, GetYourGuide, and Deliveroo

• The role of resilience, sport, and long-term thinking in business and investing

Alberto also shares his personal journey from entrepreneurship and building businesses with his brother to launching Giano Capital and creating a new asset class focused on late-stage technology investments.

5 OUTSTANDING QUOTES / LESSONS

1.
"Failure in America is part of the learning process. In Europe, failure is a disaster."

Lesson: Europe's challenge may be cultural as much as financial.

2.
"The due diligence is the beginning of the journey, not the end."

Lesson: Great investors keep working after the deal closes.

3.
"Everything has to be already tested before we invest."

Lesson: Giano seeks to eliminate execution risk before investing.

4.
"The loneliness of the entrepreneur is real. I lived that."

Lesson: The best investors bring empathy, not only capital.

5.
"You need to reach the top, and then you have the descent."

Lesson: Investing and endurance sports both reward patience and resilience.

TIMESTAMPS

(00:00:00) Intro

(00:03:00) Why secondaries suddenly matter

(00:07:19) Why IPOs are no longer enough

(00:12:44) Where Giano fits between VC and PE

(00:17:06) Why private information changes returns

(00:21:41) How Giano helps founders beyond capital

(00:26:19) Not pre IPO but three years earlier

(00:31:23) Europe must think beyond countries

(00:37:56) Alberto Chalon on loss and entrepreneurship

(00:42:12) From search engines to professional investing

(00:46:21) How fashion arbitrage shaped his investing

(00:53:47) Building a privacy search engine in Europe

(01:00:51) Ruthless focus without forcing others

(01:07:38) What late-stage governance requires

(01:11:50) Why Giano chose late-stage secondaries

(01:15:32) Inside Giano Capital's deal funnel

(01:19:07) Why community matters in secondaries

(01:24:29) GetYourGuide and Revolut as examples

(01:27:29) How long a secondary deal takes

(01:29:11) Cycling as leadership training

(01:36:23) Giano Capital's ten-year ambition

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

Only one in three eligible lung cancer patients receives the targeted therapy they should get.

That is not a failure of science.

It is a failure of delivery.

After more than two decades of precision oncology, biopharma has never had better tools: cell and gene therapy, in vivo CAR-T, antibody-drug conjugates, AI-enabled diagnostics, organoids, multi-omics, and global clinical data.

Yet too many breakthroughs still fail to reach the bedside.

Patients fall through fragmented systems.
Data does not move cleanly.
Community oncologists are overloaded.
Tests are missed, delayed, or misread.
Promising assets die in quarterly portfolio reviews.
And healthcare systems built for pills, tablets, and chronic disease management are now being asked to deliver personalized medicine at scale.

In this SPARK20 highlight episode, Alasdair Milton, PhD, Principal at KPMG and leader of the firm’s Precision & Advanced Therapies practice, explains why the future of biopharma will not be decided by science alone.

It will be decided by translation.

From lab bench to boardroom.
From data to decisions.
From treatment to prevention.

Alasdair brings more than 20 years of experience across life sciences strategy, commercial due diligence, precision medicine, advanced therapies, cell and gene therapy, biopharma M&A, diagnostics, and global healthcare transformation.

This conversation moves from the precision medicine delivery crisis to China’s biotech acceleration, from AI and organoids to trapped pharma assets, from lifelong wellness to the one skill every future biotech leader needs:

The ability to translate complex science into business strategy, capital allocation, and patient impact.

What You’ll Learn in 22 Minutes

Why only one third of eligible lung cancer patients receive targeted therapy
(00:01:53)
And why precision medicine still breaks in everyday clinical practice.

Why science keeps compounding even when systems fail
(00:04:33)
Including in vivo CAR-T, functional cures, gene therapy, and antibody-drug conjugates.

Why innovation does not move in a straight line
(00:05:20)
How technologies can look dead for years before suddenly changing the market.

Why China’s biotech speed matters
(00:07:36)
How AI, organoids, scale, and execution are changing the global innovation map.

Why great science dies inside Big Pharma
(00:09:20)
And how deprioritized assets can become billion-dollar companies when externalized properly.

Why the industry must move from sickness to lifelong wellness
(00:10:03)
Alasdair’s vision for a more proactive, preventive, data-driven healthcare system.

Why pharma needs better ways to rescue shelved assets
(00:13:06)
Including examples such as SpringWorks, Cerevel, and new models for unlocking trapped value.

How a 400-person Scottish island shaped Alasdair’s worldview
(00:15:07)
The personal story behind his resilience, discipline, and leadership style.

Why careers and companies are never linear
(00:17:19)
What Alasdair learned after moving to Boston and losing his role within weeks.

Why the future belongs to translators
(00:20:06)
The most valuable skill in biotech: explaining complex science to business leaders, investors, and boards.

How to connect with Alasdair Milton and the KPMG Precision & Advanced Therapies team
(00:21:47)

Quotes to Carry With You

📌 “We’ve been doing precision medicine in lung cancer for decades, over two decades, and we’re still not getting it right.”
(00:01:53)

📌 “This is where this incredible world of genomic science bumps up against the realities of everyday clinical practice.”
(00:03:31)

📌 “When I was doing my PhD 28 years ago, the idea that you could even have a targeted cell therapy was almost like science fiction.”
(00:04:41)

📌 “The speed was just astonishing.”
(00:07:47)

📌 “We’ve been a sickness industry. We’ve treated disease, chronic disease. But can we move more towards lifelong wellness and preemptive health?”
(00:10:03)

📌 “There’s not a systematic way to collect all of the incredible science and incredible assets that go on the shelf every quarter.”
(00:13:06)

📌 “There’s great science that never sees the light of day because it’s killed in a quarterly portfolio review.”
(00:15:00)

📌 “Your career is never linear.”
(00:17:19)

📌 “You have to be able to build the bridge between the lab and the business world.”
(00:20:06)

Why This Conversation Matters

Precision medicine is often described as the future of healthcare.

But the future does not arrive because the science is ready.

It arrives when diagnostics, data, reimbursement, clinical workflows, manufacturing, capital, leadership, and incentives finally work together.

That is the real challenge now facing biopharma.

Not whether innovation can happen.
It already is.

The question is whether leaders can build the systems that allow innovation to reach patients.

Alasdair Milton is one of the rare voices who can explain that challenge across science, strategy, capital, and execution.

If you are a founder, investor, operator, scientist, board member, policymaker, or family office looking at the future of biotech, precision medicine, advanced therapies, pharma M&A, AI in healthcare, or China’s rise in biopharma, this episode is worth your time.

👉 Listen now.
Share it with someone building the future of medicine.
Follow Beginner’s Mind for more conversations with the people shaping biotech, capital, and healthcare.

Topics: precision medicine, biopharma, biotech, KPMG, Alasdair Milton, cell and gene therapy, in vivo CAR-T, targeted therapy, lung cancer, oncology, AI in healthcare, organoids, China biotech, pharma M&A, SpringWorks, Cerevel, advanced therapies, diagnostics, translational science, venture capital, healthcare strategy.

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

Some books explain how the world works.

Influence explains why people move.

Why someone takes the meeting.
Why an investor leans in.
Why a customer trusts.
Why a team follows.
Why a board stays stuck.
Why a founder keeps defending a decision that stopped making sense months ago.

Robert Cialdini’s Influence: The Psychology of Persuasion is one of those books that becomes more valuable the longer you build, invest, sell, negotiate, hire, and lead.

Because at some point, you realize something uncomfortable:

Most decisions are not made after perfect analysis.

They are made under pressure.

With incomplete information.

With too many options.

Too little time.

And a nervous system looking for shortcuts.

That is where Cialdini’s work becomes powerful.

He shows that human beings rely on recurring decision triggers: reciprocation, liking, social proof, authority, scarcity, commitment and consistency, and unity.

These are not tricks.

They are part of the operating system of human behavior.

And if you build or invest in companies from Series A to IPO and beyond, these forces are everywhere.

They show up in fundraising.
In sales.
In hiring.
In pricing.
In board meetings.
In investor updates.
In partnerships.
In leadership.
And in the quiet signals people read before they ever say yes or no.

A founder can have the better product and still lose because nobody trusts the signal.

A CEO can have the right strategy and still fail because the team never feels real unity.

An investor can see the data and still follow the crowd because social proof feels safer than independent judgment.

A service provider can have rare expertise and destroy their own value by being too available.

A board can keep supporting a flawed decision because everyone wants to stay consistent with what they already said.

That is why this book matters.

Not because it teaches manipulation.

But because it teaches respect for human nature.

The best builders do not work against psychology.

They work with it.

They understand that a small act of generosity can open a door.

That people need to like you before they seriously negotiate with you.

That visible proof often matters before deep proof gets examined.

That authority begins before you speak.

That scarcity protects value.

That commitment can create momentum — or trap you.

And that the strongest companies often feel less like transactions and more like “we.”

In this episode, I translate Cialdini’s seven principles into practical lessons for founders, CEOs, investors, and operators building companies in the real world.

Not as abstract psychology.

As boardroom practice.

As fundraising practice.

As sales practice.

As leadership practice.

As reputation practice.

And as a defense system against being influenced by people who understand these principles better than you do.

What We Cover

Reciprocation
Why small, right-sized generosity works better than aggressive asking.

Liking
Why manners, presence, and positive repeated contact still matter more than most people admit.

Social Proof
Why people judge you by the company you keep — and why markets often follow visible signals before they examine fundamentals.

Authority
Why titles, suits, posture, calmness, and credibility shape decisions before logic enters the room.

Scarcity
Why unlimited availability destroys value — and why thoughtful limits can increase demand.

Commitment and Consistency
Why small yeses become large decisions, and why founders must learn to ask: “Knowing what I know now, would I still choose this?”

Unity
Why the deepest form of influence is not persuasion, but the feeling that “we are in this together.”

Timestamps

(00:00) Introduction
(02:05) Big Idea – Instant Influence: Primitive Consent for an Automatic Age
(05:35) Author’s Background
(07:38) Reciprocation – The Old Give and Take… and Take
(13:34) Liking – The Friendly Thief
(18:55) Social Proof – Truths Are Us
(24:41) Authority
(32:10) Scarcity – The Rule of the Few
(38:00) Commitment and Consistency – Hobgoblins of the Mind
(45:00) Unity – We-Ness and the Power of Shared Identity
(51:19) Key Takeaways
(53:53) Personal Reflection
(56:18) Final Words

Why This Episode Matters

If you raise capital, this episode helps you understand why investors lean in before they fully understand the deck.

If you sell, it helps you see why trust is often built before the formal pitch begins.

If you lead, it helps you design cultures where people commit because they identify with the mission, not because they were told to comply.

If you invest, it helps you protect yourself against false signals: fake authority, fake scarcity, fake social proof, and beautifully packaged nonsense.

And if you build companies, it reminds you of something simple:

Human nature is not a side issue.

It is the terrain.

The best founders, investors, and leaders learn to read it.

Because capital does not move only toward logic.

People do.

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

Influence: The Psychology of Persuasion, Revised Edition

View Details

Most leaders think negotiation begins when both sides sit down to talk numbers.
By then, trust, incentives, timing, internal alignment, and first impressions have already shaped the outcome.
That is why smart founders, executives, investors, and board members can have the right facts and still walk away with the wrong result.

In this episode of Beginner’s Mind, Stefanie Schubert explains why negotiation is not a last-minute performance at the table. It is a leadership capability that starts much earlier, in the way people prepare, build trust, frame value, listen, manage emotions, and understand what the other side truly needs.

Stefanie is a Professor of Economics at SRH University Heidelberg, a Negotiation Advisor, Keynote Speaker, and ICF-certified Executive Coach. Her work combines behavioral economics, game theory, negotiation, executive coaching, and real-world business practice, with experience in complex business environments, alliance management, and biopharma.

This conversation moves from the practical to the profound: why intelligent people still make weak decisions, why preparation often matters more than persuasion, why pushing people creates resistance, how ballroom dancing explains negotiation better than many textbooks, and why investors, scientists, founders, and corporate leaders often speak past each other without realizing it.

We also explore John Nash, A Beautiful Mind, first offers, anchoring, emotional decision-making, AI-driven profiling, trust in virtual environments, and why rejection in fundraising is not necessarily the end of the negotiation.

As Stefanie puts it:

(01:50:33) “You bring in something. It’s not that you beg for money with the investor.”

That may be the core lesson of the episode.
Good negotiation is not domination. It is not theatre. It is not a bag of tricks. It is the discipline of understanding value, shaping the game, and entering the room with enough clarity to build something useful with another person.

Selected moments

(00:00:00) Why smart people lose negotiations early
(00:04:24) Negotiation starts before the table
(00:07:57) Why smart people still decide poorly
(00:13:25) Influence creates value not manipulation
(00:18:21) Human shortcuts quietly kill opportunities
(00:25:08) Ballroom dancing reveals negotiation resistance
(00:28:44) Active listening creates leadership leverage
(00:34:06) Authenticity beats dominance in leadership
(00:37:05) How to de-escalate emotional negotiations
(00:45:05) Game theory without mathematical intimidation
(00:52:57) A Beautiful Mind and collaboration traps
(01:00:47) First offers and anchoring pressure
(01:06:37) Internal alignment before external negotiation
(01:12:25) Why emotions can be rational
(01:17:20) Fast thinking versus sustainable judgment
(01:32:25) AI profiling can poison first impressions
(01:40:59) Trust building before formal deals
(01:45:04) Why investor rejection is not final
(01:47:24) Designing negotiations from first contact
(01:48:11) Create value before dividing value
(01:50:28) Confidence before asking for capital

Follow Beginner’s Mind for long-form conversations on leadership, capital, technology, negotiation, and the people shaping what comes next.

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

Most people still treat climate solutions as a cost.

Wanwipa Siriwatwechakul argues that this is exactly why so many leaders miss the real opportunity.

The next industrial era will not be built by patching old systems, but by redesigning them from the ground up.

In this episode of Beginner’s Mind, Wanwipa explains why industrial decarbonization is not mainly about sacrifice, compliance, or adding expensive fixes to yesterday’s infrastructure. It is about building better systems, stronger companies, and entirely new categories of value creation.

A chemical engineer trained at MIT and Princeton, former professor, and Partner at Vectors Capital, Wanwipa works at the intersection of climate tech, synthetic biology, industrial innovation, and early-stage venture capital. Her perspective is grounded in both science and scale: what matters is not only whether a breakthrough works in the lab, but whether it can survive the journey from one gram to one ton, from prototype to product, from curiosity to adoption.

We talk about why the strongest climate companies redesign industries instead of decorating old ones, why synthetic biology is emerging as a new industrial toolkit, how startups like Huue Bio, Ingrediome, and Solidec reveal very different scale-up strategies, and why the best founders treat breakthroughs as hypotheses to test rather than theories to defend.

As Wanwipa puts it:
(01:57:02) “See climate solutions not as cost, but as funding the next industrial era.”

What you’ll hear in this episode

Why decarbonization becomes far more powerful when industries are redesigned, not merely optimized
How synthetic biology can replace toxic, waste-heavy industrial chemistry with cleaner production models
Why great science is only the starting point, and why scale is where most companies really live or die
What founders can learn about resilience, coachability, timing, and relentless customer discovery
How climate tech can create competitive advantage, new revenue streams, and distributed industrial resilience
Why Southeast Asia may become a powerful region for the next wave of climate and bioindustrial growth

Selected moments

(00:00:56) From Professor to Climate Tech Venture Capital
(00:09:27) Why Climate Change Became Personal in Thailand
(00:14:11) From Pure Discovery to Real Market Impact
(00:23:00) Decarbonization by Redesigning Industry
(00:30:06) The Climate Tech Mistake Costing Investors Money
(00:34:17) Solidec and the Future of Distributed Manufacturing
(00:38:50) Why Big Companies Resist Industrial Reinvention
(00:46:21) How Great Founders Turn Pivots Into New Markets
(00:50:50) Customer Discovery in Deep Tech and Climate Startups
(00:53:08) Great Science Must Become Products People Use
(01:00:39) Synthetic Biology as the New Industrial Toolkit
(01:10:15) How Climate Startups Find Early Adopters
(01:13:19) Founder Resilience and the Stomach of Steel
(01:21:15) Venture Capital and the Crucial Why Now
(01:57:02) Climate Solutions as Funding the Next Industrial Era

Follow the show for more long-form conversations on technology, capital, leadership, and the people shaping what comes next.

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

Power demand is rising faster than the systems meant to support it.
AI, electrification, and industry all need stable energy, but the dominant story sold to the public was far simpler than reality.
In this episode, Bret Kugelmass explains why the real bottleneck was never just climate ambition, but how the West misunderstood energy itself.

For years, nuclear was framed as too dangerous, too slow, too expensive, and politically untouchable. Meanwhile, electricity demand kept rising, industrial resilience became strategic again, and the gap between energy ambition and physical reality widened.

This conversation gets underneath the narrative. (Recorded November 2023)

Bret Kugelmass, Founder and CEO of Last Energy, argues that the nuclear debate was never only about science or safety. It was also about incentives, regulation, public perception, delivery models, and the failure to distinguish what is inherent to the technology from what is imposed by the system around it.

Drawing on his path from Silicon Valley entrepreneurship into deep energy infrastructure, Bret explains why he believes the West solved for the wrong variables, why wind and solar alone cannot carry modern industrial societies in many regions, and why the real breakthrough in nuclear may not come from reinventing the reactor, but from reinventing how power plants are built, sold, and deployed.

As he puts it:
(00:33:11) “Solve the wrong problem brilliantly and you’ll be the only one who cares.”

This episode is not just about nuclear energy.
It is about first-principles thinking, product-market fit in deep tech, and the kind of contrarian founder logic required to build where politics, infrastructure, and capital collide.

What You’ll Learn in This Episode
1️⃣ Why Bret says the West misunderstood the real energy bottleneck
2️⃣ Why net zero may be the wrong framing for climate ambition
3️⃣ What most people still get wrong about nuclear waste, safety, and Fukushima
4️⃣ Why nuclear’s real challenge is cost and construction, not physics
5️⃣ How Last Energy reframed the business by selling electricity, not reactors
6️⃣ What founders can learn from solving the right problem before scaling

Selected Timestamps
(00:04:29) Introduction
(00:04:29) Defining climate goals beyond net zero
(00:13:46) Bret discovers nuclear mission and truth
(00:19:44) Chernobyl versus Fukushima what truly matters
(00:21:39) Nuclear's unmatched physics for abundant energy
(00:30:08) Ideal world nuclear plants in 18 months
(00:36:02) Solving the right problem before building
(00:42:58) First principles simplicity as Last Energy’s edge
(00:51:16) Securing 30 billion through true product market fit
(00:54:05) Last Energy vision for tens of thousands of gigawatts
(00:56:12) Taking ultimate responsibility to drive massive global progress

🎙️ Beginner’s Mind
Top 10% globally. Conversations for founders, investors, executives, and policymakers shaping biotech, deep tech, energy, and industrial transformation.

Follow the show for more long-form conversations on technology, capital, and the people building what the future will actually run on.

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

Most investors think they’re rational.

Most founders think they’re disciplined.

Most boards think they’re strategic.

They’re usually wrong.

In this episode, we unpack Fast Forward Thinking by Luis Pareras — a physician turned deep-tech venture capitalist who distilled decades of investing under scientific uncertainty into 40 brutally structured rules.

This is not a summary.

It’s a decision upgrade for founders, operators, board members, and capital allocators navigating the high-stakes terrain from Series A to IPO and beyond — where bias compounds, capital misallocates, and timing determines survival.

Across seven tightly structured lessons, we explore how elite investors actually think:

Why consensus is often a red flag
Why opportunity abundance demands ruthless selectivity
Why the first meeting should never close
Why innovation compounds through milestones — not miracles
Why exit logic must exist from day one
Why managing error asymmetry beats being “right”
And why teams — not ideas — determine survival under pressure

This episode translates Pareras’ venture logic into executive practice — with direct applications for capital allocation, hiring, governance, and strategic design.

You’ll walk away with frameworks, sharper filters, and board-level questions that immediately improve judgment.

Key Takeaways

Bias Is the Silent Capital Killer
Consensus feels safe. It often destroys upside.

Selectivity Is Survival
Abundance demands disciplined rejection.

Curiosity Beats Closure
The first meeting earns the second.

Innovation Is Staged
Breakthroughs are milestone-based progressions.

Exit Thinking Is Structural
Capital is deployed against time horizons.

Error Asymmetry Shapes Returns
Managing Type I and Type II errors defines long-term performance.

Teams Outperform Ideas
Execution discipline and cognitive flexibility win under uncertainty.

Timestamps

(00:00) Introduction
(04:17) The Big Idea
(08:33) Who Is Luis Pareras
(12:03) Takeaway 1: Cognitive Bias Is the Hidden Enemy of Good Decisions
(18:55) Takeaway 2: Deal Flow Is Abundant — Selectivity Is the Real Skill
(24:16) Takeaway 3: The First Meeting Is Not About Closing
(29:04) Takeaway 4: Innovation Is a Process
(35:20) Takeaway 5: Exit Awareness Shapes Investment Logic
(39:59) Takeaway 6: Error Types Matter More Than Individual Outcomes
(44:38) Takeaway 7: Teams and Judgment Matter More Than Ideas
(49:15) Key Takeaways: The Fast Forward Operating System
(54:25) Personal Reflection and End

Why Listen

Upgrade how you evaluate opportunities — before committing capital.

Sharpen how you structure innovation — before chasing breakthroughs.

Design decision systems that reduce catastrophic error.

And build organizations that survive uncertainty.

If this episode sharpens your thinking:

Follow the show.
Share it with someone who allocates capital.
And bring these questions into your next board meeting.

Because in venture, public markets, and corporate strategy alike —

returns are rarely accidental.

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

Most biotech breakthroughs don’t fail in the lab.
They fail when science meets manufacturing reality.
And by the time this bottleneck appears, tens of millions are already sunk.

This episode examines the most under-discussed failure point in modern biotech: the gap between scientific discovery and scalable, usable healthcare solutions.

While science has never been stronger—and big pharma excels at market access—companies that can translate breakthrough biology into industrialized medicines remain rare. Manufacturing, regulation, clinical design, usability for patients and physicians, and global scalability still form a narrow bottleneck where most value is lost.

In this conversation, Björn Cochlovius, CEO of Eleva, explains why so many promising biologics fail late—and how Eleva deliberately built a platform designed not to replace existing systems, but to rescue projects that would otherwise be abandoned.

Drawing on decades across immunology, biotech leadership, and translational medicine, Björn offers a grounded, operator-level view on what it actually takes to move from elegant science to real-world impact.

As he puts it:
(00:28:59) “In biotech, courageous decisions often look wrong—until years later.”

This discussion goes beyond manufacturing alone. It explores why turning scientific concepts into ready-to-deploy healthcare solutions—complete with clinical data, regulatory pathways, scalable production, and high usability—remains one of the hardest industrial challenges of our time.

What You’ll Learn in This Episode
1️⃣ Why biologics often fail late—after science already worked
2️⃣ Why manufacturing is only one part of a deeper industrial bottleneck
3️⃣ How Eleva approaches risk when others walk away
4️⃣ Why courage, not optimization, drives breakthrough biotech decisions
5️⃣ How AI supports discovery—without replacing human judgment
6️⃣ What Europe gets right—and still gets wrong—about scaling biotech

🧭 Selected Timestamps
(00:03:00) Why biotech breakthroughs fail at manufacturing
(00:07:18) Three takeaways for founders and investors short on time
(00:08:36) Why biologics production breaks at scale
(00:11:41) Salvaging proteins that standard systems cannot produce
(00:15:27) The hidden opportunity in “failed” proteins
(00:17:21) Why late-stage manufacturing failure destroys value
(00:19:35) Why Eleva builds its own pipeline, not just a platform
(00:22:46) Glycosylation as a source of better efficacy
(00:27:03) Courageous decisions when everyone else has failed
(00:30:04) Risk management through parallel scientific bets
(00:32:08) Why similar proteins behave differently in patients
(00:37:08) AI as a tool, not a replacement for human judgment
(00:41:02) Why humans must remain accountable in drug discovery
(00:44:25) The tension between basic research and development
(00:46:01) Managing the handover between scientific universes
(00:50:38) The CEO’s real job: building teams smarter than yourself
(00:53:11) Leadership humility and protecting the team
(00:56:11) How leaders recharge under long-term pressure
(00:59:13) Europe’s biotech bottleneck and why there is still hope
(01:02:20) Final reflection: turning science into systems that scale

🎙️ Beginner’s Mind
Top 10% globally. Conversations for founders, investors, executives, and policymakers shaping the future of biotech, deep tech, and healthcare.

Follow the show for more episodes where science meets strategy—and leadership determines what actually scales.

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

Nine out of ten startups fail, yet Europe keeps funding them the same way.
Governments replace judgment with bureaucracy, capital replaces experience, and failure is misunderstood instead of learned from.

This conversation exposes why venture capital is a profession, not a policy tool — and why getting this wrong quietly kills innovation.

In this episode, Jim Pulcrano, Adjunct Professor at IMD and longtime venture investor, explains why most venture capital systems fail before capital is even deployed.

Drawing on four decades across Silicon Valley, Europe, and academia, Jim dismantles the myth that VC success comes from spreadsheets, credentials, or government programs. Instead, he shows why pattern recognition, lived experience, and exposure to failure are the real differentiators.

As Jim puts it:
(01:13:27) “Silicon Valley is the world’s capital of failure — and also the capital of learning.”

That mindset difference explains why Europe struggles to scale founders, why governments unintentionally create zombie companies, and why operators consistently outperform theorists when backing the next generation of companies.

This is not a motivational episode.
It’s a structural diagnosis of how innovation ecosystems actually work — and where Europe still gets in its own way.

💡 What You’ll Learn in This Episode

1️⃣ Why most venture capital fails long before money is invested
2️⃣ Why governments cannot replace judgment, experience, or risk-taking
3️⃣ Why operators outperform bankers as investors
4️⃣ Why failure is data — not stigma — in high-performing ecosystems
5️⃣ What Europe must change to unlock its next innovation cycle

👤 About Jim Pulcrano

Jim Pulcrano is an Adjunct Professor at IMD with over four decades of experience across venture capital, entrepreneurship, and executive education. He has worked extensively in Silicon Valley and Europe, advising founders, investors, and institutions on scaling companies, leadership development, and venture capital as a professional discipline.

💬 Quotes

(01:13:27) “Silicon Valley is the world’s capital of failure — and also the capital of learning.”
(01:33:58) “You have to be there at midnight when you’re trying to make a decision on Sunday night.”
(01:40:14) “I’ve never met a successful entrepreneur who hasn’t been weeks from running out of money.”
(01:23:21) “A government purchase order is worth more than the same amount in cash.”

🧭 Timestamps

(00:04:25) Why most startups fail — and why that’s not the real problem
(00:09:55) Why Europe still misunderstands venture risk
(00:16:42) Why founders matter more than ideas
(00:24:13) Why governments create zombie startups
(00:32:34) Why operator VCs outperform financial engineers
(00:40:14) Failure as data, not disgrace
(00:48:26) Why venture capital cannot be taught without simulation
(01:04:48) What LPs should really look for in fund managers
(01:19:46) Government as customer vs government as controller
(01:30:10) Why young people should not rush into VC
(01:32:38) Why empathy separates great investors from average ones
(01:45:13) Leadership shifts from startup to scale-up
(01:50:06) Three changes Europe must make now

🎙️ Beginner’s Mind

Top 10% globally. The leading podcast for founders, investors, and policymakers shaping the future of biotech, deep tech, and innovation.

Follow the show to explore more conversations like this one — where science meets strategy and leadership builds the future.

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

Most goals don’t fail because of laziness or lack of ambition.

They fail quietly — buried under daily noise, competing priorities, and forgotten intentions.

By March, even the most meaningful goals have slipped down the list… replaced by urgency, meetings, and excuses.

In the last years, whenever I work with companies or people in my executive coaching a pattern showed up frequently.

In private life: marathons abandoned, educations postponed, mountains left unclimbed.

In business: bold visions diluted, priorities scattered, companies losing momentum — not because the goal was wrong, but because it was never protected.

This Year in Review 2025 episode is my answer to that problem.

After working with founders, executives, and teams throughout the year, one truth became unavoidable:

Big goals don’t fail because people stop caring. They fail because they lose daily contact.

So I stripped goal-setting down to what actually works.

To make it memorable, I revisited the conversations of 2025 and selected six voices — from politics, investing, entrepreneurship, and professional sport — each illustrating one essential principle for achieving meaningful goals.

No hype. No motivational slogans.
Just a clear, calm framework you can apply immediately to your most important goal for 2026.

🧭 What You’ll Learn in This Episode

1️⃣ Why discipline and motivation are overrated — and what replaces them
2️⃣ How goals quietly disappear without friction or resistance
3️⃣ Why choosing one goal is the highest-leverage decision you can make
4️⃣ How to keep goals present without pressure or obsession
5️⃣ Why process builds identity — and outcomes don’t
6️⃣ What real commitment looks like when nobody is watching

⏱️ Timestamps

(00:00) Why New Year’s Resolutions Collapse — and What Actually Works
(02:57) Karl Nehammer — “Sometimes there is no guidebook”
(04:19) How Goals Quietly Disappear
(07:56) Alex Dang — Focus, Selection, and Knowing When to Fold
(11:45) Hack Away the Unessential — Choosing One Goal
(14:05) Fabrizio Conicella — Skills Entrepreneurs Need in 2026
(17:54) Why You Must Review Goals Daily
(19:43) Jason Foster — Setting Big Goals and Chipping Away
(20:48) Process Over Outcome
(22:48) Alasdair Milton — Doing the Work When Nobody Is Watching
(26:05) Start Now — Before It Feels Comfortable
(27:50) Vadim Fedotov — What Commitment Really Means
(30:54) Before You Leave — Ed Sheeran’s Approach to Progress

🎙️ About This Episode

This episode isn’t about setting more goals.
It’s about protecting one goal that actually matters — whether you’re building the next NVIDIA, scaling a company, or working toward a personal milestone.

If 2025 taught us anything, it’s this:
Clarity beats intensity. Direction beats urgency. Process beats motivation.

May 2026 be the year your most important goal doesn’t get lost.

I’m glad you’re here.

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

Breakthrough science has never been stronger — yet patients still miss life-saving therapies.

Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery.

The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not.

Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem.

As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge scientific depth with incentives, execution, and real-world delivery. Capital follows speed and scale — not intention — and healthcare systems built decades ago are failing to keep up.

In this episode, Alasdair Milton, Principal at KPMG, explains where innovation actually breaks — and what must change for cures to reach patients at scale. From diagnostics and data silos to capital allocation and prevention models, this conversation reframes the next decade of precision medicine.

💡 What You’ll Learn in This Episode

1️⃣ Why only a fraction of eligible patients receive precision therapies
2️⃣ How delivery systems — not science — kill innovation outcomes
3️⃣ Why prevention is the next major value shift in healthcare
4️⃣ How capital allocation decisions quietly determine patient access
5️⃣ What leaders must change now to compete in the next biopharma cycle

👤 About Alasdair Milton

Alasdair Milton is a Principal at KPMG advising global biopharma leaders on strategy, transactions, and innovation models. With a PhD in cancer biology and two decades at the intersection of science and capital, he works with executives navigating precision medicine, prevention, and large-scale healthcare transformation.

💬 Quotes That Reframe the Debate

(01:00:20) “Great science only creates value when translated into clear commercial decisions.”
(01:37:24) “Power has swung decisively to pharma, with biotechs now starved for capital and leverage.”
(01:36:10) “Markets shift fast, but leverage always follows capital, data, and disciplined execution.”
(02:26:30) “Life sciences must move from treating sickness to predicting risk and sustaining lifelong wellness.”
(01:46:24) “China is catching up fast, and by the 2030s, truly innovative molecules may originate there.”

🧭 Timestamps

(00:04:04) Shifting from treating disease to preventing it
(00:05:32) Turbulent markets, steady scientific progress
(00:07:03) In-vivo CAR-T and the next leap in cellular medicine
(00:11:00) From chronic disease management to functional cures
(00:20:20) Bridging specialized science with corporate strategy
(00:21:55) Translating lab precision into business language
(00:22:07) Bridging scientific depth to business acumen
(00:57:40) Turning complex science into decisive commercial implications
(01:08:46) Why in-person collaboration still drives leadership and learning
(01:11:48) Navigating the $200B biopharma patent cliff through M&A
(01:17:25) Capital concentrates on de-risked teams with proven leadership
(01:18:17) Interpreting the biotech market recovery and tailwinds
(01:28:26) Long-term capital returns as pharma reclaims deal leverage
(01:38:03) Navigating IRA impacts and macro headwinds
(01:43:39) China’s rapid ascent in the global monoclonal pipeline
(01:46:24) China accelerates the eastward shift in global innovation
(02:07:31) Precision medicine redefines individualized healthcare outcomes
(02:09:03) Standardized data transforms healthcare delivery
(02:16:57) AI across the precision medicine continuum
(02:26:30) From reactive treatment to proactive lifelong wellness

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

Most founders obsess over ideas.
Breakthrough companies obsess over inflections, conviction, and structure.

This episode unpacks Pattern Breakers by Mike Maples Jr.—a book that quietly explains why most startups never break out… and why a small minority reshape entire categories.

But this isn’t a book summary.

It’s a thinking upgrade for founders, operators, board members, and investors navigating the most fragile phase of company building: Series A to IPO, where timing, conviction, and structure matter more than features or pitch decks.

Across seven tightly structured lessons, this episode explores how pattern-breaking companies are built before the world is ready for them—and why success is rarely about genius ideas, and almost always about seeing the future early and designing for it deliberately.

You’ll hear why:

breakthroughs start with external inflections, not internal brainstorming
winning companies are non-consensus and right, long before they’re popular
movements outperform products when markets get noisy
MVPs test interest, but prototypes test desperation
productive disagreeableness protects insight when pressure rises
corporate success quietly creates biases that kill innovation
and why structure—not culture—is the hidden lever behind breakthroughs

Each lesson is grounded in real company examples, translated into today’s market reality, and finished with coaching questions you can use immediately—in leadership meetings, boardrooms, or investment decisions.

Key Takeaways

Inflections Beat Ideas
Breakthrough timing comes from external change, not creativity.

Non-Consensus Is the Signal
If everyone agrees, upside is already gone.

Movements Outrun Products
Identity compounds longer than features.

Test Desperation, Not Interest
Scalability starts with craving, not curiosity.

Protect Conviction
Consensus feels safe. It rarely creates breakthroughs.

Design for Breakthroughs
Small, protected, fast teams outperform bureaucracy every time.

Timestamps

(00:00) Intro
(02:58) The Big Idea Behind Pattern Breakers
(05:19) Who Is Mike Maples — and Why His Perspective Matters
(07:35) Lesson 1: Start With Inflections, Not Ideas
(12:36) Lesson 2: Be Non-Consensus and Right
(17:31) Lesson 3: Prototype the Future, Not the MVP
(21:31) Lesson 4: Recruit, Lead, and Scale Through Movements
(26:20) Lesson 5: Master Productive Disagreeableness
(30:04) Lesson 6: Break the Corporate Biases That Kill Breakthroughs
(35:00) Lesson 7: Structure for Breakthrough Execution
(39:41) Key Takeaways — The Lenses and Habits That Matter
(42:21) Personal Reflection & Critique

Why Listen

Learn how category-defining companies are built before markets open
Upgrade how you evaluate startups, strategies, and leadership teams
Replace product thinking with inflection, conviction, and structure
Walk away with questions that immediately sharpen decisions

Found this valuable?
Like, share, and follow.

Every signal helps grow the show—and brings you more thinking frameworks from people and companies who didn’t follow patterns… they broke them.

Send us Fan Mail

Support the show

Join the Podcast Newsletter: Link

View Details

The world has grown quiet about climate change. Too quiet.

We scroll past floods, fires, droughts… and move on with our day.
As if the problem solved itself.
As if we’ve earned the luxury to look away.

Janos Pasztor (full episode) has spent 40 years inside the rooms where climate decisions are made — from serving as UN Assistant Secretary-General for Climate Change to advising presidents, prime ministers, and global institutions.

And in this SPARK20 highlight episode, one truth stood out:

We are not done with climate change.
We are only entering its most consequential chapter.

This is not a doom story.
It is the story of a man who still believes humanity can choose a better future — if we’re willing to face the questions we’ve been avoiding.

What You’ll Learn in 20 Minutes

Why global warming accelerates even as we reduce emissions
(00:01:15)
And why governments are still “not addressing the issue sufficiently.”

Why adaptation alone cannot save us
(00:01:54)
And what the real limits of adaptation look like.

Why Janos believes we may need to cool parts of the planet
(00:02:32)
And why no political leader wants to say it out loud.

How climate diplomacy changed since the 1980s — and why it matters now
(00:03:32)
Including the rise of China in global negotiations.

Why capitalism itself may need to evolve
(00:08:05)
And what this means for investors, innovation, and global stability.

What geoengineering really is (and is not)
(00:09:16)
Forget the internet myths — this is the factual explanation.

Why volcanic eruptions hold a clue to future climate solutions
(00:12:04)

Why SRM is scientifically feasible — and politically dangerous
(00:17:11)
The technology is simple. The governance is not.

Why the biggest risk of SRM is not cost — but consent
(00:17:44)
And what happens when societies don’t get a say.

What a unilateral climate intervention could trigger
(00:20:33)
A scenario every policymaker should hear.

Why Janos still believes in a brighter future
(00:21:07)
A rare moment of optimism from someone who has seen every side of the crisis.

Quotes to Carry With You

📌 “Global temperatures continue to rise — and the world is not ready.”
(00:01:15)

📌 “We must consider whether the time has come to start cooling parts of the planet.”
(00:02:32)

📌 “Three degrees of warming is cuckoo land. You simply cannot adapt to that.”
(00:18:23)

📌 “Technology is not the issue. It’s cheap. The real question is: do societies want this?”
(00:17:11)

📌 “I wouldn’t be here if I didn’t believe we can still get this right.”
(00:21:07)

Why This Conversation Matters

Because climate change isn’t a chapter we finished.
It’s the foundation on which every other chapter of the future will be written — our economies, our food systems, our borders, our investments, and the lives of our children.

And while Elon Musk may one day take humans to Mars, no one alive today will move there.
This planet is the one we must keep habitable.

Janos Pasztor is a reminder that realism and hope are not opposites — they’re partners.

👉 Listen now. Share it fo

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Europe leads the world in discovery — yet too often, its breakthroughs never become global companies.

Billions in research funding turn into patents, not products.

While others build empires from ideas, Europe risks becoming the world’s laboratory — brilliant, but broke.

That’s the paradox at the heart of this conversation.

In this episode, Karl Nehammer, Vice-President of the European Investment Bank (EIB) and former Chancellor of Austria, joins Christian Soschner live at BIO-Europe 2025 to discuss how Europe can turn its world-class science into world-class companies.

He shares how leadership forged in crisis can rebuild confidence, competitiveness, and growth — and why every crisis hides an opportunity to start thinking differently.

💡 What You’ll Learn in This Episode

1️⃣ Why Europe’s innovation system struggles to turn discovery into scale
2️⃣ How the EIB can bridge the gap between science, capital, and market impact
3️⃣ Lessons from leading through COVID-19, the energy crisis, and diplomatic challenges
4️⃣ Why changing culture and regulation is key to Europe’s competitiveness
5️⃣ The mindset Europe needs to move from surviving to building

💬 Quotes from Karl Nehammer

(00:03:33) “Every crisis is also maybe a chance — you learn a lot, decide quickly, and think in totally new ways.”
(00:07:00) “We have the knowledge now of what we must change — it’s a window of opportunity.”
(00:20:03) “Empower yourself. Don’t wait for another person — you can do it yourself.”

🧭 Timestamps

(00:00:00) Opening – Why Europe Struggles to Scale
(00:03:33) Karl Nehammer – Leadership Lessons from Crisis
(00:06:21) Europe’s Innovation Challenge – Science vs. Commercialization
(00:09:17) Life-Science Resilience – Lessons from COVID-19
(00:12:52) A Realistic Vision for Europe’s Future
(00:17:05) Inside the European Investment Bank – Building Bridges Between Capital and Innovation
(00:18:59) Empowering Founders – Karl Nehammer’s Message to Europe’s Builders
(00:20:14) Closing – Optimism, Collaboration, and Confidence

🎙️ Beginner’s Mind

Top 10% globally. The leading podcast for founders, investors, and policymakers shaping the future of biotech, deep tech, and innovation.

Follow the show to explore more conversations like this one — where science meets strategy and leadership builds the future.

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Most founders dream of raising millions. Few survive the 153 “no’s” it takes to get there.

Behind every biotech breakthrough lies exhaustion — late-night calls, failed rounds, and investors who walk away at the finish line.

What separates the ones who make it isn’t luck or timing — it’s resilience built into process.

In this episode, Jason Foster, CEO of Ori Biotech, shares how he transformed relentless rejection into a billion-dollar trajectory. From rebuilding cell-therapy manufacturing to leading global teams through economic storms, Jason reveals how founders can systematize grit, master storytelling, and survive when everything seems to fall apart.

You’ll learn how to navigate fundraising winters, why leadership begins with self-care, and how to build companies that endure long after the hype fades.
If you’ve ever doubted your path as a builder, this conversation will remind you that resilience is not a trait — it’s a practice.

💡 What You’ll Learn in This Episode

1️⃣ The real reason most founders fail long before capital runs out
2️⃣ How to turn rejection into momentum using process and habit
3️⃣ Why storytelling is the most underrated skill in biotech leadership
4️⃣ How resilience and self-care directly drive performance and valuation
5️⃣ The mindset that separates enduring companies from short-term success

👤 About Jason Foster

Jason Foster is the CEO of Ori Biotech, a leading innovator transforming cell and gene therapy manufacturing. With 20+ years in global health, he has raised over $140M, led companies through IPO-level growth, and serves as a mentor and investor to emerging founders in life sciences. His mission: make advanced therapies accessible to every patient, everywhere.

💬 Quotes That Might Change How You Think

(00:14:09) “There are cures for cancer today, but patients can’t reach them — access must change.”
(00:37:22) “The science is extraordinary — but if we can’t make it at scale, it means nothing.”
(01:22:17) “Purpose, not money, drives talent to transform lives through innovation.”
(01:46:17) “Fundraising is a war of attrition — constant rejection tests your resilience more than your idea.”
(02:02:16) “You only have to get up one more time than you’re knocked down.”

🧭 Timestamps to Explore

(00:02:00) Embracing Hard Challenges — How Biotech Founders Build Resilience That Lasts
(00:13:40) The Unacceptable Truth: Cures Exist, Yet Patients Still Can’t Access Them
(00:26:23) Navigating Cultures — What European and American Biotech Leaders Can Learn From Each Other
(00:32:52) Why Great Science Isn’t Enough Without Commercial Viability
(00:39:19) Revolutionizing Cell Therapy Manufacturing — The Seven-Day Bottleneck Explained
(00:50:11) Automation and Digitization — Unlocking Scalable Patient Access in Cell and Gene Therapy
(01:09:30) Rethinking Capacity Utilization — Making Regional Biotech Manufacturing Centers Work
(01:14:27) Mass Personalization — The Future Delivery Model for Advanced Therapies
(01:23:00) Purpose-Driven Talent — The Secret to Retaining Top Biotech Performers
(01:32:18) Fundraisin

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Imagine waking up to find your company’s most valuable IP leaked—not by hackers, but by the very AI tools you trusted.
This isn’t a distant scenario; it’s happening inside pharma and biotech right now.
And the cost isn’t just financial—it’s patient lives, broken trust, and an industry on the edge of losing credibility.

In this episode, Kat Kozyrytska shares how leaders can act before invisible risks become catastrophic. From her personal journey in post-Soviet Ukraine to building frameworks in global biotech, Kat reveals why “yesterday problems” with AI demand urgent attention today.

You’ll learn how data privacy failures propagate quietly, why embedding organizational values into AI is essential, and how collaboration across companies can safeguard innovation and accelerate therapies.

The future of biotech won’t be secured by hype or speed—but by trust, ethics, and the courage to act before it’s too late.

🎧 What You’ll Learn in This Episode
1️⃣ Why “yesterday problems” with AI in pharma are already costing billions
2️⃣ How data privacy failures silently erode trust, IP, and patient safety
3️⃣ The difference between collaboration and competition in biotech innovation
4️⃣ Why embedding organizational values into AI is no longer optional
5️⃣ The future of drug discovery, clinical trials, and manufacturing in an AI-first world

👤 About Kat Kozyrytska
Kat Kozyrytska is the Founder of the Cell Therapy Manufacturability Program and a global thought leader at the intersection of biotech and AI. With roots in Ukraine and a career spanning MIT, Stanford, Thermo Fisher, Sartorius, and global biotech startups, she bridges technical depth with ethical foresight.

💬 Quotes That Might Change How You Think
(00:14:50) "AI can amplify good or bad behaviors — the choice is ours."
(00:38:14) "Discovering dark personalities is like learning Santa isn’t real — traumatic, but suddenly everything makes sense."
(01:03:26) "AI speaks with absolute confidence, but confidence is not the same as truth."
(01:20:22) "AI gives us a rare chance to embed ethics and values into innovation."
(01:57:01) "If personalized therapies work better, we have an ethical duty to deliver them."

🧭 Timestamps to Explore
(00:05:16) From Math to Medicine – Kat’s unexpected path from equations to biotech leadership
(00:09:38) Inside a Nobel Lab – How neuroscience breakthroughs shaped her ethical lens
(00:12:27) Shadow AI – Why biotech leaders can’t wait to govern hidden systems
(00:23:03) Data Sharing Paradox – Collaboration vs confidentiality in pharma innovation
(00:31:31) Neurobiology of Manipulation – How dark personalities exploit human trust
(00:41:18) Hidden Privacy Risks – What your everyday data footprint really reveals
(00:52:17) Soviet Control vs American Individualism – Lessons for AI governance today
(00:57:30) The Danger of One Answer – Why converging on a single AI truth is risky
(01:02:51) Confidence ≠ Expertise – Rethinking how we trust AI in science
(01:18:16) Embedding Core Values – How leaders can align AI with human ethics
(01:51:28) Breaking Down Silos – Th

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Most founders obsess over products. Jensen Huang built a $3 trillion company by obsessing over inevitabilities.

This episode unpacks The NVIDIA Way by Tae Kim—the definitive account of how NVIDIA went from near-death startup to the world’s most valuable chipmaker. More than a history, it’s a manual for founders and VCs navigating the messy, high-stakes stretch between Series A and IPO.

But this isn’t just about NVIDIA.

It’s about you—if you’re scaling in deep tech, where survival depends less on genius inventions and more on how you engineer resilience, culture, and urgency into your system.

I walk you through 7 scaling lessons that matter now—from why pain is a founder’s greatest teacher to how vision and culture become moats no competitor can copy. Each principle is grounded in NVIDIA’s story, translated into today’s market reality, and wrapped with coaching prompts you can act on this week.

Key Takeaways:

Pain Builds Resilience: Intelligence helps, but scars compound faster.
Reputation Is Currency: Your first product isn’t a chip or an app—it’s trust.
Defy the Innovator’s Dilemma: Don’t chase quarters—build inevitabilities.
Lead with Context: Replace bottlenecks with clarity and extreme ownership.
Sell the Vision: Markets follow narratives, not features.
Culture Outruns Capital: Execution habits compound longer than cash.
Urgency Wins: Complacency kills more companies than competition.

Timestamps:
(00:00) Why This Episode Matters
(02:18) The Big Idea of The NVIDIA Way by Tae Kim
(04:36) Who is Tae Kim?
(08:15) Lesson #1: Pain and Suffering Are the Recipe for Greatness
(12:35) Lesson #2: Your Reputation Is Your Currency
(17:05) Lesson #3: The Innovator’s Dilemma Will Come for You
(21:45) Lesson #4: Lead With Context, Not Control
(25:18) Lesson #5: Don’t Just Sell the Product—Sell the Vision
(30:00) Lesson #6: Culture Outruns Capital—and the Competition
(34:32) Lesson #7: Build Urgency Into the System
(38:30) Key Takeaways—3x Reading + 25 Years in Public Markets, VC, and Scaling Deep Tech
(41:24) Reflection

Why Listen:

Learn how NVIDIA survived near-death and built inevitabilities that defined AI.
Get 7 leadership and culture principles designed for Series A–IPO scale-ups.
See how to evaluate companies not by products, but by the systems that endure.
Upgrade your founder or investor lens with actionable coaching questions.

Found this valuable? Like, share, and follow.
Every signal grows the show—and helps bring you more playbooks from the world’s most resilient companies.

🎙️ - Beginner's Mind. Top 10% global. #1 deep tech podcast. 200+ episodes.

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

How do you succeed in a business where being wrong is the norm?

Marc Penkala has lived both sides of the table: as an entrepreneur who built, sold, and failed with companies—and now as a venture capitalist running his own fund. What makes his story different is the radical honesty about what actually drives success in venture: failure, timing, and taking risks that look stupid at first.

This Spark20 episode distills Marc’s hard-earned lessons into a 20-minute masterclass for founders, investors, and policymakers navigating uncertainty.

What you’ll learn

Why timing, not brilliance, often decides who wins.
Why failure is the ultimate credibility builder for investors.
How European founders hold themselves back—and what mindset shift is overdue.
Why down markets are the best time to build companies.
How the “stupidest ideas” sometimes create the biggest outliers.

Timestamps & Quotes

📌 (00:00:38) Entrepreneur → VC
“My route into venture capital felt like a paid executive MBA… I built, I sold, I bankrupted, and then I joined the so-called evil side to truly understand investors.”

📌 (00:03:31) Failure as Fuel
“Failure is the bigger success… many of my failures turned into the best things that ever happened.”

📌 (00:05:32) Credibility Through Scars
“If I had never built a company, how could I authentically tell a founder I can help them?”

📌 (00:07:29) Wrong = Right in Venture
“As a VC, you’re more often wrong than right. And strangely, the more you’re wrong, the higher your actual output.”

📌 (00:10:38) When Tourists Arrive, Leave
“The moment angels and LPs with no clue flood the market, you literally have to stop investing. That’s when the tourists arrive.”

📌 (00:12:22) Outliers Make the Portfolio
“One angel had ten bets—two of them gorillas and Tier. Didn’t matter what else he had—the outliers alone defined him.”

📌 (00:13:02) Europe vs. US Mindset
“US startups think in billions. European startups think in millions. That mentality shift is everything.”

📌 (00:15:02) Stupid Ideas Win
“If everyone agrees it’s a great deal, don’t do it. The best investments sound like the stupidest idea at first.”

📌 (00:17:42) Why Down Markets Build Giants
“In down markets, founders get humble, go back to fundamentals, and focus on capital efficiency. That’s why the best companies come from downturns.”

This isn’t just a highlight reel—it’s a reminder that in venture capital and entrepreneurship, the rules are upside down. Being wrong isn’t a weakness—it’s proof you’re taking the swings that matter.

👉 Listen now, and share it with someone who needs to think bigger.

🎙️ With over 200 interviews, panels, and livestreams, Beginner’s Mind ranks in the Top 10% globally—and is recognized as the leading deep tech podcast for

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Here’s the harsh truth: If your business model can’t survive a spreadsheet, it won’t survive the market.

Every year, ambitious founders pour months into product, pitch, and brand—yet the single biggest reason startups die isn’t funding, it’s flawed modeling.

What are the four variables investors use to spot winners before anyone else?

In this episode, investor and hands-on builder Alex Oppenheimer (Founder & GP at Verissimo Ventures, ex-Facebook IPO, ex-NEA, Monday.com advisor) reveals why most startup advice misses the point—and how the best founders reverse-engineer success long before a single euro is raised.

🎧 Watch now to learn:
1️⃣ The business model simulation Alex uses to kill (or greenlight) a deal in under an hour
2️⃣ The one thing top VCs always ask founders—but almost nobody prepares for
3️⃣ Why a founder’s “calling” is more important than their credentials
4️⃣ How to avoid the European trap of ignoring leverage and failing to scale
5️⃣ The subtle mindset shift that separates bold investors from the herd—and how to apply it to your own company

👤 About Alex Oppenheimer
Stanford-trained engineer, ex-Morgan Stanley tech banker, NEA Series A investor, Monday.com operator, and now founder of Verissimo Ventures—a fund that bets on weird tech and next-gen software models in Israel, the US, and Europe.

💬 Quotes That Might Change How You Think:
(00:59:00) “If I don't build this, nobody else will—that’s the founder’s true calling.”
(01:12:45) “How can you know what data to collect if you don’t know the model?”
(01:22:36) “The real job of an investor is helping great founders not mess it up.”

🧭 Timestamps to Explore:
(00:04:00) Quitting Corporate Venture—The Decision That Changed Everything
(00:11:50) What Business Modeling Is (and Isn’t)
(00:18:30) Trusting the Founder Over the Deck
(00:24:40) Venture Capital and the Power of Naivete
(00:34:03) Inside the Facebook IPO Data Room
(00:44:38) Lessons from Betting on Outliers
(00:49:48) Leaving NEA to Build Israel’s Next Scaleups
(01:02:32) From Frustration to Founding a Venture Fund
(01:10:57) Why Business Modeling Remains a Blind Spot
(01:14:09) Redefining Value Investing in Venture Capital
(01:15:50) Decoding Value with Core Variables
(01:22:36) Helping Founders Avoid Unnecessary Pitfalls Early

🔔 Like what you hear?
Follow the show and share this episode with one builder, founder, or investor you respect.
Every share helps us bring new industry leaders and sharper insights straight to you.
Subscribe now—your next breakthrough could be one episode away.

🎙️ Beginner’s Mind
Top 10% globally. The leading podcast for VCs, operators, and anyone obsessed with building what comes next.

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Why do Europe’s brightest founders still feel forced to leave for Silicon Valley—no matter how much money or talent we pour into the region?
Every year, ambitious startups across Europe and CEE struggle to scale—not for lack of ideas, but because of invisible barriers that keep global success out of reach.

Is it really just about capital—or is there a deeper mindset and playbook that only a handful of founders ever discover?

In this episode, venture insider Enis Hulli (General Partner at e2vc, investor in 40+ startups, 3 unicorns, and builder of bridges from Istanbul to the Bay) pulls back the curtain on the real reasons US-based startups keep winning—and how founders from Turkey, Eastern Europe, and beyond can finally turn the tables.

🎧 Watch now to learn:
1️⃣ The “power law” that decides which founders build generational companies—and why most never see it coming
2️⃣ Why relationships, not pitch decks, determine who actually gets funded—and how to break through if you don’t have the right connections
3️⃣ How emotional resilience and founder mindset shape the fate of entire regions—not just individuals
4️⃣ The little-known risks of playing the European “safe game”—and how to engineer luck for outsized results
5️⃣ Tactical lessons on team building, brand, and why your anti-portfolio (the deals you missed) might matter even more than your winners

👤 About Enis Hulli
Enis is General Partner at e2vc, a leading early-stage venture fund focused on scaling tech startups from Emerging Europe to global markets. With investments in 40+ companies (including three unicorns), he’s spent his career helping founders unlock the path from local player to world-class leader.

💬 Quotes That Might Shift Your Thinking:
(01:30:44) “I don’t think we’ll see founders choosing Europe over the US in our…”
(01:34:37) “There are twenty different ways to kill a reputation on any side of the…”
(01:38:31) “To avoid complacency, I surround myself with people who make me feel like I…”

🧭 Timestamps to Explore:
(00:16:58) How the Bay Area’s Talent Network Effect Became Unstoppable
(00:20:48) Work-Life Balance vs. Blitzscaling—What It Really Takes to Go from Zero to One
(00:25:43) Why Founders Trump Pitch Decks Every Time
(00:30:38) The Perils of Planning for an Exit Too Soon
(00:34:34) The Three Qualities Every VC Looks For—And Why Mindset Still Wins
(00:40:30) How IPO Markets Shape (and Break) Venture Capital
(00:43:52) Fundraising Mistakes That Kill FOMO and Crush Deals
(01:12:58) Why Bay Area Mindset Still Outpaces Europe’s Best
(01:30:44) The Real Reason Europe Loses Its Unicorns
(01:34:37) Reputation, Relationships, and the Hidden Dangers of VC Control
(01:38:31) How Top Investors Avoid Complacency and Stay Hungry

🔔 Follow the show and leave a review. Every follow, like, and share brings new global voices, industry leaders, and sharpest insights straight to you.

🎙️ Beginner’s Mind ranks in the Top 10% globally—and is recognized as the

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Still trying to optimize your health with guesswork and generic advice?
Most people settle for “one-size-fits-all” supplements and hope for the best-missing out on the breakthroughs that only real data and personalization can offer.
In a world flooded with empty promises, few realize how quickly tailored, science-backed solutions can transform energy, focus, and longevity.

Enter Vadim Fedotov—ex-pro athlete, CEO, and co-founder of Bioniq, the health tech company bringing truly personalized care to the world’s top leaders, innovators, and athletes.

In this eye-opening conversation, Vadim reveals why your biology is as unique as your fingerprint—and why the future belongs to those who personalize, measure, and adapt.
Discover the systems, mindsets, and science behind optimizing human potential—without wasting time, money, or hope on outdated approaches.

🎧 Watch now to explore:
1️⃣ The fatal flaw in “one-size-fits-all” wellness—and how personalization is rewriting the rules
2️⃣ How AI, data, and regular feedback loops empower you to outpace your peers—at work, in health, and in life
3️⃣ Lessons from elite sports: why discipline, team dynamics, and feedback matter in business
4️⃣ The “feedback loop” secret that’s changing the supplement industry forever
5️⃣ Vadim’s vision for a future where your fridge, wearable, and AI coach work together to help you thrive

👤 About Vadim Fedotov
Vadim is the co-founder and CEO of Bioniq, former CEO at Groupon, and a former professional basketball player with the German National Team and Buffalo Bulls. Driven by his passion for health optimization, he’s building a global, interdisciplinary network of thought leaders to put cutting-edge, personalized care within everyone’s reach.

💬 Quotes That Might Shift Your Thinking:
(00:08:27) "Personalized health isn't a trend; it's the future of wellness."

(00:15:54) "There is no single right diet, exercise, or routine—every body truly needs something different."

(00:44:11) "Personalization in health is not a luxury anymore; it’s quickly becoming a necessity."

(01:06:26) "You only fail when you give up—resilience defines success."

(01:23:21) "Seventy percent of your health is determined by nutrition, not pharmaceuticals or medicine."

🧭 Timestamps to Explore:
(00:03:32) Why Visionary Leaders and Families Move to Dubai
(00:08:27) Personalizing Health Revolution How Data-Driven Wellness Changes Everything
(00:09:27) Health as the New Wealth Post-Covid Insights
(00:15:52) Busting Health Myths There’s No One-Size-Fits-All
(00:18:28) Data Over Opinion Navigating Health Complexity
(00:21:03) Olympic Research Sparks Personalized Health Innovation
(00:23:51) When Obvious Solutions Don’t Exist—The Birth of Bioniq
(00:25:40) When a "Dumb Idea" Becomes a Massive Opportunity
(00:31:01) Setting Personal Health Goals With AI and Data
(00:34:40) Real-World Feedback Loops Cut Through Wellness Hype
(00:40:07) Data-Driven Breakthroughs That Save Lives
(00:44:11) Why Health Personalization Is Now a Necessity
(00:54:31) Leadership, Discipline, and Lessons from El

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

How do you lead at the cutting edge of health, data, and AI—while staying deeply human?

Angeli Möller has led global data science teams across pharma giants, co-founded one of Europe’s most ambitious AI alliances, and now builds high-performance biotech strategies with precision. But what truly sets her apart isn’t just her technical fluency—it’s her clarity, courage, and care in how she builds teams, solves problems, and pushes the boundaries of innovation.

In this episode, Angeli opens up about the quiet frustrations that fuel her mission, the invisible cost of ignoring innovation, and the principles that guide her client work today. Whether you’re an investor, founder, or policymaker, her journey will reshape how you think about leadership, AI, and what truly moves the needle in healthcare.

Here’s what you’ll take away:

Why most AI projects fail—and how to spot the ones that won’t.
How to lead technical teams with vision, warmth, and accountability.
Why proprietary data matters more than fancy algorithms.
What real innovation feels like—and how to know when you’re missing it.

At the center of it all: a calm, fiercely smart leader who sees through the noise and builds what matters.

As she says:
“Start with the real problem. If you don’t understand the problem, AI won’t help you.”

Timestamps & Topics

📌 (01:08) Missed AI Integration Costs – “It’s faster, more effective, cheaper—but it’s not part of the core business yet.”

📌 (03:57) AI vs. Real-World Drug Impact – “The question isn’t: does it use AI? It’s: does the medicine work?”

📌 (04:48) Post-Hype AI Fallout in Pharma – “Fraud led to disillusionment. And investors paid the price.”

📌 (06:39) Corporate Blind Spots in Innovation – “It’s a danger in business to think there’s nothing to learn from others.”

📌 (09:40) Building a European AI Alliance – “At first, pharma didn’t take us seriously. That changed with the data.”

📌 (11:02) Data Ethics and Regulatory Risk – “You can massively hurt your business through accidental bias.”

📌 (13:19) Data Access for Rare Diseases – “The only solution is to make that data safely available.”

📌 (15:22) Leadership Shift: From Bayer to Startup – “It felt too obvious. I needed something riskier, more meaningful.”

📌 (21:23) Three Core Leadership Traits – “Vision. Technical understanding. And knowing when to bring in others.”

📌 (22:27) Frictionless Health Tech Adoption – “It’s inevitable. The economics—and behavior nudges—are already shaping it.”

This episode offers more than insight—it’s a playbook for building what’s next in health, tech, and leadership.

👉 Listen now, and share it with someone ready to shape the future.

🎙️ With over 200 interviews, panels, and livestreams, Beginner’s Mind ranks in the Top 10% globally—and is recognized as the leading deep tech podcast for

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Most founders add layers to gain control. Reed Hastings built an empire by removing them.

This episode unpacks No Rules Rules—the leadership playbook behind Netflix’s rise from a DVD mail service to a global entertainment powerhouse. Co-authored by founder Reed Hastings and INSEAD professor Erin Meyer, the book reveals how to scale not through policy, but through trust, talent density, and extreme transparency.

But this isn’t just about Netflix.

It’s about you—if you’re building or investing in companies between Series A and IPO, where culture either compounds performance or quietly kills it.

I walk you through 7 operational principles that deep-tech teams can apply now—lessons forged in crisis, growth, and reinvention. You’ll learn how to sunshine mistakes, pay like a pirate, and lead without becoming a bottleneck.

Each principle is translated into coaching prompts, ready to implement this week.

Key Takeaways:

Culture Outruns Capital: Don’t optimize the engine—reinvent the vehicle.
Pro Team > Family: Loyalty is earned through excellence, not tenure.
Candor Drives Speed: Build feedback loops that fuel progress.
Pay Top of Market: Buy peace of mind. Unlock creative flow.
Bet Boldly: Seek dissent. Test. Learn. Repeat.
Context Beats Control: Share the why. Let them own the how.
Transparency = Trust: Open up, even when it’s uncomfortable.

Timestamps:

(00:00) Intro – Why Netflix Scaled Faster by Removing Rules, Not Adding Them
(04:30) Who Is Reed Hastings? – From Math Teacher to Global Disruptor
(09:13) Book Snapshot – What Makes No Rules Rules a Real Operating System
(11:35) Lesson 1: Culture Outruns Capital – How Netflix Survived 4 Disruptions, Blockbuster Didn’t Survive One
(17:25) Lesson 2: Build a Pro Team, Not a Family – Talent Density Over Loyalty
(22:48) Lesson 3: Radical Candor = Speed – The Feedback Model That Fuels Innovation
(27:34) Lesson 4: Pay Like a Pirate – Why Netflix Pays Top of Market—No Games, Just Outcomes
(32:20) Lesson 5: Bet Bold, Fail Proudly – The 4-Step Innovation Cycle That Keeps Netflix Ahead
(39:12) Lesson 6: Lead with Context, Not Control – Scaling Leadership Without Becoming a Bottleneck
(43:28) Lesson 7: Transparency Builds Velocity – How Truth-Telling Became Netflix’s Superpower
(48:15) 7 Key Takeaways – The Culture Playbook Every Growth-Stage Founder Needs
(50:15) Personal Reflection – What I Questioned, What I’ll Steal, What Gave Me Pause
(52:00) Call to Action + What’s Next – Support the Show + Tease of the Next Episode

Why Listen:

Learn how Netflix scaled without micromanagement
Get 7 principles that push your org design, talent strategy, and leadership edge
Discover where you're still playing defense—when your culture should be your offense
Upgrade your leadership thinking with real examples and immediate applications

Found this useful? Like, share, and follow.
Every

Send us a text

Support the show

Join the Podcast Newsletter: Link

No Rules Rules: Netflix and the Culture of Reinvention

View Details

Most cancer drugs fail. Not because the science is wrong—because we’re solving the wrong problems.

The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there’s no second chance.

Behind the headlines of “precision medicine,” there’s a deeper story nobody’s telling. Until now.

🎯 Enter Rafael Rosengarten, the scientist-turned-founder who’s rewriting the rules of drug development.

In this gripping conversation, we unpack how RNA, AI, and deep empathy could finally close the loop between biology, data, and the patient in the room.

🎧 Watch now to explore:
1️⃣ Why drug failure isn’t a tech problem—it’s a strategy problem
2️⃣ How “information companions” will guide every medicine to the right patient
3️⃣ What pharma keeps getting wrong about biomarkers—and how to fix it
4️⃣ The untold story behind turning down a chef’s job on a Mediterranean yacht
5️⃣ The real reason Genialis may one day go out of business (and why Rafael hopes it does)

👤 About Rafael Rosengarten
Rafael is CEO and co-founder of Genialis, the RNA biomarker company reshaping precision oncology. From academic labs to Michelin-star kitchens, his journey is anything but linear—but his mission is clear: make medicine make sense. With partners across pharma, diagnostics, and AI, Genialis is creating a world where every patient gets the treatment they actually need.

💬 Quotes That Might Shift Your Thinking:
(00:58:37) “Our AI biomarkers de-risk clinical trials, slashing costs and saving lives.”
(01:54:46) “Every drug will have an information companion guiding it to the right patient.”
(01:14:32) “AI should free humans for empathy and creativity, not replace them.”
(00:14:13) “We now have the tools to treat every cancer as unique to each patient.”
(01:31:38) “Stop selling technology; sell solutions to real problems.”

🧭 Timestamps to Explore:
(00:03:52) Inside the World’s Largest Medical Center
(00:10:30) How AI Is Rewiring Precision Medicine
(00:13:51) Why Precision Medicine Is Scaling Now
(00:17:34) Startups Must Solve Market Needs First
(00:23:53) Culture First, Then Business: Startup Blueprint
(00:27:57) Cancer Isn’t One Disease—It’s Thousands
(00:31:44) Predicting Drug Success with AI Biology
(00:36:40) Reimagining Biomarkers Using RNA and AI
(00:47:45) Why Early Detection Still Saves Lives
(00:57:30) Why Most Cancer Drugs Still Fail
(00:58:37) AI Biomarkers That De-Risk Clinical Trials
(01:09:42) Rethinking Dosage with Predictive Algorithms
(01:13:33) Why Human Intuition Still Matters in Science
(01:36:41) The Crystal Ball Question Pharma Can’t Ignore
(01:50:19) The moment where time disappears—and the real future begins.
(01:53:39) Every Drug Will Have an AI Companion

🔔 Let’s Rebuild Trust in Medicine—Together
If this episode sparked a new thought—or just gave you pause—don’t let it end here.

Subscribe. Share it with someone who still believes medicine can be both scientific and deeply human.

Every action brings in minds like Rafael’s… and gets us one step closer to trea

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Europe has the science. The talent. The breakthroughs.

But when an idea feels too uncertain, our systems shut it down before it has a chance to breathe.

And with every safe bet… we quietly lose the next cure, the next Car-T, the next AI that could change everything.

🚨 Risk-aversion, fragmentation, and bureaucracy are draining Europe’s innovation power—and nobody dares to name it out loud.

But Fabrizio Conicella, VP of Open Innovation at Chiesi Group, isn’t holding back.

💡 In this deep, urgent conversation, Fabrizio shares how Europe can build the ecosystems we need to turn bold ideas into real-world impact—without compromising ethics, patients, or long-term value.

🎧 Watch now to explore:
1️⃣ Why uncertainty, not risk, is the true frontier of innovation
2️⃣ The hidden reasons startups leave Europe—and how to keep them
3️⃣ How Chiesi’s “The Impulse” model flips corporate R&D on its head
4️⃣ What every policymaker, CEO, and scientist must change before it’s too late
5️⃣ A bold new playbook for turning visionary science into trusted medicine

👤 About Fabrizio Conicella:
As one of Europe’s leading voices in health innovation, Fabrizio is pioneering how pharma collaborates across startups, data, and ethics. His mission: create environments where the best ideas don’t get shut down—they get built.

💬 Quotes That Might Just Change Your Thinking:
(01:58:01) "Be bold enough to dream, but pragmatic enough to make it real."
(01:07:22) "Science is essential, but turning it into a product requires a different kind of wisdom."
(01:04:35) "Visionary entrepreneurs see the future and change the game."
(00:16:51) "Innovation today is no longer a race for ownership, but a journey of collaboration."
(00:47:55) "If the idea is truly bold, no pharma company can replicate it without you."

⏱️ Timestamps:
(03:00) Europe’s Innovation Crisis: A Wake-Up Call
(08:19) Chiesi’s Bold B Corp Strategy
(16:26) Building Healthcare Innovation Ecosystems
(22:09) Predictive Medicine and Patient Data
(29:49) Pharma vs. Startup Ecosystems Today
(34:38) Why R&D Must Go External
(35:06) The End of Buy-and-Wait Pharma
(41:42) Ethics First: Pharma’s New Mandate
(44:06) Respecting Founders, Not Just IP
(47:23) Debunking the 'Pharma Steals Ideas' Myth
(54:10) Why Pharma Moves Slowly—but Must Adapt
(59:25) Market Acumen: Startups’ Missing Ingredient
(01:04:35) What Makes a Visionary Entrepreneur
(01:29:22) Embracing Failure to Spark Innovation
(01:46:01) Europe’s Risk Culture is Holding Us Back

🔔 Help Us Grow the Future of Thoughtful Innovation
If this conversation sparked something in you—an insight, a question, a sense of urgency—help us keep it alive.
Subscribe. Leave a comment. Share it with someone who still believes bold ideas deserve a fighting chance.
Every action brings in deeper minds, bigger questions, and the kind of leadership our systems so desperately need.

Book mention: The Venture Mindset

🎧 Watch now—and join the movement to rebuild Europe’s innova

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

What if the only way to save the planet... is to cool it?
Not figuratively—literally.
Because the heatwaves, floods, and fires you’ve seen so far? They’re just the beginning.

🌍 Emissions keep rising. Global cooperation is slowing. And the window to act is closing fast.
Now, world leaders are quietly weighing a radical idea: Should we artificially cool Earth before it’s too late?

💥 In this explosive episode, we dive into the most controversial climate strategy on the table today: solar radiation modification.

But who decides how much cooling is “enough”?
What happens if we act too late—or worse, too soon?

📌 In this episode, Janos Pasztor—former UN Assistant Secretary-General for Climate Change and climate advisor to Ban Ki-moon—breaks his silence on the plans world leaders are only now beginning to confront.

🎧 Watch now to uncover:

1️⃣ Why geoengineering may soon become a global necessity—not a fringe idea.
2️⃣ What governments aren’t telling you about unilateral climate interventions.
3️⃣ The ethical, political, and scientific minefield behind planetary cooling.
4️⃣ Why some scientists say this tech could save millions—and others call it madness.
5️⃣ What it will take to govern Earth’s thermostat before someone does it alone.

👤 About Janos Pasztor:
With nearly 50 years of experience in climate policy, diplomacy, and governance, Pasztor has shaped global climate strategy from inside the UN and beyond. From the 1992 Earth Summit to the corridors of the UN Security Council, he’s been advising heads of state on how to confront the world’s most complex crisis—and now, he’s sharing what’s coming next.

💡 Quotes to Challenge Your Thinking:
(00:08:41) “We must ask: is it time to start cooling parts of the planet?”

(01:21:07) “Stratospheric aerosol injection could cool the planet—yet we barely understand its consequences.”

(01:11:03) “The real question is whether capitalism can evolve beyond its dependence on resource extraction.”

(02:24:41) “Three degrees of warming is cuckoo land—it’s beyond what humanity can realistically adapt to.”

(02:47:03) “Climate policy isn't just climate—it’s about everything we do as a society.”

⏱️ Timestamps:
(00:04:12) Urgent Climate Crisis: Rising Emissions Explained
(00:10:15) Inconvenient Truth 2.0: What We Missed
(00:18:32) China’s Green Tech Revolution Unpacked
(00:26:20) Can Climate Forums Deliver Real Action?
(00:32:50) Designing Just, Achievable Climate Goals Globally
(00:40:06) How Growth Triggers Today’s Polycrisis
(00:45:08) Rethinking Economies for Sustainable Living
(00:53:00) Why We Need Mixed Energy Strategies
(01:17:24) Geoengineering vs Terraforming: Climate Futures Debate
(01:26:20) Who Funds Carbon Removal Technologies?
(01:37:06) Why We May Need to Cool Earth
(01:40:41) Warming Beyond 3°C: What’s at Risk
(01:48:02) How Fossil Fuels Hide True Heat
(02:08:00) The Hidden Risks of Cheap Climate Fixes
(02:24:41) 3 Degrees Warming: Scientifically Unmanageable?

🔔 Help Us Grow
If this conversation gave you insight, urgenc

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

What if your business ran like a well-designed machine—one that could evolve, self-correct, and outperform your competition over decades?

In this episode, I unpack Principles by Ray Dalio, the billionaire investor and founder of Bridgewater Associates, the world’s largest hedge fund. It’s not a traditional business book—it’s a blueprint for decision-making, culture design, and long-term scaling, rooted in clarity, transparency, and radical self-honesty.

This episode is built for venture capitalists, executives, and operators leading at scale—those who are no longer improvising but building enduring systems.

You’ll hear the 7 most actionable principles Dalio used to scale Bridgewater, reimagined for anyone building the future—from biotech to AI, from global funds to market-leading enterprises.

We cover how to engineer feedback cultures, design for evolution, and drive decisions that compound over time. And we tackle the big question: Can you be both a high-performance machine and a human-centered leader?

Key Takeaways:

Think Like a Machine: Build systems that run without your constant input.
Get the People Right: Talent isn’t enough—character and growth capacity matter most.
Radical Transparency: Trust is built by saying the hard things early and often.
Idea Meritocracy: Don’t default to consensus. Weight decisions by experience.
Shaper Thinking: Zoom out to vision, zoom in to execution—and toggle constantly.
Diagnose the Root Cause: Don’t waste time solving symptoms.
Open-Mindedness as Strategy: Challenge your thinking before reality does.

Timestamps:

(00:00) Intro: The Principles
(02:15) Why This Book Matters If You’re Building or Investing in the Future
(04:14) Who Is Ray Dalio?
(06:21) The Snapshot: What Principles Is Really About
(10:05) Build Your Company Like a Machine, Not a Hero’s Journey
(15:29) Get the People Right
(20:40) Radical Truth & Transparency Are Force Multipliers
(26:08) Build an Idea Meritocracy
(32:26) Shapers Win—They Dream Big, Think Clear, Execute Ruthlessly
(37:37) Diagnose Root Causes, Not Symptoms
(44:02) Be Radically Open-Minded
(50:12) Key Takeaways & Personal Reflection

Why Listen:

Learn how billion-dollar systems are designed and scaled
Identify blind spots in your leadership, org design, or investment theses
Equip yourself with 7 operating principles you can implement this quarter
Reframe your relationship to truth, conflict, and growth
Decide whether to build a machine—or remain the operator

If these ideas resonate, I strongly recommend reading Principles in full. Or better yet—share this episode with someone you think is ready to level up how they lead and build.

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

What does it take to turn extreme adversity into extraordinary leadership? Suzanne Heywood’s life reads like a novel—shipwrecked at seven, isolated at sea for a decade, forging her father’s signature to survive, and ultimately earning a place at Oxford through sheer determination. Today, she’s a top executive and investor, steering multi-billion-dollar companies with resilience, clarity, and innovation.

In this episode, Suzanne shares the defining moments that shaped her, the mindset that helped her thrive in crisis, and the leadership lessons she applies in business today. Whether you’re an investor, entrepreneur, or leader, this conversation will leave you inspired and armed with valuable insights:

How to stay calm under extreme pressure and make clear decisions.
Why resilience isn’t about being tough—but about perspective.
How diversity fuels innovation and why biases hold companies back.
The ‘Critical Friend’ approach to leadership and board dynamics.

At the heart of it all, Suzanne’s journey is a testament to perseverance and purpose. As she says:

"You’ll learn things from adversity that people with an easier life never will."

Timestamps & Topics

📌 (01:00) Overcoming Extreme Adversity – A childhood lost at sea, a future built from nothing.
📌 (03:43) Knowing Which Mountains Are Worth Climbing – How to distinguish real challenges from distractions.
📌 (06:05) Resilience Under Pressure – From shipwreck to boardroom calm.
📌 (07:51) The Dangers of Bias in Innovation – Why lack of diversity kills progress.
📌 (09:39) Creating Sustainable Innovation – What great leaders prioritize for long-term success.
📌 (13:48) The ‘Critical Friend’ in Leadership – Balancing support with hard truths.
📌 (16:43) Metallica Meets Electric Trucks – A masterclass in creative partnerships.
📌 (18:29) Education as the Ultimate Investment – How learning transformed her life.

Powerful Quotes

💡 (03:43) "I picked kiwifruit… earned enough for a one-way ticket—Oxford changed my life."
💡 (06:58) "Nobody's life is in danger—we will get this sorted out."
💡 (20:39) "You’ll learn things from adversity that people with an easier life never will."

This episode is more than an inspiring story—it’s a blueprint for navigating uncertainty, making tough decisions, and leading with conviction.

👉 Listen now, take notes, and if this sparks something in you, share it with someone who needs to hear it!

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

ATMPs, gene therapies, and cancer breakthroughs are here—but outdated regulations, high costs, and logistical bottlenecks are blocking access. What needs to change for hospitals to deliver these cures to patients who need them most?

💡 Here’s the harsh reality:

Patients are waiting, but hospitals aren’t ready.
The science exists, but regulations haven’t caught up.
The treatments work, but they’re too expensive to scale.

So what’s the solution? And who’s taking action?

📌 In this episode, Kristina Levan—ATMP innovation leader and biotech strategist—breaks down the challenges and opportunities shaping the future of advanced therapies.

🎧 Watch now to learn:
1️⃣ How gene therapy is curing blindness—and why it almost didn’t happen.
2️⃣ The biggest bottleneck preventing hospitals from offering life-saving treatments.
3️⃣ How AI and automation could unlock personalized medicine for everyone.
4️⃣ The real reason ATMPs are so expensive—and what must change.
5️⃣ Why healthcare leaders, policymakers, and investors must rethink how we manufacture cures.

👤 About Kristina Levan:
Kristina Levan has spent years at the cutting edge of cancer research, clinical trials, and ATMP development. She’s helped shape Sweden’s national ATMP strategy, connecting industry, healthcare, and academia to push these breakthroughs forward. Now, she’s tackling the next big challenge—getting these treatments to patients faster.

💡 Quotes to Challenge Your Thinking:
(00:12:05) "ATMPs don’t just treat symptoms—they have the power to cure diseases."
(00:23:36) "Gene therapy is giving children a future—restoring sight and transforming their lives forever."
(01:27:52) "Imagine a future where hospitals create customized gene therapies on-site for every patient."
(01:43:13) "ATMPs could transform lives by treating the untreatable."
(01:45:42) "If we can cure early, we don’t just save lives—we reshape them."

Timestamps:
(00:05:32) How ATMPs Will Reshape Global Healthcare
(00:13:54) CAR-T Therapy: The Next Cancer Treatment Revolution
(00:23:36) Gene Therapy Restores Sight—The Future of Medicine?
(00:28:33) AI-Powered Therapies: Can Hospitals Manufacture Cures?
(00:37:55) Why Cutting-Edge ATMPs Struggle to Reach Patients
(00:53:36) Personalized Medicine & Real-Time Health Monitoring
(01:09:02) From Research to Reality: Scaling ATMP Treatments
(01:12:54) The True Cost of ATMPs—Can We Afford Innovation?
(01:27:15) Cell Therapy Manufacturing: The Next Big Disruption
(01:33:03) AI & Automation in Healthcare: What’s Next?

🔔 Help Us Grow

If this episode gave you insight, inspiration, or a new perspective—here’s how you can help:

📢 Hit SUBSCRIBE, like, and leave a comment. It’s a small action, but it has a huge ripple effect. Every engagement helps us bring in bigger guests, deeper insights, and more industry-changing conversations.

Right now, we’re in the global top 10%—let’s push for the top 1% together.

🎧 Watch

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

In 2021, biotech IPOs were soaring. Valuations hit record highs. Investors were throwing money at anything that moved.

Then… the market crashed. Funding dried up. Growth stalled. Biotech founders and investors were left scrambling.

So what really happened? And more importantly—how do you navigate what’s next?

📌 In this episode, Christopher Uhde—Senior Pharma & Biotech Equity Analyst at SEB—breaks down the brutal realities of biotech IPOs, investor sentiment, and the high-stakes game of survival in a post-boom world.

🎧 Watch now to learn:

1️⃣ Why valuations aren’t about science—but about demand.
2️⃣ The biggest mistake biotech founders make after going public.
3️⃣ How to raise capital before you actually need it.
4️⃣ The European biotech advantage—and how to leverage it.
5️⃣ How to attract the right investors and avoid the wrong ones.

👤 About Christopher Uhde:

Christopher Uhde is a Senior Pharma & Biotech Equity Analyst at SEB, one of Europe’s leading financial institutions. With a PhD in neurodevelopmental systems biology and postdoctoral research in drug discovery, he’s spent years studying the biotech market—from billion-dollar giants to early-stage startups—analyzing their success, failures, and what separates winners from the rest.

💡 Quotes to Challenge Your Thinking:
📌 (00:16:29) "Valuation isn’t about science; it’s about demand and the right investors."
📌 (00:49:17) "The power of the right team in biotech can’t be overstated."
📌 (01:13:08) "European startups struggle not from lack of innovation, but from a lack of ownership mindset."
📌 (01:38:39) "The long-term equity story isn’t just about share price—it’s about trust and vision."
📌 (01:50:44) "Biotech isn’t just about breakthrough science—it’s about strategy, trust, and long-term vision."

⏰ Timestamps:
(00:09:48) IPO Market Realities and Investor Sentiment
(00:17:59) Why European biotech should think beyond US listings
(00:25:15) The hidden challenges of taking a company public
(00:28:45) Preparing for IPO Compliance
(00:37:11) Public company leadership demands strategic communication
(00:49:17) The power of the right team in biotech
(00:52:48) Planning for success in biotech acquisitions
(01:13:08) Incentivizing Innovation in Europe
(01:23:33) Nordic IPO culture shaping biotech success
(01:36:16) Realistic Communication in Biotech
(01:50:44) Europe’s Biotech Global Edge

🔔 Help Us Grow

If this episode gave you insight, inspiration, or a new perspective—here’s how you can help:

📢 Hit SUBSCRIBE, like, and leave a comment. It’s a small action, but it makes a huge difference. Every engagement helps us bring in more top-tier guests, deeper insights, and the conversations that keep you ahead.

Right now, we’re in the global top 10%—let’s push for the top 1% together.

🎧 Watch now and make sure your biotech strategy is built to last. 🚀

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

🚀 Most investors chase consensus. The best ones? They bet against it.

If everyone agrees on an investment, it’s probably not bold enough. That’s why the greatest venture capitalists don’t just follow trends—they seek out the hidden outliers that redefine industries. But how do they spot the next Amazon, Google, or Tesla before anyone else? And why do so many leaders play it safe and miss out?

📌 In this episode, Alex Dang—former Amazon and McKinsey leader—breaks down how elite investors think, how to cultivate the venture mindset, and why risk isn’t the enemy—short-term thinking is.

🎧 Watch now to learn how to think like the world’s top investors.

🎙️ What’s in the Episode:

1️⃣ Conviction Over Consensus – Why the best decisions often go against the crowd.
2️⃣ The VC Playbook – How top investors filter out noise and double down on outliers.
3️⃣ Risk vs. Regret – The hidden cost of playing it safe.
4️⃣ The ‘Day One’ Mentality – How Amazon avoids stagnation and bureaucracy.
5️⃣ From Poker to Investing – The mindset shift that separates amateurs from professionals.

👤 About Alex Dang:

Alex Dang has lived the venture mindset firsthand—at Amazon, where he built new businesses; at AWS, where he launched cutting-edge AI solutions; and at McKinsey, where he helped Fortune 500 leaders scale transformative innovations. A Stanford GSB graduate, he’s spent nearly two decades guiding decision-makers through high-risk, high-reward environments.

💡 Quotes to Challenge Your Thinking:

📌 (01:21:31) "Conviction beats consensus. If everyone agrees, the idea isn’t bold enough."
📌 (01:49:18) "VCs don’t fear losing money. They fear missing the next Google."
📌 (00:31:08) "Home runs matter, strikeouts do not in the venture capital game."
📌 (00:58:46) "In business, like poker, fold early or double down—there’s no in-between."
📌 (00:47:00) "The moment you abandon a Day One mentality, bureaucracy wins."

⏰ Timestamps:

(00:04:58) AI's Next Big Disruption
(00:20:08) Predictability vs. Innovation in Business
(00:30:45) Venture Capital’s Risk Culture Explained
(00:38:00) How Amazon Built a Venture Mindset
(00:46:34) Day One vs. Day Two Thinking
(00:53:22) Writing for High-Stakes Decision Makers
(00:57:51) Poker Mindset in Venture Investing
(01:11:07) Why Failure Leads to Billion-Dollar Wins
(01:21:31) Conviction vs. Consensus in Investing
(01:26:46) Avoiding the Crowd, Finding Outliers
(01:32:47) Playing the Long Game in Venture
(01:54:59) Optimism in Innovation’s Unpredictable Future

🔔 Help Us Grow

If this episode challenged your thinking, hit follow, like, and share. The bigger the show gets, the bigger the guests we can bring you—so you get even more game-changing insights.

🎧 Watch now and start making billion-dollar bets like the world’s best investors. 🚀

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

What if your greatest asset in business was how you think under pressure?

In this episode, I dive into The Venture Mindset by Alex Dang and Ilya Strebulaev, unpacking seven transformative lessons drawn from the world of venture capital and deep-tech entrepreneurship. These principles aren’t just for investors—they’re a roadmap for anyone navigating uncertainty, from startup founders to corporate innovators.

Alex Dang, a veteran innovator, and Ilya Strebulaev, a leading academic in venture capital, combine decades of hands-on experience and rigorous research. Together, they reveal how to embrace risk, think strategically, and build ventures that thrive in chaotic environments.

As an entrepreneur and investor, I’ve found these lessons invaluable. This episode explores how to prepare your mind for contrarian thinking, align incentives for growth, and make bold decisions when it matters most. Whether you’re building groundbreaking technology or adapting to a disruptive market, these insights will reshape how you approach challenges.

Key Takeaways:

This episode covers seven critical lessons, including:

1️⃣ Home Runs Matter, Strikeouts Don’t: Embrace failure as a stepping stone to transformative success.
2️⃣ Prepare Your Mind for Contrarian Thinking: Spot opportunities others miss and thrive in uncertainty.
3️⃣ Bet on the Jockey, Not Just the Horse: Prioritize resilient founders over flashy ideas.
4️⃣ Double Down or Quit: Make disciplined decisions to invest or cut losses.
5️⃣ Get Outside the Four Walls: Source ideas from diverse networks and unexpected places.
6️⃣ Make the Pie Bigger: Align incentives to foster collaboration and shared success.
7️⃣ Great Things Take Time: Cultivate patience and a long-term vision to achieve exponential impact.

While this episode highlights actionable takeaways, The Venture Mindset is packed with even more insights and strategies for anyone looking to excel in unpredictable environments.

Timestamps:

(00:00) - Introduction: Why This Episode Matters
(01:20) - The Book’s Relevance for Entrepreneurs and Innovators
(02:02) - Author Spotlight: Alex Dang and Ilya Strebulaev
(04:15) - Book Overview: A Roadmap for Thriving in Uncertainty
(06:56) - Key Takeaway 1: Home Runs Matter, Strikeouts Don’t
(12:43) - Key Takeaway 2: Prepare Your Mind for Contrarian Thinking
(19:07) - Key Takeaway 3: Bet on the Jockey, Not Just the Horse
(24:00) - Key Takeaway 4: Double Down or Quit
(29:22) - Key Takeaway 5: Get Outside the Four Walls
(34:00) - Key Takeaway 6: Make the Pie Bigger
(38:53) - Key Takeaway 7: Great Things Take Time
(43:55) - Closing Reflections and Final Insights

Why Listen:

Embrace Bold Thinking: Learn how to thrive in uncertainty with strategies from venture capitalists and entrepreneurs.
Master Decision-Making: Equip yourself with tools to adapt and act decisively in chaotic environments.
Drive Innovation and Growth: Gain insights into fosteri

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

What does it take to redefine venture capital while empowering founders to disrupt industries and drive meaningful change? Meet Dan Bowyer, a bold investor from Superseed VC reshaping the game with a no-nonsense approach and a passion for impactful innovation.

In this episode, Dan shares his journey from entrepreneur to VC and dives deep into what’s wrong with traditional venture capital. He reveals the personality traits that define world-changing founders, the importance of customer obsession, and the stark realities of boardroom dynamics. Dan’s candid insights and thought-provoking lessons are as entertaining as they are eye-opening.

Whether you’re an aspiring founder, an experienced investor, or someone intrigued by the startup world, this conversation will teach you:

Why venture capital doesn’t work for 99.9% of founders—and what needs to change.
The three personality traits that separate great founders from the rest.
How misaligned boards and outdated practices can derail even the best startups.

At the heart of it all, Dan’s passion for connecting people, products, and processes shines through. As he says, “The next wave of commercial activity is about making money and doing good—it's not just about the bottom line anymore.”

Curious for more? Listen to the full episode here and dive deeper into Dan’s bold vision and unfiltered perspective.

Quotes:

(3:44) "Most VCs have never worked in a startup, so how can they advise one?"
(9:42) "The greatest founders are not just charming—they’re determined, disagreeable, and unrelenting in disrupting the status quo."
(22:02) "We've moved on from 'don’t be a dick' to 'do some good'—and that’s how we transform the future."

Timestamps

(01:37) Bridging the Gap: Why Venture Capital Fails 99% of Founders
(03:44) Startup Struggles: The Hard Truths Founders Need to Hear
(09:42) Decoding Greatness: Traits of Exceptional Founders
(12:58) From Prototype to Profit: Why Customer Obsession Wins
(17:01) Boardroom Battles: Misaligned Boards and Startup Success
(21:02) A New Era: Making Money While Doing Good

Don’t miss this chance to learn from Dan Bowyer’s dynamic journey, sharp insights, and inspiring approach to venture capital. Press play, and let’s spark some bold ideas together!

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

What makes a year unforgettable? Is it the challenges conquered, the bold ideas pursued, or the connections that shaped us?

As 2024 comes to a close, this special episode celebrates the lessons, breakthroughs, and visionary insights that defined the year. Through 9 remarkable stories, hear from leaders, investors, and innovators who are shaping the future.

🎙️ In This Episode:

Suzanne Heywood: Discover the balance of trust and challenge that makes great leaders.
Shlomo Noy: Explore how Israel transformed challenges into global innovation success.
Charlie Munger: Learn why a latticework of mental models is the ultimate leadership tool.
Hampus Jakobsson: Understand how empathy and diverse perspectives drive venture success.
Marc Penkala: Uncover the mindset shift Europe needs to compete with U.S. venture capital.
Jeff Bezos: Dive into the principles of customer-driven innovation from Invent and Wander.
DC Palter: Find out why startups fail without the right mix of technical expertise and business acumen.
Joe Panetta: Learn the secret sauce behind California’s thriving biotech ecosystem.
Marina Schmidt: Reimagine food systems with agroforestry—a sustainable, resilient alternative to industrial farming.

💡 Key Quote Highlights:

“The ideal board member is a critical friend—someone who challenges you when times are good and supports you when they’re tough.” – Suzanne Heywood
"Israel’s innovation story is a testament to how bold policies and restless minds can turn challenges into a thriving tech ecosystem." – Shlomo Noy
“In Europe, we focus on what could go wrong; in the U.S., they focus on what could go right.” – Marc Penkala
"A great product without the right team is like a rocket without a pilot—it won’t fly far." – DC Palter
"Empathy isn’t just a soft skill—it’s a leadership superpower." – Hampus Jakobsson
“Agroforestry isn’t just farming—it’s nature’s blueprint for a resilient, abundant food system.” – Marina Schmidt

⏰ Timestamps:

(00:00) This Was 2024 – 9 Stepping Stones into 2025
(04:34) Suzanne Heywood: How Great Leaders Build Trust and Challenge
(14:36) Shlomo Noy: How Israel’s Innovation Ecosystem Transformed Challenges Into Global Success
(22:54) Charlie Munger – Poor Charlie’s Almanack: The Power of Thinking Across Disciplines
(29:37) Hampus Jakobsson: Empathy, Fiction, and Business Success
(37:31) Marc Penkala: Europe vs. U.S.—Bridging the Venture Capital Divide
(45:13) Jeff Bezos – Invent and Wander: Solving Problems, Not Selling Tech
(51:58) DC Palter: Why Great Inventions Fail Without Business Expertise
(01:02:13) Joe Panetta: California's Risk-Taking Culture and

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Our global food systems are at a breaking point. Climate change, geopolitical tensions, and industrial farming are pushing us closer to food insecurity every day. Can we find a way to feed 10 billion people while safeguarding the planet?

Marina Schmidt, founder of Red to Green Solutions, reveals groundbreaking ideas that reimagine how we grow, consume, and sustain food for a resilient future.

🎙️ What’s in the Episode:
1️⃣ Building Food System Resilience: How to adapt agriculture to survive droughts, floods, and supply chain disruptions.
2️⃣ Passive Impact for Lasting Change: Discover how creating systems can drive sustainable results—even while you sleep.
3️⃣ The Global Food Paradox: Why efficiency in food systems comes at a cost, and how agroforestry could be the answer.

👤 About Marina Schmidt:
Marina Schmidt is the visionary Founder of Red to Green Solutions, the leading global podcast on food tech and sustainability. Ranked in the top 5% globally, Marina's work spans research, policy influence, and media, making her a trusted voice for transforming global food systems.

💡 Quotes to Inspire:
(06:38) "Food is not just sustenance; it’s a gateway to health and sustainability."
(01:01:50) "Globalization makes food systems efficient but at the cost of stability."(01:12:20) "Agroforestry mimics nature, creating resilient ecosystems that feed both people and biodiversity."
(01:50:19) "Food system resilience is key to surviving climate disruptions."(02:01:00) "Create systems for passive impact, change while you sleep."

⏰ Timestamps:
(03:34) From Health Crisis to Food Sustainability
(05:50) Transforming Health Challenges into Purpose
(31:30) The Surprising Global Journey of the Potato
(45:28) Vibrant Plate Colors and Nutritional Benefits
(58:21) Globalization’s Impact on Food Systems
(01:08:55) Fixing Farming Subsidies for Sustainability
(01:15:35) Agroforestry: Nature-Inspired Food Systems
(01:22:26) The Monsanto Legacy and Pesticide Debate
(01:27:18) Why Europe Leads in Food Safety Regulations
(01:35:52) Western Diets Reshaping China’s Food Culture
(01:50:19) Building Resilient Food Systems for Climate Change
(02:01:00) Creating Lasting Change Through Passive Impact

If you care about food security, climate resilience, and innovative solutions that can sustain future generations, this episode is for you.

🔔 Subscribe, comment, and share to help grow the show and bring more transformative ideas to leaders and changemakers like you.

👀 Watch the full episode to uncover the tools and strategies that can redefine our food future—before it’s too late.

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

What does it take to tackle the world's biggest challenge—climate change—while driving profit and innovation? Meet Doerte Hirschberg, a visionary investor reshaping industries with bold ideas and data-driven solutions.

In this episode, Doerte takes us on a journey of how her team at Climentum Capital uses measurable CO2 impact as their guiding star. She shares insights into why the future of sustainable industries lies in rethinking systems, embracing new technologies, and focusing on the bigger picture. From transforming dairy into vegan alternatives to unlocking the potential of the hydrogen economy, her lessons are as inspiring as they are actionable.

Whether you're an aspiring entrepreneur, an investor, or someone passionate about sustainability, this conversation will teach you:

Why CO2 is the most powerful KPI to measure climate impact.
How industries like food and transport are being revolutionized with technology like precision fermentation.
The secret to avoiding overhyped trends while investing in solutions that truly make a difference.

At the heart of it all, Doerte’s optimism, strategic mindset, and passion for innovation make this episode a masterclass in balancing ambition with sustainability. As she says, “The world doesn’t need more overhyped investments. It needs smarter ones.”Curious for more? Listen to the full episode here and dive deeper into Doerte’s remarkable journey.

Quotes:

(10:40) "We need to feed 7 billion people with less land, less animals, and less CO2—this isn't just a challenge, it's an opportunity to rethink the future of food."
(17:26) "Imagine a world where climate change isn’t just a problem we talk about, but a challenge we’ve conquered—with measurable impact and real change."
(14:01) "Biases are everywhere—even in venture capital. The industry claims it wants women, yet the system subtly works against them. It's time for that to change."

Timestamps

(0:00) Can We Balance Profit with Saving the Planet?
(1:08) Why CO2 is the Key Metric for Climate Impact
(3:07) The Challenges and Opportunities of Climate Tech
(8:10) Why LPs Should Invest in Elemental Capital
(11:12) The Future of Vegan Cheese with Fermify
(14:01) Breaking Biases in Venture Capital
(18:46) Vision for a Sustainable Future

Don't miss this chance to learn from Doerte Hirschberg's journey, her inspiring vision, and her sharp strategies to reshape the future. Press play, and let’s spark some change together!

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

What if your greatest advantage in business was how you think about the future?

In this episode, I explore Richer, Wiser, Happier by William Green, unpacking seven actionable lessons inspired by legendary investors like Warren Buffett, Charlie Munger, and Sir John Templeton. These lessons go beyond money—they’re about mastering long-term thinking, simplifying complexity, and building resilience to thrive in uncertainty.

William Green, a journalist with decades of experience interviewing investing icons, distills their timeless principles into strategies for entrepreneurs, investors, and anyone looking to improve their decision-making.

As an entrepreneur and investor, I’ve applied these lessons to my journey. From the power of focus to managing emotions and embracing change, this episode equips you with tools to sharpen your priorities, think strategically, and navigate today’s ever-changing landscape.

Key Takeaways:

This episode covers seven transformative lessons, including:

Say No to Almost Everything: Focus on what truly matters and eliminate distractions.
The Willingness to Be Lonely: Step away from the herd to achieve extraordinary gains.
Resilience Is the Ultimate Strength: Prepare for downturns and thrive through tough times.
Beware of Emotions and Ignorance: Manage emotional reactions and make informed decisions.
Think Long-Term and Embrace Change: Play the long game to build lasting success.
Simplicity Is Strength: Distill complexity into clarity for impact and growth.
Success Is Built on Habits and Incremental Progress: Double down on what works and refine continuously.

While this episode highlights actionable takeaways, Richer, Wiser, Happier dives even deeper, offering stories and frameworks that can transform your approach to business and life.

Timestamps:

(00:00) - Introduction: Why This Episode Matters
(01:14) - The Book’s Relevance for Entrepreneurs and Investors
(02:36) - Author Spotlight: William Green’s Unique Perspective
(03:35) - Book Overview: Lessons Beyond Investing
(05:17) - Key Takeaway 1: Say No to Almost Everything
(10:39) - Key Takeaway 2: The Willingness to Be Lonely
(15:12) - Key Takeaway 3: Resilience Is the Ultimate Strength
(20:56) - Key Takeaway 4: Beware of Emotions and Ignorance
(25:41) - Key Takeaway 5: Think Long-Term and Embrace Change
(30:11) - Key Takeaway 6: Simplicity Is Strength
(34:59) - Key Takeaway 7: Success Is Built on Habits and Incremental Progress
(39:17) - Closing Insights and Final Reflections

Why Listen:

Master Resilience and Focus: Build a mindset that thrives during challenges.
Think Like a Legend: Apply strategies from iconic investors to your goals.
Navigate Uncertainty: Gain tools to adapt and succeed in volatile environments.
Actionable Insights: Practical coaching questions to reflect and grow immediately.

If these lessons resonate, I encourage you to explore

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

What does it take to lead a global biotech company tackling diseases like cancer and Alzheimer’s—and still treat every team member, from executives to production staff, as equals?

In this 20-minute highlight episode, we meet Philipp Baaske, the visionary CEO of NanoTemper. From his small Bavarian village roots to global biotech innovation, Philipp shares the leadership lessons and personal philosophies that shaped his journey.

Quotes:

(00:01:05) “Leadership is all about emotions. It’s not about you—it’s about your people. A leader is defined by their followers, and they follow because they trust and believe in you.”
(00:04:19) “Complaining is just an excuse not to work on what you can change. Focus on improving instead.”
(00:15:54) “Every month counts when fighting cancer. If we release a drug even one month earlier, we save lives.”

Curious for more? Listen to the full episode here and dive deeper into Philipp’s remarkable journey.

Timestamps:

(00:00:00) Welcome to Spark20: Innovating Leadership
(00:01:15) Top Leadership Lessons: Walk the Talk
(00:02:33) From Bavaria to Biotech Visionary
(00:06:01) Science Fiction & Physics: Philipp’s Inspiration
(00:12:50) Launching to Space with NASA
(00:16:00) Fighting Cancer: The Push for Better Tools
(00:19:20) Leadership Challenges: Tough Decisions

If you’re ready to discover actionable leadership insights, hear how innovation fuels impact, and learn why values truly matter in leadership, this is your episode. Dive into Philipp’s story, and don’t miss the chance to see how he turns bold visions into real-world breakthroughs.

Listen now and be inspired.

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Startups promise innovation, but why do so many fail to secure the funding they need?

Investors demand results before committing, yet startups require resources to build. This paradox leaves founders stuck in what angel investor DC Palter calls the "pit of hell." How can startups navigate this critical gap and convince investors to bet on their vision?

🎙️ What's in the Episode:
1️⃣ Cracking the Funding Code: Learn why most pitches fail and how founders can craft stories that eliminate investor doubts and inspire confidence.
2️⃣ The Angel Investor's Playbook: Discover how to manage long-term returns and why patience is critical in high-stakes investing.
3️⃣ The Climate Tech Challenge: Explore why building billion-dollar solutions demands more than innovation—it requires grit, strategy, and understanding the full business cycle.

👤 About DC Palter:
DC Palter is a seasoned venture investor, startup founder, and award-winning author. With 25 years of experience in tech, he bridges the worlds of business and storytelling. His expertise spans hard tech, climate tech, and helping startups succeed through mentorship, scrappiness, and vision.

💡 QUOTES:
(01:01:19) "The best pitches show why failure isn’t just unlikely—it’s impossible."

(01:44:59) "Batteries are the key to unlocking sustainable energy solutions."

(02:15:58) "The biggest challenge is investors want a finished product, but startups need funds to build."

(01:19:52) "The best solutions don’t sell themselves; they solve real problems customers feel deeply."

(01:16:48) "The CEO’s role isn’t just building products; it’s creating a sustainable business.

⏰ Timestamps:
(02:40) The Power of Storytelling in High-Stakes Business and Writing

(11:49) Bridging Science and Business: The Role of Mentorship

(17:31) Balancing Angel Investing and Flexibility

(20:42) Shifting from Corporate to Startup Mindset

(39:06) The Startup Funding "Pit of Hell"

(45:49) Why Founders Must Pitch a $100M Vision, Not Just a Great Product

(53:36) Crafting a Pitch Investors Can't Resist

(01:08:58) Understanding Hard Tech: Beyond Invention

(01:19:02) The Hard Work of Product-Market Fit

(01:42:44) Batteries: The Key to Renewable Energy

(02:05:44) The Global Privacy Paradox

(02:19:48) The Long Game of Angel Investing

If you’re ready to uncover the secrets of startup success, learn how to navigate hard tech challenges, and master the art of pitching, this episode is for you.

👀 Stay Tuned: Watch the full episode to discover the tools, strategies, and stories that can transform your approach to investing and entrepreneurship.

🔔 Subscribe, comment, and share to support the show and bring more transformative insights from leaders like DC Palter to light.

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Europe’s biotech sector is facing a crisis: despite its scientific achievements, it struggles with funding gaps and an exodus of top talent to the US. As biotech innovations drive global healthcare, Europe risks losing its edge—and the potential for groundbreaking medical advancements that affect us all. How can Europe regain its competitive advantage and transform scientific discoveries into real-world solutions?

In this special episode from BIO-Europe’s 30th anniversary in Stockholm, industry veterans Cormac Sheridan, Jonathan Smith, Christian Soschner, and Mike Ward reveal the path forward. They tackle the critical challenges in Europe’s biotech landscape, from funding shortfalls and talent loss to opportunities in AI and the promise of global partnerships. Discover the strategies that could redefine Europe’s role in biotech and keep innovation thriving on the continent.

🎙️ What’s Inside:

1️⃣ The Funding Dilemma: Why Europe’s investment landscape hinders biotech and how new models could change the game.
2️⃣ Talent Exodus: How the brain drain to the US is affecting Europe’s biotech ambitions and what it takes to retain top innovators.
3️⃣ AI in Biotech: Uncover the power of AI and digital tools in transforming drug development and patient care in Europe.
4️⃣ Global Collaboration Opportunities: Why Europe needs to shift its focus eastward and the potential of partnerships beyond US borders.

👤 Meet the Panelists:

Cormac Sheridan: A seasoned biotech journalist, covering industry trends for over two decades, who reminds us that biotech’s success is rooted in resilience: “Fail faster, fail better.”
Jonathan Smith: Biotech correspondent with insights into the complex regulatory and financial hurdles in Europe’s biotech ecosystem.
Christian Soschner: CEO and biotech advisor, who shares powerful strategies on funding, partnerships, and global competitiveness.
Mike Ward: Renowned analyst with a keen eye on market dynamics and investment trends shaping the future of biotech.
Millie Nelson: Panel Host

💡 QUOTES:

(05:18) "The future of biotech lies in integrating AI into medicine—beyond the hype." – Cormac Sheridan

(00:17:22) "Failure is embedded in biotech. It's a risk-based enterprise; success demands resilience." – Cormac Sheridan

(00:22:39) "and this brain drain when someone has a great idea that has..." - Christian Soschner

⏰ Timestamps:

(00:00) Meet the panelists - industry experts with decades of biotech insight
(07:15) Innovative funding paths and geopolitical impacts in biotech
(06:30) Navigating Global Investment Challenges
(00:16:07) Europe's biotech strength - powerful innovation, but struggles with commercializing scientific breakthroughs
(00:22:39) Brain drain in Europe - how US incentives pull top talent across the Atlantic
(00:29:06) Neuroscience breakthroughs - positive signs for neurodegenerative disease treatments spark new interest
(00:34:08) Europe’s opportunity - global collaboration could drive biotech growth beyond US partnerships

Join us

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Healthcare investment is booming, but why do so few initiatives actually deliver lasting impact? While funding flows into biotech and life sciences, many leaders overlook the complex strategies needed to bridge research and real-world application. Are you ready to discover the key to successful healthcare innovation and make informed decisions that truly drive change?

In this episode, Shlomo Noy, a pioneer in biotech investment and former VP of R&D at Sheba Medical Center, breaks down the secrets behind impactful investments in healthcare. From reshaping the DNA of institutions to aligning incentives for breakthrough results, Shlomo reveals the strategies that fuel successful innovation on a global scale.

🎙️ What’s Inside:

1️⃣ The Art of Incentives: Discover how to balance researcher motivations with long-term institutional gains for innovation that sticks.

2️⃣ Israel's "Silicon Wadi" Secret: Learn how Israel transformed its natural limitations into a biotech powerhouse—and what other regions can learn from this approach.

3️⃣ Opportunities in China's Healthcare Market: Shlomo shares his insights on the untapped potential of China's rapidly growing healthcare sector, including strategic entry points for Western companies.

👤 About Shlomo Noy:
With over 25 years of experience, Shlomo Noy has led R&D at one of the world’s top-ranked hospitals and spearheaded healthcare investments worldwide. His expertise in aligning financial, clinical, and technological insights offers a rare, multidimensional view on successful healthcare innovation.

💡 QUOTES:
(00:08:14) "In life sciences, bridging finance with clinical insight isn’t optional; it’s essential."
(00:29:39) "Transforming healthcare innovation requires reshaping the DNA of an entire organization."
(00:41:02) "Our natural resource isn’t oil or gas—it’s the innovative minds of our people."
(01:34:49) "China’s healthcare market is ready for innovation—and the opportunity is enormous."
(02:12:54) "In the next 5-10 years, China's focus on women's health will redefine global markets."

⏰ Timestamps:

(00:04:10) Shlomo Noy's Journey in Healthcare and Biotech Leadership
(00:07:38) Multidisciplinary Teams: A Key to Biotech Investment Success
(00:19:22) Protecting Researchers with In-House Tech Transfer Support
(00:29:39) Transforming Healthcare: Changing the DNA of Innovation
(00:38:36) Israel’s Silicon Wadi: The Biotech Innovation Boom
(00:48:35) How Incentives Drive Institutional Tech Transfer Success
(01:04:50) AI's Role in Drug Discovery and Patient Recruitment Challenges
(01:20:02) China’s Healthcare Market: Uncovering Growth Opportunities
(01:28:53) Clinical Trials in China: Scale and Efficiency Advantages
(01:37:00) How Biotech Companies Can Navigate China’s Clinical Trial Landscape
(01:53:03) Global Investment: Aligning Interests in Healthcare Innovation
(02:17:13) Key Takeaways: Managing Innovation and China’s Healthcare Market

If you’re ready to uncover the strategies behind impactful healthcare investments and explore new markets with confidence, this episode is packed with insights yo

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

What if you could rewire your thinking to solve life’s toughest problems? In this episode, we dive into Charlie Munger's timeless insights from Poor Charlie's Almanack, revealing 9 core principles for smarter investing, better decision-making, and a well-rounded life.

Munger’s success is rooted in clear, simple principles that help avoid pitfalls and achieve long-term results. Poor Charlie's Almanack offers a unique blend of investing strategies, life lessons, and mental models that have shaped Munger’s extraordinary career.

As an entrepreneur and investor, I’ve applied many of Munger’s lessons. In this episode, I break them down for you. From problem-solving through inversion to understanding cognitive biases, you’ll learn how to apply these principles to business and personal growth.

Whether you're a venture capitalist, founder, or looking to improve decision-making, this episode equips you with the tools to build a strong foundation for success.

Key Takeaways:

This episode covers 9 transformative principles, including:

Inversion Thinking: Simplify problems by thinking backward.
Mental Models: Integrate knowledge from various fields for better decisions.
Mastering Envy & Emotional Management: Develop resilience against destructive emotions.
Compound Interest: See how consistent improvements lead to exponential growth.
Biases and Cognitive Fallacies: Avoid common cognitive traps.
Character and Culture: Build strong culture for long-term success.
Munger’s Investment Checklist: Learn Munger’s method for picking winners.
How to Fail in Life: Munger’s humorous guide on what not to do.
Incentives in Organizations: Align incentives to avoid failure.

Though this episode offers an overview, Poor Charlie’s Almanack contains much more. It’s a must-read for those looking to deepen their knowledge on investing and life.

Timestamps:

(00:00) Introduction
(06:01) Portrait of Charlie Munger
(11:00) Overview of Poor Charlie’s Almanack
(18:21) Inversion Thinking
(24:35) Mental Models
(29:39) Ego and Emotional Management
(36:51) The Power of Compound Interest
(43:17) Biases and Cognitive Fallacies
(50:52) Character and Culture
(57:39) Munger’s Investment Checklist
(01:08:00) How to Fail in Life
(01:18:05) Incentives in Organizations
(01:25:28) Key Takeaways
(01:32:00) Reflection & Closing

Why Listen:

Master Problem-Solving: Learn how to simplify and solve complex problems using Munger’s inversion technique.
Build Long-Term Success: Apply the power of compound interest and strong character to your business or investments.
Avoid Common Pitfalls: Identify biases and cognitive traps that can derail decision-making.
Actionable Insights: Munger’s investment checklist and character-focused advice will help you make smarter business and life decisions.

If you’re interested in learning more, I encourage you to grab a copy of Poor Charlie’s Almanack. It’s a deep well of wisdom that can help you on your journey towa

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Artificial intelligence is revolutionizing healthcare, but what if the real danger lies in the industry's carbon footprint?

Despite healthcare’s purpose of saving lives, the industry contributes up to 10% of CO2 emissions in developed countries. Can patient care and sustainability go hand in hand, or are we risking the planet's health for human survival?

In this episode, Jordi Ferrer Rendé, Investment Director at Ship2B Ventures, reveals why healthcare's environmental impact is often overlooked and how intentional, impact-driven investing can reshape the future.

🎙️ What's in the Episode:

1️⃣ The Alarming Environmental Cost of Healthcare: Discover how healthcare contributes to CO2 emissions and what can be done to reduce them without compromising care.

2️⃣ Preventing Problems Before They Happen: Learn how shifting investments from treatment to prevention could transform patient care and healthcare sustainability.

3️⃣ Regulation vs. Consumer Demand: Understand why Jordi believes regulators, not just consumers, will drive the necessary changes for a more sustainable future in healthcare.

👤 About Jordi Ferrer Rendé:
Jordi Ferrer Rendé is the Investment Director at Ship2B Ventures, a European impact VC firm focused on transforming healthcare for chronic patients and the elderly. With over 12 years of experience, he is passionate about driving measurable social impact alongside financial returns, particularly in the areas of healthcare sustainability.

💡 QUOTES:

(00:21:39) "What if we invested in prevention rather than just treating diseases after they appear?"
(00:39:12) "What if we measured healthcare’s CO2 impact? We could reduce emissions without compromising care."
(00:56:21) "Consumers are pushing for change, but real sustainability will only come through regulation."
(01:07:18) "Europe has incredible science and scientists at a very efficient cost – this is a place with huge potential."
(01:53:04) "Success isn't just about ideas, it's about staying committed even through hard times."

⏰ Timestamps:
(00:04:00) Jordi Ferrer Rendé on the Power of Impact Investing in Healthcare
(00:21:12) How the Healthcare System Prioritizes Treatment Over Prevention: A Dangerous Imbalance
(00:37:30) The Alarming Truth: Healthcare’s Massive Contribution to CO2 Emissions
(00:38:18) CO2 Emissions in Healthcare: 10% Contribution to Climate Change
(00:56:21) Consumer Demand vs. Regulatory Power: The Future of Sustainability in Healthcare
(00:58:59) How Investors Can Catalyze Sustainability in Healthcare
(01:08:33) Europe as a Hub for Healthcare Innovation: Untapped Potential
(01:33:00) Purpose-Driven Teams: Why Belief in the Mission Ensures Long-Term Success
(01:43:06) Intentionality in Impact Investing: The Key to Understanding Founders and Their Purpose
(02:02:41) Essential Advice for Aspiring Healthcare Investors from Jordi Ferrer Rendé

If you’re ready to uncover the hidden environmental costs of healthcare and explore how impact investing can create a more sustainable future, this episode is a must-watch. Subscribe, comment, and share to help us bring more valuable insights from leaders like Jordi Ferrer Rendé.

👀 Stay Tuned: Watch the entire episode to discover how healthcare can be transformed by focusing on prevention, sustainability, and impactful investments.

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Artificial intelligence is heralded as the future of healthcare, but why do so many innovations fail to make a tangible impact?

Despite the hype, countless companies are missing critical opportunities to leverage AI effectively. What’s holding them back?

In this episode, Angeli Möller, CEO of Sequoia Growth, reveals why healthcare AI often falls short and what leaders must do to turn potential into reality.

🎙️ What's in the Episode:
1️⃣ The Real Barriers to AI in Healthcare: Explore why many organizations struggle to integrate AI into their core business, and how to overcome these challenges.

2️⃣ Unlocking True Innovation: Learn from Angeli’s experience at Bayer Pharma and Roche on why understanding the problem is the first step to meaningful solutions, not jumping on the latest tech trend.

3️⃣ Building High-Impact Teams: Discover the critical role of diverse, specialized teams in navigating complex healthcare landscapes and driving sustainable growth.

👤 About Angeli Möller:
Angeli Möller is the founder and CEO of Sequoia Growth, a consultancy dedicated to bridging the gap between AI innovation and practical healthcare applications. With a background that spans senior roles at Bayer Pharma and Thomson Reuters, she’s a thought leader at the intersection of data science and healthcare, advocating for AI solutions that truly improve patient outcomes.

💡 QUOTES:
(31:08) "Leadership is not about knowing every detail; it's about having vision and empowering others."
(55:31) “Success starts with choosing the right team—motivated, competent individuals who share your vision.”
(01:11:43) “For any company that doesn’t find a way to make the right tool part of its core business, they risk losing to competitors who will.”
(01:14:58) "The real bottleneck isn't the lack of algorithms or computing power; it's the lack of quality data."
(02:03:38) "Do you deeply understand the problem you're trying to solve? It goes beyond what customers tell you they need."

⏰ Timestamps:
(04:31) Industry Experience as a Foundation for Career Growth
(08:24) Embracing Berlin's Vibrant Culture and Innovative Spirit
(17:41) Leadership is About Vision and Strategy, Not Knowing Every Detail
(32:59) The Power of International Collaboration in Research
(38:34) Redefining Leadership: Embracing Caregiving and Global Impact
(50:15) Be Clear on Your Communication Style and Personal Boundaries
(01:03:07) Biotech's AI Revolution: From Skepticism to Clinical Success
(01:10:33) Beyond the Hype: AI's Practical Integration in Pharma
(01:19:35) The Interplay of Data and Intelligence
(02:02:46) Understanding Customer Needs is Key to Transforming Science into Impactful Solutions

If you’re ready to dive deep into the real challenges of healthcare innovation and learn how to harness AI’s potential, this episode is a must-watch. Subscribe, comment, and share to help us bring more insightful content from leaders like Angeli Möller.

👀 Stay Tuned: Watch the entire episode to uncover how companies can turn AI potential into impactful healthcare solutions and drive sustainable growth.

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Many companies today face increasing security challenges, yet few are leveraging the power of AI and robotics to protect their most critical assets. But what if these groundbreaking technologies could not only reduce costs but also provide a more efficient and secure future? In this episode, Alessandro Morra, CEO of Ascento, shares how AI-powered robotics are reshaping industries and why embracing this transformation is essential for future success.

🎙️ What's in the Episode:

1️⃣ AI & Robotics in Security: Discover how AI-driven robots are revolutionizing the way companies safeguard their outdoor properties, from manufacturing plants to data centers.

2️⃣ Overcoming Challenges: Learn how Alessandro Morra navigated unexpected obstacles and breakthroughs, including viral moments that helped Ascento achieve product-market fit.

3️⃣ The Future of Automation: Explore the next frontier of robotics and AI, and how these innovations will enable the workforce to focus on higher-value tasks.

👤 About Alessandro Morra:
Alessandro Morra is the visionary CEO of Ascento, a company specializing in AI-powered robotic guards designed to patrol large outdoor properties. His mission is to transform the security industry by leveraging the latest advances in robotics and AI to offer smarter, more efficient solutions to companies across sectors like manufacturing, energy, and luxury goods.

💡 QUOTES:
(41:01) "With robotics, we're just starting to scratch the surface of what's possible. "
(50:46) "We found a great problem for our overly engineered solution, and that changed everything."
(01:15:48) "We see robotics as a pivotal moment in innovation, and we're just getting started."
(01:20:16) "Fundraising is like building a company - you need a plan to be profitable."
(01:47:10) "We want to help the workforce of the future focus on what people do best."

⏰ Timestamps:

(10:10) From Zurich to Startup Success: Alessandro's Journey
(11:40) How Ascento robots were created
(29:28) How Robots Are Transforming Security and Reducing Costs
(41:19) Unlocking the Future of Security with Robotics and Data
(50:44) Viral videos: the unexpected boost that propelled Ascento forward
(51:50) From Viral Videos to Focused Solutions: Ascento's Journey to Product-Market Fit
(01:09:49) Expanding Beyond Borders: The Inevitability of Global Expansion
(01:16:34) Ascento's Vision: From Security to Predictive Maintenance
(01:27:01) "Fundraising is like dating - do your due diligence!"
(01:44:40) Will robotics revolutionize human tasks in the next decade? Morra's vision for Ascento's future

Books mentioned:
The Power Law
The Hard Things About Hard Things
Influence Cialdini
Meditations

If you’re ready to explore how AI and robotics are transforming industries and ensuring a safer future, this episode is a must-watch. Subscribe, comment, and share to help us grow the show and bring you more groundbreaking insights from leaders like Alessandro Morra.

👀 Stay Tuned:
Watch the entire episode to discover how robotics can unlock new efficiencies and opportunities in security and beyond.

Send us a text

Support the show

Join the Podcast Newsletter: Link

Influence, New and Expanded: The Psychology of Persuasion

The Hard Thing About Hard Things: Building a Business When There Are No Easy Answers

The Power Law: Venture Capital and the Making of the New Future

View Details

What’s the secret to building a trillion-dollar company from scratch? In this episode, we uncover Jeff Bezos' game-changing strategies from Invent and Wander, revealing how Amazon became a global powerhouse.

In the world of business and investing, visionary ideas alone are not enough. Invent and Wander reveals that it's a relentless focus on long-term thinking, innovation, and customer needs that differentiates industry leaders from the rest.

Throughout my career, I’ve learned that building a company is not just about executing on today's goals—it's about building toward the future. Drawing on my experience as an entrepreneur and investor, I’ll break down the key lessons from Amazon’s journey to help you understand what it takes to create a business that thrives in the long term.

This episode dissects 10 powerful principles from the book, offering insights into leadership, innovation, and decision-making. From leveraging technology to solve real customer problems to the art of long-term planning, we’ll uncover how you can apply these principles to your own ventures and investments.

Book on Amazon:

[Link to Amazon]

Problems This Solves:

Overwhelmed by complex business strategies? This episode simplifies Bezos' core principles into actionable insights.
Unsure how to build a long-term vision? We’ll provide real-world examples and strategies for future-proofing your business.
Curious how Amazon fosters continuous innovation? Learn how to stay ahead of the competition by focusing on what truly matters.

Why Listen:

Discover the 10 Key Principles for Success: Understand the strategies that turned Amazon into a global powerhouse.
Learn from Real-World Case Studies: Explore examples like the Kindle and Alexa to see these principles in action.
Apply Bezos' Insights to Your Own Journey: Gain practical takeaways to foster long-term innovation and resilience in your business.

Quotes:

"We will continue to make investment decisions in light of long-term market leadership considerations."
"Listen to customers, but don’t just listen to customers—also invent on their behalf."
"What’s good for customers is good for shareholders."

Timestamps:

(00:00) Introduction to the Episode – Tl;DR 1
(03:49) Who is Jeff Bezos? – Tl;DR 2
(09:52) Overview of the Book – Tl;DR 3
(14:44) The Essential Character Traits of Founders
(21:57) The Regret Minimization Framework and Goal-Oriented Planning
(28:57) The Five Principles Behind Amazon's Success
(37:16) Using Technology to Solve Customer Needs
(42:55) Timeless Hiring Principles from the 1998 Letter
(51:15) Embracing Moore's Law to Build Toward the Future
(58:31) What Is Good for Customers Is Good for Shareholders
(01:05:03) Constantly Investing in New Things with Clear Market Goals
(01:11:45) The Kindle Case Study - Innovating by Working Backwards from Customer Needs
(01:18:47) Listen to Customers, But Invent for Them

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Many European startups are trapped in a mindset that limits their potential, aiming for millions when they should be thinking in billions. But what if this conservative approach is holding them back from global success? In this episode, Marc Penkala, a leading venture capitalist, reveals the secrets to breaking free from this limiting mindset and how embracing calculated risks can lead to extraordinary rewards.

🎙️ What's in the Episode:

1️⃣ Mindset Shift: Learn why European startups need to aim higher and adopt the billion-dollar mindset that drives U.S. success.

2️⃣ Contrarian Strategies: Discover the power of going against the grain in venture capital—why the best deals often come from the least obvious places.

3️⃣ The Role of Failure: Understand how embracing failure as a crucial learning tool can pave the way for long-term success in both entrepreneurship and investing.

👤 About Marc Penkala: Marc Penkala is the driving force behind Altitude Venture, Europe’s first SME Tech Fund. With a wealth of experience as both an entrepreneur and investor, Marc is on a mission to revolutionize the European startup ecosystem by challenging traditional norms and pushing for bigger, bolder ambitions.

💡 QUOTES:

(01:13:14) "European startups think in millions, while U.S. startups think in billions—think bigger."

(01:19:01) "In Europe, we focus on what could go wrong; in the U.S., they focus on what could go right."

(01:40:50) "The best companies are created in down markets where money is scarce, and innovation thrives."

(01:07:48) "The more often you're wrong, the higher the actual output of your fund."

(00:43:34) "When the tourists arrive, you should leave."

⏰ Timestamps:

(00:07:05) Lessons from Early Entrepreneurial Ventures

(00:14:31) The Reality of Entrepreneurship: Embracing Failure and Persistence

(00:19:26) The Tough Decisions in Venture Capital: Investing vs. Divesting

(00:26:30) Building Relationships: The Key to Successful Fundraising

(00:34:30) Unveiling the Full Picture: The Business of Guiding Emerging Funds

(00:39:03) Choosing the Right People to Journey With

(00:43:08) Timing is Everything: The Importance of Market Dynamics in VC

(00:43:34) The "Tourists" in Venture Capital: Recognizing Market Exuberance

(00:51:26) The Untapped Potential of the SME Tech Market

(00:53:32) Fundraising in a Down Market: The Power of Relationships

(01:03:33) Is Europe Ready for Mega Funds or Better Suited for Micro Funds?

(01:13:13) Think Bigger: The Difference Between US and European Startup Mentalities

(01:21:35) Risk Aversion: The Key Difference Between European and US VC

(01:31:37) Fostering European Innovation: Overcoming Challenges and Seizing Opportunities

(01:38:10) The Importance of a Long-Term Vision in Venture Capital

If you're ready to rethink your approach to startups and venture capital, this episode is a must-watch. Subscribe, comment, and share to help us bring more insightful content to you for free.

👀 Stay Tuned:

Watch the entire episode to unlock the strategies that could transform your startup's trajectory and help you achieve extraordinary success.

Send us a text

Support the show

Join the Podcast Newsletter: Link

View Details

Ever wondered what it takes to build a tech giant from the ground up? Is it just about having a great idea, or is there a secret formula for success? In this episode, we dive into Jimmy Soni's The Founders, uncovering the key principles that propelled PayPal from a fledgling startup to a cornerstone of the digital economy.

In the world of investing and entrepreneurship, having a visionary idea is just the beginning. "The Founders" reveals that it’s the combination of vision, timing, and an unrelenting focus on execution that separates successful companies from the rest.

Throughout my career, I’ve learned that building a business is like solving a complex puzzle. Each piece—whether it’s hiring the right people, navigating market challenges, or building a sustainable business model—needs to fit perfectly. Drawing on my experience as an entrepreneur and investor, I’ll break down the stories and strategies from PayPal’s early days to help you understand what it really takes to create a company that lasts.

This episode dissects 10 crucial lessons from the book, each one offering valuable insights into leadership, innovation, and resilience. From taking calculated risks and building trust, to the power of culture and strategic partnerships, we’ll explore how these principles can help you build a winning team and a sustainable business.

Book on Amazon

[Link to Amazon]

Problems This Solves:

Overwhelmed by the sheer volume of business books? This concise summary delivers the most impactful lessons from "The Founders."
Unsure how to translate entrepreneurial principles into action? We'll provide actionable takeaways and reflection questions to guide your journey.
Curious about the minds behind PayPal and its lasting impact? Gain insights into the challenges, strategies, and collaborative spirit that fueled their success.

Why Listen:

Discover the 10 Lessons for Success: Uncover the strategies that turned PayPal into a tech powerhouse.
Learn from Real-World Examples: Hear stories from the book and my own experiences that illustrate these principles in action.
Apply the Lessons to Your Own Ventures: Reflect on how you can foster innovation and build a resilient business.

Quotes:

“On the eve of its IPO, a prominent trade publication declared that the country needed PayPal ‘as much as it does an anthrax epidemic.’”
“Properly understood, PayPal’s story is a four-year odyssey of near-failure followed by near-failure.”
"PayPal started off as a product with no use case. Then we had a use case but no business model. Then we had to build a sustainable business."
"Your life will be shaped by the things you create, and the people you make them with."

Timestamps:

(00:00) Intro

(03:03) Jimmy Soni

(06:28) Overview of the Book

(10:42) Vision, Persistence, and Hiring the Right People

(17:08) Elon Musk's Bold Moves: Risk and Reward

(23:07) Peter Thiel's Contrarian Thinking: Market and Monopoly

(30:20) Max Levchin’s Obsession with Security: Building Trust

(35:36) PayPal's Viral Growth: User-Centric Design

(41:54) Surviving the eBay Wars: Strategic Partnerships

(48:10) The IPO and Beyond: Timing and Execution

(54:00) The Role of Culture: From Chaos to Cohesion

(59:42) PayPal Mafia: Legacy and Impact

(01:05:30) Entrepreneurship Challenges: Navigating Uncertainty

(01:11:12) Wrap-Up and Key Takeaways

Send us a Text Message.

Support the Show.

Join the Podcast Newsletter: Link

View Details

Did you know the secret to venture success isn't just in groundbreaking ideas? It's in the people behind them. Learn how empathy and grit fuel extraordinary success in this insightful episode. Many investors fail by only chasing ideas.

Discover why focusing on the right founders can unlock revolutionary outcomes.

Join us as Hampus Jakobsson reveals how empathy and grit are the true drivers of innovation and success. Most investors miss out on potential unicorns by focusing only on concepts. What if the real key to revolutionary success lies in the unique qualities of the founders?

🎙️ What's in the Episode:

1️⃣ Empathy and Grit: Learn why these traits are essential for founders aiming to make a significant impact.

2️⃣ Market Understanding: Understand the importance of having a clear vision for the future and how it influences investment decisions.

3️⃣ Investing in Resilience: Discover why Hampus Jakobsson focuses on people who are not just smart, but incredibly resilient and unconventional.

👤 About Hampus Jakobsson:

Hampus Jakobsson is the co-founder of Pale Blue Dot, a venture capital fund focused on climate tech innovation. He believes that the future belongs to those who think differently and have the resilience to turn their unconventional ideas into reality.

💡 LINKS TO MORE CONTENT Christian Soschner

💡 Quotes:

(09:58) "Reading fiction builds empathy, allowing us to experience the world through others' eyes."
(28:45) "Any time in life I've been the smartest person in the room, I usually try to find other rooms."
(00:57:35) "The mobile industry missed innovation due to medieval-like alliances and rigid structures."
(01:03:01) "Innovators and entrepreneurs drive progress; managers often stifle it by prioritizing efficiency."
(01:50:49) "The greatest founders combine empathy and grit to navigate the toughest challenges."

⏰ Timestamps:

(02:00) Mastering Multiple Accents and Languages
(07:00) The Power of Fiction and Top Podcast
(09:49) Building empathy through fiction's diverse perspectives
(11:27) Imagining the future: mind uploading and lunar economy
(17:53) Authenticity vs. Performance: The Inner vs. Outer Self
(21:39) Bitcoin: A Catalyst for Metaphysical Conversations about Value
(27:02) Explore vs. Exploit: Balancing Algorithmic Strategies for Growth
(30:57) The Burning Library: Empathy and the Destruction of Knowledge
(38:15) The Turning Point: From Arts to Mobile Technology
(40:44) "The Birth of the Business Card: A Humorous Tale of Entrepreneurial Resourcefulness"
(43:46) Landing a Major Client by Chance
(52:44) Samsung's Speed to Market Philosophy: Thriving in a Fast-Paced Tech Environment
(53:41) Competing Giants: Motorola, Samsung, Sony Ericsson, and Nokia's Battle for Supremacy
(57:35) Market Saturation and Innovation: What the Mobile Industry Missed
(01:03:00) Steve Jobs' Philosophy: Wasting Time in a Great Way
(01:09:07) Apple vs. Google: Contrasting Paths to Innovation
(01:12:00) Pride and Passion: The Secret Sauce of Successful Companies
(01:16:00) Building Trust and Relationships: A Venture Capitalist's Perspective
(01:19:01) Finding the Right Founder-Investor Relationship
(01:20:08) Investing in the Extraordinary
(01:28:00) Investing in extraordinary people and their unconventional visions
(01:36:00) The drive to win is essential for great entrepreneurs
(01:28:

Send us a Text Message.

Support the Show.

Join the Podcast Newsletter: Link

View Details

Discover how Dan Brisse, a former X Games gold medalist, transformed his passion for snowboarding into a thriving real estate empire. In this episode of [Podcast Name], we delve deep into Dan's journey, exploring the resilience, focus, and determination that propelled him from professional sports to building Granite Towers Equity Group.

🎙️ What's in the Episode:
1️⃣ The Power of Resilience: Learn how Dan's sports background instilled a never-give-up attitude, crucial for navigating the ups and downs of real estate investing.
2️⃣ Focus and Determination: Discover the importance of unwavering focus and determination in achieving success, whether in sports or business.
3️⃣ Passion-Driven Success: Understand how Dan leveraged his passion for snowboarding to fuel his entrepreneurial journey, turning challenges into opportunities.

👨‍💼 About Dan Brisse: Dan Brisse is a former professional snowboarder and X Games gold medalist who transitioned into real estate investment. As the co-founder of Granite Towers Equity Group, Dan now focuses on multifamily investments and creating sustainable income streams for investors.

💡 LINKS TO MORE CONTENT Christian Soschner

📌 Quotes:
(00:04:15) "Creating multiple income streams through real estate transforms challenges into opportunities."
(00:28:07) "Certainty comes from thousands of reps; it's like walking, not a leap of faith."
(00:37:08) "Commitment means doing what's necessary without backing down, even when facing major setbacks."
(01:06:32) "To win the game of business, you need to know and play by the rules."
(01:36:55) "As long as we can get through the next six months with cash flow, we'll thrive."

⏰ Timestamps:
(00:01:00) Discover the Secrets of Multifamily Investment Success
(00:06:00) Insights on Inflation, Interest Rates, and Real Estate
(00:12:02) From Passion to Profession: Dan's Snowboarding Journey
(00:18:13) Hard Work and Dedication: Life of a Pro Snowboarder
(00:21:11) "Overcoming Limits: The Reality of Top-Tier Snowboarding"
(00:27:00) "Balancing Risk and Family: A Professional Snowboarder's Journey" (00:31:33) The Importance of Starting Early in Competitive Sports
(00:35:08) Overcoming Major Setbacks to Achieve Success
(00:43:15) The Importance of Defining Success for Goal Achievement
(00:49:38) True Passion vs. Novelty: Differentiating Between Real and Fleeting Interest (00:52:09) Overcoming Boredom by Setting New Goals
(00:56:12) Transitioning from Snowboarding to Real Estate Investing
(01:06:11) Embracing Freedom in Real Estate Investment
(01:12:19) The Importance of Education and Confidence in Investing
(01:18:23) Real Estate Investment Strategy for Passive Income and Investor Partnership
(01:23:11) Challenges and Lessons from Real Estate Investments During Volatile Markets
(01:30:57) Understanding Real Estate Emotions and Market Reactions
(01:36:32) Securing Cash Flow and Riding Market Cycles
(01:44:28) The Discipline of Saying No in Investing (01:45:47) Learning from Pain: The Path to Successful Investing

📣 Call to Action: If you’re inspired by Dan Brisse's journey and want to learn how to harness resilience, focus, and determination for your own success, this episode is for you. Subscribe, leave a comment, and share this podcast. Your support helps us bring more insightful content to you for free.

👀 Stay Tuned: Watch the entire episode to uncover the full depth of Dan Bris

Send us a Text Message.

Support the Show.

Join the Podcast Newsletter: Link

View Details

Ever wondered how the digital revolution came to be? Was it the work of lone geniuses, or was there something more at play? In this episode, we delve into Walter Isaacson's "The Innovators," uncovering the collaborative efforts and key principles that have shaped our technological landscape.

In the world of investing and entrepreneurship, building a multidisciplinary mental model is key to success. "The Innovators" reveals that diverse, collaborative teams have historically been the driving force behind groundbreaking solutions.

In my martial arts days, a coach taught me to study exceptional role models – a strategy akin to the famous Harvard Business Cases. Analyze success, discover core principles, then adapt them to your own unique path. After all, as Bruce Lee said, "Absorb what is useful, reject what is useless, and add what is essentially your own."

That's the lens I bring to biographies – extracting valuable lessons amidst the complexities of each individual story.

This episode dissects 10 crucial tools for fostering innovation, drawing on stories from the book and my own experiences as an entrepreneur and investor. From visionary thinking and customer-centricity to the power of persistence and collaboration, we'll explore the strategies that can help you identify winning teams and create an environment where innovation thrives.

Book on Amazon

[Link to Amazon]

Problems This Solves:

Overwhelmed by history books? This concise summary delivers the most relevant insights for entrepreneurs and investors.
Unsure how to apply innovation principles? We'll provide actionable takeaways and reflection questions.
Curious about the minds behind the digital age? Gain insights into the collaborative spirit that drives technological progress.

Why Listen:

Discover the 10 tools for innovation: Uncover the strategies that have fueled successful collaborations and groundbreaking technologies.
Learn from real-world examples: Hear stories from the book and my own experiences that illustrate these principles in action.
Apply the lessons to your own ventures: Reflect on how you can foster innovation and build winning teams in your own organization.

Quotes:

"Creativity is a collaborative process. Innovation comes from teams more often than from the lightbulb moments of lone geniuses." - Walter Isaacson
"The best way to predict the future is to invent it." - Alan Kay (as quoted in "The Innovators")

Timestamps:

(00:00) Intro

(04:18) Walter Isaacson

(08:21) Overview of the Book

(12:28) Tool #1: Ada Lovelace and the Power of Visionary Thinking

(18:01) Tool #2: Collaborative Teamwork

(23:13) Tool #3: Craftsmanship

(29:00) Tool #4: The Entrepreneurial Spirit and Culture of Innovation

(35:32) Tool #5: Leadership that Breeds Innovation

(42:13) Tool #6: Persistent Innovation

(47:19) Tool #7: Public Awareness and Advocacy

(53:48) Tool #8: Customer Centricity

(58:51) Tool #9: Technicians Collaborating with Business People

(01:03:20) Tool #10: Building Collaborative Ecosystems

(01:07:55) Key Takeaways

(01:14:00) Tl;dr Episode Summary

Send us a Text Message.

Support the Show.

Join the Podcast Newsletter: Link

View Details

🚀 Discover the Secret Sauce Behind California’s Biotech Success with Joe Panetta

Unlock the keys to California’s biotech boom as we delve into the insights of Joe Panetta, President and CEO of Biocom California. In this episode, we explore the unique factors that have made California a global leader in biotech innovation. Whether you’re a CEO, investor, or biotech enthusiast, this episode offers invaluable lessons and strategies.

🎙️ What's in the Episode:

1️⃣ Convergence of Science and AI: Learn how the integration of advanced technologies is revolutionizing biotech.

2️⃣ Risk-Taking Culture: Understand the cultural elements that drive California’s unparalleled biotech success.

3️⃣ Strategic Global Collaborations: Discover how international partnerships are shaping the future of biotech in California.

👨‍💼 About Joe Panetta:

Joe Panetta is a pivotal figure in the biotech industry, leading Biocom California, which represents over 1,800 members. With decades of experience, Joe provides a deep dive into the strategies and innovations that have positioned California at the forefront of biotech.

💡 LINKS TO MORE CONTENT

Host: Christian Soschner

📌 Quotes:

(00:08:28) "We're on the verge of an era where science and AI converge for better results."

(00:26:14) "California's secret sauce is its culture of risk-taking and pursuit of great rewards."

(00:29:34) "An open market for pricing and selling drugs attracts biotech innovators to the U.S."

(00:46:10) "Companies will seek secure alternatives for manufacturing and research, not solely depend on China."

(00:57:42) Joe Panetta: "It's a shame our governor's office offers no support to the biotech industry."

⏰ Timestamps:

(00:02:00) Insights from BIO 2022: Key Takeaways and Future Trends

(00:08:00) Convergence in Biotech: Merging Technologies and Global Collaboration

(00:15:36) Expanding Biocom's Influence: From Local to National Impact

(00:21:23) Global Partnerships: California's Strategy for International Biotech Collaboration

(00:26:14) California's culture of risk-taking: The secret sauce for biotech success

(00:32:08) Embracing failure: The key to thriving in California's biotech ecosystem

(00:42:40) California Dreamin': The Importance of a California Office for Biotech Companies

(00:47:25) The Changing Face of Bio: New Technologies and Global Partnerships at the Forefront

(00:55:27) Building Bridges: Governor Schwarzenegger's Biotech Legacy

(00:59:38) Collaborative Catalyst: Government's Role in Biotech Advancement

Send us a Text Message.

Support the Show.

Join the Podcast Newsletter: Link

View Details

Send us a Text Message.

Are you ready to discover the secret behind successful investments? Join us as we delve into the mind of Luis Pareras, a venture capital expert, as he reveals the critical investment principle many founders overlook.

🚀 What if the key to successful investments isn't just about having a solution, but finding the right problem to solve?

🎙️ In this Clip:
1️⃣ Learn why identifying and solving big problems is essential for investment success.
2️⃣ Discover the value of elegant solutions with strong biological rationale.
3️⃣ Understand how tackling underlying issues leads to impactful and profitable investments.

👨‍💼 About Luis Pareras: Luis Pareras is a seasoned venture capitalist with a deep understanding of biotech and innovation. His approach focuses on investing in companies that address significant issues with groundbreaking solutions.

📈 Why Watch: Whether you're an investor or an entrepreneur, this clip offers valuable insights into how focusing on the right problems can transform your investment strategy.

👍 Call to Action: Don't miss out on these essential investment tips! Watch the full clip, like, comment, and share to spread the knowledge. Subscribe for more insights and stay ahead in the world of venture capital.

🔗 Links to More Content:

Watch the full episode on YouTube
Listen to the podcast on Buzzsprout

Support the Show.

Join the Podcast Newsletter: Link

View Details

Send us a Text Message.

Imagine spending a decade of your childhood adrift at sea, facing shipwreck and isolation. Could you turn that adversity into a springboard for a remarkable career?

Suzanne Heywood, COO of Exor and author of the captivating memoir "Wavewalker," did just that. In this episode, we unpack her incredible journey from a life of hardship to leading a global investment firm.

Uncover the secrets to:

1️⃣ Resilience: Learn how to harness adversity as fuel for personal and professional growth.

2️⃣ Unconventional Thinking: Discover the power of challenging the status quo and forging your own path.

3️⃣ Transformative Education: Understand how education can break barriers and unlock your full potential.

Suzanne's story is a testament to the human spirit's ability to thrive, even in the face of immense challenges.

Join us to explore her unique insights on:

How education changed her life and opened doors to new opportunities.
Strategies for overcoming self-doubt and embracing your individual strengths.
The power of determination and consistent effort, even in small increments.

Suzanne's story is a beacon of hope for anyone who has ever faced adversity. It's a reminder that your past doesn't have to define your future.

Watch the full episode now and be inspired to rewrite your own story. Don't forget to like, comment, and share this video with anyone who could use a dose of inspiration. Your support helps us bring you more incredible stories like Suzanne's.

💡 LINKS TO MORE CONTENT

Host: Christian Soschner

Book: Wavewalker

📌 Quotes:

(00:15:10) "Wavewalker is the story of a seven-year-old girl trapped on a boat for ten years."
(00:31:04) "Getting into Oxford completely changed my life; it was an incredible turning point."
(00:39:03) "When told not to do something, I often go and do it anyway."
(00:44:24) "Unusual people with unusual experiences can open doors that most people wouldn't imagine."
(00:56:59) "Most people...will either encounter something bad or they will know somebody who's encountered something bad."

⏰ Timestamps:

(00:06:38) A Life of Contrast: From Shipwreck to Boardroom
(00:11:42) Innovation in the Startup World: Fresh Eyes and Customer Focus
(00:15:30) Confronting the Past: The Emotional Journey of Writing a Memoir
(00:19:27) Crafting a Story: The Art and Efficiency of Writing
(00:21:28) The Transformative Power of Education: Changing Lives Through Learning
(00:27:31) Gendered Expectations: Cooking and Cleaning on the Boat
(00:30:20) Abandoned in New Zealand: A Year of Isolation and Survival
(00:48:43) Resilience: Overcoming Adversity and Staying Calm
(00:50:47) Unconstrained by Expectations: Embracing Unconventional Paths
(00:51:47) Finding Time: Writing a Book in 15 Minutes a Day
(00:58:55) Putting Problems in Perspective: Overcoming Challenges with Resilience
(01:10:29) The Temptation of Excess: Navigating Sudden Wealth
(01:13:30) Lifestyle Inflation: The Dangers of Upgrading Your Life
(01:16:51) Technology and the Future of Education
(01:27:13) Recognizing and Overcoming Unconscious Bias
(01:30:19) Unmasking Bias: The Perils of Assumptions
(01:39:06) Not a Popularity Contest: Leading with Difficult Questions
(01:47:30) Iveco Group and Metallica: An Unexpected Collaboration
(01:50:42) A New Book: Extreme Childhoods and Their Outcomes

Support the Show.

Join the Podcast Newsletter: Link

View Details

Send us a Text Message.

Ever wondered how Jeff Bezos transformed a humble online bookstore into the global powerhouse that is Amazon? This biography summary by Influential Individuals uncovers the core principles that propelled Bezos to become the world's richest person.

That's the lens I bring to biographies – extracting valuable lessons amidst the complexities of each individual story. T

This episode is dedicated to dissecting the life and lessons of Jeff Bezos. We'll dive into his childhood curiosity, his relentless drive, and the unconventional strategies that led to Amazon's meteoric rise. We'll also explore his venture into space exploration with Blue Origin, showcasing his unwavering belief in the power of innovation.

Book on Amazon

Problems This Solves:

Feeling overwhelmed by lengthy biographies? This concise summary delivers the key takeaways in a fraction of the time.
Unsure how to apply entrepreneurial principles to your own business? We'll provide actionable insights and reflection questions to guide your thinking.
Curious about the mindset of a billionaire entrepreneur? Gain a deeper understanding of Bezos's thought processes and decision-making strategies.

Why Listen:

Get the inside scoop: Explore Bezos's childhood, his early career, and the challenges he faced in building Amazon.
Discover his core principles: Uncover the ten key principles that have shaped Bezos's success, from embracing failure to thinking long-term.
Apply the lessons: Reflect on how you can implement these principles in your own entrepreneurial journey.

Quotes:

"If you double the number of experiments you do per year you're going to double your inventiveness" – Jeff Bezos (p. 5)
"From the very start, Bezos was more concerned about getting a huge market share, even if that came at the expense of profits" – Influential Individuals (p. 25)
"In the beginner's mind there are many possibilities, but in the expert's mind there are few." - Shunryū Suzuki

Timestamps:(00:00) Introduction Jeff Bezos

(03:15) The Life of Jeff Bezos

(11:05) #1: Regret Minimization Framework

(16:45) #2: Surround yourself with the right people

(21:00) #3: Think Long-Term and Take One Step at a Time

(26:00) #4: Embrace a Failure Culture

(31:15) #5: Pivot When You Get Data Pointing in a Different Direction

(34:20) #6: Keep Your Vision

(38:55) #7: Possess a Beginner’s Mind

(45:25) #8: Forever Evolve

(48:55) #9: Make Your Own Rules – 6-Page-Method

(54:00) #10: Follow the 2 Pizza Rule+

(58:00) Tl;Dr Episode Summary

Support the Show.

Join the Podcast Newsletter: Link

Jeff Bezos: The Life, Lessons & Rules For Success

View Details

Send us a Text Message.

Unlock the secrets of future-proof investing and transformative innovation in this compelling episode. Join us as we delve into the mind of Luis Pareras, Managing Partner at Invivo Partners, a venture capital fund pioneering investments in cutting-edge biotech. Discover how to navigate the rapidly evolving landscape of science and technology to drive meaningful change and unparalleled success.

🎙️ What's in the Episode:

1️⃣ Ethical Decision-Making in Venture Capital: Learn how to balance profit and ethics in investment decisions.
2️⃣ The Power of Contrarian Thinking: Luis Pareras explains why going against the tide can lead to groundbreaking innovation.
3️⃣ Transforming Ideas into Reality: Discover the importance of execution over mere conceptualization.
4️⃣ AI's Role in Biotech: Explore the future of artificial intelligence in revolutionizing biotech and healthcare.
5️⃣ Managing Human Factors: Understand why interpersonal dynamics are crucial in overcoming challenges within companies.

👨‍💼 About Luis Pareras:Luis Pareras is a visionary venture capitalist with a rich background in neurosurgery and neuroscience. As the founder and managing partner at Invivo Partners, he has a stellar track record in investing and guiding biotech companies towards success. Luis is also an accomplished author, artist and educator, sharing his expertise in innovation and future-thinking.

🎥 Watch this episode to gain unparalleled insights into the future of biotech and venture capital. Luis Pareras' unique perspective is essential for CEOs, investors, and anyone intrigued by the intersection of science and entrepreneurship.

💡 LINKS TO MORE CONTENTHost: Christian Soschner
Book Fast Forward Thinking

📌 Quotes:

(03:18) "The ability to sustain two opposing ideas in your mind and debate with yourself is a very important quality."
(19:12) "Art serves as an emotional outlet and helps me mentally detach from daily challenges."
(28:23) "True innovation often feels uncomfortable and uncertain at first."
(43:17) "Ideas are worth nothing; execution is everything in bringing them to life."
(01:57:33) "AI is going to be the major change, and everyone is at risk here."

⏰ Timestamps:

(00:03:43) Ethical Decision-Making in Venture Capital
(00:05:14) The Value of Contrarian Thinking
(00:16:21) Exploring the Intersection of Technology and Ethics
(00:18:17) The Future of Leadership in a Digitally Connected World
(00:21:52) Art as a Mental Equalizer
(00:31:03) The Discomfort of True Innovation
(00:40:47) Synthetic Biology and AI in Biotech
(00:45:55) Ideas are worth nothing without execution
(00:54:56) Choosing Problems to Solve Over Companies
(00:58:46) Contrarian thinking and its role in successful investments
(01:06:54) Transforming scientific

How to Start a Podcast Guide: The Complete Guide
Learn how to plan, record, and launch your podcast with this illustrated guide.
Make More with Matt Heslin
Explore strategies to thrive financially, build legacy, and enhance life experiences.
Listen on: Apple Podcasts Spotify

Support the Show.

Join the Podcast Newsletter: Link

View Details

What if there was a funding source that could supercharge your startup's growth without diluting your equity? It's not a pipe dream. It's venture debt – a powerful tool that many founders and investors haven't fully explored.

In this episode, we channel the spirit of learning from industry leaders, just as in the famous Harvard Business Cases. We dissect innovative financing strategies, focusing on venture debt – a secret weapon for companies looking to scale without sacrificing ownership.

We're joined by Gergely Krajcsi, a Senior Investment Officer at the European Investment Bank (EIB), Europe's leading provider of venture debt.

He'll reveal:

The hidden benefits of venture debt that 90% of startups are missing
How EIB's tailored solutions can supercharge your company's trajectory
Real-world success stories of European innovators fueled by venture debt

If you're a CEO or investor seeking a competitive edge, this episode is your blueprint. Uncover the funding strategy that could be the key to your next breakthrough.

Problems This Solves:

Funding Gap: Learn how to bridge the gap between venture capital rounds and unlock the capital you need to scale.
Equity Dilution: Discover how to fuel growth without sacrificing ownership in your company.
Limited Knowledge: Gain insider knowledge from the EIB's expert on the untapped potential of venture debt.

Why Watch:

Expert Insights: Get actionable advice directly from a leading venture debt provider.
Success Stories: See how other startups have used venture debt to achieve remarkable results.
Strategic Advantage: Gain a competitive edge by understanding this underutilized financing tool.

Key Quotes:

"Venture debt is a game-changer for startups looking to accelerate growth." - Gergely Krajcsi
"The EIB is committed to supporting European innovation through tailored financing solutions." - Gergely Krajcsi

Timestamps:

00:00 - Intro

01:30 - What is Venture Debt?

05:45 - Benefits for Founders

09:20 - Benefits for VCs

13:15 - Tailored Solutions

17:00 - The EIB's Unique Role

22:30 - Case Study: Successful European Company

28:00 - Q&A

35:00 - Closing Remarks

How to Start a Podcast Guide: The Complete Guide
Learn how to plan, record, and launch your podcast with this illustrated guide.
Support the Show.

Join the Podcast Newsletter: Link

View Details

Ever wondered what drives Elon Musk, the world's most controversial innovator?

This biography summary by Walter Isaacson dives into the complex mind of the man behind rockets, EVs, and the Twitter takeover.

That's the lens I bring to biographies – extracting valuable lessons amidst the complexities of each individual story. This time, we're dissecting Elon Musk. Walter Isaacson's fascinating book reveals the controversial genius behind Tesla, SpaceX, and his Twitter takeover.

Ever wondered what drives the world's most disruptive innovator?

Discover the secrets of Musk's ambition, his unconventional leadership, and the price of disrupting the status quo.

Booklink at Amazon

Problems This Solves:

Feeling hesitant to take bold steps? Learn how Musk's embrace of risk fuels his extraordinary achievements.
Confused by his leadership tactics? Understand Musk's controversial style and question if it's the only path to world-changing innovation.
Unsure how to navigate ambition vs. ethics? Reflect on Musk's legacy and grapple with the genius vs. villain debate.

Why Listen:

Get the inside scoop. Explore Musk's childhood, his relentless drive, and the controversies he sparks.
Question the nature of leadership. Discover if Musk's methods are the future of industry disruption.
Challenge your own worldview. Decide where you stand on Elon Musk – visionary, ruthless, or something far more complex.

Quotes:

"I need to shift my mindset away from being in crisis mode, which it has been for about fourteen years now" - Elon Musk
"Could he have been more chill and still be the one launching us toward Mars and an electric-vehicle future?" - Walter Isaacson

Timestamps:(00:00) Intro to Elon Musk
(03:10) Who is Walter Isaacson?
(05:02) TLDR: Overview Biography Elon Musk by Walter Isaacson
(07:30) Method and Focus of this Episode: Entrepreneurship and Investing Lessons Learned
(09:30) Part 1: Childhood in South Africa – (P1-40)
(15:30) Part 2: Starting With Nothing, Building an Empire (p 41 – 60)
(19:00) Part 3: Early Ventures, Hard Lessons (p 60-82)
(25:45) Part 4: Reaching for the Stars – Disrupting the Space Industry (p 83 – 123)
(32:16) Part 5: Disruption Meets Drive (p 124 – 174)
(39:28) Part 6: On the Brink – Resilience in the Face of Failure (p 174 – 222)
(47:11) Part 7: The Musk Algorithm: Disruptive Leadership at Breakneck Speed (p 223 – 324)
(56:00) Part 8: The Paradox of Musk: Visionary Drive vs. Personal Toll (p. 325 – 427)
(01:02:00) Part 9: The Twitter Ta

How to Start a Podcast Guide: The Complete Guide
Learn how to plan, record, and launch your podcast with this illustrated guide.
Coaching Conversations in 2024
In 2024 we're going to be going to monthly themes and I would also encourage you to...

Listen on: Apple Podcasts Spotify

Support the Show.

Join the Podcast Newsletter: Link

View Details

🚀 Investing with Impact: Squire Servance on Health Equity & Venture Capital

Unlock the power of venture capital to address health disparities and drive positive social change. In this insightful episode, we speak with Squire Servance, founder of health equity fund Syridex Bio. Discover his unique approach to investing in companies tackling underserved health needs, proving that profitability and purpose can coexist.

🎙️ What's in the Episode:
1️⃣ Investing in Overlooked Markets: Learn how health disparities create massive untapped opportunities for innovation and investment.
2️⃣ The Power of Diversity: Squire Servance explains why investing in diverse founders and solutions yields better outcomes for both society and investors.
3️⃣ Data-Driven Impact: Discover how Servance evaluates companies to ensure they drive both health equity progress and financial returns.

👨‍💼 About Squire Servance:
Squire Servance is a visionary VC on a mission to accelerate health equity while generating transformative returns. His commitment to investing in solutions for underserved populations offers a powerful blueprint for venture capital that creates a healthier, more equitable world.

🎥 Watch this episode to gain valuable insights into how venture capital can be a force for good. Squire Servance's perspective is essential for impact-driven investors and anyone interested in the intersection of health and innovation.

💡 LINKS TO MORE CONTENT
Host: Christian Soschner

📌 Quotes:
(00:08:10) "The love just kind of grew, grew from there."
(00:39:02) "Accelerating health equity, while generating returns, transforms lives and society."
(00:57:45) "You can do good and do well by directing capitalism towards health equity."
(01:17:35) "We're leaving money on the table by not investing in diverse founders."
(01:25:46) "Everyone has blind spots; that's why diverse teams perform better."
(01:45:29) "There's no shortcut for success."

⏰ Timestamps:
(00:00:00) Introduction
(00:02:42) The Genesis of a Life Sciences Revolution
(00:08:48) Blueprint to Venture Capital: Squire's Journey
(00:15:11) Igniting Change: The Genesis of a Health Equity Fund Amidst COVID
(00:27:09) Venture Capital's Role in Bridging Health Disparities: A New Focus
(00:28:58) Market Volatility: A Contrarian VC's Perspective
(00:33:52) Health Equity as a Massive Global Market
(00:48:00) The Evolution of Biotech Funding: From Genentech to Today
(00:54:45) Tackling Health Equity: The Need for Collective Action
(00:56:48) Harnessing Capitalism for Health Equity
(01:03:30) The Role of Social Media and AI in Advancing Biotech Ventures
(01:10:18) The Digital Footprint: How Online Presence Shapes VC Decisions
(01:16:26) The Underrepresentation Crisis in VC Funding
(01:24:54) Investing with a Broader Vision:
(01:29:32) Investing in Health Equity
(01:42:18) Expanding the Scope of Health Equity Investment
(01:44:54) Success is Not a Shortcut: The Power of Consistency

Support the show

Join the Podcast Newsletter: Link

View Details

Venture capital funding is drying up, but is this a crisis or an opportunity? Squire Servance, founder of Syridex Bio,, explains the "denominator problem," why savvy investors are targeting overlooked assets, and how his fund addresses health disparities.

Link to full episode

Support the show

Join the Podcast Newsletter: Link

View Details

Witness the raw truth as Squire Servance, founder of Syridex Bio, a healthcare impact investor, sheds light on the glaring health disparities in the US.

In this exclusive clip (full episode coming this week!), Squire dives deep into the root causes – from social determinants to systemic issues – and why a concerted effort across sectors is crucial for achieving true health equity.

This conversation matters to investors and C-level executives seeking to understand the hidden market potential and the social responsibility of addressing these disparities. Stay tuned!Link to full episode

Support the show

Join the Podcast Newsletter: Link

View Details

Ever wondered how Apple became a trillion-dollar empire, even after the loss of Steve Jobs?

This Tim Cook biography summary reveals the operational genius and the ethical leadership strategies that redefined the company.

Discover secrets of Apple's growth, innovation, and Cook's unwavering commitment to privacy.

Problems This Solves:

Feeling overwhelmed by market volatility? Discover Cook's calculated risk-taking and long-term vision that secured Apple's success.
Struggling to build the right team? Learn how Cook fostered a culture of collaboration, cross-functional thinking, and relentless focus on excellence.
Unsure how to navigate ethics in a profit-driven world? Get inspired by Cook's unwavering commitment to privacy, diversity, and sustainability.

Why Listen:

Gain insights normally reserved for Apple insiders. Understand the strategies behind their most iconic (and risky) product launches.
Learn from a master of operational efficiency. Break down how Cook perfected the global supply chain, fueling Apple's growth.
Become a more values-driven leader. Discover how Cook built a company that's both massively profitable AND a force for good.

Link to the Book

Timestamps:

(00:00) Intro to the Tim Cook: The Genius Who Took Apple to the Next Level by Leander Kahney

(02:35) The Author: Leander Kahney

(06:21) TLDR: Book Overview

(09:04) The Introduction Chapter

(14:21) Chapter 1: The Death of Steve Jobs

(18:35) Chapter 2: A Worldview Shaped by the Deep South

(23:50) Chapter 3: Learning the Trade at Big Blue

(29:00) Chapter 4: A Once-In-A-Lifetime Opportunity to Join a Near-Bankrupt Company

(34:00) Chapter 5: Saving Apple Through Outsourcing

(38:45) Chapter 6: Stepping into Steve Jobs' Shoes

(44:30) Chapter 7: Finding his Feet with Hot New Products

(48:15) Chapter 8: A Greener Apple

(51:02) Chapter 9: Cook Fights the Law and Wins

(54:35) Chapter 10: Doubling Down on Diversity

(59:00) Chapter 11: Robot Cars and the Future of Apple

(01:02:00) Chapter 12: Apple's Best CEO

(01:06:00) Key Takeaways and Reflection

**Ready to unlock the secrets of visionary leadership? Dive into this revealing book summary!

Did you enjoy the episode? Then you might enjoy these too:**

Support the show

Join the Podcast Newsletter: Link

Tim Cook: The Genius Who Took Apple to the Next Level

View Details

🚀 Navigating the Future: Owen Reynolds' Blueprint for Venture Capital Success!

Join us in this riveting episode as we explore the visionary mind of Owen Reynolds, a leading figure at Teklas Ventures, renowned for his strategic foresight in the venture capital arena. Delve into how Owen's innovative approach is not just navigating, but pioneering new pathways for startups to scale from groundbreaking ideas to global phenomena.

🎙️ What's in the Episode:
1️⃣ The Hardware Revolution: Owen discusses the critical role of hardware in catapulting technological advancements beyond current limitations.
2️⃣ Sustainable Energy for an Addicted World: Insights into the quest for cleaner, more sustainable energy sources to fuel our future.
3️⃣ Europe's Hidden Gems: Unveiling the untapped potential within Europe's tech landscape and the unique opportunities it presents.

👨‍💼 About Owen Reynolds:
With a profound background in venture capital and a keen eye on industrial and energy sectors, Owen Reynolds stands at the helm of Teklas Ventures, steering investments towards automation, robotics, and sustainable energy solutions. His passion for marrying innovation with sustainability drives his mission to foster startups that not only succeed financially but also contribute positively to society. Owen's philosophy revolves around embracing risk for monumental returns, setting a new benchmark in venture capital.

🎥 Immerse yourself in this enlightening episode to journey into the future of venture capital with Owen Reynolds. Discover the strategies shaping the next wave of startup success and innovation with Teklas Ventures.

💡 LINKS TO MORE CONTENT
Host: Christian Soschner

📌 Quotes:
(00:07:45) "If I could do this for the rest of my life, it would be incredible."
(00:17:11) "I invest in people that scare me a little bit."
(00:43:03) "We can't get big capital flows without doing above market returns."
(00:52:06) "Expecting market returns demands a mature set of founders and asset managers."
(01:10:03) "Creative destruction is part of a healthy ecosystem, revitalizing it for future cycles."
(01:24:33) "Every investment opportunity has its own risks and return profile, requiring a calculated approach."
⏰ Timestamps:
(00:07:45) The Genesis of a Venture Capitalist's Passion
(00:11:50) Envisioning the Future of Startups
(00:17:11) Owen Reynolds on Seeking Founders Who Challenge Him
(00:25:15) Discussing Modern Portfolio Theory in Venture Capital
(00:42:04) Measuring Success in Venture Investment: Returns, Impact, Technology
(00:43:03) Prioritizing Returns in Venture Capital for Sustainable Impact
(00:43:49) Navigating ESG: Beyond Compliance to Genuine Impact
(00:50:24) Investing in Down Markets: Overcoming Fear with Strategic Capital Allocation
(00:59:16) Navigating Investment Strategies
(01:10:03) Creative Destruction in the Venture Ecosystem
(01:13:27) Navigating Venture Capital in a Shifting Market: Strategies for the Future
(01:22:21) Envisioning the Venture Landscape: A Mature, Grounded Future for Startups
(01:24:33) "Every investment opportunity has its own risks and return profile, requiring a calculated approach."
(01:25:45) Exploring the Limits of Software in Technological Advancements
(01:27:57) Envisioning a Future Shaped by Diverse Energy Sources and Sustainable Innovation

Support the show

Join the Podcast Newsletter: Link

View Details

🚀 Revolutionizing the Game: Dan Bowyer's Vision for the Future of Venture Capital!

In this compelling episode, join us as we unravel the insights and strategies of Dan Bowyer, a pioneering force in the venture capital world with SuperSeed VC. Discover how his unique approach is not just reshaping, but revolutionizing how startups navigate the journey from conception to global impact.

🎙️ What's in the Episode:
1️⃣ Disrupting Traditional Enterprises: Dan shares his mission to challenge the status quo, focusing on startups that enhance productivity and efficiency.
2️⃣ The SuperSeed Approach: Learn about SuperSeed VC's innovative strategy in investing early in technical founders, transforming how the world works.
3️⃣ Building Impactful Businesses: Insights into how Dan Bowyer and SuperSeed VC are fostering companies that prioritize both profitability and positive societal impact.

👨‍💼 About Dan Bowyer:
With over 20 years of entrepreneurial and investing experience, Dan Bowyer is a co-founder and partner at SuperSeed VC, focusing on B2B, European AI-first startups. His passion lies in aiding technical founders to navigate the early stages of their journey, ensuring they not only achieve financial success but also make a meaningful impact in their sectors and beyond. Dan's philosophy is centered around making money and doing good, setting a new standard in the venture capital ecosystem.

🎥 Tune in to this insightful episode to delve into the visionary world of venture capital with Dan Bowyer. Discover the future of startup success and innovation with SuperSeed VC.

💡 LINKS TO MORE CONTENT
Host: Christian Soschner

📌 Quotes:
(00:06:18) "My passion is reflecting to founders the realities of raising capital."
(00:20:55) "I discovered a thousand ways not to build a lightbulb."
(00:36:52) "I just want to mess with enterprise, to truly disrupt the productivity and efficiency."
(01:02:49) "We care that it transforms sectors, not about the sector itself."
(01:04:24) "We use client engagement as a diligence process to gauge market pull."
(01:22:37) "Solve problems. If you're not solving problems every board meeting, it's wrong."
(01:32:02) "Make money and do good. Whether you're a founder or investor, improve the world."

⏰ Timestamps:
(00:03:00) The Genesis of a Venture Capitalist: Dan Bowyer's Diverse Path
(00:10:31) Tech Transformation: From Pop Star to Tech Savant
(00:18:57) The Paradox of Success and the Joy of Building
(00:21:17) Navigating Failures: The Pathway to Innovation
(00:27:16) Europe's Reluctance to Risk and Its Global Impact
(00:32:56) Harnessing European Talent and Innovation for Global Leadership
(00:40:01) Bridging the Gap: Venture Capital and Societal Change
(00:46:24) Defining True Entrepreneurship: Disruption and Transformation
(00:51:49) Transforming Enterprise: Beyond Destruction to Innovation
(00:59:23) The Evolution of Industry Giants: A Look Ahead
(01:04:24) Validating Market Pull Through Founder Diligence
(01:09:55) Deep Tech: Defining the Future Beyond Traditional Business Models
(01:14:11) Betting on World-Class Teams to Solve AI Challenges
(01:22:37) The Core Role of a Board: Problem Solving for Growth

Dive into this transformative discussion on venture capital, innovation, and making a positive impact. Remember to like, comment, and share to help grow our show and bring more insightful content like this to our community.

Support the show

Join the Podcast Newsletter: Link

View Details

Venture capital is the lifeblood of innovation, transforming bold ideas into groundbreaking realities.

Yet, navigating this high-stakes world is fraught with challenges that only the daring overcome. "The Power Law" by Sebastian Mallaby reveals the untold stories of the mavericks who dared to invest in the improbable, shaping our world with technologies once deemed impossible.

Why This Summary is a Must-Watch:

Decipher the DNA of Venture Success: Understand the principles that have propelled companies like Apple, Google, and Facebook to astronomical heights.
Learn from the Masters: Insights from legendary investors and firms like Sequoia Capital and Andreessen Horowitz.
Navigate the Highs and Lows: Real-life tales of venture capital hits and misses, including the meteoric rise of unicorns and the cautionary tales of Theranos and WeWork.

Purchase "The Power Law" now and embark on a journey to mastering the art of venture capital

🎙️ Here's what you'll discover in this summary:

The Architect Behind 'The Power Law': A look into Sebastian Mallaby's background and how his insights offer a unique perspective on the VC world.
Decoding "The Power Law": Explore the main concepts that govern venture capital success and failure.
Quick Guide: The 7 Key Takeaways from the book for those short on time.
Chapter Summaries: A detailed walkthrough of each chapter, highlighting crucial lessons, from the origins of VC to the latest trends shaping the future of technology and investment.
Personal Reflection: My personal journey through the lens of Venture Capital and how "The Power Law" has reshaped my understanding of what it takes to succeed.

Don't miss out on this essential guide that could very well dictate the success of your next big venture or investment. Click to watch the episode now and step into the world of Venture Capital as you've never seen it before.

⏰ Timestamps:
(00:00) Opening words
(02:00) Sebastian Mallaby’s background
(05:00) Main Concepts in “The Power Law”
(08:33) Too long did not listen: The 7 Key Takeaways from the book
(14:30) Chapter: Introduction
(18:55) Chapter 1: Arthur Rock and Liberation Capital
(23:01) Chapter 2: Finance without Finance
(26:05) Chapter 3: The Genentech story
(30:00) Chapter 4: The Whispering of Apple
(34:04) Chapter 5: Silicon Valley’s culture of open collaboration and mutual support – Metcalfe’s Law
(37:36) Chapter 6: Chance favors only the prepared mind combined with character and discipline
(40:45) Chapter 7: Softbank’s 100 Million for everybody
(44:00) Chapter 8: How to Build a Startup in a Saturated Market
(47:20) Chapter 9: How Y-Combinator Redefined Early-Stage Investing
(51:00) Chapter 10: The Rise of the Chinese Dragon
(54:10) Chapter 11: Redefining Global Communication
(57:20) Chapter 12: The Principle of Incremental Margins in Growth Investing
(01:01:34) Chapter 13: Community fostered by Sequoia Capital
(01:04:50) Chapter 14: What would Success in Venture be Without Failures Like Theranos or Wework?
(01:08:25) Chapter: Conclusion by Mallaby
(01:11:30) My conclusion

Support the show

Join the Podcast Newsletter: Link

View Details

🚀 Europe's Tech Transformation: David Dana's Vision for the Future!

In this episode, join me, Christian Soschner, for an enlightening conversation with David Dana, a leading figure in the European tech investment landscape. Discover how his strategic approach at the European Investment Fund (EIF) is driving innovation and shaping the future of technology in Europe.

🎙️ What's in the Episode:
1️⃣ Europe's Growing Tech Influence: David Dana discusses Europe's evolving role in the global tech market and its potential to become a key player.
2️⃣ The Art of Risk and Reward: Explore how embracing risk is essential for significant returns in the European investment scene.
3️⃣ Quantum Tech Revolution: Insights into the burgeoning field of quantum technologies and its global impact.
4️⃣ Collaborative Tech Transfer: Understanding the importance of openness in tech transfer to enhance ecosystem value.
5️⃣ Beyond Investing: Learn about EIF's strategic approach to deploying capital for broader market growth.

👨‍💼 About David Dana:
David Dana, Head of VC Investments at EIF, is a mastermind in disruptive tech and innovation. With over a decade of experience at EIF and a profound understanding of various tech sectors, David is at the forefront of supporting Europe's tech sovereignty. His expertise in AI, Blockchain, Space, and Quantum Technologies, among others, is driving Europe's tech revolution.

🎥 Don't miss this insightful episode where we delve into the strategies and visions shaping Europe's tech future with David Dana. Tune in now to uncover the transformative power of European innovation.

💡 LINKS TO MORE CONTENT
Host: Christian Soschner

📌 Quotes:
(00:06:42) "Europe has a role to play in the global market."
(00:27:34) "If you don't take the risk, you will not get the rewards."
(00:34:50) "Quantum technologies are at the beginning of something potentially huge."
(00:46:25) "Opening to other shareholders helps to value and support the ecosystem more effectively."
(01:04:16) "We need to generate returns; it's not just about deploying, it's about investing."
(01:20:30) “Europe has the capacity, knowledge, and brains to innovate and change the world.”
(01:27:51) "We need to empower others by trusting them, giving them autonomy and responsibility."

⏰ Timestamps:
(00:03:00) Discovering the European Investment Fund: David Dana's Journey
(00:06:10) The Evolution of the European Tech Market: Insights from David Dana
(00:17:46) Navigating Risk in Alternative Investments: David Dana's Perspective
(00:21:05) The Exit Market Challenge: Europe vs. US in Venture Capital
(00:31:45) Cultural Shift for European Innovation: Breaking National Barriers
(00:34:50) Quantum Technologies: The Potential for Revolutionary Impact
(00:45:50) Early Stage Funding and Tech Transfer in Europe: Challenges and Opportunities
(00:48:32) Balancing Global Expansion and European Growth: Strategies for Tech Companies
(00:59:30) Convincing Success: The Key to Gaining EIF Support
(01:06:11) Navigating the Investment Process: EIF's Rigorous Due Diligence Approach
(01:12:50) EIF's Rigorous Investment Process: Ensuring Quality and Due Diligence
(01:24:32) Evolving Role of EIF: Focusing on Specialized Strategies in Europe
(01:25:31) Empowering Teams for Decision-Making
(01:38:15) Navigating Investment Successes and Failures
(01:40:17) Confronting the Future with a Brave Initiative
(01:50:19) Fostering a Supportive Ecosystem for Innovation

Support the show

Join the Podcast Newsletter: Link

View Details

Ready to make 2024 your best year ever?

If so, this episode is tailor-made for you. We've hand-picked the five most impactful, insightful, and exhilarating pieces of advice from various episodes of 2023, each poised to help you navigate the coming year with greater clarity and confidence.

First and foremost, a heartfelt thank you to every speaker who graced my show. Each conversation was a journey, each insight a treasure.

As I set out to select the five most inspiring, impactful, and insightful clips from different episodes for this special 'Best of 2023' compilation, I realized how every moment was invaluable.

Grateful for every guest, I turned to ChatGPT to impartially choose five episodes that offer guidance, wisdom, and foresight to navigate 2024 with clarity and purpose.

🔥 Are you ready to embrace 2024 with the wisdom of the past year?
Dive into this meticulously curated episode that brings together the brilliance of thought leaders from diverse fields. This isn't just another podcast episode; it's a guidebook for your journey through 2024 and beyond.

In this episode, discover:

The transformative tale of a biotech entrepreneur's Christmas Eve breakthrough.
Insightful perspectives on the evolving landscape of mental health.
Innovative economic strategies transforming New Jersey's growth.
Urgent messages from the frontlines of climate change.
The promising potential of climate tech in creating a greener future.

Speaker in this episode:

Philipp Baaske
Matias Serebrinsky
Kara Moore
Kimberley Miner
Yair Reem

Each segment is more than just a story; it's a beacon of knowledge and inspiration to guide you through the year. And to enrich your experience, we've included timestamps for each featured clip, allowing you to delve into the sections that resonate most with you.
⏰ Timestamps:(02:50) "The Christmas Eve Breakthrough: Nanotemper's Leap to Success" – Discover how a single crucial experiment on Christmas Eve catalyzed a biotech startup's journey to triumph.
(09:26) "Redefining Mental Health: A New Era with AI and Psychedelics" – Explore Matias Serebrinsky's vision of the future of mental health treatment.
(18:02) "New Jersey's Economic Revolution: Transforming Challenges into Opportunities" – Unveil Kara Moore's insights on New Jersey's innovative strategies for economic growth.
(24:04) "Climate Urgency: A Scientist's Warning from Everest to NASA" – Delve into Dr. Kimberley R. Miner's compelling narrative on the immediate threats of climate change.
(30:11) "Green Gold Rush: Yair Reem's Vision for Climate Tech" – Learn about the massive potential in climate technology with Yair Reem's forward-thinking approach.
Join us on this enlightening journey as we explore, learn, and grow together. If this episode sparks curiosity, resonates with you, or inspires change, please like, comment, and share. Your engagement helps us continue bringing transformative conversations to light.

👉 Follow us for more insightful episodes: https://youtube.com/playlist?list=PLlZfrwd6iXrQWqnPV5UfnEMXeoX3wkycm&si=6BEIBb4gZIqcwknf

Remember, while this podcast is a treasure trove of knowledge, it is not a substitute for professional advice. It's a companion in your quest for personal and professional growth.

We can't wait to have you on this j

Support the show

Join the Podcast Newsletter: Link

View Details

Dive into the future with 'Beginner’s Mind' as I unveil the 2024 vision, a groundbreaking journey through the world of deep tech. In this special episode, join me for a riveting exploration into the minds of tech giants like Jeff Bezos, Warren Buffett, and Elon Musk. Discover exclusive insights that are shaping the future of technology and investment.

We're not just talking about trends; we're discussing real impact and growth. As we expand and professionalize our content, each conversation becomes a beacon for entrepreneurs and investors seeking a deeper understanding of the evolving digital landscape. From invaluable book reviews to compelling dialogues with leading figures, this episode is a treasure trove of wisdom for our ambitious audience.

Expect more than just interviews - get ready for a series of engaging, SEO-optimized discussions that not only resonate with your aspirations but also provide practical insights for your professional journey. Be part of a thought-provoking experience that connects you with the heart of innovation and investment in 2024.

Don't forget to support us with a like, comment, or a 5-star review on Apple Podcasts and Spotify, and subscribe on YouTube. Your engagement is our driving force in bringing more impactful content to the forefront of the deep tech world. Tune in to 'Beginner’s Mind' and transform the way you perceive the future of technology and business.

Support the show

Join the Podcast Newsletter: Link

View Details

In this episode, we dive into a groundbreaking conversation with Matías Peire, a trailblazer in the biotech venture capital space. Discover how his innovative approach at GRIDX is reshaping the future of biotech in Latin America.

🎙️ What's in the Episode:
1️⃣ Bridging Science and Business: Matías discusses the unique challenges and opportunities in connecting Latin American scientific talent with global markets.
2️⃣ The GRIDX Approach: Discover how GRIDX is pioneering a new model for venture capitalism in biotech, focusing on nurturing startups right from the idea stage.
3️⃣ Latin America's Untapped Potential: Insights into the rich biodiversity and scientific talent in Latin America and how they can revolutionize biotech globally.

👨‍💼 About Matías Peire:
Matías Peire, a visionary in the venture capital world, has a unique approach to investing in biotech startups. With a background in business administration and finance, and a deep passion for technology and science, Matías is leading GRIDX to transform scientific ideas into successful, impactful businesses. His journey is a testament to the power of visionary leadership in the biotech sector.

🎥 Don't miss this insightful episode where we delve into the world of biotech venture capitalism with Matías Peire. Tune in now to discover the future of biotech innovation in Latin America.

💡 LINKS TO MORE CONTENT
Christian Soschner
Matías Peire

📌 Quotes:
(00:06:32) "We want to transform how scientists create companies in Latin America."
(00:34:35) "Scientists should become entrepreneurs and own their companies, licensing technology from universities."
(00:48:07) "The only reason to become an entrepreneur is if you feel you'll regret not doing it."
(00:57:50) "It's your responsibility to find a way to bring scientific alternatives to the table."
(01:13:32) "You have a huge pool of talent, and almost none are working in the private sector."
(01:32:43) "You need flexibility, ambition, and a soul in the game to succeed."
(01:37:23) "Ambition to transform science into impact in Latin America."

⏰ Timestamps:
00:03:55) Climate Change and Venture Capital: Insights from Washington D.C.
(00:05:43) Expanding Horizons: GRIDX's Growth Strategy in Latin America
(00:18:03) Creating a Venture Capital Fund with a Company Builder Model in LATAM
(00:26:49) Building Confidence in Latin American Science for Global Competitiveness
(00:35:46) Bridging the Gap: Scientists and the Private Sector in LATAM
(00:42:05) Professionalizing University Participation in Venture Capital Processes
(00:51:54) Navigating the Storm: Impact as a Connector in Business and Science
(00:58:50) The Responsibility of Transforming Production with Science
(01:07:57) Achieving Success in Latin America: The Journey of Raising Funds Abroad
(01:14:32) Leveraging Latin America's Talent Pool and Biodiversity for Global Impact
(01:20:49) Latin American Projects: Showcasing Competitive Science on the Global Stage
(01:33:03) Essential Qualities for Success: Learners, Builders, and Ambitious Minds
(00:37:00) Keep pushing, it's going to be okay. Follow what you feel and keep pushing.
(01:37:23) Ambition to transform science into impact in Latin America.

Support the show

Join the Podcast Newsletter: Link

View Details

📢 About This Memorable Moment
This festive season, I reflect on the journey we've shared through the 'Beginner’s Mind' podcast and our collective mission in the deep tech world.

📘 Inspiration Behind the Message:
Drawing from the insights in Sebastian Mallaby’s 'The Power Law', I discuss how we’ve aimed to nurture connections within the deep tech ecosystem. My message intertwines the philosophies of my Christian and Buddhist heritage, emphasizing the importance of kindness and mutual respect.

🥋 Philosophy and Martial Arts:
Explore how teachings from Jesus Christ, Viktor Frankl, and the principles of martial arts like Bujinkan have influenced my approach to life and business. These philosophies guide us to not take things personally, to ask questions, and to separate people from problems.

📊 Applying Philosophies to Business:
Discover five simple yet impactful actions that can elevate startups, scale-ups, and public companies. These include active listening, understanding perspectives, creating win-win negotiations, and more.

🙏 A Universal Message:
As we celebrate this festive season, let's embrace the spirit of the Golden Rule - a philosophy of kindness and mutual respect that transcends cultures and beliefs.

📌 Join the Conversation:
I invite you to watch, reflect, and share your thoughts on how these philosophies resonate with you in your personal and professional life.

Support the show

Join the Podcast Newsletter: Link

View Details

Dive into a groundbreaking discussion with Matias Serebrinsky from Psymed Ventures, as we uncover the astonishing potential of psychedelic therapy in mental health. In this exclusive clip, Matias reveals groundbreaking clinical trial results for MDMA in treating PTSD, showing unprecedented remission rates and long-term healing. He also discusses the shift from traditional symptom management to actual healing, marking a paradigm shift in psychiatric treatment.

Discover how these therapies are not only changing lives but also reshaping our approach to mental health care. Don't miss Matias's insights into this revolutionary field. Watch the full episode for more in-depth analysis and discussions on the future of mental health treatments.

Full Episode

Support the show

Join the Podcast Newsletter: Link

View Details

Did you know that the intersection of mental health and cutting-edge technology is paving the way for revolutionary therapies that could redefine our approach to mental health and wellness?

Imagine a future where AI and novel therapies like psychedelics work together to unlock new realms of mental health treatment. Matias Serebrinsky and Psymed Ventures are at the forefront of this innovation, not just envisioning it—they're actively shaping it.

Tune in to explore the new horizons of mental health!

🎙️ What's in the Episode:
1️⃣ Mental Health Reimagined: He discusses the urgent need for innovative solutions in a world where mental health issues are a growing concern.
2️⃣ The Investment in Innovation: Discover how Psymed Ventures is not just a fund—it's a visionary platform that brings together groundbreaking research and entrepreneurial spirit to transform mental health care.
3️⃣ The Revolutionary Potential of Psychedelics: He shares insights into the promising future of psychedelic therapy, AI's role in personalized care, and how these could drastically improve outcomes for patients worldwide.

👨‍💼 About Matias Serebrinsky:
He isn't just an investor; he's a catalyst for change. A passion has marked his journey from Argentina to Silicon Valley for disruptive technologies. As the force behind Psymed Ventures, Matias leverages his expertise in AI and his entrepreneurial background to champion a new era of mental health treatments that prioritize healing and holistic care. His philosophy is simple yet profound: invest in solutions that heal the mind and uplift humanity.

🎥 Don't miss this compelling episode where we delve into the future of mental health. Tune in now to understand how to join this mental health revolution.

💡 LINKS TO MORE CONTENT
Christian Soschner
Matias Serebrinsky

📌 Quotes:
(00:06:29) I'm keeping my Nvidia shares because Jensen is a once-in-a-generation type of founder, and you never want to bet against someone like that.
(00:20:10) Mental health disorders are rapidly becoming the largest burden of disease for society, more costly than cancer and cardiovascular disease.
(00:52:51) Psychedelics like iboga are being explored for opioid use disorder, showing significant effectiveness in initial studies.
(01:07:13) Psychedelics can alleviate the lack of therapy supply. Comparing 40 hours of psychedelic therapy to 150 hours of traditional therapy shows where the equation makes more sense.
(01:18:34) Some universities have streamlined the process, incentivizing professors to out-license or spin-out companies.

⏰ Timestamps:
(00:02:15) Insights on Nvidia and Investment Strategy
(00:05:53) Visionary Leadership: Nvidia's Strategic Shift to AI
(00:09:00) Matias’ Journey from Argentina to Psymed Ventures
(00:17:32) Veritas Health: A $2 Billion Success in Metabolic Dysfunction Treatment
(00:19:37) Reducing Mental Health Stigma and Addressing Growing Needs in Society
(00:33:56) Exploring Innovative Business Models in Mental Health Investment
(00:41:43) Interventional Psychiatry: Revolutionizing Mental Health Treatment with Psychedelics
(00:48:41) The Therapeutic Mystery of Psychedelics in Mental Health
(00:52:51) Exploring Psychedelics for Addiction Treatment: Beyond Traditional Methods
(01:06:41) Psychedelic Therapy: A New Paradigm in Mental Health
(01:15:24) Innovating Mental Health Treatment: Neurostimulation at Home
(01:17:25) Exploring Global Investment Opportunities in Mental Health Innovations
(01:26:54) IST Austria's Role in Adv

Support the show

Join the Podcast Newsletter: Link

View Details

Did you know that New Jersey is rapidly emerging as a powerhouse of innovation, especially in the life sciences and technology sectors?

Join us in this enlightening episode with Kara Moore from the New Jersey Economic Development Authority (NJEDA), as she unveils the state's strategic initiatives and opportunities for businesses and investors.

🎙️ What's in the Episode:
1️⃣ Financial Incentives for Growth: Kara discusses New Jersey's unique financial advantages for businesses, including converting net operating losses into non-dilutive capital.
2️⃣ Biomanufacturing and Industry Trends: Learn about New Jersey's focus on staying ahead in biomanufacturing through state-of-the-art facilities and training programs.
3️⃣ Helix Innovation Hub: Discover the significant investment in the Helix Innovation Hub, aimed at propelling health and life sciences R&D.
4️⃣ Diverse Talent Pool: Explore why New Jersey's dense and diverse population makes it an ideal location for companies seeking skilled talent.
5️⃣ Sci Tech City and Digital Health: Uncover the role of Sci Tech City in advancing digital health and A.I., marking New Jersey as a hub for technological growth.

👩‍💼 About Kara Moore:
Kara Moore is a visionary leader at NJEDA, driving New Jersey's growth and positioning it as a key player in the global innovation market. Her focus on collaboration, innovation, and sustainable growth is shaping the state's future in business and technology.

💡 LINKS TO MORE CONTENT
Host: https://www.linkedin.com/in/christiansoschner/
Speaker: https://www.linkedin.com/in/karamoore/

📌 Quotes:
(00:16:33) "It's like having free money. Our unique program allows companies to sell off their New Jersey net operating losses for non-dilutive capital."
(00:25:17) "We're keeping on top of trends, developing programs like our biomanufacturing Pathways, and building facilities like the first simulated clean room in the state."
(00:33:57) "We're building an Innovation Hub in New Brunswick, New Jersey – a $731 million investment in health and life sciences, dubbed Helix."
(00:50:44) "We have about 445,000 life science workers in New Jersey. We're the most densely populated and fourth most diverse state in the country."
(01:03:19) "Sci Tech City in Jersey City, just outside New York, will feature an eight-story incubation center focused on digital health and A.I. innovations."
(01:04:33) "We partner with Hacks, a hard tech accelerator focusing on climate tech, offering significant funding and support for innovative companies in New Jersey."

⏰ Timestamps:
(00:03:43) The Journey from Academia to Economic Development
(00:07:43) How AI Transforms PR Work
(00:09:43) Pioneering Life Sciences Growth in New Jersey
(00:16:58) Transforming Tax Credits into Capital: How Companies Benefit
(00:25:17) Bridging Trends and Training: New Jersey's Strategic Approach in Life Sciences
(00:30:43) Shaping the Future Workforce: Collaborative Training in Biomanufacturing
(00:33:57) Helix: A $731 Million Leap in Health and Life Sciences Innovation
(00:44:18) Empowering Investors: New Jersey's Angel Tax Credit Program
(00:50:44) New Jersey's Talent Magnet: Attracting Life Science Workers
(00:56:52) Bridging Cultures: The Impact of Workforce Exchange Between Europe and the U.S.
(01:02:14) Envisioning the Future: Life Science Innovations and Developments in New Jersey
(01:04:02) Building the Hospital of the Future: Sheba Medical Center's Vision
(01:06:58) Strategic Innovation Centers: Fostering Collaboration in Tech

Support the show

Join the Podcast Newsletter: Link

View Details

Navigating the startup landscape is fraught with challenges that can make or break the boldest of visions. In this entrepreneurial climate, it's the audacious, the resilient, who rise to the top. Dive into this exclusive clip to discover the strategies that made Facebook a global phenomenon.

In a rare and revealing conversation, Mark Zuckerberg, the visionary founder and CEO behind Facebook, talks with Sam Altman, the respected president of Y Combinator and co-chairman of OpenAI, about the pivotal moments and decisions that shaped Facebook's destiny. From its inception in a college dorm to becoming a tech titan, Zuckerberg's insights are a treasure trove for aspiring entrepreneurs.

By watching, you'll delve into
(01:41) Early Days of Facebook - Explore Zuckerberg's initial foray into what would become a global phenomenon.
(04:03) Decision to Not Sell Facebook - Uncover the resolve behind rejecting a billion-dollar buyout.
(07:07) Advice for Building Products - Gain foundational tips from a tech titan on product development.
(10:48) Learning and Innovation Culture at Facebook - Get an insider look at fostering creativity and progress.
(13:21) Hiring Philosophy - Learn Zuckerberg's strategy for assembling a team that disrupts and innovates.
(16:05) Risk-Taking and Decision Making - Understand the calculated risks and decisions that shape the future of tech.

This episode is a beacon for entrepreneurs searching for guidance and inspiration. For a deeper exploration into the strategies that craft empires and the minds that envision them, watch the full interview for a comprehensive dive into the world of high-impact entrepreneurship:

Watch the Full Interview Here

Step into the arena armed with knowledge and ready to make your mark.

If the insights shared here strike a chord with you, take a moment to subscribe, like, comment, and share. Each interaction from you helps to elevate our conversation, bringing more profound insights and inspiring stories like this to light.

Support the show

Join the Podcast Newsletter: Link

View Details

Munich, Bavaria - a picturesque city known for its rich history and Oktoberfest. But did you know it's also the epicenter of Europe's biotech revolution? Dive into this captivating conversation with Dr. Daniel Vitt, the driving force behind Immunic Therapeutics, as he unravels the secrets of Munich's meteoric rise in the biotech realm.

1️⃣ Munich's Meteoric Rise:
Discover how Munich transformed into one of Europe's most dynamic biotech ecosystems, and the role of visionary political decisions in its ascent.

2️⃣ Inside Immunic's Journey:
From its inception to its transformative stages, journey with Dr. Vitt as he shares the challenges and triumphs of leading a biotech giant. Learn about Immunic's groundbreaking developments and its innovative approach to treating diseases like multiple sclerosis.

3️⃣ About Dr. Daniel Vitt:
Dr. Daniel Vitt, CEO of Immunic Therapeutics, is a biotech luminary with a rich legacy, including co-founding 4SC AG. His insights offer a rare glimpse into the intricacies of the global biotech landscape, from Europe to the US.

Full Episode

📢 Engage with Us:
If this narrative resonates with you, please subscribe, like, comment, and share. Your support amplifies our voice, bringing more such enlightening tales to the forefront.

🎉 Dive In:
Embark on this enlightening journey into the world of biotech innovation. Let's explore the stories of those shaping our tomorrow.

Support the show

Join the Podcast Newsletter: Link

View Details

Every year, 18 million souls are diagnosed with cancer - that's akin to the entire population of the Netherlands. But what if there was a way to release a cancer medication just a month earlier? Imagine the countless lives saved. Dive into this riveting conversation with Philipp Baaske, the visionary behind NanoTemper, as he unveils the power of perseverance, innovation, and the audacious ambition to treat every ailment known to humanity.

1️⃣ The Stark Reality:
Grasp the magnitude of the global cancer crisis and the urgency of finding a cure.

2️⃣ What Awaits Inside:

Journey with Philipp Baaske from NanoTemper's humble beginnings to its groundbreaking contributions in biotech.
Discover the transformative tools reshaping drug discovery and their potential in the fight against cancer.

3️⃣ About Philipp Baaske:
Philipp Baaske, co-founder and CEO of NanoTemper, is on a mission to arm scientists with cutting-edge tools, accelerating medical marvels. His story is a beacon of hope, belief, and relentless pursuit of a world where every disease is treatable.

Full episode

📢 Engage with Us:
If this narrative resonates with you, please subscribe, like, comment, and share. Your support amplifies our voice, bringing more such enlightening tales to the forefront.

🎉 Dive In:
Embark on this enlightening journey into the world of biotech innovation. Let's explore the stories of those shaping our tomorrow.

Support the show

Join the Podcast Newsletter: Link

View Details

🎯 Empowering Entrepreneurs with Ash Ravikumar!
Join us for an enlightening conversation with Ash Ravikumar as he delves deep into the world of tech transfer, the essence of entrepreneurship, and the pivotal role of academics in innovation.

🚀 Main Points:
1️⃣ Optimizing Entrepreneurial Time: Ash's unique approach to maximizing time and processes to uplift entrepreneurs and startups.
2️⃣ The Heart of Tech Transfer: The indispensable role of academics and the trust dynamics in the tech transfer landscape.
3️⃣ Global Technological Race: Ash's insights on Europe's fragmented approach and the need for a unified front to rival tech giants like the USA and China.

👤 About Ash Ravikumar:
A visionary with a keen sense of innovation, Ash Ravikumar has been at the forefront of tech transfer, emphasizing the importance of academics and trust. With a passion for optimizing processes, he champions the cause of entrepreneurs, ensuring they have the tools and support to succeed.

💡 LINKS TO MORE CONTENT
Host: https://www.linkedin.com/in/christiansoschner/
Speaker: https://www.linkedin.com/in/ashravikumar/

🗣️ Top Quotes from Ash Ravikumar:
(00:03:15) "Life is beautiful; if our only complaint is about the weather, then life is truly good."
(00:57:26) "Success is not by chance; it's designed."
(01:12:16) "You won't compete with a large, unified country moving at a fast pace."
(01:55:59) "You're good at what you do. Seek experts outside of your realm; you don't have to understand everything."
(02:01:13) "Our only hope for addressing challenges, from climate change to poverty, lies in science."

⏰ Timestamps:
(00:03:15) Life's Beauty: Embracing Challenges and Weather
(00:09:56) The Serendipity of Tech Transfer and Global Impact
(00:14:23) Optimizing Time for Entrepreneurial Success
(00:20:50) Navigating IP Challenges in Startups
(00:25:38) Standardizing Agreements for Efficiency
(00:33:42) Building Trust and Serving Academics
(00:36:25) Academics' Service Level and Politics
(00:37:47) The Ugly Side of Equity in Startups
(00:48:32) European University Access vs. U.S. Student Debt
(00:54:15) The Power of Alumni Networks and Global Impact
(01:00:20) Leveraging Technology in Large Companies vs. Startups
(01:08:22) The Ecosystem: Europe's Technological Landscape vs. the US
(01:10:53) "Europe needs to beat the USA and China in technological advances."
(01:12:02) The Dilemma of Localized Photonics Centers
(01:18:13) The Global Mindset: From Europe to the U.S. and Beyond
(01:24:02) Patent System's Evolution: From Mechanics to Modernity
(01:31:10) AI in Business Planning: Efficiency vs. Insight
(01:35:29) Optimizing Superconducting Material Combinations
(01:40:44) Embracing AI: Beyond Fear and Biases
(01:45:39) Technological Biases: Unintended Consequences of Regulation
(01:54:08) The Dynamics of Billion-Dollar Valuations in Energy Sector
(01:57:05) Embracing Humility: Knowing When to Seek Help
(02:01:57) Science as Art: Celebrating Unsung Scientific Heroes

📣 Seeking tools to manage the entrepreneurial chaos? Dive into the world of innovation with Ash Ravikumar and discover how to optimize your processes for success.

Support the show

Join the Podcast Newsletter: Link

View Details

🔥 The Metaverse is more than just a digital realm; it's a goldmine waiting to be tapped. But how can entrepreneurs and investors navigate this new frontier without getting lost?

1️⃣ The Problem Amplified:

Are you struggling to understand the convergence of crypto and fintech in the Metaverse?
Feeling overwhelmed by the rapid technological advancements and unsure how to capitalize on them?
Concerned about missing out on the next big opportunity in the digital economy?

2️⃣ What You'll Get in This Clip:

Insights into the fusion of crypto and fintech within the Metaverse and its implications for businesses.
Strategies to leverage these technologies for maximum profit and growth.
Expert advice from Alexander Valtingojer, a pioneer in the field, to guide your entrepreneurial journey.

3️⃣ About Alexander Valtingojer:
Alexander Valtingojer is the CEO of the crypto fintech Coinpanion. From his school days, he was deeply involved with cryptocurrencies, leading him to work on various projects in this domain. He developed a Bitcoin PayPal marketplace and later, during his studies, actively traded cryptocurrencies. Alexander even worked on his own ICO and spoke at the C³ Crypto Conference in Berlin.

Full Episode

Subsequently, he founded a sole proprietorship for software services. For the past four years, he has delved deep into the financial markets and was a trader on Coinpanion's previous version. Today, Coinpanion has grown into a thriving company with 30+ employees, aiming to assist everyone in entering the crypto market with smart portfolios.

📢 Engage with Us!:
If you found this content valuable, please subscribe, like, comment, and share. Your support helps us bring more insightful content and attract thought leaders to share their expertise.

🎉 Enjoy the Clip:
We hope you find this video enlightening and beneficial. Dive deep into the world of the Metaverse and discover the opportunities that await!

Support the show

Join the Podcast Newsletter: Link

View Details

Ever find yourself constantly contemplating a fallback? That nagging thought of a Plan B might just be what's holding you back from true entrepreneurial success. Many top achievers know that to excel truly, you need an all-in mindset.

In this episode, you'll discover the seven core principles from the groundbreaking book "Burn the Boats" that have transformed the journeys of countless entrepreneurs. Dive deep into a mindset shift that could redefine your path to success and understand why having a safety net might be your biggest setback.

The insights are based on the book "Burn the Boats" by Matt Higgins, a battle-hardened entrepreneur with a track record of success.

[Get the book here: https://amzn.to/3PMr4l5]

Your narrator, Christian Soschner, isn't just an avid reader but a seasoned executive coach with over 30 years of experience. As the host of the 'Beginner's Mind Podcast' and with a vast network spanning life sciences, biotech, and deep tech, Christian brings a wealth of knowledge and insights to the table. His mission? To share transformative business wisdom with you.

Don't miss out on these game-changing strategies. Listen to the full episode now and embark on an unyielding path to your entrepreneurial triumph!

Support the show

Join the Podcast Newsletter: Link

Burn the Boats: Toss Plan B Overboard and Unleash Your Full Potential

View Details

🎯 Challenging the Biotech Status Quo with Jon Chee of Excedr!
Dive into a transformative conversation with Jon Chee, the CEO and Co-founder of Excedr, as he shares his journey from the wet labs of UC Berkeley to revolutionizing the way life science startups access mission-critical equipment.

🚀 Main Points:
1️⃣ The Excedr Mission: Discover how Excedr is bridging the gap between life sciences and financial services, offering founder-friendly equipment leases to accelerate high-impact research.
2️⃣ The Power of Leasing: Uncover the benefits of leasing over purchasing, from improved cash flow to accelerated research timelines.
3️⃣ The Vision for the Future: Jon's long-term vision for Excedr and how it aims to improve health outcomes globally.

👤About Jon Chee:
With over a decade in the life sciences industry, Jon Chee co-founded Excedr to alleviate the financial burdens faced by early-stage life science companies. His academic background in Molecular Toxicology from UC Berkeley and his passion for entrepreneurship drive his mission to support groundbreaking research.

💡 LINKS TO MORE CONTENT
Host:
Speaker

🗣️ Top Quotes from Jon Chee:
(00:12:45) "Entrepreneurship started when I wanted to alleviate obstacles impeding our lab's ability to research."
(00:28:41) "I enjoy challenging the status quo and constantly asking, 'Why?'"
(00:56:34) "Having a mission you truly believe in makes facing rejection worthwhile."
(01:09:03) "Finding win-win situations is more than just business; it's about living a life worth remembering."
(01:45:58) "Over time, challenges net out and head in the right direction. As long as our North Star is clear, we'll be just fine."

⏰ Timestamps:
(00:02:26) The Art of Starting a Podcast: Joe Rogan and Lex Fridman
(00:06:31) Conversations Over Drinks: The Essence of Podcasting
(00:13:13) From Gaming to Entrepreneurship: A Journey of Building
(00:15:35) The Art of Game Theory in Poker
(00:16:28) Disrupting Predictable Strategies
(00:19:39) Poker's Parallels to Business and Investing
(00:28:41) Challenging the Status Quo: The Power of Asking Why
(00:29:56) Growing the Pie: Value for All Stakeholders
(00:38:22) Expanding Horizons: Serving the US Research Community
(00:42:03) Navigating Europe's Complex Landscape
(00:43:51) The Entrepreneurial Shift: Berkeley vs. Stanford
(00:51:56) Bridging the Gap: Science Meets Finance
(00:54:22) "Embracing the Village Mentality in Science"
(00:56:34) "Mission-Driven Persistence Amidst Rejection"
(01:04:48) "Defining Value in Stakeholder-Centric Deals"
(01:07:05) Building for a 100-Year Journey
(01:08:39) Living Life with Win-Win Situations
(01:14:42) Demystifying Entrepreneurship in Science
(01:20:53) Improving Health Outcomes: A North Star
(01:21:52) The Digital Revolution: Global Accessibility and Connection
(01:29:40) Navigating Financial Challenges in Startup Ecosystems
(01:34:36) Deep Dive into Lab Equipment Financing
(01:37:01) Distributed Bio: A Success Story
(01:44:36) The Future of Venture Capital in Silicon Valley
(01:48:18) Europe's Unique Science Funding Landscape
(01:49:43) U.S. Ecosystems Beyond Silicon Valley
(01:56:45) Nurturing Biotech Leaders with nucleate.xyz

📣 Looking to extend your cash runway and get the equipment your lab needs? Excedr offers flexible leasing solutions tailored to your needs. Dive into a world of efficiency and innovation. Reach out to us today at www.excedr.com.

Support the show

Join the Podcast Newsletter: Link

View Details

The digital age has brought forth a plethora of opportunities, but with it comes a maze of complexities, especially when it comes to patenting digital innovations. Many tech-savvy entrepreneurs find themselves lost, patenting solutions that are either meaningless or purely artificial. But what if the problem isn't with the technology, but with the approach?

🔹 Discover the Misconceptions: Understand why starting with technology can lead you astray and how a customer-centric approach is the key.
🔹 The AI Paradox: Dive into the intricacies of patenting AI and why mentioning the tech might not always be the best strategy.
🔹 Real-world Examples: Learn from a groundbreaking patent involving salmon and lasers, illustrating the essence of unique patenting.

Meet Prof. Alexander Wurzer, a luminary in IP management and a professor at CEIPI, University of Strasbourg. With a rich tapestry of over 200 publications and a revolutionary method in IP design, he unravels the enigma of intellectual property in the digital realm.

📢 If this resonates with you or sparks your curiosity, hit that subscribe button and dive deeper into the world of digital patenting with us. Your support amplifies our mission to bring more insights like these to the forefront.

This episode was recorded in December 2020.
Full episode: https://www.buzzsprout.com/779930/6934757

👉 Don't miss out on this game-changing conversation. Click below to watch the full episode or listen to the entire podcast.

🎉 Special thanks to our sponsors for making this episode possible.

Support the show

Join the Podcast Newsletter: Link

View Details

Are you part of the 70%?
Vitamin D deficiency is a silent crisis affecting both the U.S. and Europe. The lack of this essential nutrient can lead to severe mental health issues, including depression and anxiety, due to its role in serotonin production. Physical health is also at risk, with increased chances of respiratory issues and even cancer. In this eye-opening episode, we delve into the Huberman Lab Podcast, where Dr. Andrew Huberman and his guest Dr. Rhonda Patrick, discuss the alarming rates and severe health consequences of Vitamin D deficiency.

Who are Dr. Andrew Huberman and Dr. Rhonda Patrick?
Dr. Andrew Huberman is a renowned neuroscientist and professor at Stanford University. His guest, Dr. Rhonda Patrick, is an expert in nutritional health. Together, they unpack the science behind Vitamin D, its crucial role in our body, and why you should be concerned about your Vitamin D levels.

Who Needs to Watch This?
If you care about your mental and physical health, this episode is a must-watch. Whether you're in the U.S. or Europe, young or old, the information here is vital for everyone.

What You'll Learn:

The science behind Vitamin D and its production in our body
How Vitamin D affects your mood and immune system
The relationship between skin color and Vitamin D production
Practical tips for proper Vitamin D supplementation

Timestamps:
(01:22) Introduction to Vitamin D's Importance
(01:46) Vitamin D and Skin Color
(03:17) Vitamin D Deficiency in the Population
(04:49) Vitamin D and Gene Regulation
(04:59) Vitamin D and Serotonin
(07:15) Importance of Testing Vitamin D Levels
(07:27) Vitamin D Supplementation Dosage

Take Control of Your Health
Don't be part of the statistics. Consult your physician or pharmacy today to get your Vitamin D levels checked. Your health is in your hands.

🎧 Don't forget to leave us a review and share this episode with your network!
🎧 Subscribe for more exclusive content from industry leaders.
🎧 Special thanks to our sponsors. Check out the companies that make this podcast possible!

Support the show

Join the Podcast Newsletter: Link

View Details

Did you know that the fight against climate change is shaping up to be the biggest business opportunity since the rise of the internet?

Imagine a multi-trillion-dollar market waiting to be tapped! Yair Reem and his €300M venture capital firm, Extantia Capital, are not just imagining it—they're building it.

Tune in to discover how you can be part of this green gold rush!
🎙️ What's in the Episode:1️⃣ The Urgency of Climate Change: Yair discusses why climate change is not just an environmental issue but a ticking time bomb that affects every sector of the economy.
2️⃣ The Role of Venture Capital: Learn how Extantia Capital is more than just a fund—it's a €300M platform that unites mission-driven entrepreneurs, scientists, and business leaders to advance the transition to a greener future.
3️⃣ The Multi-Trillion Dollar Opportunity: Yair shares insights into how the fight against climate change creates unprecedented business opportunities, potentially even 100x bigger than the internet revolution.

👨‍💼 About Yair Reem:
Yair Reem is more than an investor; he's a builder. From childhood Legos to Electrical Engineering and co-founding Extantia Capital, his path is fueled by a drive to make impact. With experience on both sides of investment, he knows what makes a firm succeed. His motto, "Do well by doing good," shows his belief that profit and impact can coexist.

💡 LINKS TO MORE CONTENT
Host:
Speaker

📌 Quotes:
(21:10) "The technologies we have today can only take us halfway to net zero emissions. There's a lot of technology that still needs to be developed and scaled to make it ready for the mass market."
(23:38) "To bridge the 50% gap in fighting climate change, we need to deploy capital to motivate scientists to develop new solutions and companies to scale those solutions."
(57:58) "When we look at the intersection of public and private sectors, we see that regulators are essential for both basic research and for making certain industries profitable where they currently aren't. But the key question remains: How do we ensure that these profits are reinvested to drive down costs and improve processes, rather than being siphoned off for other uses?"
(1:07:08) "The worst time to raise money is when you need it; the best time is when you don't."
(1:36:32) "We don't just take a good team and build a good product with them; we take a good team with a good product and help make that an excellent business."
(2:01:12) "My wish is that we will see much more peace in the future, thanks to ubiquitous and cheap energy."

⏰ Timestamps:
(03:30) Yair Reem's Journey: Electrical Engineering to Climate Tech
(09:33) Urgency of Climate Change
(21:10) Tech Gap: Net Zero Emissions by 2050
(22:06) Tech Innovation in Climate Change
(23:38) Bridging the 50% Gap
(30:36) Sustainability, Growth, Social Justice
(40:38) Short-Term Sacrifice for Long-Term Gain
(42:31) Role of Regulation in Climate Solutions
(48:47) Financial Returns in Climate Investments
(59:01) Airline Profits: Bankruptcy to Flourishing
(1:03:34) The Tim Cook Effect
(1:13:02) VC Ecosystems: Secret Sauce
(1:19:57) Art of Syndication in High-Stakes
(1:28:35) Retrofitting the Future
(1:39:40) Uninvestable Cap Tables
(1:40:56) Negotiating Equity with Universities
(1:47:44) Double-Edged Sword of Secondary Investments
(2:01:05) Future of Energy: Ubiquitous, Free Access

Support the show

Join the Podcast Newsletter: Link

View Details

"Are you tired of the long, winding road of drug discovery, full of dead-ends and costly detours? Do you wish there was a more efficient way to navigate the complex landscape of pharmaceutical R&D?

In this episode, we bring you the solution that promises to be the 'Google Maps' for drug discovery. Samantha Dale Strasser, PhD, CSO and co-founder of Pepper Bio, shares her revolutionary approach to drug discovery that's already making waves in the healthcare industry.

👉 Don't miss out on this game-changing conversation. Click below to watch the full episode or listen to the entire podcast.

🎉 Special thanks to our sponsors for making this episode possible.

Join my newsletter
Christian Soschner
Samantha Dale Strasser

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

In this special episode, we bring you exclusive insights from Warren Buffett and Charlie Munger, straight from the Berkshire Hathaway 2023 Shareholder Meeting. They tackle the age-old investor's dilemma:

How to balance short-term profits with long-term sustainability. Whether you're a retail investor or running a multi-billion dollar fund, this episode is packed with wisdom you won't want to miss.

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Is revolutionizing patient care through biotechnology an ambitious dream, or is it the future of medicine? Dr. Daniel Vitt, a leading figure in the biotech world, challenges the status quo and brings a fresh perspective to these questions.

Dr. Daniel Vitt is the CEO of Immunic Therapeutics, a company at the forefront of developing groundbreaking treatments for chronic inflammatory and autoimmune diseases. With a background in molecular biology and a passion for innovation, he is steering Immunic towards a future where patients have more effective and safer treatment options.

In this episode, we delve into:

• The visionary approach of Immunic Therapeutics in treating multiple sclerosis and leaky gut.
• The challenges and triumphs of bridging European and American biotech markets.
• The role of serendipity in scientific discovery and innovation.
• The future of Immunic: clinical trials, stock prices, and global expansion.
• Daniel’s three key lessons for anyone daring to start their own company in the biotech industry.
• Don't miss out on this insightful conversation. Subscribe to our channel and join us in exploring the future of biotech with Dr. Daniel Vitt.

💡 LINKS TO MORE CONTENT
Youtube
Christian Soschner:
Today’s speaker is Dr. Daniel Vitt:

📖 Memorable Quotes:
(00:02:23) "Every morning, when I go to work, I enjoy being part of an industry that improves patients' lives."
(00:05:26) "Understanding the key and lock principle in biology is our path to curing diseases."
(00:24:49) "Serendipity means you're searching for a needle in a haystack, but you find something unexpected and even more valuable."
(01:13:23) "If you are early and have a big vision, you can succeed easily."
(01:32:35) "Expect the unexpected and be prepared. Adaptability is key in our rapidly changing industry."

⏰ Timestamps:
(00:01:15) Unveiling the Future of Patient Care
(00:05:26) Decoding the Key-Lock Principle in Biology
(00:11:16) The Dynamic Dance of New Technologies in Healthcare
(00:16:54) Misconceptions: Multiple Sclerosis vs. Parkinson's
(00:17:41) Exploring the Link: MS, Parkinson's, and Neurodegeneration
(00:24:15) The Power of Serendipity in Scientific Discovery
(00:35:07) Addressing Celiac Disease: A New Approach
(00:39:10) The Challenges of Multicenter Multinational Studies
(00:48:49) A Potential Game-Changer: Restoring the Gut
(00:50:38) Western Lifestyle's Impact on Gut Health
(00:52:18) The Balance of Lifestyle and Disease
(01:02:12) The True Cost of Drug Development
(01:08:31) Unveiling a Multi-Billion Opportunity: The Market Potential
(01:12:40) The Bavarian Biotech Boom: A Tale of Visionary Politics
(01:22:31) Crossing the Atlantic: European Biotech’s Path to U.S. Success
(01:23:51) Navigating the Global Biotech Landscape: Daniel Vitt's Perspective
(01:26:41) The Next Leap: Interim Analysis of a Pivotal Phase Two Study
(01:32:35) Adaptability in Biotech: Learning from Biontech's Success Story

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Ever wondered how AI is revolutionizing drug discovery?

Dive into this insightful conversation with Marco Schmidt, the brilliant mind behind Biotx.ai.

As the CSO, Marco has been at the forefront of leveraging AI and genetics to predict drug success. In this clip, he shares his journey from data interpretation to predictive statistics, the inception of Biotx.ai, and the transformative impact of artificial intelligence on drug development.

Discover the future of medicine and the role of AI in shaping it.

If you find this intriguing, don't forget to like, comment, subscribe, and share.

Let's drive the conversation forward!

Full episode

Join my newsletter
Check out the sponsors to support the show
Full Episode
Christian Soschner
Marco Schmidt

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Ever feel like your emotions are driving your investment decisions? You're not alone. It's a wild ride in the investment world, and it's all too easy to let our emotions take the wheel. But here's a secret from two of the greatest investors of our time, Warren Buffett and Charlie Munger.

In this clip from the 2023 Berkshire Hathaway Shareholder Meeting, they spill the beans on how they keep their emotions in check. They've made their fair share of bad investment decisions, but they've never let their emotions dictate their choices.

This is a game-changer, folks. The market is a roller coaster, and if we let fear and greed take over, we're in for a bumpy ride. But Buffett and Munger remind us to stay cool, calm, and collected.

Investing isn't about making a quick buck or panicking when things go south. It's about making smart choices based on solid research and sticking to your guns, even when the market is doing somersaults.

So the next time you feel your heart racing or your palms sweating over your investments, take a deep breath and channel your inner Buffett. Keep those emotions in check, stay disciplined, and keep your eyes on the prize.

Check out the clip to hear it straight from Buffett and Munger. And don't forget to share it with your fellow investors. The more we learn, the better we can navigate the wild world of investing.

Youtube

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Climate change is here, and it's urgent.

In this clip, Dr. Kimberley R. Miner, a Climate Scientist at NASA, unveils her top three actions to combat climate change.

From halting carbon emissions to preserving biodiversity, Kimberley's insights are a must-listen for anyone concerned about our planet's future.

Tune in to discover what we can do today to safeguard tomorrow.

Don't forget to subscribe for more insights! This is a conversation you won't want to miss.

Join my newsletter
Check out the sponsors to support the show
Full Episode
Christian Soschner
Kimberley Miner

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

"Believe in the team, invest the money." This is Philipp Baaske, founder and CEO of NanoTemper Technologies.

His company, a global biotech powerhouse, is on a mission to create a world where every disease is treatable.

Philipp's journey from a small Bavarian village to leading a global team of 240 is inspiring. His company now generates over 35 million in annual revenue.

His secret? Start small, dream big, and invest profits back into the business.
In this clip, Philipp shares his insights. He talks about the importance of angel investors in startups.

They're not just financial backers. They're partners. They're believers in the team and the vision.

His story echoes the audacity of tech giants. Like Bill Gates selling an operating system before it was fully developed. Like Steve Jobs' relentless focus on customer experience at Apple.

Join us for this enlightening conversation. Philipp offers a rare glimpse into the world of startups. He talks about the dynamics between startups and their angel investors. He emphasizes the importance of trust.

Click play. Dive into the world of startups and angel investing.

Don't forget to subscribe for more insights! This is a conversation you won't want to miss.

Join my newsletter
Check out the sponsors to support the show
Full Episode
Christian Soschner
Philipp Baaske

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Is investing in climate tech just a trend, or is it the future of venture capital? Doerte Hirschberg, a leading figure in the VC world, challenges the status quo and brings a fresh perspective to these questions.

Doerte Hirschberg is the co-founder and managing partner of Climentum Capital, a venture capital firm that focuses on climate tech investments. With a background in traditional investments, she has transitioned into the climate tech space, bringing with her a wealth of knowledge and a unique perspective on the intersection of business viability and environmental sustainability.

In this episode, we delve into:

The transition from traditional investments to climate tech.
The intersection of climate tech and business viability.
The role of women in venture capital and the gender gap in VC investment.
The role of regulations and capital in shaping Europe's climate tech future.
Balancing work and family life in the demanding world of venture capital.
Don't miss out on this insightful conversation. Subscribe to our channel and join us in exploring the future of climate tech investing with Doerte Hirschberg.

💡 LINKS TO MORE CONTENT
Youtube
Christian Soschner
Today’s speaker is Doerte Hirschberg

📖 Memorable Quotes:
(04:49) "Installing solar and investing in energy-saving technologies make sense from a business case point of view."
(15:04) "Climate change and CO2 emissions are measurable impact topics, making our fund's impact target as credible as our financial ones."
(35:04) "In the VC investment field, you mostly have male teams or one woman, especially in the industrial sector."
(39:17) "The traditional venture capital game is about the winner. Women, making up 50% of consumers, can see many trends and insights more clearly."
(01:06:37) "My aspiration is a transition towards a more sustainable industry and society, reducing extreme poverty and maintaining Earth as a livable place."

⏰ Timestamps:
(00:01:00) Initiating Discussion on Climate Change Investments
(00:02:42) Transitioning from Traditional Investments to Climate Tech
(00:05:33) The Intersection of Climate Tech and Business Viability
(00:12:02) Exploring the Power of University Innovations
(00:14:10) The Art and Science of CO2 Investing
(00:20:16) The Intersection of Technical Expertise and Global Reach
(00:26:02) Pragmatism in Green Transition
(00:30:02) The Role of Capitalism in Green Innovation
(00:34:02) Embracing Diversity in the Green Sector
(00:38:47) Risk Aversion: Women as Better Investors?
(00:40:07) Closing the Gender Gap in VC Investment
(00:46:06) The Role of VCs in Startup Success and Growth
(00:51:14) Unveiling the Unique Selling Proposition in Venture Capital
(00:52:13) The Journey of a New Fund: From First Closing to Future Aspirations
(01:01:32) The Role of Regulations and Capital in Shaping Europe's Climate Tech Future
(01:05:46) Investing in Venture Funds: The Right Time and Momentum
(01:06:37) Vision for a Sustainable Future: From Dreams to Reality
(01:09:08) Investing in Innovation: The Case of Vegan Cheese
(01:20:58) Harnessing Power and Energy from Diverse Engagements
(01:22:46) Efficiency in Balancing Work and Family Life
(01:25:24) The Role and Impact of White Papers in Investment

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Failure is a common theme among entrepreneurs, but it's how you handle it that sets you apart.

In this video, you'll hear from NVIDIA's CEO, Jensen Huang, t how he overcame failure and achieved success.

He has weathered the storm of failure, only to emerge stronger and more determined leading NVIDIA to a 1 trillion dollar market cap in 2023.

On this channel, we're all about unearthing these inspiring stories and delivering motivational content that fuels your ambition.

Tune in to this episode to gain invaluable insights and ignite your drive to conquer your own entrepreneurial journey.

Youtube

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Join Tobias Silberzahn, a Partner at McKinsey's Berlin office and a leader in the global Health Tech Network, as he delves into the crucial role of lifestyle habits in maintaining mental health and well-being.

In this enlightening talk, Tobias discusses the importance of sleep, nutrition, mobility, fitness, and purpose, providing practical advice that viewers can apply in their daily lives. He also explores the biochemical processes involved and the effects of sleep deprivation and lack of movement on anxiety levels.

Don't miss this opportunity to learn from a leading expert in healthcare innovation and digital transformation.

Join my newsletter
Check out the sponsors to support the show
Full Episode

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

In a world on the brink of climate catastrophe, one woman stands at the forefront of scientific discovery and action. "We found the highest microplastics in the world on Mount Everest, a sad Guinness World Record to hold," reveals Dr. Kimberley R. Miner in this gripping episode.

Dr. Miner is a Climate Scientist and Program Manager at the NASA Jet Propulsion Lab, a Guinness World Record holder, and an adventurer who has braved the extreme environments of the North Pole, Antarctica, and Mt. Everest. Her groundbreaking research on climate risks has garnered international recognition, with features in the BBC, NYT, and GQ.

This episode takes you on a journey from the icy slopes of Everest to the cutting-edge labs of NASA. It delves into the pressing issues of climate change, the surprising discovery of microplastics at extreme altitudes, the role of art in science communication, and the importance of diverse perspectives in tackling global challenges. It also offers a sneak peek into Kimberley's upcoming book on how younger generations can plan for climate change.

This is a riveting exploration of our planet's most pressing issue, through the eyes of a scientist who has literally seen it from top to bottom. A must-listen for those seeking to understand the real-world implications of climate change and the solutions that science and innovation can offer.

💡 LINKS TO MORE CONTENT
Youtube
Christian Soschner:
Today’s speaker is Kimberley R. Miner:

📖 Memorable Quotes:
(00:07:00) "We're changing Earth's dynamics faster than ever before."
(00:15:36) "We can create a healthier, more natural planet with advanced tools."
(00:24:15) "Forecasting changes due to climate change is a monumental task."
(00:40:39) "Stop releasing carbon, dedicate land to wilderness, and engage in conversations about our planet's reality."

⏰ Timestamps:
(0:00) Kickoff
(4:53) Current Status of Climate Change: A Global Perspective
(8:22) The Sixth Mass Extinction: Biodiversity Loss and Ecosystem Collapse
(11:11) Unveiling the Power of Emit: NASA's Methane Tracker
(16:07) The Journey to Becoming a Climate Scientist at NASA
(21:03) The Arctic Methane Challenge: A Collaborative Effort
(22:22) Unraveling the Climate Crisis - Microbes, Methane and Melting Permafrost
(25:29) The Immediacy of Climate Change - A Matter of Decades
(29:43) The Invisible Threat - Toxic Chemicals in a Changing Climate
(33:30) Unveiling the Highest Microplastics on Mount Everest
(36:30) The Top Three Actions to Combat Climate Change
(42:47) The Role of Biodiversity in Addressing Climate Crisis

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Join us as we dive into a captivating discussion with Brian Feroldi, a financial educator and author, who simplifies the complex world of investing.

In this episode, Brian shares his insights on why the stock market goes up, the power of cost averaging, and his biggest investment mistake.

Subscribe and learn how to navigate the financial world with ease.

Join my newsletter
Check out the sponsors to support the show
Full Episode

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

ive into the untold stories of PayPal's meteoric rise!

This video takes you back to the 90s, a time when the internet was just beginning to transform business. It was a challenging era, with limited access to information and a lack of understanding about the potential of the internet.

Fast forward to today, and we see the fruits of the labor of PayPal's founders. They not only survived the dot-com bubble but also thrived, becoming some of the most influential figures in the tech industry.

How did they do it? What lessons can we learn from their journey?

This video explores how PayPal's founders drove 21st-century innovation and entrepreneurship, forming, funding, and advising some of the leading companies of our era, including Tesla, Facebook, YouTube, Space X, Yelp, Palantir, and LinkedIn.

Tune in to discover the secrets behind their success, gain unprecedented insights from hundreds of interviews and thousands of pages of internal material, and learn how you can apply these lessons to your own entrepreneurial journey. Don't forget to like, share, and subscribe for more inspiring content!

Join my newsletter
Check out the sponsors to support the show
Full Episode

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Welcome back to another episode of Memorable Moments. Today's spotlight is on the conversation with Sebastian Mallaby, acclaimed author of 'The Power Law'.

Venture capital, often a labyrinth of jargon and complex concepts, is made accessible through Mallaby's unique storytelling approach. This episode reveals the meticulous process behind his writing, showcasing the comprehensive research and interviewing methods that shape his work. It's a testament to the power of storytelling in making even the most complex subjects engaging.

The journey continues with the uncovering of the stories behind venture capital. These narratives, brought to life through Mallaby's exceptional storytelling, offer a fresh perspective on the world of venture capital.

Curiosity about the evolution of venture capital or a simple appreciation for great storytelling makes this episode a must-listen. This memorable moment with Sebastian Mallaby invites listeners to immerse themselves in the fascinating world of venture capital. Listen now, and let the journey begin.

Join my newsletter
Check out the sponsors to support the show

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Entrepreneurs and investors often grapple with the complexities of the biotech industry. The high risk associated with drug development, coupled with the intricate regulatory environment, can make biotech investments seem daunting. Moreover, the need for substantial capital and the long timeline for potential returns can further complicate the investment decision.

This clip provides a comprehensive overview of the biotech investment landscape, offering valuable insights from industry experts. By watching this clip, you will understand the challenges and opportunities in biotech investments, learn about the importance of patient capital, and discover strategies to mitigate risks. This knowledge can empower you to make informed investment decisions, potentially leading to high returns and contributing to advancements in healthcare and medicine.

📖 Quote:
(04:44) And we would have lost all of our money. And that's what investors have to go through every day. And so we're trying to put it in language so that every Joe understands that if you price fix these drugs, you will stop the cures of the future.

⏰ Timestamps
00:00:00 "High Stakes in Biotech Investing"
00:01:24 "Standing Up for Science"
00:02:36 "Price Fixing Stifles Innovation"

Watch the full video:

💡 LINKS TO MORE CONTENT
Podcast: https://beginnersmind.buzzsprout.com/779930/12959749
Rich Masters: https://www.linkedin.com/in/rimasters/
Christian Soschner: https://www.linkedin.com/in/christiansoschner/

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Navigating the biotech industry's rapid advancements and complex regulations can be daunting. High-stakes investments and the pressure to innovate further add to the challenge.

Rich Masters, the CMO of BIO (Biotechnology Innovation Organization), is a seasoned expert in this field. His role in organizing the BIO International Convention and his extensive industry experience equips him with unique insights to tackle these challenges.

In this fantastic podcast episode, we delve into:

🔬 The behind-the-scenes experience of organizing and attending the BIO International Convention 2022 in San Diego.
🔬 Rich's journey to the helm of BIO as CMO and his vision for the organization.
🔬 The meticulous preparations for the upcoming BIO International Convention 2023 in Boston, anticipated to be a landmark event in the biotech calendar.
🔬 The innovative features and services introduced for the BIO International Convention 2023, including the BIO Podcast series and the BIO News platform.
🔬 Rich's perspective on the future of the biotech industry, discussing potential challenges and opportunities for 2024 and beyond.

💡 LINKS TO MORE CONTENT
Youtube
Christian Soschner:
Rich Masters

📖 Memorable Quotes:
(13:50) "The majority of biomedical and drug innovation investments fail... This ecosystem is crucial and needs protection."
(15:00) "Developing a drug is an expensive process... Without investment, the engine of innovation stalls, we don't see new drugs on the market."
(16:38) "If you price fix these drugs, you are going to stop the cures of the future."
(20:01) "What we're witnessing worldwide is an attack from socialist-minded groups against intellectual property, our only asset."
(26:18)"Our main focus may be on Washington, but we work closely with our International Biotech Association based in Brussels. We have numerous international partners."
(29:09) "As the next pandemic looms, the question is, do we want all drug development concentrated in one country, or a viable drug development market in the West?"
(42:12) "We can't continue to stifle innovation and science and then expect to create the next generation of cures... we're eliminating entire classes of diseases."
(44:10) "Biotechnology provides the solution for eliminating food insecurity, transitioning from fossil fuels to green energy sources, and ending disease... we need to establish policies that encourage, rather than stifle, innovation."

⏰ Timestamps:
(03:45) - [Recap: BIO Convention Collaboration Success]
(05:18) - [BIO Event Excellence: Future Planning Insights]
(10:36) - [Inside BIO: CMO's Role & Event Portfolio]
(17:05) - [Decoding Biomedical Investment Ecosystem]
(20:31) - [Behind BIO Conventions: Passion & Effort]
(22:15) - [Biotech Investment: Price Fixing & IP Challenges]
(27:41) - [Capital Formation in Biotech: Navigating Economic Shifts]
(29:33) - [Global Biotech Politics: Washington & Brussels Focus]
(32:24) - [Fu

The Physician Syndicate: Angel Investing | Venture Capital | Startups | Personal Finance
The Physician Syndicate Podcast: A podcast for physicians to jump into the startup world.
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Navigating the investment landscape can be a daunting task. It's easy to feel like you're constantly making the wrong moves and not achieving your financial goals. This episode brings you the wisdom of legendary investor Mohnish Pabrai, who shares his insights on overcoming these hurdles and achieving success in investing.

Here's what you can expect from this episode:

Understanding Cognitive Biases Time Marker: (01:44): Our brains, evolved over millennia, are not naturally wired for investing. Mohnish Pabrai explains how understanding our cognitive biases can help us become better investors.
The Importance of Patience Time Marker: (03:28): Successful investing requires a long-term approach and a willingness to hold on to great businesses. Pabrai shares his thoughts on why patience is a virtue in investment.
Lifelong Learning Time Marker: (05:04): The investment landscape constantly changes. Pabrai emphasizes the significance of continual learning in staying ahead in the investing game.

By the end of this episode, you'll better understand how to navigate the investment landscape and make more informed decisions. So, tune in, take notes, and let's embark on this journey to financial growth together.

Don't forget to share this episode with your friends and colleagues who might find it useful. And if you enjoyed this episode, please leave us a review. Your feedback helps us improve and reach more people like you.

Youtube

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Are you tired of seeing the world struggle with global health crises? It's a harsh reality that many vaccine-preventable diseases continue to devastate vulnerable populations. But there's hope on the horizon!

In this eye-opening episode, we dive deep into a conversation with Colin McCann, a key player at the International Vaccine Institute (IVI), who shares incredible insights into their innovative approach to combatting these health challenges. You'll discover the groundbreaking strategies and collaborative efforts reshaping how we develop and deliver life-saving vaccines to those who need them most.

Don't miss out on this unique opportunity to learn about the future of global health and how the IVI is making a real difference. Click now to watch the full episode and get inspired!

💡 LINKS TO MORE CONTENT
Youtube
Christian Soschner:
Colin McCann

📖 Memorable Quotes:

(29:30) "IVI's role is to pick up challenges that the pharma industry would turn down, starting with comprehensive disease burden studies and surveillance to determine the true burden of neglected diseases."
(40:02) "There's the great problem of the translational graveyard - we have lots of wonderful vaccine candidates sitting on shelves around the world collecting dust, instead of saving lives."
(41:47) "European developers should realize that they could manufacture their vaccines in Africa, Latin America, or Asia and maintain profitability in doing so."
(55:51) "Countries that are often in tension with each other are able to cooperate on vaccine development."
(01:01:46) "By linking low & middle income countries together, they can train each other and build upon each other's abilities."
(01:18:44) "IVI's proven model: developing a vaccine from evidence through licensure & delivery, takes a comprehensive approach."

⏰ Timestamps:
(02:28) Vienna: The Hub for IVI's European Expansion
(07:55) The Unconventional Path to Joining the International Vaccine Institute
(11:09) Colin's journey: From wind turbine engineer to IVI member
(17:51) Bridging the gaps in vaccine development and scaling
(21:47) IVI's role in growing South Korea's biotech sector
(28:31) IVI's Role in Addressing Unmet Vaccine Needs
(35:56) Exploring IVI's Role in Clinical Development and Vaccine Manufacturing
(38:31) Facilitating Industry Partnerships and Filling Global Health Gaps
(42:42) Attracting Private Investors and Venture Capital in Vaccine Development
(45:50) The Role of CEPI in Addressing the Funding Gap for Vaccine Development
(49:35) ASEAN: Coordinating Vaccine Development and Streamlin

The Sales Warrior Within
Discover and Empower The Sales Warrior Within You
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Discover the groundbreaking journey of Nanotemper Technologies as CEO Philipp Baaske shares his passion for space exploration, science fiction, and the company's ambitious project aboard the International Space Station. Learn how microgravity is poised to revolutionize biotech research and redefine our understanding of protein stability. Don't miss this exclusive conversation with one of the most innovative minds in the industry!

Quote:
(02:44) "To really understand what temperature alone does to [antibodies] without flows, you have to switch off gravity, which you can't do on Earth. But on the International Space Station, with microgravity, there's nearly no influence of gravity, so we can study the stability of antibodies without the influence of gravity or thermal convective flows."

⏰ Timestamps
(00:44) Passion for Space Exploration: Star Trek, Star Wars, and SpaceX
(03:25) Organizing a Space Project: Collaboration and Opportunities
(05:16) Pursuing Exciting Projects for Fun and Scientific Advancement
(06:39) Inspirations from Science Fiction: Isaac Asimov's Lucky Star

Watch the full video:

💡 LINKS TO MORE CONTENT
Podcast: https://beginnersmind.buzzsprout.com/779930/12585340
Philipp Baaske: https://www.linkedin.com/in/philipp-baaske/
Christian Soschner: https://www.linkedin.com/in/christiansoschner/

nanotemper #spaceexploration #microgravity #philippbaaske

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Discover the secrets behind Elon Musk's captivating Powerwall presentation and learn how to engage your audience like a true visionary! Another special episode on the podcast unmasking presentation secrets.

In this episode, we dive deep into the art of storytelling, persuasion, and communication used by Musk during his groundbreaking Tesla Powerwall speech. Uncover the key techniques that made this presentation so influential and explore how you can apply them to captivate your own audience. 🚀

🔹 Time Markers:
(00:36) Introduce a Villain
(01:15) Agitate the Problem
(01:51) Spark Intrigue
(02:26) Offer the Missing Piece of the Puzzle
(02:44) Show, Don't Tell
(04:12)Sell Benefits, Not Features
(05:01) Create Urgency
(05:46) Build Trust
(06:43) Demonstrate the Potential
(08:02) Show Your Long-Term Vision

Youtube video: https://youtu.be/6YpO3XS_x8U

By analyzing these powerful moments, we'll unlock the keys to Elon Musk's presentation success. Learn how to inspire, educate, and captivate your audience, just like the Tesla CEO himself.

Don't miss this opportunity to transform your own presentations and make a lasting impact! 🌍🔋

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

In this captivating episode of our podcast, we address the pressing issue of gender diversity within the tech and venture capital sectors, inviting Jeevan Sunner, a distinguished investor from Playfair Capital, to share her invaluable insights on the matter. Jeevan emphasizes the importance of promoting female representation in the industry and explores the vast opportunities that can arise from embracing diverse perspectives.

As CEOs and investors, understanding the immense value of nurturing a more inclusive environment is essential to unlock the full potential of the tech sector and maximizing investment returns. This episode sheds light on the challenges faced by women in tech and venture capital and discusses the actions that can be taken to create a more equitable landscape.

Tune in to this enthralling conversation and learn how your organization can foster change and benefit from increased diversity in the tech and venture capital fields. Don't miss this chance to listen to a leader who is spearheading the movement for inclusivity and championing the transformative power of gender equality in the tech world.

Subscribe to our podcast and stay informed on the latest trends and insights that will help you navigate the ever-evolving landscape of the tech and venture capital industries.

Link to full episode

⏰ Timestamps
(00:00) Intro
(01:00) Jeevan Sunner talks about the Gender GAP in the Startup World

💡 LINKS TO MORE CONTENT
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Watch on Youtube
Jeevan Sunner
Christian Soschner

Support the show

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Unlock the secrets to startup success! Dive into an engaging conversation with DC Palter, a seasoned startup founder, CEO, and angel investor, as he shares invaluable insights and advice for CEOs and investors. Explore resilience, Japanese culture's impact on business, and innovative strategies. Don't miss out!

💡 LINKS TO MORE CONTENT
Check out our partners
Youtube
Christian Soschner
Today’s speaker is DC Palter

📚 Book mentions in the episode:
To Kill a Unicorn
The Power Law

📖 Memorable Quotes:
(14:42) "We need to think outside the box, have a goal, a dream; sometimes it works out spectacularly, and a lot of times it doesn't, but we tried and that's the building blocks for the next one."
(42:23) "The number that's always quoted is “90% will fail”, but that doesn't mean fail outright. That means not succeeding as expected. About half of those will actually fail outright and give you no return, and then another four will give you something like your money back, maybe a little bit more, maybe a little bit less. So we call that a failure anyway, even though they haven't really completely failed."
(01:01:56) "You can have a really simple idea, but if you have a lot of customers for it, if you know how to market it and build up a brand name, you can make a lot of money – and that's what investors are looking for."
(1:27:57) "Marketing is about understanding the business, the market, and the customers, and becoming part of that community, so that customers find you."
(1:48:07) “Embrace resilience, for every day is a challenge. You may be familiar with the English expression, 'three steps forward, two steps back.' However, in the world of startups, it's more like taking three steps forward and 2.9 steps back. Indeed, each day is a roller coaster ride.”

⏰ Timestamps:
(01:46) Tea Ceremony, Japanese Culture, and Shared Interests
(05:15) Who is Satoshi Nakamoto?
(06:39) Silicon Valley Life, Work, and Writing Experience
(07:22) Arnold Schwarzenegger and the Startup World
(13:00) Tesla's Success: Overcoming Skepticism in Electric Vehicles
(16:21) Theranos: Fake it Till You Make It
(20:04) The Valley of Death: Challenges in Raising Money for Hard Tech Startups
(24:42) Defining Financial Investor: Angel vs. Venture Capitalist
(29:03) Investing in Startups: Balancing Personal Interests and Group Expertise
(36:56) Uncovering success in the startup landscape
(41:57) The long game of angel investing and managing expectations
(48:23) The Mindset and Motivations of Angel Investors
(56:34) Key Advantages of Angel Investments and Avoiding Startup Pitfalls
(01:01:59) Crafting the perfect pitch: focus on product, market, and customers
(01:07:09) Diversifying startup funding: alternatives to venture capital
(1:12:12) Unraveling a Startup's Dark Secret: Discovering the True Intentions of Super Duper

Make People Better Podcast
Science fiction is becoming science fact. In 2018, the team behind this podcast...
Listen on: Apple Podcasts Spotify

The LSG2G Partners
Experts in Life Science

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Join us in this episode as we talk to Philipp Baaske, CEO of Nanotemper, and explore the ins and outs of building a successful biotech startup. We cover topics such as bootstrapping, finding customers, developing effective leadership skills, and more. Gain valuable insights and advice from Philipp's experiences as a business angel and entrepreneur. Tune in to learn how to build and scale a successful biotech startup.

💡 LINKS TO MORE CONTENT
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Philipp Baaske
Christian Soschner

📖 Memorable quotes:
(36:18) "First of all, I disagree with Steve Jobs, it's important to talk with customers about their problems, but it's really about the problem, not talking about a technical solution."
(48:17) "If you don't fail, you do something wrong because if it always works, you don't do the risky thing; you just do the easiest thing."
(01:10:20) "This is my advice on startups: sell. Sell a product before you have it because if the customer gives you money for it, you know that it's worth developing it."
(01:12:39) "We never thought about failing. Failure was not in our mind."
(01:19:31) “I strongly believe that every disease is treatable.”

⏰ Timestamps:
(00:00) Introduction
(02:30) The Impact of SVP Bankruptcy on Entrepreneurship
(06:41) The Importance of Proper Risk Management
(09:51) Absolute Focus on the Things You Can Influence
(12:05) Managing a Global Team: Trust, diversity, and decentralized decision-making
(14:56) Trusting the Best People
(17:01) Hiring with Gut Feeling and CV-Application Letter Match
(20:32) Marketing and Cultural Diversity
(28:43) The Importance of Product-Market Fit Over Funding and Investors
(29:12) Finding Customers vs Finding Investors
(33:43) Milestones and Helping Customers
(38:00) Talking to Customers About Their Problems
(40:06) Identifying Markets and Competitors
(42:56) Unlocking New Cancer Treatment Pathways
(45:26) Overcoming Failure in Startups and Drug Discovery
(48:49) Breaking Out of Confinement and Pursuing Goals
(56:37) Impact of Upbringing on Entrepreneurial Spirit
(57:33) Stop complaining, start improving: lessons from Vienna
(01:00:04) Curiosity-driven education: finding a passion for physics
(01:03:21) Experimenting in microgravity: sending projects to the ISS
(01:14:20) Startup advice: focus on sales and steady growth
(01:12:39) Overcoming adversity: believing in our technology
(01:15:31) The potential of every disease being treatable
(01:18:22) The impact of smoking on cancer risk
(01:23:17) Leadership lessons: walking the talk and starting with yourself
(01:26:35) Emotional Side of Leadership: How Emotions Drive Success
(01:28:57) Balancing Kindness and Assertiveness in Leadership
(01:31:49) Fostering Trust and Transparency in the Workplace
(01:35:35) Maintaining the Spirit of Innovation While Scaling a Company
(01:41:04) Struggles and Support from Business Angel Experience
(01:42:13) Learning as a Business Angel: Insights and Expectations
(01:45:01) The Impact of Toxic Behavior on Company Growth
(01:48:56) Defining the Role of Business Angels in Startups
(01:55:09) Balancing Executive and Investor roles
(01:56:09) Investing in Teams You Can Trust
(01:57:33) Building a Successful Company During Shutdowns
(01:58:25) Advice to Younger Self: Do Your Thing and Reconsider the Impossible

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

In today's episode, we uncover the hidden crisis in the pharmaceutical industry as we explore the alarming state of R&D productivity. Our guest, Dr. Jack Scannell, is a renowned scientist and entrepreneur with extensive experience in both the biotech and investment fields. He shares his valuable insights into the concept of Eroom's Law, which reveals the inverse relationship between input efficiency and output efficiency in drug research and development.

Listen in as we discuss the challenges of measuring R&D productivity and how financial return and number of drugs approved per unit input serve as key indicators of productivity. Dr. Scannell helps us understand the reasons behind the decline in R&D productivity since the 1950s and the factors that have contributed the most to this concerning trend.

Don't miss this enlightening conversation that exposes the harsh reality of pharmaceutical R&D productivity, and be sure to share your thoughts and opinions by leaving a review or engaging with us on social media. We'd love to hear from you!

Stay informed on the latest developments in pharmaceutical R&D productivity and other pressing global challenges by subscribing to our podcast. Your support helps us continue to bring you thought-provoking discussions and expert insights.

Link to full episode

⏰ Timestamps
00:00 Intro
01:00 Jack Scannell Explains Eroom's Law

💡 LINKS TO MORE CONTENT
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Watch on Youtube
Jack Scannell
Christian Soschner

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

In this video, I review the science fiction novel "Project Hail Mary" by Andy Weir. As a fan of the genre, I was excited to dive into this action-packed and thought-provoking book that takes a critical look at some of the global issues we face today.

I discuss the strengths and shortcomings of the book, as well as its potential pleasures and delights for science fiction enthusiasts. Join me as I explore the captivating story of Ryland Grace, a science teacher who wakes up alone in a spacecraft and must use his knowledge and skills to save the earth from an alien threat.

Don't forget to leave a comment with your thoughts on the book and whether you would recommend it to others.

💡 LINKS TO MORE CONTENT
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Check out our partners: https://linktr.ee/lsg2
Watch on Youtube
Christian Soschner

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Welcome to our new series, Memorable Moments!

In this series, we bring you highlights from past episodes that contain some of the most memorable insights and important information that you won't want to miss.

In this episode, we explore the groundbreaking potential of AI in drug discovery and anti-aging research.

Listen in as we share clips from our interview with Alex Zhavoronkov, who is leading the charge in this revolutionary technology that cuts costs, increases success rates, and drastically shortens the time it takes to develop new therapies.

Join us as we share memorable moments and life-changing insights that will help you discover the incredible potential of the future of medicine. Don't miss out on this powerful and inspiring episode of our podcast - tune in now!

Listen to the full episode

⏰ Timestamps
00:00 Intro
00:44 Alex Zhavoronkov Explains how his solution increases the probability of success, cuts costs and timelines in Drug Discovery and Development
07:20 Shout out to our new subscribers on Buzzsprout+

💡 LINKS TO MORE CONTENT
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Watch on Youtube
Alex Zhavoronkov
Christian Soschner
Check out the organizations that make the podcast possible

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Are you ready to dive into the future of medicine and the revolutionary advancements being made with artificial intelligence? In this episode, I sit down with Alex Zhavoronkov, the founder and CEO of Insilico Medicine, a global company focused on the discovery of novel therapeutics utilizing cutting-edge technology in healthcare.

From longevity research to anti-aging treatments, Alex shares his expertise on the
most impactful field of our time, discussing his work in protein target
discovery and the design of small molecule drugs using generative AI.

But it doesn't stop there. Alex also shares insights into the development of aging
clocks, biomarkers of aging, and precision medicine. Discover how generative AI
is transforming the pharmaceutical industry, improving clinical trials, and
providing a revolutionary new approach to drug discovery methods.

Don't miss out on this incredible opportunity to learn from one of the leading
experts in AI and healthcare innovation. Tune in now and join us on this
fascinating journey into the future of medicine.

📖 Memorable quotes:
(10:50) “Insilico Medicine synthesized and tested the first AI generated drug in 2017.”

(23:09) “Generative AI in Drug Discovery and Drug Development has the potential to improve the probability of success by 50%”

(24:00) “Generating 11 preclinical candidates in 2.5 years - is a pretty cool number.”

(29:48) “We developed a clinical candidate in 18 months at a 3 million dollar cost with the help of AI. The traditional route takes 2 years at about 400 million expeonses.”

(01:08:48) “Generative AI will transform our lives beyond recognition in every way.”

⏰ Timestamps:
(02:00) Introduction to Alex Zhavoronkov at World Government Summit 2023

(03:00) About World Government Summit 2023

(04:20) Alex's longevity research at Insilico Medicine

(08:20) Accelerating drug discovery with AI

(13:00) AI in synthetic biologic data

(15:00) Generative AI in reducing cost and increasing output

(23:30) Generative AI in increasing probability of success

(25:00) Why traditional drug R&D takes over 10 years and 2 billion 2010 dollars

(28:45) AI-driven drug discovery at Insilico Medicine

(30:30) Insilico Medicine's pipeline and case study

(38:09) Regulators' perception of AI in drug development

(45:26) Generative AI in clinical development

(49:15) Audience question on AI and microbiome research

(53:30) Operating a company between China, Middle East, and North America

(57:54) Insilico Medicine's fully automated robotics lab

(01:03:15) Ageing as the most important disease in the world (

01:08:00) Future impact of generative AI on medicine

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Are you struggling with your creative process?

Do you feel stuck in a rut or blocked by perfectionism? You're not alone. In this episode, I explore the remarkable letter from artist Sol LeWitt to Eva Hesse, which has inspired creatives for decades.

Not only creatives can get stuck and blocked. Also, entrepreneurs, scientists, and investors can have to face such situations in their lives.

Read by Benedict Cumberbatch for Letters Live at the Freemason's Hall in London, LeWitt's timeless advice urges us to stop overthinking and DO.

Embrace the process, let go of perfectionism, and believe in your ability to create.

Join me as I discover the wisdom of emptiness and how it can help you unleash your full potential. From conceptual art to minimalism, I delve into the fascinating lives of Sol LeWitt and Eva Hesse, two American artists who embarked on a supportive friendship that would inspire them both.

So sit back, relax, and let's listen to the words of Sol LeWitt as read by Benedict Cumberbatch. This episode is a must-listen for anyone looking to break free from creative blocks and unleash their full potential.

⏰ Timestamps
(00:00) Unleashing Your Creative Potential: The Remarkable Letter from Sol LeWitt to Eva Hesse Read by Benedict Cumberbatch
(01:15) Background Information to Sol LeWitt, Eva Hesse, and their Inspiring Correspondence
(04:00) Sol LeWitt's Timeless Advice to Eva Hesse: Stop Overthinking and Just DO
(06:25) Perfectionism Kills Creativity
(08:57) Embrace the Process, Don’t Focus on the Outcome
(10:09) Believe in your ability to create

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Do you ever wonder why it takes so long for new drugs to hit the market? Have you ever questioned the efficiency of the pharmaceutical industry?

Join me in this episode as we talk to Jack Scannell, a pharmaceutical industry expert, and discover the hidden efficiency secrets of drug development. In this episode, we delve into the critical factors that have shaped drug development over the last 60 years and analyze the industry's current state.

Throughout the podcast, Jack draws on his extensive industry knowledge and provides insights on the importance of decision quality, the role of AI in drug discovery, and the economics of the research model.

If you're looking to gain a better understanding of the pharmaceutical industry and its inner workings, join us in uncovering the efficiency secrets of drug development. Tune in to this episode.

💡 LINKS TO MORE CONTENT
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Watch on Youtube
Jack Scannell
Christian Soschner

📖 Memorable quotes:

(11:41) “Between 1950 and 2010, Drug Development saw a halving time: Every nine years, the number of drugs developed per billion dollars spent halved.”
(24:58) “4 Reasons for the Decline of Drug Development Productivity: Better Than the Beatles Problem, Higher Regulatory Hurdles, Throw Money at it Problem, Misindustrialisation of Science
(26:30) “Metformin is the Pharmaceutical Equivalent to the Beatles”
(45:15) “In early drug discovery, predictive validity, the degree to which your model output correlates with human clinical utility is critically important”
(01:19:31) “If the only tool you have to measure the height of the fruit is the rate at which you are picking fruit, and you notice that the rate of picking fruit is declining, you will always blame the low hanging fruit problem.”
(01:34:15) “When capital is freely available, the average quality is going down”

⏰ Timestamps:

(00:00) Introduction: Uncovering Drug Development Efficiency Secrets
(06:30) Background Jack Scannell: Pharma Journey
(09:15) Finding erooM’s Law: Playful Experiment Leads to Discovery
(12:00) Inversion of Output Efficiency: More Capital, Fewer Drugs
(13:15) Best Key Figure for R&D Productivity?
(20:24) Factors Behind R&D Productivity Decline - 1950 to 2010
(25:30) The Beatles Inform Drug Development
(28:34) The Regulatory Problem
(30:00) Throwing Money at the Problem & Misindustrialisation of Science
(31:00) Turnaround in Drug Development Efficiency from 2010
(38:30) Speeding Up Early-Stage R&D
(45:45) Technical & Managerial Components to Improve Speed
(47:10) Improving Predictive Quality of Models - Alzheimer's Case Study
(57:00) Interplay of Different Forces in Complex Problem Solving
(01:02:30) Model Quality Matters the Most for High R&D Quality
(01:12:45) Making Pharma Value Chain More Effective
(01:18:00) Appropriate Success Measure for Drug R&D?
(01:21:05) Role of AI in Drug Discovery Process
(01:29:32) Limiting Factor of AI in Biology?
(01:31:00) Ava

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Uncover the Secrets of Success with Arnold Schwarzenegger - Mastering the 6 Rules.

In this episode, join us as we delve into the mind of one of the greatest action heroes and successful entrepreneurs of our time.

Arnold Schwarzenegger shares his personal experiences and lessons learned as he reveals the key elements of his famous "6 Rules for Success" speech. Get inspired and motivated as you discover the blueprint for achieving your goals and realizing your dreams.

⏰ Timestamps:
(01:34) Rule #1: Have a Vision
(13:12) Rule #2: Ignore the Naysayers
(22:18) Rule #3: Work your A** Off
(28:01) Rule #4: Don’t have a Plan B
(33:38) Rule #5: Give Back
(39:52) Rule #6: You Need Help

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Are you curious about what it takes to be a female venture capitalist in 2023?

Join us as we sit down with Jeevan, a successful woman in the industry, to discuss the world of female entrepreneurship and venture capitalism. With her insights on the tech focus areas of 2023, the challenges of attracting women into the VC world, and the importance of warm referrals, Jeevan offers a unique perspective on the startup investment landscape. Get a glimpse into the life of a female VC as she shares her journey and valuable lessons learned. Tune in now to learn what it takes to become a venture capitalist in 2023 and expand your knowledge on the exciting world of startup investments.

📖 Memorable quotes:
(49:33) “Linkedin Made Investors in Silicon Valley Accessible”
(49:55) “Communication, Accessibility, Relationship building, and Information sharing make social media super powerful.”
(55:40) “Take your time and do your due diligence on investors to understand whether their values are aligned with yours and whether you see that 10-15 years partnership happening.”
(59:30) “We are flexible in the way we collaborate with founders. It can be a more passive approach, or for first-time founders more hands-on”
(01:09:00) “When it comes to dilution, we rather have a smaller slice of a bigger pie, than a massive slice of a smaller pie”

⏰ Timestamps:
(00:00) Unlocking the Secrets of Venture Capital: An Insider's View
(03:15) Brave the Winter of England with Jeevan in December 2022
(05:44) The Journey to Becoming a Top Venture Capitalist in 2023
(11:00) Spotting the Next Big Tech Trend in 2023
(14:20) Empowering Female Entrepreneurs and VCs to Create Change
(20:00) Breaking Barriers: What it Takes to Attract More Women in Tech VC
(23:00) The Power of Warm Referrals and How VCs Evaluate a Pitch deck
(26:00) Timing is Everything: When is the Right Moment to Approach a VC?
(30:30) A Day in the Life of a Busy Venture Capitalist
(39:30) Decoding Job Titles in Venture Funds: What They Really Mean
(44:15) The Human Side of Investing: Why Relationships are Key
(46:15) 2 Vital Lessons for Founders from a VC's Perspective
(48:55) The Rise of Social Media in the Startup Investment World 2023
(50:35) Podpower: The Importance of Podcasts in Building Relationships in 2023
(52:25) Jeevan's Must-Listen Podcast List for Entrepreneurs and Investors
(56:50) Expectations Beyond Returns: What VCs Look for in Founders
(01:04:30) The Investors' Role in Board Functions and Aligning Interests
(01:09:50) Finding the Perfect Match: Product/Market Fit
(01:13:50) Jeevan's Most Exciting Deal: Behind the Scenes
(01:16:25) The Art of Closing a Deal: A VC's

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Are you ready for the grand finale of our Year in Review Recording?

The final episode of 2022 is here, and it's one for the books! We've explored the cutting-edge innovations and technologies shaping the future of the biotech industry with some of the most brilliant minds in the field. From Kurt Höller of EIT Health, to Albert Missbichler from Fianostics, Caroline Heil from the new meat company, Mauricio Agudelo and Lina Toro from Bialtec, Kimberly Cornfield from the UCL, Collin Ewald from ETH Zurich, and Guido Gualdoni from G.ST Antiviral, we've had some truly enlightening conversations.

But we saved the best for last!

Get ready for an exclusive interview with Dr. Thomas Schubert, CEO of 2bind, a provider of biophysical outsourcing solutions that is revolutionizing the way we study molecular interactions and protein stability. Don't miss out on this one-of-a-kind episode.

Tune in now!

This cutting-edge biotech company is revolutionizing how we study molecular interactions and protein stability. They're doing it with a track record of over 1400 successfully completed tasks in research projects with over 350 customers in the last 11 years.

In this episode, you'll get an inside look at the driving force behind 2bind and the expert knowledge that sets them apart in the biophysics field. From breakthrough moments to industry trends, you'll gain a deeper understanding of the future of biotech and the role that companies like 2bind will play in shaping it.

But that's not all! You'll also hear from Dr. Schubert about the company's partnerships with leading device producers and how they navigate the digital world to stay ahead of the curve. Plus, you'll get insight into the supply chain challenges that 2bind faced in the last years and how they overcame them.

Don't miss out on this opportunity to learn from the best in the business! Tune in to our latest podcast episode and join the conversation on the future of biotech.

Trust us; this episode is a must-listen for anyone in the biotech industry or anyone passionate about innovation and the future of medicine. It's packed with valuable insights and information you won't miss.

💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Check out our partners: https://linktr.ee/lsg2
Watch on Youtube
Thomas Schubert
Christian Soschner

⏰ Timestamps:
00:00) Introduction
(02:00) Unveiling the mastermind behind 2bind, Dr. Thomas Schubert
(04:05) Insider tips for starting your own biotech company
(07:36) A glimpse into the future: 2022 for 2bind's CEO
(10:40) Navigating the digital world: Pros and cons of technology in biotech
(14:16) Overcoming obstacles: A look at 2bind's supply chain challenges
(18:21) Game-changing developments in biophysics for 2022
(19:53) What's next for the industry? A preview of

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

On this episode of "Year in Review Recording," we speak with Guido Gualdoni, Co-Founder, and CEO of G.ST Antivirals, a clinical-stage biotech company revolutionizing how we treat viral infections of the respiratory tract.

Guido shares the science behind G.ST Antivirals' innovative host cell-based strategy to develop broad-spectrum antivirals and how it completely eliminates viral reproduction without the risk of resistance development. He also delves into the public funding and startup ecosystem in Vienna, Austria, which has been instrumental in the company's success.

He also talks about the future plans for G.ST Antivirals and the deep scientific tech valley in Central Europe. This episode is a must-listen for anyone interested in the latest advancements in biotech and the companies leading the way in treating viral infections.

💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2
Watch on Youtube
Guido Gualdoni
Christian Soschner

⏰ Timestamps:
(00:00) Welcome to the Episode: Exploring the Public Funding and Eco-System in Vienna, Austria
(02:35) Meet Guido Gualdoni, CEO of G.ST Antiviral
(04:00) Discovering the StartUp Labs, Vienna Business Agency, AWS, FFG, Austrian Business Agency, LISA Vienna and their role in supporting startups
(07:35) Exploring the Scientific Deep Tech Valley in Central Europe: Munich, Vienna, Zurich, Prague
(10:15) G.ST Antiviral's 2022 Outlook
(11:22) Uncovering the Innovative Technology Behind G.ST Antiviral
(14:30) Guido's Biggest Takeaways from 2022
(16:15) Why Optimism Bias Can be a Challenge for Entrepreneurs
(18:15) Comparing the Scientific and Entrepreneurial Mindsets
(24:00) The Surprising Companies that Succeeded During Economic Downturns
(25:00) Examining the Latest Trends in Antiinfectious Diseases
(27:45) Charting the Growth of G.ST Antiviral in 2023

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Introducing "The Year in Review Recordings", a series where we reflect on the past year and look forward to the coming one. Hosted by Christian Soschner, this podcast brings you expert speakers from previous episodes and partners of the podcast to give you an in-depth analysis of the latest advancements in their fields and an outlook for the future. This is the 6th conversation in the series.

In this episode, we have Dr. Collin Y. Ewald, founder and president of the Swiss Society for Aging Research and head of the Extracellular Matrix Regeneration Laboratory at the Department of Health Sciences and Technology. Dr. Ewald has a longstanding interest in the molecular biology of healthy aging and age-related pathologies. He is a leading expert in the field and has received multiple awards, including NYAS Future Entrepreneur, recognized by the New York Academy of Sciences. He is named among the top 1000 Longevity Leaders worldwide and the top 15 Longevity Influencers in Switzerland.

We'll be discussing Dr. Ewald's recent work on the expression of extracellular matrix genes during aging, the role of the mTOR kinase in aging, and the challenges of bridging gaps in longevity research between scientific disciplines and languages. We'll also be discussing the Ewald Lab's recent work on the expression of extracellular matrix genes during aging, the role of the mTOR kinase in aging, and the challenges of bridging gaps in longevity research between scientific disciplines and languages.

This episode also includes topics such as Longevity Research and Horizon Europe, How to Bridge the Gap in Horizon Programs between scientific disciplines and different languages, The 9 Hallmarks of Ageing, Solving the Clinical Trial Challenges in Longevity Research, Food Supplements for Longevity in 2023, Collin Ewald’s Spin Out Company, The 10 Simple Rules to Start a Successful Spin-Off Company, 2023 in Longevity Research – Upcoming Trends.

Don't miss out on this episode of "The Year in Review Recordings," where we dive into the world of longevity research with Dr. Collin Y. Ewald and stay informed about the latest advancements in the field.

💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2
Watch on Youtube
Collin Ewald
Christian Soschner

⏰ Timestamps:
(00:00) Intro

(03:00) Welcome Note Collin Ewald

(04:25) Longevity Highlights in 2022 in the Ewald Lab, ETH Zurich

(07:08) Published Results of a 9 year study to understand the mTOR Kinase and its role in ageing better

(08:52) Longevity Research and Horizon Europe

(11:08) How to Bridge the Gap in Horizon Programs between scientific disciplines and different languages?

(14:35) Highlights in the Longevity Research Area in 2022

(17:08) The 9 Hallmarks of Ageing

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Are you ready to unlock the secrets of securing funding and achieving impact in the world of European research and innovation?

In this episode of our podcast, we explore the latest trends and developments in research and innovation with Kimberly Cornfield, Assistant Director (Project Development & Management) and Head of European Research and Innovation at University College London (UCL). UCL is one of the top-performing universities under the EU's Horizon 2020 program and has secured around €400 million over the last seven years to support its research and innovation activities.

Kimberly and her team connect scientists and businesses around EU collaborative funding opportunities and offer a suite of support services to improve the chances of success in obtaining funding and achieving impact objectives.

We'll discuss the current state of European research funding, the challenges and benefits of virtual meetings, and the future for research and innovation.

💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2
Watch on Youtube
Kimberly Cornfield
Christian Soschner

⏰ Timestamps:
(00:00) Introduction Kimberly Cornfield, UCL, and Horizon Europe
(05:12) Highlights UCL and Horizon Europe Grant Funding in 2022
(07:20) Advantages and Challenges – Virtual or Real Life Meetings?
(09:00) Benefits of the Virtual World for UCL Research Projects
(10:21) Horizon Europe
(14:28) Future Trends in Research
(17:28) The Rise of Social Sciences
(19:28) The Relevance of Fairy Tales for Research
(23:05) The Horizon Europe Work Programme for 2023
(26:00) Wishes for 2023

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Are you ready to discover the secrets of precision nutrition and AI in the animal protein industry?

Join us as we speak with the founders of BIALTEC, Mauricio Agudelo and Lina Maria Toro, to gain exclusive insights on the industry's challenges and opportunities.

From tackling logistics and inflation to understanding the future of animal nutrition, this episode is packed with game-changing information you won't want to miss.

Tune in now and get ready to be inspired by the innovation and vision of BIALTEC.

💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2
Watch on Youtube
Christian Soschner
Mauricio Agudelo
Lina Toro

⏰ Timestamps:
(00:00) Introduction Lina Toro and Mauricio Agudelo, Founders at Bialtec
(05:54) Creating Microbiomes for Animals
(09:13) Big Challenges in 2022 for Bialtec – Logistics and Inflation
(11:38) How did Lina Toro, CFO of Bialtec, deal with the global environment
(13:31) Perceived Inflation Rate in the Bialtec Eco-System
(14:19) Energy Prices in South America in 2022
(16:40) Bialtec’s Activities in Europe
(20:22) 3 Improvements for Founding a Company in Europe
(25:28) Trends in the Animal Nutrition Industry in 2023

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Are we on the brink of a technological revolution that will render content creators obsolete?

Join us as we explore the rise of ChatGPT and its potential impact on the creative industry. From its capabilities as a natural language processing tool to its comparison to Bitcoin in the financial world, we'll discuss the pros and cons of this game-changing technology. Tune in to discover the truth behind the hype and what it means for content creators like you.

Youtube Video

⏰ Timestamps:
(00:00) What Novel Technology Means
(03:30) What is ChatGPT?
(04:50) What Does ChatGPT Mean for the Creative Industry - ChatGPT Usecases
(06:45) How ChatGPT can help in the Brainstorming/ideation Phase
(10:00) Utilizing the Research Phase with ChatGPT
(12:15) How can ChatGPT Help with Producing a Piece of Content?
(15:38) ChatGPT as a Team for Rewriting, Editing, and Repurposing Content to Make it Native to Different Platforms
(18:00) Ethical and Legal Questions

🔗 Podcastlinks:
Episodes
Full Youtube Playlist
Full Clips Playlist
Partner Links
Christian Soschner

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Celebrate with us as we reach our 100th podcast episode!

Join us as we look back on the past three years and revisit the 5 most downloaded episodes.

From exploring the use of blockchain technology in the energy sector, to gaining valuable insights into the daily life of a VC and learning how to succeed in the competitive world of drug development, this special episode has something for everyone.

Thank you for being a part of our journey and for supporting our mission to promote scientific entrepreneurs and shape a bright future for humanity. Don't miss out on this celebratory milestone episode!

💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2

⏰ Timestamps:
(00:00) Episode 100
(03:15) #5: Sascha Bucher – Forty51 Ventures
(14:35) #4: Ana Trbovich – Grid Singularity
(28:22) #3: Jonathan Sporn – Gilgamesh Pharmaceutical
(44:35) #2: Heike Schön – Lumis International
(01:04:00) #1: Alexander Belcredi – Biontech Austria
(01:18:00) Outlook for 2023

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Welcome to the third part of "This was 2022 - A Year in Review," a special edition of the Beginner's Mind Podcast.

I'm your host Christian Soschner and I'm excited to be joined by Albert Missbichler, a business angel with over thirty years of experience in biochemistry and clinical diagnostics.

In this episode, we'll be discussing the highlights of 2022, the differences between scientific B2B and B2C, and the challenges of translating science into simple words.

We'll also be exploring the lifestyle habits and health literacy of Gen Z, as well as the crucial habits for longevity.

Finally, we'll be discussing the changes in the post-pandemic conference industry and the big trends to look out for in 2023 in diagnostics.

Stick around for all of this and more with Albert Missbichler on the Beginner's Mind Podcast.

💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2
Watch on Youtube

⏰ Timestamps:
(01:23) Prediction Caroline Heil for 2023
(02:06) Introduction Albert Missbichler and Fianostics
(03:00) Highlights Albert Missbichler in 2022 – from B2B to B2C
(04:40) The Biggest Differences between Scientific B2B and B2C
(07:00) Challenges of Translating Science into Simple Words
(11:30) Lifestyle Habits and Health Literacy of Gen Z
(17:45) Crucial Habits for Longevity
(21:15) Postpandemic Meeting Habits – What changes, what remains
(25:20) Changes in the Post-Pandemic Conference Industry
(28:00) Big Trends in 2023 in Diagnostics
(32:00) Inoolab and Fluobolt

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Welcome to the first days of 2023! As we bid farewell to the past year, I wanted to take a moment to appreciate all the amazing conversations on my podcast over the past 12 months. From global crises to personal triumphs and failures, 2022 has been a year like no other.

I covered various topics on the show, from venture capital to clinical development, psychedelics, virtual reality, and biophysics. In honor of these incredible episodes, I have decided to end the year with a compilation of the best moments from the previous 12 months.

It was difficult for me to choose just five standout conversations from the many I've had, so I enlisted the help of ChatGPT to generate five numbers between 60 and 97 randomly. These five episodes are the ones I've chosen to highlight.

But as we enter the new year, it’s also a time to look ahead and plan for what lies ahead. In the words of CS Lewis, "The future is something which everyone reaches at the rate of sixty minutes an hour, whatever he does, whoever he is." So grab your holiday cheer, join me as I reflect on the past year’s highlights, and look ahead to what’s in store in the new year. The clock is ticking, and the future is waiting. So, don't miss out and tune in to this YouTube video for all the exciting details!

💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2
Watch on Youtube

⏰ Timestamps:
(00:00) Welcome 2023
(03:02) Episode 70: Bruno Montanari - Seroba Life Science - The Role of Venture Capital
(13:00) Episode 71: Heike Schön - Lumis International - How to Rescue Clinical Trials
(24:45) Episode 79: Jonathan Sporn - Gilgamesh Pharmaceuticals - Psychedelic Drugs
(39:21) Episode 94: Adrian Brodesser - Somareality - Digital Diagnostics with Virtual Reality
(54:22) Episode 93: Thomas Schubert - 2bind - Biophysics
(01:09:00) Beginner’s Mind Podcast: Outlook to 2023

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

The LSG2G Partners
Experts in Life Science

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Hey everyone, this is Christian Soschner from the Beginners Mind Podcast I just wanted to take a quick moment to say thank you for following the podcast channel in 2022. Your support and engagement mean the world to me, and I am truly grateful for each and every one of you.

As we head into the new year, I want to assure you that I will continue to bring you valuable content in health, healthcare, pharma, artificial intelligence, entrepreneurship, and investing. These topics are close to my heart, and I am dedicated to sharing the latest research, insights, and trends with you.

But it's not just about the content but the connection. I am committed to building a community of like-minded individuals who are passionate about these topics and are eager to learn and grow together.

So let's make the most of this new year. Let's decide today who we will become, what we will give, and how we will live. And let's do it with purpose, passion, and a desire to impact the world around us positively.

Thank you again for your support. I look forward to continuing to bring you valuable content and being a part of this amazing community in 2023 and beyond.

And before you leave for the new year's celebrations, please consider hitting the like button, leaving a comment, and following our channel. Your support helps me grow my podcast and allows me to reach more people who can benefit from my content. And if you have a moment, please consider leaving a 5-star review on Apple Podcasts and Spotify – it really helps me out. Thank you again and have a happy new year!

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Welcome to the second part of "This was 2022 - A Year in Review," a special edition of the Beginner’s Mind Podcast as we close the year and look ahead to 2023. I'm your host Christian Soschner, and I'm excited to be joined by Caroline Heil, CEO of The New Meat Company.

Caroline is a seasoned investor passionate about revolutionizing the food industry sustainably and healthily. She has worked for EY as a lawyer. She has experience advising clients on corporate aspects of M&A transactions and VC investments, with a focus on the alternative protein and meat market, food security, and sustainability.

The New Meat Company is a purpose-driven impact investment company based in Berlin that invests in game-changing companies and founders disrupting the traditional meat industry with sustainable, nutritious, and tasty alternatives. They have a buy-and-build strategy, consolidating established pioneers and emerging game-changers in the alternative meat space and partnering with innovative individuals who prioritize animal welfare and reducing the ecological footprint of meat production.

In this episode, Caroline will share her insights on the key trends in the food industry, the importance of proper nutrition for long-term health, and her advice for startups and scaleups seeking investment. She'll also give us a preview of what to expect in 2023 and the ideal investment opportunity for The New Meat Company.

So sit back, relax, and get ready to learn from one of the top investors in the food industry as we close out the year and look ahead to the future.

We have a full schedule of speakers lined up, including Kurt Höller from EIT Health, Albert Missbichler, a business angel, Lina Toro and Mauricio Agudelo from Bialtec, Kimberly Cornfield from UCL, Collin Ewald from ETH Zurich, Guido Gualdoni from G.ST Antivirals, and Thomas Schubert from 2bind.

We'll be tackling questions such as:
•What excited you the most in 2022?
•What should change in 2023?

I hope you enjoy the episode from this exciting year-in-review event.

💡 LINKS TO MY OTHER CHANNELS:
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Watch in Youtube

⏰ Timestamps:
(00:00) Introduction Caroline Heil and the New Meat Company

(05:00) Why Eating Habits are Key to a Long and Healthy Life

(05:30) Getting the Nutrition Habits Right in Society has the potential to reduce healthcare expenses by 90%

(08:45) The Optimal Nutrition Habits for 2023

(11:50) Highlights of 2022 – Caroline Heil and The New Meat Company

(12:50) The Investment Approach of The New Meat Company

(14:25) Big Trends in the Food Industry in 2022

(17:00) Availability of Capital in the Food Industry For Startups and Scaleups

(19:30) Investment Insights in the Old Economy

(20:45) Investors Advice for Startups

(23:00) The Ideal Investment Opportunity for TNMC

(28:15) The Big Trends in the Food Industry for 2023

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

The LSG2G Partners
Experts in Life Science

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Welcome to the year-in-review podcast for 2022!

As the year comes to a close, I am excited to reflect on the successes and learnings from the past 12 months and look ahead to what 2023 has in store.

I have an incredible lineup of speakers from 90 previous podcast episodes; the event was live-streamed before Christmas on LinkedIn, YouTube, Twitter, and Facebook, so listeners could tune in from anywhere.

To conclude the year and start into 2023, each speaker will be featured in their podcast episode.

As a starter, I am thrilled to have Kurt Höller from EIT Health joining. Kurt will share his most memorable moments from 2022, his biggest successes and learnings, and his expectations for 2023. We'll also be discussing EIT Health and getting an overview of the LSG2G community.

Kurt Höller is the Director of Business Creation at EIT Health, a leading healthcare initiative supporting over 750 startups and providing access to key industry players. He has a wealth of experience in healthcare, including founding and directing several companies, and a strong background in research, with a focus on health innovation.

We have a full schedule of speakers lined up, including Caroline E. Heil from The New Meat Company, Albert Missbichler, a business angel, Lina Toro and Mauricio Agudelo from Bialtec, Kimberly Cornfield from UCL, Collin Ewald from ETH Zurich, Guido Gualdoni from G.ST Antivirals, and Thomas Schubert from 2bind.

We'll be tackling questions such as:
•What excited you the most in 2022?
•What should change in 2023?

I hope you enjoy the episode from this exciting year-in-review event.

💡 LINKS TO MY OTHER CHANNELS:
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Watch in Youtube

⏰ Timestamps:
(00:00) Intro to Year in Review, Kurt Höller, And EIT Health
(03:00) Chat GPT as a helper to find questions for the podcast recording
(04:30) Kurt shares his personal highlights from 2022
(07:30) EIT Health in 2022
(08:30) Events after the pandemic – From EIT Health Summit to Bits and Pretzels
(11:00) Bits & Pretzels – The European Woodstock for Startup Entrepreneurs
(12:55) Bavaria, White Sausages and Beer Habits
(14:30) Kurt’s New Role as Managing Director of InvestHealth
(17:30) The Venture Capital Situation in Europe in 2022
(21:28) Healthtech Investment Trends in the Coming Years
(23:30) Europe Becomes a Single Market for Health Apps
(34:00) Estonia – Leader in Digital Adoption in Many Categories

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

In this episode, I unlock the untold stories behind PayPal's meteoric rise and the entrepreneurs who made it possible.

The author Jimmy Soni explores the captivating story of PayPal and the entrepreneurs who helped shape Silicon Valley.

From Elon Musk to Peter Thiel and many others whose stories have never been told, hear about the scrappy online payments start-up that faced fierce competition and internal strife on its journey to becoming one of the world's foremost companies.

⭐ EPISODE Links:
Jimmy Soni
Please support this show by checking out the companies that make it possible.
Youtube

📚 Book Mentions:
Jimmy Soni, The Founders
Sebastian Mallaby, The Power Law

🗣️ We are talking about:
• The Inspiration for writing this book
• Dissecting Jimmy’s Writing Process
• The Origin Story of the Paypal-Mafia
• The Role of Chess and The Secret Code Hidden in the Book
• Storytelling Lesson for Entrepreneurs
• And much, much more

📖 Memorable quotes:
(20:55) “I do my books while working full-time. All my books are morning and weekend exercises.”
(24:46) “I interviewed almost 300 people for this book.”
(35:45) One executive said: "Calling Paypal a Mafia is an insult to the Mafia. They are far more organized than we were back then."
(51:04) “David Sacks said: … as easy as email”
(56:50) “The most important question for business owners: Who in the team is obsessed with how the end-user thinks and uses the product?”
(01:34:30) People forget that startups are stories.

⏰ Timestamps:
(00:00) Intro from the Recording the Day after Thanksgiving 2022
(05:55) What inspired Jimmy Soni to write the Founders?
(10:00) The Entrepreneurs who Shaped Silicon Valley
(16:15) Peter Thiel: How to Learn the Right Lessons in Entrepreneurship
(19:24) How long does it take to write a book like the Founders?
(22:15) Writing Books as a Side Hustle to writing as a profession
(23:00) Exploring the Challenges of Writing Biographies of Historical and Modern Figures
(25:23) Uncovering the Truth: Strategies for Sorting Through Conflicting Narratives in Interviews
(27:30) The Writing Scorecard: Number of Words per Day
(28:40) Uncovering the Journey from Idea to Publication: A Look at Jimmy Soni's Writing Process
(30:30) Max Levchin and Tetris
(32:17) The Origin Story of the Term “Paypal-Mafia”
(39:00) From Beaming Money to Venmo: 20 Years of Product Development
(43:00) David Sacks Halts the Progress of Groundbreaking Beaming Technology and the Birth of Digital Payment Solutions
(49:40) How Paypal Found Product Market Fit
(53:42) The Switch challenges from finding a solution to focusing on scaling up the solution.
(58:00) The Role Chess Plays in Jimmy Soni’s Book and Paypal’s History
(01:02:27) The Secret Code Hidden in the Book: Crack the Code and Get a Signed Copy
(01:03:00) The Bad Bishop Situation
(01:06:00) Bitcoin, the Paypal Mafia, and the New World Currency Tagline
(01:15:00) Elon Musk's challenges in finding the right decisions during his early twen

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

The Founders: The Story of Paypal and the Entrepreneurs Who Shaped Silicon Valley

View Details

As the holiday season has started, I wanted to take a moment to wish you all a very Merry Christmas. I hope this time of year brings you joy, peace, and happiness.

Remember to stay positive and hopeful as we look ahead to the new year.

2023 is a new opportunity to set goals, make positive changes, and achieve our dreams.

I hope you can spend this holiday season with loved ones, surrounded by warmth and cheer.

May your Christmas be filled with love, laughter, and everything that brings you joy.

Merry Christmas and Happy Holidays to you all!

Youtube Video

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

Which Role do Wearables like Virtual Reality Devices play in the Future of Diagnostics?

In this episode, I am excited to talk with Adrian Brodesser, CEO of Somareality, to explore the latest technological developments and their impact on society.

Adrian will be joining us to discuss the use of VR in diagnosing neurological diseases and how these devices are revolutionizing the way we approach healthcare. From Alzheimer's to Parkinson's, virtual reality is providing doctors with new tools to understand and treat these complex conditions.

So join us as we delve into the world of VR and healthcare with Adrian Brodesser and learn how this technology is changing the game for the diagnosis and treatment of neurological diseases.

⭐ We discuss topics like:
•How to find product market fit for VR
•Core Business of Somareality
•VR Use Cases in Healthcare and Sports
•Use Cases for VR-based Diagnostics
•Challenges of Entrepreneurship

⭐ EPISODE Links:
Today’s speaker is Adrian Brodesser, CEO of Somareality

Youtube

📖 Memorable Quotes
(10:00) "Entrepreneurship is really hard."
(48:10) "With Eyetracking, we can measure if the person is overwhelmed with parts of the process."
(50:30) "The AI helps people to understand where they are struggling and which steps they should take from here on."
(01:00:09) "A lot of great insights into the early-stage dedication of diseases can be derived from eye-tracking."
(01:10:30) "Technology-based Diagnostics will be vastly available in the future"
(01:32:00) "3 pieces of Advice for New Entrepreneurs"

📚 Book Mentions:
(17:30) Jimmy Soni The Founders

⏰ Timestamps
(00:00) Kick Off
(06:40) Entrepreneurship in 2022
(12:40) The Art of saying no
(20:30) The Magic of Finding Product Market Fit
(24:05) Selling – The Most Important Skill for Startups
(28:34) How to Sell to the Healthcare Industry
(32:15) Core Business of Somareality – Usecases for VR
(41:00) How VR helps to understand the User Better
(44:12) Commercial Potential of VR – Intuitive Surgical, Lufthansa and Somareality
(52:15) Use Cases in Healthcare and Sports for Attention Tracking
(56:00) Digital Diagnostics with VR
(59:15) The Research Behind Eyetracking with VR for Diagnostics
(01:02:23) Aware Virtual Reality Systems – The Future of VR
(01:10:26) The Long-Term Future of VR-based Diagnostics
(01:16:25) Near Future Use Cases for VR-based Diagnostics
(01:19:00) Elevator Pitch for VR-based Diagnostics
(01:22:35) Objective Pain Measurement with VR
(01:29:00) Fundraising
(01:30:50) Custom Solutions for the B2B Environment
(01:31:00) 3 Points for Entrepreneurs who start a business

Links:
New study will look at how virtual reality can help diagnose dementia | Brain Sciences - UCL – University College London

[Virtual reality and dementia] - PubMed (nih.gov)

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

What is the Role of Biophysics in Drug Development and Drug Discovery?

In this episode, I speak with Dr. Thomas Schubert, CEO of 2bind, a provider of biophysical outsourcing solutions for the pharmaceutical. Dr. Schubert discusses the role of biophysics in drug development and the importance of outsourcing in the pharmaceutical industry.

⭐ In this episode, we talk about:
The Role of Biophysics in Drug Development
The Role of Biophysics in Antibody Research
Success Stories in Biophysics
The Development of the Life Science Industry in Europe from the Biophysicist's Perspective
Future Trends in Drug Discovery and Drug Development

⭐ EPISODE Links:
Today’s speaker is Thomas Schubert, CEO of 2bind

Dr. Thomas Schubert received his Ph.D. in Biochemistry in 2012 from the University of Regensburg. Dr. Schubert joined 2bind in 2012 and was called for the CEO position in 2013. Dr. Schubert received the degree Betriebswirt (business economist) in 2014.

Youtube

📚 Book mentions in the episode:
The Power Law
Das Netzwerkunternehmen

📖 Memorable Quotes:
(04:30) “At 2bind, we are active with Webinars to educate people.”
(08:15) “Biophysics is using physical measurement and interpretation to understand Biology"
(24:40) “Many different changes in the environment of drug discovery occurred, and all of them pushed Biophysics.”
(52:30) “Always employ people that are better than you”
(01:29:27) “Biophysics will play a big role in Drug Discovery in 10 years”

⏰ Timestamps:
(00:00) Intro
(02:00) Recap Bio Europe in Leipzig and Bio International in San Diego after the Pandemic Break
(04:15) Integrating Social Media into Business Strategies
(07:30) The Role of Biophysics in Drug Development
(11:00) Background Thomas Schubert and 2bind
(20:00) How has the Role of Biophysics in Drug Development evolved over the last 10 years
(26:30) The Role of Biophysics in Antibody Research & Development
(29:30) Biophysics and ADCs
(33:00) 2bind’s position in the pharmaceutical value chain
(38:30) How to combine scientific and development mindsets in the industry
(43:30) Competition and Expertise in the Biophysics World
(46:15) Technologies used in biophysical research projects
(52:19) Challenges for Entrepreneurs Running a Deep Tech Service Business
(56:30) Success Story #1: Lead Identification with 2bind
(58:30) Success Story #2: Formulation Study with an HIV Vaccine Candidate
(01:03:00) The Big Challenges for Pharma in this Century – Antibiotics, HIV, Cancer
(01:10:00) The Development of the Life Science Industry in Europe
(01:17:00) Outsourcing – when is it the best solution for companies?
(01:24:00) Future Trends in Drug Discovery and Drug Development from the Biophysicist’s Perspective
(01:36:00) Epigenetics, AI, and Chess
(01:43:00) How to Connect with Thomas Schubert

The Unlocking Growth Show
The show where we unlock the secrets to scaling your...
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

How did Venture Capital evolve? When did it start? Get the answers right here in the book The Power Law by Sebastian Mallaby.

⭐ In this episode, we talk about:
• Storytelling Methods and a Writers Work Process
• What is Venture Capital – From the Writers Perspective
• How Did Silicon Valley Evolve into the Center of the Innovation World?
• The 3 Most Crucial Moments in the Development of Venture Capital
• The Future of the European Tech Eco-System
• And much, much more

⭐ EPISODE Links:
Today’s speaker is Sebastian Mallaby.
Youtube

📖 Memorable Quotes:
(09:39) “In a Content Creators Economy where a lot of people spend a lot of time creating, it is worthwhile to spend 5 years writing a book”
(12:46) “Do Venture Capitalists create innovation, or do they just show up for it?”
(18:51) “Europe is fundamentally full of great engineers. It is a great market. Why wouldn’t it rival the United States if it got the right Venture Capital to take the risk.”
(23:10) “The European culture is not as risk-friendly as the US. But it’s changing fast.”
(27:45) “Genentech was the beginning of staged investments.”

⏰ Timestamps:
(00:00) Speaker and Book Intro
(02.25) Storytelling Methods and a Writer's Work Process
(08:00) Development of the Methodology – From Nelson Mandela to Venture Capital
(10:33) What is Venture Capital – From the Writer's Perspective
(16:00) How Did Silicon Valley Evolve into the Center of the Innovation World?
(19:39) Why Cover the Majority of the Stories about the US and Asia and very few stories about Europe?
(27:41) The 3 Most Crucial Moments in the Development of Venture Capital
(29:45) How Sequoia got into the hot tub with Atari
(32:00) Softbank – Everybody Needs a 100 Million
(39:00) Alibaba
(43:45) The Future of Venture Capital
(47:15) The Future of the European Tech Eco-System

⭐ Please support this podcast by checking out our partners: https://linktr.ee/lsg2g

Sebastian Mallaby is the Paul A. Volcker senior fellow for international economics at the Council on Foreign Relations (CFR). An experienced journalist and public speaker, Mallaby contributes to a variety of publications, including Foreign Affairs, the Atlantic, the Washington Post, and the Financial Times, where he spent two years as a contributing editor. He is the author of five books, most recently The Power Law: Venture Capital and the Making of the New Future.

After Hours Entrepreneur: Your Guide to Profitable, 6-Figure Years
Quit your job. Make more money.
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

What is the Role of Artificial Intelligence in Drug Development and Drug Discovery?

⭐ In this episode, we talk about:

Deep Mind’s Alphafold
Investing in Life Science companies
The State of AI in Drug Development and Drug Discovery
How does GDPR limit the development of AI in Drug Discovery
The Human Genome and AI

Today’s speaker is Marco Schmidt, CSO of Biotx.ai
Marco had an exceptional academic career. He won the best PhD of the year award in Chemistry in his home country Germany and then went on to do a Post-Doc at the University of Cambridge.

⭐ EPISODE Links:
Marco Schmidt on Linkedin
Youtube

📖 Quotes:
(24:45) “Eroom's law is the observation that drug discovery is becoming slower and more expensive over time”
(56:05) “We need more data”
(58:13) “Biobanks provide the infrastructure that we really need in the future”
(01:16:39) “Prediction Models of Type 2 Diabetes Have 99% Accuracy”
(01:17:50) “There is no longevity gene. There are shortevity genes.”
(01:53:45) “We are living in fantastic times”

⏰ Timestamps:
(00:00) Kick Off and Intro
(06:15) Deep Mind’s Alphafold
(07:06) Background to Marco Schmidt and Biotx.ai
(12:00) Business Model in AI for Drug Development – from Service Provider to Developer
(13:15) Basic Definition of Drug Discovery and Drug Development for the Listeners of the Episode
(17:20) For Retail Investors who have an eye on investing in public drug development companies: What is a Ligand?
(20:09) Why is Drug Discovery Expensive and Lengthy?
(23:30) Success and Failure Rate in Drug Development
(24:30) What is erooms Law?
(27:25) What is the right place for innovation? Startups or Big Corporations?
(30:00) The Value Chain in the Pharma Industry – From Research to Marketed Products.
(34:00) Investing in Life Science Companies
(50:15) Why is Artificial Intelligence an Attractive Area?
Speaker and Company
(55:00) The State of AI in Drug Development and Drug Discovery – What is Science and What is Still Fiction.
(58:00) Accessibility of Data – Is this the bottleneck in Artificial Intelligence Based Drug Discovery?
(01:10:00) What would change in Drug Development if scientists could access healthy population data?
(01:12:30) Prediction Models for Cancer, Alzheimer, and other diseases
(01:16:00) Understanding the progression of diseases and the role lifestyle plays in AI
(01:19:00) How does GDPR limit the development of AI in Drug Discovery
(01:24:00) Data Curation in AI
(01:28:45) Is Capital a Limiting Factor?
(01:34:26) The Human Genome and AI
(01:40:00) Is it possible to simulate the entire drug development process from lab to market?
(01:46:00) Service Offerings of biotx.ai
(01:51:30) How can AI help select the right patients?
(01:59:00) Synthetic clinical trials
(02:01:00) The Role of Excel in Machine Learning

📚 Book Mentions:
Drug Discovery and Drug Development
The Power Law

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

The Power Law: Venture Capital and the Art of Disruption

View Details

Do you understand the dynamics of the stock market? Here is an episode with Brian Feroldi, Writer at the Motley Fool, on his new book “Why the stock market goes up?”

We are talking about
⭐ The Global Problem With Financial Literacy
⭐ Why Did Brian Feroldi Write a Book About Investing for Beginners?
⭐ Why Does the Market Crash from Time to Time?
⭐ Cost Averaging and Index Investing – A Powerful Tool for People who don’t have time to diligently follow the market
⭐ What was Brian’s Biggest Investment Mistake?

A basic understanding of the stock market is mandatory for every deep tech entrepreneur, business angel, and venture capitalist. A stock market is a place where companies can get more liquidity for scaling their business and provides an exit for early investors.

Brian Feroldi describes the mechanics of the stock market in his latest book: Why does the stock market go up? I enjoyed his unique way of explaining complex economic situations in easy-to-understand layman’s terms.

Brian Feroldi is a financial educator, YouTuber, and author. Since college, he has been intensely interested in money, personal finance, and investing.

⭐ EPISODE Links:
Brian Feroldi on Youtube
Youtube Video

📖 Quotes:
(05:31) "A lack of financial literacy is a global phenomenon"
(14:50) "...it took me about 18 months to write it. ... I think we needed a book that explains in plain English what the stock market is - for beginners."
(16:11) "If you look back on stock market history - it is very clear: Every ten years ... or so ... things go to hell!"
(33:00) "Only Business Profits drive the Stock Market in any given direction"
(43:53) "Investing in an Index Fund is totally fine for 99% of investors because they have no interest in reading SEC filings or doing research."
(01:08:00) "Think Long-Term"

⏰ Timestamps:
(00:00) Introduction
(01:52) Why Deep tech Entrepreneurs Need a Basic Understanding of the Stock Market.
(04:00) Brian Feroldi's studio
(05:17) The Problem With Financial Literacy
(06:35) How Brian got Into Investing?
(08:00) The Motley Fool
(10:05) Why Did Brian Feroldi Write a Book About Investing for Beginners?
(15:00) Reflecting on the Tech Market Correction in 2022 and Other Stock Market Crashes
(19:19) The 2000 and 2008 Crash Experience
(23:20) Why Does the Market Crash from Time to Time?
(27:50) Crowd Mentality, Market Timing, and Contrarian Investing
(32:55) The 3 Major Forces That Drive the Stock Market Up
(36:55) Why Should People Invest When Fear, Uncertainty, And Doubt are on the Market?
(39:32) What were your biggest questions when you started investing?
(43:25) Warren Buffetts S&P500 ETF Strategy for People who don't have time for market research
(45:23) Cost Averaging and Index Investing – A Powerful Tool for People who don't have time to diligently follow the Market
(48:00) What is Compounding?
(51:11) What is the Magnitude of Stock Market Fluctuations
(55:05) Brian Feroldi's on Cathie Wood's Ark Innovation Fund

After Hours Entrepreneur: An Entrepreneurs Guide to 6-Figures
Take action. Build a business and life you love!
Listen on: Apple Podcasts Spotify

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

Why Does The Stock Market Go Up?: Everything You Should Have Been Taught About Investing In School, But Weren't

View Details

Where are the Big Life Science Hubs in the United States?

Here is an in-depth overview of Life Science In Georgia with many essential Key Facts and exciting stories from the beautiful state. My guest in this episode is E Jane Caraway, Director of Life Science at the Georgia Department of Economic Development.

⭐We are talking about

Life Science, Vineyards, Vampires and Zombies
Boehringer Ingelheim's Facilities in Atlanta
How Life Science Companies Help Communities
Science in Georgia
Starting a Life Science Company in Georgia as an Immigrant Entrepreneur
And much, much more

⭐About Georgia
The state of Georgia is a dynamic hub for life sciences with more than 2,000 organizations. We have the resources to assist you in getting ideas researched, tested, commercialized, produced, and delivered quickly to most anywhere in the world. New and existing companies have access to a highly educated workforce, renowned research institutions, cutting-edge technological resources, and access to the global marketplace via a robust infrastructure. Georgia’s pro-business climate, combined with a culture of collaboration and innovation, has fostered growth across all sectors of life sciences.

⭐ EPISODE Links:
E Jane Caraway: EJane Caraway, a passionate advocate for company success and community growth, has been with the Georgia Department of Economic Development for 13years. Since 2017 she has served as the Director of Life Sciences, and recently worked on projects with companies like Boehringer Ingelheim, Boston Scientific and IC Biomedical, just to name a few.
Youtube

🎤 Quotes:
(09:41) “Georgia has the second largest film industry in the world, after Canada and before Hollywood”
(18:51) “The Soccer World Championship 2026 will be in the United States”
(22:41) “Facebook has worked with local partnerships and entrepreneurs to build their own solar fields to supply energy to their facilities in Georgia”
(28:41) "Georgia had a 150% growth in the Life Science Industry in 2021"

🕛 Timestamps:
(00:00) Intro
(03:00) Recap of the #bio2022 in San Diego
(05:35) Background EJane Caraway and Life Sciences in Georgia
(08:00) What do Life Science, Canyons, Vineyards, Vampires, She-Hulk, King of Queens, and Zombies have in common?
(10:00) The Film Industry in Georgia
(15:30) Sports in Georgia – Baseball, Soccer, Football, Golf, Pickleball
(21:30) Georgia’s Leading Industries – Coca Cola, Delta Airlines, NCR, Facebook, Boehringer Ingelheim, HomeDepot, Aflac, UPS
(23:45) Boehringer Ingelheim in Atlanta, Georgia and Vienna, Austria
(28:55) Life Science in Georgia has seen a 150% Growth Rate in 2022
(33:00) The Positive Impact Life Science Companies Make in the Community – The Takeda Story
(36:12) The Boston Scientific, AMRI and Gulf Stream – Ebola Story
(41:21) Science in Georgia
(44:30) Starting a Company in Georgia as an Immigrant Entrepreneur – How is the Workforce, Labspace, and Funding Situation in Georgia?

The Brave Marketer
Many of the most memorable brand campaigns have been driven by cutting edge marketers
Listen on: Apple Podcasts Spotify

The LSG2G Partners
Experts in Life Science

Support the showDo you want to support the podcast team?

Join the LSG2G Newsletter as a paying member: Link

View Details

What are the opportunities for Biotechs in the Chinese Market? Get answers to this question in this podcast with the BFC Group.

⭐We are talking about
The BFC Group
The Capital Market Landscape in China
Deal Structuring in China
Clinical Strategies for China
Why Affordability and Accessibility of new drugs matter in China

⭐About BFC Group:
BFC Group is a China-based investment banking firm with a focus on healthcare M&A, licensing, and financing. We work with leading healthcare companies in the US, Europe, and Asia. With first-hand operational experience in both the US and China, we have a deep understanding of the challenges our clients face when establishing or expanding their companies’ presence outside of their home market.

⭐ EPISODE Links:
Jia En Chin
Thijs Spoor
Shirley Lu:
BFC Group:
Youtube Presentation best viewed on Youtube

🎤 Quotes:
(26:04) “China is now the second largest pharma market in the world, Japan being third”
(31:11) “Many of our clients are still in Clinical Phase I, when they come to China”
(33:29) “The China Market really rewards innovation in antibiotic research.”
(48:30) “China takes care to make therapeutics accessible and affordable for the population”
(51:24) “China's growing middle class wants to improve their quality of life.”
(59:45) “Finding the right partner for a Go-To-China-Strategy is key to success. Otherwise, it can become very costly and might damage the asset.”
(01:00:38) "... you want a personal connection, you want to educate and not sell..."
(01:16:30) “In Q1/2022 18 new drugs were approved in China, 12 of them came from The West.”

🕛 Timestamps:
(00:00) Introductions
(13:00) BFC Group Introduction to the Chinese Market
(15:45) Capital Market Landscape in China
(18:30) China Investment and Financing Trend
(21:43) Licensing Deal Trends in China
(25:00) Opportunities for Biotechs in China
(25:45) The biggest Pharma Markets and Innovators
(30:00) Deal-Focus of Chinese Pharma Companies
(32:00) The Therapeutic Focus in China in 2022
(33:41) Antibiotics Research in China
(36:40) The Major Player in Infectious Diseases and Cancer on the Chinese Market
(38:00) Market Potential in China for Chronic Diseases
(39:55) The KBP Business Case
(40:48) Patent Strategies for the Chinese Market
(44:24) Important Points for Preparing a Market Entry in China
(48:00) Price Dynamics and Reimbursement in China
(49:30) Why Affordability and Accessibility Matters in China
(50:30) The Necessary Data Packages for Market Entry in China
(53:00) Clinical Strategies for Market Entry in China
(56:30) Is a multi-center approach across several markets feasible in later-stage clinical trials?
(01:01:30) Similarities and Differences in Culture, Communication
(01:08:15) The Right approach for a Go-To-China Strategy
(01:13:22) The Availability of Capital on Private and Public Markets for Foreign Companies

Do you want to support the podcast?
Join the LSG2G Community: https://lsg2g.substack.com/subscribe

Dev Interrupted
What the smartest minds in engineering are thinking about, working on and investing in.
Listen on: Apple Podcasts Spotify

The LSG2G Partners
Experts in Life Science

Support the show

View Details

Fundraising in Israel and the United States – In this episode, I have a conversation with Tuvik Beker, CEO of Pangea Biomed, who has started, developed, and exited companies in the United States and Israel. Now he is developing Pangea Biomed to start the next revolution in precision oncology.

Tuvik Beker is a seasoned entrepreneur, an experienced executive, and a strong technical leader who spent the last twenty years building, scaling, and leading companies in the healthcare, financial, and aerospace domains.

Founded in 2018, Pangea Biomed is an Israeli biotech startup redefining cancer care. The company developed ENLIGHT – the world's most advanced multi-cancer, multi-therapy response predictor. By combining machine learning and deep RNA analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care for a healthier world.

⭐In this episode, we talk about:
The Startup Ecosystem in Israel
Fundraising in the United States from 2000 to 2022
3 Success Secrets to Fundraising in the US
Precision Oncology
The Enlight Technology

Youtube

🎤 Quotes:
(11:58) “Nothing is Impossible"
(31:05) “The Abundance of Capital is one important factor. Another one is, how the area around Stanford University welcomes immigration and foreign innovation."
(35:33) “Many US Investors invest only in US companies”
(40:26) “"If you want to succeed in fundraising, you need to have a wide funnel. You need to start talking to many, many venture capitalists to close a round."
(44:21) “Be mentally ready to have 100 meetings or more to get the initial cheque.”
(50:30) "The most important thing to bear in mind is building honest relationships with venture capitalists."
(01:14:06) “Pangeas approach focuses on harnessing these expression abnormalities in order to attack cancer cells and spare normal healthy cells.”

🕛 Timestamps:
(00:00) Opening
(05:32) The Origin of Pangea Biomed
(07:45) The Startup Ecosystem in Israel
(10:16) Conversation Culture in Israeli Schools
(12:05) IDF: “Nothing is Impossible”
(13:55) Compulsory Military Service Contributes to the Success of the Startup Eco-System
(19:03) Founding a Start Up in Israel
(23:15) The Big StartUp Hubs in Israel
(25:16) StartUp Life in Tel Aviv
(28:00) StartUp Life in Palo Alto & Stanford
(30:52) The Role of Silicon Valley in Entrepreneurship and Venture Capital
(33:52) Fundraising in the United States from 2000 to 2022
(40:00) The 3 Success Secrets to Fundraising in the United States
(56:00) Search Strategies During Fundraising in 2022 – signal.nfx.com
(01:01:00) Recommendations when pitching US Investors
(01:07:52) Pangea’s Solution in Precision Oncology
(01:15:44) The Enlight Technology
(01:20:30) How Pangea Helps to Find the Right Patient Population for Clinical Trials in Oncology
(01:25:00) Pangea’s Collaboration Network
(01:34:00) Enlight – Matchmaking between Patient and the right drugs
(01:36:00) Pangea’s Business Model
(01:40:00) Pangea’s Development Team
(01:42:20) What

Making Conversations Count: real actionable business tips
Small team wanting big results? This is the podcast for you!
Listen on: Apple Podcasts Spotify

The LSG2G Partners
Experts in Life Science

Support the show

View Details

In this episode, Tobias Silberzahn, McKinsey talks about biohacking 101 – habits that make a difference, digital health eco-system, and much more…

Tobias Silberzahn is a trained biochemist and immunologist and works as a Partner in McKinsey's Berlin office, where he is a member of the Healthcare and Innovation Practice. His work focuses on healthcare innovation, health tech business-building, and digital transformation.

Tobias leads the global Health Tech Network, a community of 1500+ health tech CEOs/Founders, where he hosts the quarterly Health Tech CEO Roundtable. As part of his work, Tobias also hosts the MedTech R&D Industry Roundtable and publishes the "eHealth Monitor Germany," an annual book about the digitization of the German health system.

Within McKinsey, Tobias leads the Health & Wellbeing program for employees, focused on sleep, nutrition, stress management, and fitness, that was recently awarded the Brandon Hall HCM Excellence Award in Gold.

McKinsey is a global management consulting firm committed to helping organizations accelerate sustainable and inclusive growth. McKinsey works with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. It combines bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next

Youtube(Links to articles discussed in the podcast are in the description to the Youtube Video)

We were talking about:
⭐ The European Health Care System
⭐ Biohacking 101
⭐ The Healthtech Startup Eco System
⭐Small Habits – Big Changes
⭐ The 4 Pillars of Health and Wellbeing

🕛 Timestamps:
(00:00) Introduction
(05:30) The Situation of Mental Health, Health & Well-Being in Europe
(10:10) The Role of Sleep For Health & Wellbeing
(14:00) Mobility & Movement
(18:43) Why Nutrition Matters
(23:24) Healthcare and Cancer
(29:46) Digital Tools for Managing Micro Habits
(36:30) How Important are Digital Health Solutions for the Future Healthcare System – a Journey through State of the Art System
(43:40) How Can Digital Tools Increase the Level of Health Literacy in Society?
(49:30) How to Bring Health Education to all People –Solutions by McKinsey
(58:54) How to Measure the Benefits of Happiness at Companies
(01:02:38) The Cost of health deficits for the European Society
(01:08:30) The Role Different Stakeholders Play to Improve the Healthcare System
(01:16:30) Tobias Silberzahn’s Global Healthtech Network – A Community of 1,500+ Healthtech CEOs and Founders
(01:20:30) The Future of Healthcare is Full Of Opportunities
(01:21:35) The Role of Precision Medicine

Do you want to support the podcast?
Join the LSG2G Community: https://lsg2g.substack.com/subscribe

Mortgage Connects, an MGIC Podcast
Insights and tips from top mortgage industry pros!
Listen on: Apple Podcasts Spotify

Support the show

View Details

What are decentralized clinical trials?

What are the benefits of decentralized clinical trials?

Why are decentralized clinical trials the way of the future?

Emily Mitchell, Executive Director of ICON’s DCT team, discusses the benefits of these trials and what needs to be considered to ensure these benefits are realized.

Emily Mitchell has over 15 years of experience working in the CRO industry in Data Management, Project Management, and Clinical Operations. During her tenure at ICON, Emily partnered with an actigraphy vendor to run a pilot study with employees on the wear compliance and comparison of a medical grade activity tracker to a commercial grade version.

Before the pandemic, Emily helped set up and support the first fully decentralized trial at ICON. She has continued to present at various conferences around the best practices for decentralized studies, ensuring minimized patient and site burden while optimizing data capture. Emily is an active member of the Society of Clinical Data Management (SCDM) and has presented about decentralized trials at numerous conferences.

ICON is the only CRO to offer all services (without the need to contract third-party services or technology) and deliver end-to-end integrated decentralized clinical trial solutions.

ICON supported the delivery of the first decentralized clinical trial that has had positive published results in a medical journal – Nature Medicine

We are talking about

⭐ Decentralized clinical trials
⭐How they benefit patients
⭐The impact on budgeting
⭐Successful deployment of clinical trials an
⭐ Much, much more

Youtube

🕛 Timestamps:(00:00) Intro
(03:30) Kick off with Summer Weather
(06:30) What are Decentralized Clinical Trials (DCT)
(07:30) Benefits of DCT
(08:45) Real-Life Example for a DCT from ICON Plc
(11:48) What was the Motivation to Develop the DCT Model before the Pandemic?
(14:30) Logistics in Clinical Trials
(16:20) Managing DCT
(17:45) Patient Response to DCT
(18:35) Benefits of DCT in Increasing Diversity in Patients Population
(22:30) More Diversity in Patient Population Equals More Valuable Data
(26:00) The Role of Social Media in Patient Recruitment
(27:22) Data Management in Decentralized Clinical Trials
(29:25) Improvement in Data Collection With AI/ML, Tablets, And Wearables
(31:07) DCT and associated cost
(34:08) Which Indications are suitable for DCT?
(37:30) How do decentralized clinical trials impact the duration of a trial?
(40:15) How long does the planning phase in a DCT model take?
(43:30) ICON’s Partnership Model
(47:13) The Demographics of Social Media as a Recruitment Tool for Clinical Trials
(50:10) Patient Experience in DCT
(52:57) How to Keep Patients Motivated Through a DCT
(56:00) Data Collection by Patients
(57:40) Long-term follow-ups in the DCT Model
(01:00:55) Patient Empowerment in Decentralized Clinical Trials
(01:02:45) Do You Want to Evaluate Decentralized Clin

Mortgage Connects, an MGIC Podcast
Insights and tips from top mortgage industry pros!
Listen on: Apple Podcasts Spotify

Support the show

View Details

What is the best approach to starting a novel deep tech life science company?

In this episode, I am talking with Samatha Dale Strasser, CSO, and co-founder of Pepper Bio, about her academic career at the University of Cambridge and MIT and the process of starting Pepper Bio.

Backed by VC firm NFX, Pepper Bio uses proprietary lab methods and computational abilities to unlock a new level of sophistication in drug discovery.
Called the "Google Maps for drug discovery" Pepper Bio helps partners find the safest, fastest route to new, effective drugs in clinical trials by analyzing transomics data.
So far, the company has already identified applications of its technology for rare diseases in oncology, neurology, and inflammatory.

Samantha Dale Strasser, PhD, is CSO and co-founder of Pepper Bio. Samantha co-founded Pepper Bio based on foundational work she pioneered during her PhD studies at MIT. Her development of the first trans-omic machine learning platform revolutionizes how we discover drugs and treat disease. This approach has already identified and validated previously unseen insights in inflammatory diseases and undruggable cancers. She paved the way to Pepper’s first commercial partner, eager to apply this approach to central nervous system diseases.

We are talking about:
⭐The Eco-Systems in Boston
⭐ The Importance of Aligning Vision – Mission – Goals – Actions
⭐ Challenges in Drug Development
⭐ Fundraising strategies for the United States
⭐The Story Behind Pepper Bio
⭐ And Much, Much more

🕛 Timestamps:
(00:00) Introduction Pepper Bio and Samantha Dale Strasser
(02:30) Start of the recording
(03:00) Heatwaves, Paintings, and the Sky Above Boston
(05:00) Culture in Boston/Cambridge and Cambridge, UK – MIT and the University of Cambridge
(16:08) Samantha's Motivation to Start Pepper Bio
(19:20) The Startup Eco-System in Boston, Massachusetts
(21:27) The 3 Critical Key Success Factors of the Deep Tech Eco-System in Boston
(24:40) Starting Points for Global Founders to Connect to the Eco-System in and around Boston
(26:40) Real Life and Digital Meetings – The Best of Two Worlds
(29:55) Fundraising in the United States – 3 Key Success Factors
(33:17) Relationship-building with Investors and Duration of Fundraising in 2022
(31:08) The 3 Do's and Don'ts When Fundraising with US-Based Investors
(44:05) Vision Statement – Pepper Bio
(47:10) The Story Behind Pepper Bio's Foundation
(51:12) Challenges in Drug Development to Improve Success Rates
(55:49) Novel Solutions for Making Sense of Scientific Data
(01:00:15) Pepper Bio's Team
(01:03:30) The Importance of Aligning Vision – Goals – Actions
(01:05:00) Hiring Strategy
(01:05:30) Fundraising at Pepper Bio in 2022
(01:09:10) What is the Best First Step Towards Entrepreneurship?

Podcast Links:
Podcast Community: https://lsg2g.substack.com/Community Partner: https://linktr.ee/lsg2g
Christian Soschner: https://linktr.ee/soschner
LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
Podc

Mortgage Connects, an MGIC Podcast
Insights and tips from top mortgage industry pros!
Listen on: Apple Podcasts Spotify

Support the show

View Details

What is the best methodology for presenting your Company to investors, industry partners, and public funding organizations?

Here is the answer:

In this episode, Donna LaVoie presents her famous “15-slides-methodology” in great detail.

Donna is a proven strategic communications leader in health and science innovation. She is a trusted advisor on strategic communications issues, especially around complex problems affecting multiple stakeholders. She brings a unique combination of public and investor relations expertise, including product launch experience.

LaVoieHealthScience was launched in 2001 after a corporate career with signature biotech companies leading strategic communications functions during tremendous growth, product and business launches, and international geographic expansion.

As an acknowledged leader in health science communications with public and investor platforms, LaVoieHealthScience is recognized as a top 30 independent healthcare agency in the US. The agency has received more than 35 awards for its client work. It is recognized by INC.5000 Hall of Fame – Fastest Growing Private Companies, Boston Business Journal’s top Massachusetts PR firms, PharmaVOICE 100, and O’Dwyers.

We are talking about:
↪️ Why 15 slides are sufficient in corporate presentations
↪️ Why you should have an Agenda slide
↪️ Why an Appendix is important
↪️ What is Better? Detail or Simplicity?
↪️ The interplay of Problem and Solution
↪️ Why the Team slide matters
↪️ Why you need to adapt the presentation to your audience
↪️ And much, much more

Youtube Video

🕛 Timestamps:
(00:00) Intro
(00:45) Donna LaVoie and LaVoieHealthSciences
(02:35) Content of the Episode
(03:00) Review of #bio2022 in San Diego
(04:04) The 15 Slides Presentation Methodology
(08:42) Why is the 15 Slides Methodology Relevant for Experienced Presenters?
(12:15) Why are you here – What is your ask?
(14:00) Why are conventions important?
(16:05) Should Presenters consider the different cultural backgrounds when preparing for presentations?
(16:51) The Importance of Colours
(19:33) Storytelling, Simplicity, Novelty, and Clarity – The Ingredients of Successful Pitch Decks
(24:00) Industry Dilemma
(24:30) What’s Your Story? – 15 Slides Topics Overview
(27:45) Title Slide
(31:15) Company Snapshot
(32:12) The Agenda Why Creating Anticipation as a Hook Matters in Presentations
.(33:00) Describing the Problem and the Solution – Why it Matters
(37:15) The Market and Target Product Profile
(40:00) Competitive Positioning
(42:20) The Team
(46:45) The Pipeline and Clinical Data
(50:00) Regulatory Strategy
(51:00) Manufacturing Strategy
(52:35) Commercial Strategy
(55:00) Financials
(56:45) Summary of the Presentation
(58:30) How Specific Should Deal terms be in a Pitch Presentation?
(01:01:45) Ending Slide – Cultural and Diversity Considerations
(01:03:00) How Much Time Should Executives Take to Prepare their Corporate Story for Fundraising?
(01:05:00) How LaVoie Health Science Helps Life Science Entrepreneurs and Investors

Podcast Links:
Podcast Community: https://lsg2g.substack

Mortgage Connects, an MGIC Podcast
Insights and tips from top mortgage industry pros!
Listen on: Apple Podcasts Spotify

Support the show

View Details

Happy Birthday, Inits. Today 20 years ago – July 27, 2002 – Inits – Vienna’s most important high Tech Incubation Program was created.

In this episode, I am talking with Irene Fialka, CEO of Inits. In 20 years, Inits has supported over 300 high-tech #startups with the necessary tools for a successful and sustainable market entry.

Dr. Irene Fialka is CEO of INiTS, Vienna’s University Business Incubator (UBI), supporting entrepreneurs with R&D-based business ideas serving all academic institutions in Vienna. She has a genetics/molecular biology background and has worked with deep-tech startups since 2004.

Under her leadership, INiTS was awarded three times by UBI Globalas, one of the TOP ranked UBIs in the world. INiTS’ startups have proven to be extremely successful in raising funds (12 x the average UBI-supported startup according to UBI Global) and finding strategic partners. She worked with the founders of, e.g., Apeptico, Blue Danube Robotics, Lexogen, Lithoz, Marinomed, mySugr, and many more. Marinomed is the first of over 300 companies that went public in 2019 (IPO on the Vienna Stock exchange).

In collaboration with partners such as Boehringer Ingelheim, Pfizer, and Uniqa, Dr. Fialka and her team launched the HealthHubVienna (healthhubvienna.com) in 2018, an acceleration program for international health startups to drive innovation and change in the healthcare industry in Europe.
In this episode, we are talking about:

Success Story of Inits from 2002 to 2022
Development of the Startup Eco-System in Europe
3 Major Developments of Inits in the last 20 years
Inits Vision for the coming two decades
Female Founders and
Much more

Youtube Video

I wish the team of Inits all the best for their birthday celebration. Keep up your great work – it has a huge positive impact on the startup ecosystem in Europe

🕛 Timestamps
(00:00) Kick Off
(03:00) Birthday Wishes
(04:00) When Did Inits Start?
(05:30) From 2002 to 2022 – How Did the Eco-System in Vienna Evolve?
(07:40) Early Days of Life Science in Austria – Intercell in 1997, Alexander von Gabain, Werner Lanthaler, Max Birnstiel
(08:25) What was Inits Starting Point in 2002?
(09:20) Tech Transfer in Austria Early 2000 – The Days of the “Ausseninsitut”
(12:32) Business Models of Academic StartUps and Their Challenges – from 2002 to 2022
(15:20) Impressive KPIs of Inits
(19:00) Companies are About Making Revenues
(21:16) Inits For Academic Startups in 2022
(26:35) Public Funding in Austria
(27:32) How the Campus in St. Marx Developed since 2006 – Vienna Bio Center, Start-Up Labs, Inits.
(29:45) INits Support in 2004
(31:00) Coaching, Mentoring, and Advising for Startups
(32:30) The 3 Major Developments at INITS Since 2002
(38:20) INiTs StartUps In Africa
(43:20) Challenges and Opportunities in the Global StartUp Eco-System
(45:05) StartUp Success Stories from the Inits Universe – MySugr, Shpock, Zoho, Marinomed, Origimm, Lithos, Ecop
(52:05) Consistency between Strategy and Action – Aligning Interests
(55:05) 3 Avoidable Mistakes in Startups
(58:52) Patience and Endurance as Ingredients For Success
(01:00:05) Digital Health – Health Hub Vienna
(01:01:50) Inits Vision for the Coming Two Decades
(01:02:15) Diversity and Female Founders
(01:03:25) Integrating Circular Economy Concepts & Sustainability
(01:04:00) How is the Situation for Female Founders in Europe?
(01:10:00) Diana Project
(01:14:00) Diversity in Corporate Teams – From Startups To ScaleUps, To Investments
(01:17:05) What is the First Step Into Ent

Support the show

View Details

What is happening in all things digital assets, cryptocurrencies, NFTs, and alike? The market crashed. Is it all over now?

Investing with experts is always the best idea when investing in new areas. This episode was recorded in February 2022, and I am happy that I had the chance to speak with two experts in digital assets from Austria:

Astrid Woollard and Christian Niedermüller, SMAPE Capital

Astrid is the CIO of Smape Capital. Their slogan is: We invest beyond mission-driven tokenized economies. She is also working as an independent consultant in
digitalization, digital business models, blockchain technology applications,
and IP strategy

Christian Niedermüller has been 15+ years in banking/traditional finance in very challenging roles, but finally went full time into the DLT/Blockchain and digital asset universe after being 6+ years massively involved anyway.

Topics we discuss in this episode:

Smape Capital
Satoshi Nakamoto
NFTs
DAOs
The Metaverse and
Much much more

Youtube Video

🕛 Timestamps
(00:00) Kick Off
(01:07) What is Smape Capital?
(04:15) The History of Digital Assets
(05:05) Who is Satoshi Nakamoto
(07:07) Next Generation Token
(09:53) Use Cases for NFTs
(12:40) What Is DAO?
(14:10) Astrid Woollard’s and Christian Niedermüller’s First Steps Into the Crypto Market
(21:13) The Driving Forces Behind the Digital Asset Revolution
(25:10) The Bitcoin Pizza Day
(26:11) The Tokenized Economy
(28:02) Use Cases for the Token Economy
(33:10) Useability of Tokens for Investments in Equity, Real Estate, and other Asset Classes
(37:00) Unbanking the Banked, and Banking the Unbanked
(40:11) Digital Assets and Inflation.
(42:55) The Remittance Network – An Opportunity for Digital Assets?
(46:50) Money Laundering and the Blockchain
(51:27) Digital Assets in the Metaverse – Why, What, And How
(54:42) NFTs in the Metaverse
(56:08) How NFTs Will Change the Gaming Industry
(59:00) The Availability of Capital for Digital Asset Projects
(01:01:51) New Funds in the Digital Asset Eco-System
(01:06:01) Why Should Family Offices and High Networth Individuals invest in Funds Rather Than Bitcoin
(01:12:42) The Future of Investing in Digital Assets

Podcast Links:
Podcast Website: https://www.lifescienceget2gether.com/
Podcast Community: https://lsg2g.substack.com/Community Partner: https://linktr.ee/lsg2g
Christian Soschner: https://linktr.ee/soschner
LSG2G Twitter: https://twitter.com/LGet2gether
LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
Podcast Episodes: https://pod.link/1493847125
Episodes on YouTube: https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV

Support the show

View Details

It is the 80th episode on my podcast channel. In 2020 I wanted to try how podcasts can bring value to my life science business community.

One of the first speakers on the podcast was Alexander Belcredi, Phagomed. He and Co-CEO Lorenzo Corsini started their Company in 2015 and developed Alternatives to Antibiotics.; which was also the title of Episode #9 - Alternatives to Antibiotics.

In April 2020, Alexander and Lorenzo were fundraising for their Company. Two years later, they signed an acquisition deal with the german Company BioNTech.

After the acquisition, I sometimes heard on the market that Alexander and Lorenzo's success story came a bit unexpected.

That's why I asked Alexander and Lorenzo to come back to the show to highlight how entrepreneurs create unexpected results in business.

Topics we discuss in this episode:

➡️ The Decision-Making Process to Start a Company
➡️ How to Build Processes, Structures, and Teams
➡️ The Reality of Fundraising
➡️ The 5 Key Learnings of First-Time Founders
➡️ And much, much more...

Connect with the experts on the show:
Alexander Belcredi
Lorenzo Corsini

Youtube Video

🕒 Timestamps:
(06:30) How Easy is it to Create an Overnight Startup Success?

(09:07) The Defining Moment of a New Company

(12:10) Is the Ideation Phase the Right Time to Found a New Company?

(16:19) Some Thoughts on Why 9 out of 10 Startups Fail

(17:45) From Ideation to Market – How Much Time is Needed in the Pharma Industry?

(21:16) The Complexity of Founding and Developing Life Science Companies

(25:40) The Early Days of a Company Formation – Structures, Teams, Processes

(31:33) Dealing with adversity

(36:15) Operating in a B2B Environment

(39:45) The 3 Major Obstacles During the Phagomed Journey

(44:40) Adapting the Own Expectations as an Entrepreneur

(47:10) Finding the Right Business Case for the Company

(58:10) How Important is Relationship Building During Fundraising?

(01:06:47) Finding the Right Balance Between Dilution, Control, and Fundraising.

(01:12:42) Why Downsrounds Are a Danger for the Motivation

(01:15:43) How Plannable Are Acquisitions from the Seller's Perspective

(01:24:46) 5 Key Learnings From the Phagomed Journey

(01:31:00) What is the first step towards founding a company?

Support the show

View Details

These days many sources are highlighting the shocking scale of the global mental health crisis and how this affects approx—a staggering one billion people worldwide - over one-seventh of the global population.

“Unfortunately, as harrowing and monstrous this number is”, the investor Christian Angermayer wrote in a blog post, “it is my belief this is a gross UNDER-estimate.”

Ultimately, the number of people needing mental health support is arguably all 100% of the world's population.

I invited Dr. Jonathan Sporn, CEO of Gilgamesh Pharmaceutical, to gain more insights into the unmet medical need in mental health and the promising novel psychedelic drug development sector

Jonathan Sporn MD is a Board Certified Psychiatrist, assistant professor at Columbia University, and CEO of Gilgamesh Pharmaceuticals, based in NYC, which is developing novel psychedelic-related or inspired medicines to treat mental illness.

Topics we discuss in this episode:

➡️ Global Mental Health Situation
➡️ The History of Psychedelic Drug Development
➡️ Investors in this promising area
➡️ The Background Story to the foundation of Gilgamesh Pharmaceutical and
➡️ And the Different Ingredients Needed to Structure a Novel Game-Changing Drug Development Company

Connect with Jonathan Sporn on Linkedin
Youtube Video

🕒 Timestamps:
(00:00) Introduction to Topic, Speaker, and Company
(04:00) Life in New York in 2022
(07:15) The Global Mental Health Pandemic
(10:39) Mass Shootings in the United States as a result of the Mental health Situation
(14:05) Why is it Necessary to Develop Novel Drugs to Fight Mental Health Issues in Society
(19:00) The History of Drug Development for Mental Health Patients
(24:00) How Effective Are Psychedelic Drugs to Tackle Mental Health Questions?
(25:05) Psychedelic Drugs in Pop Culture
(26:40) What Inspired Jonathan Sporn to Dedicate His Professional Life to Advance R&D in Psychedelic Drugs
(29:30) Psychedelic Drugs Help to Observe Own Behaviour
(32:30) Root Causes of Mood Disorders like Maniac Depression, Bipolar Disorder
(34:05) Psychedelic Drugs Enhance Neuroplasticity
(36:50) From Basic Research to Drug Development in the Pharma Industry
(40:10) Mental Health R&D at J&J
(43:40) S-Ketamine vs. K-Ketamine – Difference and Similarities
(46:35) Early-Stage Research in Big Pharma
(49:00) Big Pharma and Small Biotechs
(51:50) The decision to Start A New Company
(57:00) Foundation of Perception Neuroscience – From Early Stage Research to Clinical Phase 2 to Exit
(59:05) Atai Life Science – Continuing Development of the Compounds against Depression
Supporting links:
(01:00:00) Reasons for Becoming a Serial Entrepreneur After a Successful Exit Deal
(01:06:00) Drug Development is Simple – Given an Experienced Drug Development Team
(01:08:00) What is the unique approach of Gilgamesh Pharmaceutical?
(01:10:15) Target Product Profile of Psychedelic Drugs
(01:20:30) Gilgamesh Pharmaceuticals Mission and Vision
(01:23:20) Patents in Psychedelic Drug Development
(01:24:45) Business Model of Gilgamesh Pharmaceutical
(01:29:00) Artificial Intelligence in Psychedelic Drug Development
(01:33:14) Investing in the Psychedelic Drug Development Industry
(01:37:22) Life Science VCs in the Psychedelic Drug Development Industry
(01:39:00) Christian Angermayer, Peter Thiel, Mike Novogratz – Investors in Psychedelic Drug Development
(01:41:00) Investment Sentiment in the United States in Developing Novel Innovation
(01:43:00) Opinions on the Investment Market Situation in 2022+
(01:49:40) Gilgamesh Pharma Plans for the Coming Years

Support the show

View Details

Warren Buffett recommends buying companies with a great moat. Something that makes the company unique and protects the business from the competition. Patents are the best moats. Do you want to know why? Then listen to Gerda Redl.

Who is the speaker?

Dr. Gerda Redl is a patent attorney with more than 20 years of experience in the life sciences industry.

Her technical expertise is in biotechnology, biochemistry, and chemistry, including protein engineering, biologicals, small molecules, biomarkers, antibodies, alternative scaffolds, and libraries.

Before founding REDL Life Science Patent Attorneys, she held senior management positions in biotech, mid-size, and big pharma companies.
She graduated as a biochemist and received her Ph.D. in microbiology from the Technical University of Vienna.

Topics we discuss in this episode:

➡️ The Value of Patents

➡️ Fast Track Protection

➡️ Key Territories in a globalized World

➡️ Digitalization

➡️ Interdisciplinary Inventions

Youtube: https://youtu.be/mAFQeofSh7o

🕒 Timestamps:(00:00) Kick-Off

(04:33) Patents are Assets

(06:40) Different Types of Patents and their Economic Value

(12:56) Product or Platform Technology Patents – Case Study mRNA Vaccines

(15:38) When is the Right Time to File Patents?

(18:55) In What Cases Are Patents not Necessary?

(20:06) Patents, Trademarks, and Know-How

(21:22) Patent Filing and Deal Structuring – What is The Right Sequence of Events?

(22:13) What Confidentiality Agreements can and cannot do

(23:55) What is the perfect patent solution?

(27:20) Time and Capital Needed for Filing and Maintaining Patents

(31:05) The Best Patent and Business Development Strategy for Scientific Founders

(34:00) What territories should be protected?

(43:04) What effects have restrictive patent laws on motivating entrepreneurs to turn scientific inventions into products?

(45:15) How Patents Drive Investment Processes

(47:30) How to Overcome Patent Hurdles when third parties don’t want to commercialize their patents.

(52:45) Possibilities of Speeding Up Patent Processes

(58:29) China – The Innovation Leader of the World

(01:00:41) The FTO Jungle

(01:01:35) Acceleration of Patent Processes

(01:02:00) Digitalization of Patent Processes

(01:05:00) AI-based translations of Patents

(01:09:00) Unitary Patents in Europe

(01:17:45) The Convergence of Technologies and Patents

(01:23:31) What is First: Product Concept or Patent?

(01:25:00) First Step Towards Filing the First Patent Application

(01:27:35) It is About the People…

Support the show

View Details

What is going on in the world of digital assets in 2022? In May 2010, 10,000 BTC bought 2 Pizza.

Last year in November, the same amount had a value of 600 Million dollars. A lot has evolved since 2010 in the digital asset ecosystem.

That's why I asked Alexander Valtingojer, CEO of Coinpanion, to discuss the latest development in the crypto market. This episode was recorded in January 2022.

What are the topics we discuss in this episode?

Digital Natives and the Boomer Generation
Bitcoin and other Cryptocurrencies
The Biggest Wealth Transfer in Human History
NFTs, Web 3 and the Metaverse
And much, much more

🎙️ Youtube: https://youtu.be/0_m-9EgHl3M Books in this episode: Ray Dalio, The Changing World Order🕒 Timestamps:(00:00) Intro

(03:30) South Tyrol – Cultural Background

(06:00) The Development of Digital Assets in Q1/2022

(10:00) Long Term Perspective of the Crypto Eco-System

(17:30) The Future of NFTs

(20:45) What NFTs can do for books

(25:30) What Are Smart Contracts?

(27:45) Remodeling the Book Industry with Smart Contracts

(30:30) Interoperability

(31:30) Use-Cases for NFTs in the Creator Economy

(38:00) NFT become Commodities

(39:30) A Brief History of Smart Contracts

(41:30) Tokenized Shares

(45:30) How Regulation Helps the Ecosystem

(47:08) Web3 and the Metaverse

(52:30) Star Trek, Ready Player One, Mark Zuckerberg and the Metaverse

(54:30) Lex Friedman – What Happens When an AI becomes conscious?

(58:15) The Mission of Coinpanion

(01:02:06) The Story Behind the Foundation of Coinpanion

(01:04:30) The Investment Approach of Coinpanion

(01:10:30) Bitcoin

(01:16:30) The Biggest Generational Wealth Transfer in the History of Human Society

(01:18:30) Use Cases for Gold

(01:20:30) NFTs, Collectibles, and the Gaming Industry

(01:24:30) Maker and DeFi

(01:26:30) Ethereum

(01:30:30) Charles Hoskinson, Cardano, and ADA

(01:31:50) Polkadot and Link

(01:35:50) Uniswap

(01:37:57) USDC

(01:40:30) Stablecoins, Stacking, and Default Risk

(01:45:30) Coinpanion helps with investing in Digital Assets

Podcast Links:
Community Partner: https://linktr.ee/lsg2g
Christian Soschner: https://linktr.ee/soschner

Support the show

View Details

How Did the Conference Industry Change in the last two years?

Philadelphia in 2019 was the last Bio I attended in person. In March 2020, the world shut down to respond to the novel viral threat. Since then, all conferences have been digital.

What effect did this have on the conference Industry – especially the Bio US? Listen to Rich Masters, Chief Public Affairs and Marketing Officer of Bio.

As EVP for Public Affairs, Rich Masters leads integrated communications, branding, and marketing strategy for the organization, including overseeing the policy communications that support the advocacy goals across each of BIO’s sections.

What are the topics we discuss in this episode?

What are Bio and the Bio US 2022?
How Did the Conference Industry Respond to the Lockdowns?
The Availability of Capital for Innovation
Entrepreneurship in the United States and
What’s New at the Bio US 2022

📚 The Emperor of All Maladies

📰 Article: Medium

🎙️ Youtube: https://youtu.be/vIlzrV-nmxc Register today: https://www.bio.org/events/bio-international-convention/registration
🕒 Timestamps:(00:00) Intro
(01:36) Who is Rich Masters
(02:54) What is Bio?
(03:30) Opening
(04:30) How is The Situation in the United States with the Pandemic These Days?
(05:40) How did the Pharma Industry Respond to the Global Viral Threat?
(06:00) How did BIO Help Solve the Biggest Healthcare Challenge in the last 2 years?
(08:33) What Is Biotechnology Innovation Organisation (BIO)? It is not only the Bio US.
(12:10) How is the Availability of Capital for Biotechnology Product Development in the United States?
(14:20) What Are The Bio Business Solutions and how does it help SMEs?
(15:43) Is a BIO Membership for US Companies Only, Or is it Open for European and Asian Companies?
(17:40) Entrepreneurship in the United States for Bio Product Development
(18:24) Where are the Bio Hotspots in the US?
(19:15) The Different Sides of BIO
(20:15) Big Trends in Bio in 2022
(26:20) What A Convention Model Looks Like in a Post Pandemic World
(31:35) Taking the Best of Two Worlds - New On-Demand Service – All Panel Discussions, Presentations, and Speeches in One Digital Space
(33:35) Bio Impact in Omaha, Nebraska
(36:05) Are Digital Conferences a Replacement for Real-Life Versions?

Add on Services at the Bio:
(40:00) The Midway Experience in San Diego
(41:00) I am Bio
(42:05) Bio US Podcast – I am Bio
(42:30) Good Day Bio
(42:45) Bio.News

(44:25) Challenges for Conference Organizers that Came with March 2020
(41:30) How Bio Helps their Members to Overcome Challenges Ahead Especially the SMEs
(55:35) Side Events at The Bio to Meet and Mingle with the Industry
(58:25) Limitless - Rich Masters – See You on June 13-16 in San Diego to Celebrate the Work of Scientists

Podcast Links:
Community Partner: https://linktr.ee/lsg2g
Christian Soschner: https://linktr.ee/soschner

The LSG2G Partners
Experts in Life Science

Support the show

View Details

Are you interested to expand your business into Asian Markets? Then this episode might be for you.

As Program Manager of the Global Incubator Network Austria (GIN), Lisa Stöger has successfully connected the Austrian startup ecosystem with the world's most innovative startup hubs for the last 4 years. With a focus on Asian markets, she supports Austrian startups in their internationalization and market entry and introduces them to relevant, international stakeholders. Since 2016, GIN, co-managed by AWS and FFG, has been the contact point for startups regarding expansion from Austria to Asia and vice versa. Over 300 startups have benefited from the customized GIN services and internationalization programs. With her interdisciplinary academic background in Politics and Economics in Vienna and York (UK), Lisa is passionate about identifying cooperation potentials between international organizations and public institutions and is eager to apply these to promote startups and boost innovation.

What are the topics we discuss in this episode?

We cover 7 different eco-systems in Europe and Asia

Austria
Israel
China
Hongkong
Singapore
Japan and
South Korea

🎙️ Youtube: https://youtu.be/G0aY-sz82_8

🕒 Timestamps:
(00:00) Opening
(02:18) What is GIN?
(05:00) Connecting the Start-up Eco-Systems in Europe with Asia
(07:05) How Did the Pandemic Change the Way People Are Doing Business in the Startup Eco-System
(10:30) The Potential of the Digitalisation in Creating New Business Relationships
(14:04) The Start-up Eco-System in Israel – Linking Europe with Asia
(17:05) Go Global Out of the Israeli Eco-System
(18:05) The Start-Up Hub in Tel Aviv
(22:05) The Silicon Wadi in Israel
(24:40) Availability of Venture Capital in Austria
(27:00) The Availability of Venture Capital in Austria for Companies Raising Series A Rounds and Beyond
(29:15) Mainland China
(33:57) How to Overcome the Language Barrier in Business
(38:15) Contracts – Is English Sufficient?
(39:06) The Eco-System in Singapore
(41:22) The Tax Rates in Singapore
(42:00) Singapore – The Gateway to South-East Asia
(40:30) Startups in Hong Kong
(45:00) Should Startups Create Subsidiaries in foreign Eco-System to gain more credibility?
(51:53) The Start-Up Eco-System in Japan
(55:15) The Japanese Business Culture
(56:34) South Korea and Startups
(57:18) The Business Culture in South Korea
(01:01:34) The Covid Strategy in South Korea
(01:06:25) What is the best first step into Asian markets?
(01:08:35) Why Should Startups consider an entry into Asian Markets?

Support the show

View Details

Do you want to know why networking and leadership are so important to be successful in business? And why everybody, including employees, needs to learn those skills?

Then this episode is for you.

Mark is the author of The Career Toolkit, Essential Skills for Success That No One Taught You. Educated at MIT, Mark has spent his career launching and fixing new ventures at startups, Fortune 500s, and academia. He’s developed new software languages, online marketplaces, new authentication systems, and tracked criminals and terrorists on the dark web. Mark helped create the Undergraduate Practice Opportunities Program, MIT’s “Career Success Accelerator”, where he’s taught for twenty years. Mark also serves on the boards of non-profits Techie Youth and Plant a Million Corals.

📚 The Career Toolkit: https://amzn.to/395ICXU

Topics we cover in Episode Number 74:

➡️ Leadership
➡️ Entrepreneurship
➡️ What is Better: Alpha or Beta Leaders?
➡️ What Makes Exceptional Leaders like Elon Musk, Bill Gates or Steve Jobs?
➡️ And much much more

🎙️ Youtube: https://youtu.be/kMuTjlksyXM

🕒 Timestamps:
(00:00) Intro
(02:00) How has life been on the East Coast in January 2022?
(03:00) Travel Restriction and Mask Mandates in 2022
(05:30) Why Was it Necessary to Write “The Career Toolkit”?
(07:02) The 10 Most Important Skills For Entrepreneurs
(08:15) Why Are Those 10 Skills Not Taught at Universities?
(11:00) What is Leadership?
(13:15) Leadership and Influencers: What is the Difference in the skillset?
(15:30) Is Leadership Learn- and Teachable?
(17:45) Management and Leadership – What is the Difference?
(20:32) Alpha Male and Beta Male – What is Better for Leadership in this Century?
(23:30) Why Situational Leadership Matters
(28:15) Character Traits of Exceptional Leaders Like Elon Musk, Steve Jobs, or Bill Gates
(30:00) Leadership – Is it the Ceos' Job or also the duty of the Employees?
(32:15) If you want to lead from the front, you must first learn to lead from behind
(31:53) The Importance of Networking for Entrepreneurship
(38:36) The Role of Networking for Fundraising Entrepreneurs
(44:15) The Secret of Building and Maintaining Relationships
(48:15) The Power of Introductions in Networking
(49:43) Do Introduction Substitute the Relationship Building Phase?
(51:45) Why Real Life Still Matters in Relationship Building
(56:00) What Can and Cannot be done via Zoom During the Relationship Building Phase
(01:02:36) The US Startup Eco-System in 2022
(01:06:30) What is the best way to approach the startup ecosystem in the US as a startup?
(01:11:15) What is the US Eco-System Looking for in Startups?
(01:14:30) The Big Vision – Why it Matters and Why Not
(01:16:30) What is the best way to engage with the US Eco-System
(01:17:40) Professional Background of Mark Herschberg and How you Can Reach Out to Him

The LSG2G Partners
Experts in Life Science

Support the show

View Details

Do you want to know how to value a company and what Julia Roberts has to do with it? Then listen to Bharat Kanodia in this episode number 73.

Valuation is one of the most difficult exercises in the startup world. How can you put a price tag on a company that doesn’t exist yet? Get help from an expert:

Bharat Kanodia has valued over 2000 businesses and signed off on assets worth $2.6 trillion in value. He has appraised unique assets like the Golden Gate Bridge, Atlanta Airport, Uber, Airbnb, Yahoo!, Brooklyn Bridge, Mirage Casino LV, among many others. Bharat is the Founder of Veristrat, a company that helps startup founders and VCs by telling them what their companies are worth. He lives in the San Francisco Bay area with his family and enjoys sailing, golfing, skiing, and horseback riding.

In this episode number 73 we are talking about:

➡️ The History of Entrepreneurship in San Francisco
➡️ Failure Culture
➡️ Julia Roberts
➡️ NFTs
➡️ And much much more...

Books mentioned in the Podcast:
Epic Businesses: https://amzn.to/3vMZI4E
Atomic Habits: https://amzn.to/3LtSlpb

Do you want to reach out to Bharat Kanodia:

LINKEDIN:

INSTAGRAM: http://www.instagram.com/whatsitworthtv
TWITTER: https://twitter.com/whatsitworthtv
WEBSITE: http://www.veristrat.com
FACEB00K: http://www.facebook.com/whatsitworthtv
TEDx Speech: https://www.youtube.com/watch?v=zicGCnM8Hag

📝 Shownotes: tbd

🎙️ Youtube: https://youtu.be/w5_IXnNQSRU

🕒 Timestamps:
(00:00) Intro Bharat Kanodia
(04:00) History of Entrepreneurship in San Francisco
(07:08) Failure Culture on the West Coast
(08:40) The Startup Reality – 9 out of 10 attempts fail
(10:10) Veristrat – Corporate Valuations
(11:30) The Nature of Valuations
(15:31) How to Deal With Valuations in the Startup World?
(20:00) Valuating Companies on a Pitch Deck Basis
(26:50) Beeple’s Everydays NFT – How to Put a Price Tag on It
(32:00) The Valuation of Cryptocurrencies
(35:34) How to Put a Price Tag on Early Stage Drug Development Companies
(40:00) When Should Founders Start to get Professional Support for evaluating the company and their products?
(43:35) How to Put a Price Tag on Landmarks like the Eiffel Tower
(45:10) Life Habits of Successful Entrepreneurs
(47:00) Atomic Habits
(49:15) How to Reach Out to Bharat Kanodia

Support the show (https://lsg2g.substack.com/subscribe?)

Epic Business: 30 Secrets to Build Your Business Exponentially and Give You the Freedom to Live the Life You Want!

View Details

Do you want to reach out to Japanese companies and universities? Then you should know what makes Japan special and different to have a smooth business experience.

Different Cultures – Different Rules and Different ways to success

Japan is the second biggest market for pharmaceuticals globally. The area is not only interesting for its sales potential; it is also a major R&D hub in Asia.

One of the best experts in Japanese business culture in the LSG2G Community is Stefan Sandström.

Stefan Sandström is a serial entrepreneur who lived his first life in Sweden and is now living his second life in Japan. Instead of entrepreneurship, he's set up a business development consultancy in Japan aiming at the biopharma industry. After 15 years in Japan and partnering with Mr. Kuboniwa (retired from Chugai, chairman of the management committee of JBA, Japan Bioindustry Association, chairman of GTB, Greater Tokyo Bio community, and an advisor for the Japan Government), we always help find the best solutions in increasing traction or finding the right partners.

We are talking about:
➡️ Japanese Martial Arts
➡️ How is daily life in Japan
➡️ Japanese Meeting Culture
➡️ The Role of Informal Meetings and
➡️ How to Negotiate Prices in Japan

Do you want to get in touch:

⏩ Stefan Sandström: https://www.linkedin.com/in/stefan-sandstr%C3%B6m-22279053/
⏩ Manifestum AB: https://www.manifestum.com/iris-biotech-an-exemplary-performance-of-how-to-do-business-in-japan/

📝 Shownotes: tbd

🎙️ Youtube: https://youtu.be/B1HrE8XYmB4

🕒 Timestamps:
(00:00) Introduction
(02:00) Kick-Off and Greetings to Yokohama
(03:15) The Covid Situation in Japan January 2022
(05:13) Reasons to Move to Japan
(06:20) Kendo and Japanese Martial Arts
(08:12) Martial Arts and Business
(12:07) What Makes the Japanese Business Culture So Unique?
(18:55) Daily Life in Japan
(27:30) What are the 3 most important things everybody needs to know before traveling to Japan?
(30:50) How Important is it to build business relationships in Japan?
(32:40) Business Background Stefan Sandström
(35:53) What is the Right Way to Engage with Japanese Companies? – A Case Study
(41:45) Japanese Meeting Culture – What are the differences between formal and informal meetings?
(43:45) Mind not only what happens in meetings but also what doesn’t happen in meetings
(45:15) What does it mean when in subsequent meetings, similar questions are asked?
(48:17) How is it perceived to change meeting dates on short notice?
(51:55) How to set up informal meetings in Japan
(58:50) How to Negotiate the Price in Japan
(01:01:00) What is the best first step in creating business relations with Japanese companies?

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Did you know that almost 90% of all product ideas fail in clinical trials?

Surprising to me was that lack of efficacy doesn't seem to be the main reason why clinical trials fail in the first place. Other factors are at play, and most of them are manageable risks when the right team is at work.

In this episode:

Strategic considerations for setting up a clinical trial
Inhouse vs Outsourced Clinical Study Management
Why clinical trials fail
Steps to getting your clinical trial back on track
Future trends of clinical trials
and much more

Who is the expert in the show?Heike Schön is the Co-Founder of Lumis International GmbH and Lumis Life Science Consulting GmbH.

She has more than 25 years of experience in international clinical research and drug development.

📞 Book a meeting here: Link

Youtube: https://youtu.be/r0qphO8Qs3o Podcastnotes: Link Timestamps:(00:00) Intro
(02:25) Who Is Heike Schön, Lumis International and Lumis Consulting?
(04:20) Topics in the Episode
(04:30) Kick-Off
(05:00) Background to Lumis International and Heike Schön
(10:20) When is the Right Time to Start with the Planning of a Clinical Trial?
(12:10) The Role of a Sponsor of a Clinical Trial
(14:30) Who is Responsible for the Clinical Trial as a Sponsor?
(16:55) When Should a Company Start to Implement Clinical Trial Management in the Organisation?
(18:30) Funding Requirements for Clinical Trials
(20:00) The Reality of Inhouse and Outhouse Clinical Trial Management
(22:15) What to Think About When Planning Oversight Management
(25:00) Relationship and Culture Management in Clinical Trials
(27:25) Budget and Ressource Requirement for Clinical Trials
(28: 45) 3 Steps to a Successful Clinical Trial
(30:40) The 3 Main Reasons Why Clinical Trials Fail
(33:30) Considerations for Patient Enrollment as a Key Success Factor for Clinical Trials
(37:30) … and when enrolment fails, what are the steps to rescue the trial?
(42:45) Do Inhouse Studies Require Rescue?
(44:30) How to Rescue a Clinical Trial
(48:30) Root Cause Analysis as a Starting Point to Rescue a Trial
(52:25) Preventive Measures to Avoid Failure Early on
(53:30) How Important is Leadership in a Clinical Trial?
(56:30) The 3 Main Reasons to Stop a Clinical Trial – The Point of no Return
(59:00) How are the Cost Calculated for Rescue Study Management?
(01:00:15) Planning of a Clinical Trial – A Key Aspect of a Successful Trial
(01:02:15) How to Plan Realistic Timelines and Numbers
(01:07:15) The Role of Feasibility Studies in Clinical Trials
(01:09:30) How Clinical Trial Management Evolved in the last 30 years
(01:11:15) Upcoming Trends in Clinical Trial Management
(01:13:15) Decentralized Clinical Trials
(01:15:00) Artificial Intelligence And Big Data in Clinical Trial Management
(01:17:55) The Digital Twin
(01:19:15) The Human Factor and Leadership in Clinical Trial Management
(01:21:10) The Patient in Clinical Trials
(01:22:55) Planning and its contribution to clinical trial success
(01:26:55) Summary of What to Do When Clinical Trials Fail
(01:28:35) When is the Right Time to Add a Rescue Team to the Clinical Trial?
(01:31:00) A Risk Management Plan for Clinical Trials
(01:32:00) How to Contact Heike Schön and Lumis International

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Big corporations strive to bring new solutions to their customers to help them solve their most pressing problems.

To do so the corporation needs to be innovative. That's why companies like Apple, Google, Pfizer, and similar players want to cooperate with start-ups and scale-ups globally.

Such cooperations strive to collaborate with top startups, invest in them, and sometimes acquire them to have access to novel ideas. By innovating the big players stay competitive, secure growth, and also help keep their employees motivated and curious.

One of the best ways to foster innovation is creating Venture Capital funds. Venture funds collect capital to invest in high-risk early-stage innovative startups to help them grow.

In this episode, we talk about:

Why is Venture Capital important for Innovation in Life Science?
What is the Secret Sauce of Venture Capital?
Venture Capital Success Stories
What is the Current Situation of Venture Capital in Europe?
And much more

Who is the expert in the show?Bruno Montanari is a Partner at Seroba. He has a background in venture capital and in investment banking, with a focus on the pharmaceutical, biotechnology, and medical device industries.

Bruno sits on the boards of STORM Therapeutics and Coave Therapeutics.

Youtube: https://youtu.be/nG8DspNug-4 Timestamps:
(00:00) Introduction
(03:30) Start of the Conversation “How Venture Capital Supports Science & Innovation”
(03:45) What is Venture Capital?
(07:30) Why is Venture Capital Necessary?
(08:35) How Capital Intensive is Drug Development in Life Science?
(11:55) Why Do Research Organisation and Big Pharma Need Companies in Between the Value Chain?
(17:15) How Much Capital is Needed to Bring a New Therapy to the Market?
(19:10) Why do some Life Science Start-Ups Fail?
(24:30) How Can Venture Capital Help to Build Europe Into a Startup Continent?
(31:53) How Innovation Changes the World
(32:40) The Entrepreneurship Mindset between Academia and Industry
(36:45) The State of Venture Capital in Europe
(39:00) Elements Needed to Develop the Life Science Industry in Europe
(42:35) Why Do Life Science Companies in Europe get Listed on the NASDAQ?
(49:00) The Advantages of Specialized Investors
(50:50) Benefits for Family Offices and High Networth Individuals to Invest in a Venture Fund Rather than directly into early-stage startup companies
(59:00) Seroba Life Sciences
(01:00:40) Success Stories from the Venture Capital Life
(01:06:15) What kind of Deals are VCs looking for?
(01:09:15) The Importance of Gathering Information before Closing a Deal – on both sides of the negotiation table
(01:14:10) How to Balance Pitching and Relationship Building
(01:19:30) 2x/10x/100X – Why are these metrics important to VCs
(01:23:30) Deal Closed and they lived happily ever after – How does life look like post-investment?
(01:27:00) How VCs Support Their Portfolio Companies
(01:31:35) Warren Buffett vs. Venture Capital – Why is an Exit Important to VCs?
(01:39:00) How to Reach Out to Bruno Montanari and Seroba Life Science

Podcast Links:
Podcast Community: https://lsg2g.substack.com/Community Partner: https://linktr.ee/lsg2g
Christian Soschner: https://linktr.ee/soschner
Podcast Episodes: https://pod.link/1493847125

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Lately, investors and researchers have published more and more information on longevity research and development.

Investors like Sergey Young or Christian Angermayer started to bet significant capital on this topic.

What is going on in this field on the research side? What are potential applications to increase the Lifespan? And when will those innovations hit the market?

In this episode, I had a conversation in December 2021 with Prof. Collin Ewald, ETH Zürich, about his longevity research and the future impact on the pharma industry.
In this episode, we talk about:

What is the role of the extracellular matrix during aging and longevity?
Where is currently the innovation for longevity drug discoveries done?
What aging research is going on?
The Swiss Society of Ageing and Longevity Research
And much more…

Who is the expert in the show?

Prof. Ewald is Head of the Extracellular Matrix Regeneration Laboratory, Department of Health Sciences and Technology.

Collin has a longstanding interest in the molecular biology of healthy aging and age-related pathologies.

He is the founder and currently the president of the Swiss Society for Aging Research (www.ssfar.ch). He is named under the top 1000 Longevity Leaders worldwide and the top 15 Longevity Influencers in Switzerland. He has received multiple awards, including NYAS Future Entrepreneur, recognized by the New York Academy of Sciences.

Youtube: https://youtu.be/7uH3m6spb_g

Timestamps:
(00:00) Opening about the situation in Switzerland and Austria in December 2021
(05:40) Longevity, Ageing, and the Health Span
(07:05) Collin Ewald – Development of Ageing Research since the 90s
(10:45) What is Ageing?
(16:45) What is the Possible Lifespan of Human Beings? From Stone Age to the Future
(20:10) What Factors Changed in Society that helped increase the average Lifespan?
(22:45) The Importance of Education on Healthy Aging
(26:15) How Education and Research Evolved with the Internet
(27:00) Research Focus of the Collin Ewald Lab
(33:30) Doubling the Lifespan in lab trials – is it possible to translate the research into human applications?
(35:40) How to Translate Research into Products with Spin Outs.
(38:00) Spin Outs from the Collin Ewald Lab
(47:24) The Role of Extracellular Matrix in Ageing
(54:40) The Potential for Applications for Cancer Diagnostic rooted in the research of the Collin Ewald Lab
(56:15) How Artificial Intelligence Helps in Research
(59:45) The Challenges Longevity Drug Development Faces at the Clinical Stage
(01:03:45) The Role of Food & Science in Longevity Research
(01:07:45) The Swiss Society of Ageing Research & Health Policies
(01:13:00) Development of Life Expectancy
(01:17:20) Healthy Ageing and Social Security
(01:20:25) Advice to Young People Who Want to Create Lasting Change
(01:25:35) The Killer Experiment - How Failure Creates Success

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

What significant problems does the food industry face today? Which solutions are already in development?

In this episode, I am talking with Mauricio Agudelo and Lina María Toro about Sustainable Food Innovation in South America.

BIALTEC assists animal protein producers to improve productivity and profitability through precision nutrition, understanding their particular dietary needs, analyzing them through a bioinformatics platform that uses artificial intelligence, and supplying the next generation antibiotic-free additives that will facilitate performance to obtain the desired results.

In this episode, we talk about:

The Problems in the Food Industry
What Solutions are in Development?
Bialtec’s Mission
Why You Should Create a Startup and
Much More

I hope you enjoy the conversation the same way I did.

Who are the experts in the show?

Mauricio Agudelo (eMail:
Lina María Toro (eMail: lina.toro@bialtec.co)

Shownotes: tbd

Youtube: https://youtu.be/8S--mLaRJ4w Timestamps:(00:00) Intro

(02:30) Opening

(05:45) Recap of EFIB October 2021

(09:15) The Major Problems in the Food Industry in South America, North America, and Europe

(11:40) Use of Antibiotics in Agriculture

(12:45) The Two Big Problems in Agriculture

(13:45) Precision Farming and Precision Agriculture: Using AI, Big Data and Gene Editing

(16:20) Bialtec’s Mission

(19:50) Solution of Bialtec for Precision Farming

(24:15) The Importance of the Microbiome

(30:20) Big Data, Health, and Nutrition

(31:50) Let Food be thy medicine and medicine be thy Food.

(33:30) The global increase in meat consumption

(36:15) Sustainability

(38:30) Motivation to create a StartUp

(46:45) The Start-Up Eco-System in Colombia

(50:45) Live Your Dreams

(54:00) Opportunity for US and EU Bases Investors in Latin America

(58:45) Bialtec’s Plans for European Expansion

(01:01:45) What is Bialtec Looking for?

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Innovation needs collaboration on a global scale. Making things happen requires entrepreneurs who love science and work day and night to connect the best minds globally and support them to translate their science into products and businesses.

In this episode, I have a conversation with Kai Lamottke, CEO and Co-Founder of Bicoll.

Dr. Kai Lamottke is co-founder & CEO of Bicoll GmbH and Bicoll Biotechnology (Shanghai) Co. Ltd., the first German-Chinese biotechnology company. His expertise and knowledge in life science and innovation sectors in China and Europe are requested by corporates, SMEs, and organizations, like European Commission. The excessive network of business, academic and political contacts allowed him to achieve business governmental grants with a value of over 23 Mio. € up to now

The Bicoll Group is a privately-owned biopharmaceutical company which includes Bicoll GmbH headquartered near Munich in Planegg / Martinsried, Germany, and its wholly-owned subsidiary Bicoll Biotechnology (Shanghai) Co. Ltd.

In this episode, we talk about

From Science to Business
Bicoll’s Mission
Finding the Business Model
How to Establish Business Between Continents
Operating in a Pandemic World

I hope you enjoy the conversation the same way I did.

Who is the Expert in the show?

Kai Lamottke
Bicoll

Shownotes: https://lsg2g.substack.com/p/67-kai-lamottke-bringing-innovationVideo to the Episode: https://youtu.be/K5_7nKZ6KCI Timestamps:(00:00) Start

(02:30) Science During the Pandemic

(07:05) Introduction Kai Lamottke and Bicoll

(13:00) Entrepreneurship

(17:30) Bicoll’s Mission

(19:50) The Process of Finding a Business Model – Example Bicoll

(25:00) World of Entrepreneurship

(29:15) The Magic of Drug Discovery

(35:00) How to Deal with Failure

(41:00) How to Start a Company in China

(47:45) Founding Companies in Asia at the beginning of the Millenium

(51:45) How to Communicate Across Continents Without Social Media, Smartphone and Highspeed Data Highways?

(57:45) Managing International Business in a Pandemic World

(01:01:30) Similarities and Differences Between Asian and European Work Ethics

(01:09:05) The Benefits of the Chinese Education System

(01:16:10) What is the Best First Step Into the Chinese Market?

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Part 7 of the Year in Review Recording.

1 hour minutes of inspiring conversations with speakers from previous podcast episodes and business partners of the hosts.

What was hot in 2021, and what do our speakers expect for 2022?

In this episode, we talk about

Formula 1 Fuels
Hand Sanitization
Open Source and
Technology

I hope you enjoy the conversation the same way I did.

Who are the Experts in this episode:

Martin Popilka
Denis Roio

Video to the Episode: https://youtu.be/d4_aQMOabb8

Timestamps:(01:00) Martin Popilka – Pivoting from Formula 1 Race Fuels to Hand sanitizer During the Pandemic

(05:30) Hand Sanitizer as a Service for Companies

(08:00) Data Collection and GDPR Compliance

(11:15) Plans for 2022

(12:00) Challenges of Running 3 Companies at the same time

(15:15) P1 Fuels

(21:30) Hand sanitizing to Stay Healthy – Will it Stay After the Pandemic?

(25:15) How Was the Experience of Recording 7:30 Hours Straight?

(33:12) Denis Roio – Open Source

(46:00) Dyne.org

(52:00) Techies against Technocracy

Podcast Links:
Community Partner: https://linktr.ee/lsg2g
Christian Soschner: https://linktr.ee/soschner
Podcast Community: https://lsg2g.substack.com/
LSG2G Twitter: https://twitter.com/LGet2gether
LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
Podcast Episodes: https://pod.link/1493847125
Episodes on YouTube: https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV
Podcast Website: https://www.lifescienceget2gether.com/

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Part 6 of the Year in Review Recording.

1 hour minutes of inspiring conversations with speakers from previous podcast episodes and business partners of the hosts.

What was hot in 2021, and what do our speakers expect for 2022?

In this episode, we talk about

NFTs
Metaverse
NanoMetaGames
Austrian Entrepreneurship Week
From Morning Moonshots to Future Weekly
Apple & Spotify Podcast Algorithms

I hope you enjoy the conversation the same way I did.

Who are the Experts in this episode:

Paul Polterauer
Philipp Peinsold
Markus Raunig

Video to the Episode: https://youtu.be/RpPpO5hDlBI

Timestamps:(02:00) What are NFTs?

(03:42) The Metaverse

(04:08) More about NFTs

(07:20) NanoMetaGames

(17:00) NFTs in Games

(19:13) NFT and digital collectibles from games

(22:57) Usecases for NFT

(23:53) When You Have Just 1 Wine and 1 NFT…

(25:09) What Do a Shirt and an NFT Have in Common?

(27:45) What Legal Challenges do NFTs Face Today?

(34:21) NanoMetaGames – Outlook for 2022

(36:00) Markus Raunig – Austrian Startups – How was 2021?

(37:00) The Austrian Entrepreneurship Week

(39:37) From Morning Moonshots to Future Weekly

(41:00) The backstory to Future Weekly – How did it all start?

(43:45) The Three Biggest Success @ Future Weekly

(45:39) The Apple & Spotify Charts Algorithm

(48:26) Outlook for 2022

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Part 5 of the Year in Review Recording.

1 hour minutes of inspiring conversations with speakers from previous podcast episodes and business partners of the hosts.

What was hot in 2021, and what do our speakers expect for 2022?

In this episode, we talk about

The Effects of the Pandemic on Business Life
The Future of ADCs in Oncology
Mental Health
Psychedelic Drug Development
Gilgamesh Pharmaceutical, Christian Angermayer, and Atai Life Science
As well as Podcast notes

I hope you enjoy the conversation the same way I did.

Who are the Experts in this episode:

Walter Stockinger
Yoni Falkson

Video to the Episode: https://youtu.be/O8hsqfEVgmI

Timestamps:(00:00) – Walter Stockinger - Introduction Hadean Ventures

(01:00) – Success 2022 – Hadean Ventures

(03:00) – Personal Interactions Matter

(03:36) – Work-Life at Hadean Ventures During the Pandemic

(05:18) – The Effects of the Pandemic on Travelling and the Learnings that Came with it

(07:18) – Portfolio Success in 2021

(11:52) – Difference of Ticket and Round Sizes in Europe and the US

(14:00) – Availability of Capital on the Market for Life Science Projects

(17:11) – Future Potential of ADCs in Oncology

(23:51) – The Future of mRNA Vaccines

(28:47) – Outlook for 2022

(30:00) – Yoni Falkson – Introduction

(31:05) – Gilgamesh Pharmaceutical and Podcast notes

(33:38) – Psychedelic Drug Development – Players on the field

(35:52) – Fundraising in the United States during the Pandemic

(38:04) – The Psychedelic Drug Development Area

(40:50) – Development of Mental Health in the US

(44:10) – Microbiome, Mental Health, and Diagnostics

(47:44) – Mission of Podcast Notes

(51:35) – Podcast notes, Beginner’s Mind, and the Antibacterial Space

(54:23) - The Podcast Notes Community

(55:37) The USP of Podcast Notes

(56:21) Outlook for 2022 – Yoni Falkson

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Part 4 of the Year in Review Recording.

1 hour minutes of inspiring conversations with speakers from previous podcast episodes and business partners of the hosts.

What was hot in 2021, and what do our speakers expect for 2022?

In this episode, we talk about

Biotech in Austria
Culture of Success
Business Angels, Investment and Market Perspective
Customer Needs and Entrepreneurship

I hope you enjoy the conversation the same way I did.

Who are the Experts in this episode:

Albert Missbichler
Peter Llewellyn-Davies

Video to the Episode: https://youtu.be/IGybV1SsTko

Timestamps:(00:00) Opening Christian Soschner / Albert Missbichler
(02:00) Peter Llewellyn-Davies Biotech in Austria
(03:22) How was 2021 for Life Science Entrepreneurs?
(05:12) How was 2021 for Biotech Austria?
(06:45) The situation of Life Science Infrastructure in Austria
(08:00) Lab Space in Austria
(09:30) Europe Needs a Culture of Success
(12:25) English Proficiency in Austria
(14:08) Agenda 2022 – Biotech Austria – 3 Main Goals
(16:30) Goal #4: Availability of Capital for Life Science Investments
(18:10) Goal #5: Availability of Funding for Clinical Trials
(19:30) Goal #6: Have Fun
(20:15) Astrid Wollard / Christian Soschner / Matthias Tarasiewicz– Education – Health and Financial Literacy – Beginner’s Mindset
(25:30) Why Beginner’s Mind Matters More Than Ever
(28:18) The Entrepreneurial Spirit in Oxford
(30:05) How Did the Start-Up Scene in Europe Evolve since the 90s?
(32:25) Albert Missbichler – Entrepreneurship & Business Angel in Life Science
(35:00) Fianostics – Diagnostics during Covid
(37:25) From Prototype Stage to Market Entry
(38:35) How Important Is Market and Financing Expertise in the Early Stages of a Company?
(43:04) Entrepreneurship Mindset and Customer Needs
(47:00) Outlook to 2022 – Importance of Meeting in Real Life
(49:20) Direct Contact to Customers in the Digital World
(52:00) Content Marketing Helps to Build Trust Online
(56:30) How Building Business Relationships Changed During the Pandemic

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Part 3 of the Year in Review Recording.

1 hour 15 minutes of exciting conversations with speakers from previous podcast episodes and business partners of the hosts.

What was hot in 2021, and what do our speakers expect for 2022?

In this episode, we talk about

Content Marketing with a Podcast
Life Science Industry in Austria
Content Marketing and Social Media for B2B Businesses
History of the Vienna Stock Exchange

I hope you enjoy the conversation the same way I did.

Who are the Experts in this episode:

Christian Soschner
Johannes Sarx
Philipp Hainzl
Stefanie Rösel
Julia Resch

Video to the Episode: https://youtu.be/CkYOd0q9B-A

Timestamps:

(00:00) Christian Soschner & Stefanie Rösel – Podcast & Content Marketing
(03:45) The Gary V. Content Strategy Applied at the Podcast
(05:30) What Kind of Companies Can Use A Podcast for Their Marketing Purposes?
(07:15) Valuations – Quo Vadis?
(11:35) Macro Trends & Market Crashes
(17:15) Johannes Sarx and Philipp Hainzl – How Did Life Science Evolve in the Last 10 Years in Austria – Audio Only
(18:00) More than 1,000 Life Science Companies in Austria
(22:35) Marinomed, Tamirna, or Valneva – Companies that started before 2008 in Austria
(25:35) Expectations for 2022 – Will the Industry Move Forward at the Same Speed Like in 2020-21?
(28:45) EIT Health – Co-Location Center in Vienna
(30:10) In-Person Events in Austria in 2022
(33:00) Stefanie Rösel – Life Science Content Marketing & Social Media
(35:35) How The Pandemic Changed The Behaviour in Business on Social Media
(37:16) The Digital Presence of People and Companies Matters More Than Ever
(39:45) Why Online Content Marketing Matters for B2B Companies
(42:41) The Most Important Platforms for B2B Companies in 2022
(44:00) Biggest Lesson From 2021
(45:50) Outlook for 2022 – Content marketing
(46:35) How Will the Transition von Web 2.0 to Web 3.0 affect Content Marketing
(51:45) Julia Resch – Vienna Stoch Exchange – 250 Years
(52:35) The Austrian Stock Market in 2021 – 40% Performance
(53:45) The European IPO Market
(54:15) Life Science and the European Stock Market
(55:40) Industries on the Austrian Stock Exchange
(56:35) Investment Trends from the Austrian Stock Market Perspective
(57:50) Digital Assets on the Stock Markets
(01:01:35) Outlook 2022 on the Stock Market
(01:03:45) Matthias & Astrid - Overview over Topics from Year in Review
(01:07:35) What was going on in Tech in 2021
(01:12:35) Content Marketing for Profiling

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Part 2 of the Year in Review Recording.

1 hour 15 minutes of exciting conversations with speakers from previous podcast episodes and business partners of the hosts.

What was hot in 2021, and what do our speakers expect for 2022?

In this episode, we talk about

Health Literacy and the Healthcare System
Venture Capital in 2021
Digitalization in Drug Development
The Golden Age of Biotech
Home Office – How Work-Life will Look like in the Post Pandemic World

I hope you enjoy the conversation the same way I did.

Who are the Experts in this episode:

Bettina Resl
Sascha Berger
Tilmann Buerckstuemmer
Thomas Moser
Kimberly Cornfield

Video to the Episode: https://youtu.be/HL-z1c_1XaU

Timestamps:(02:00) Bettina Resl - Christmas Greetings
(03:11) Review of 2021 - Challenges for the Healthcare System in 2021 Beyond Covid 19
(06:32) Healthy Habits are the First Step to Longevity
(07:32) How Do Pharma Reach Patients?
(09:12) The Importance of Health Literacy – Concept and Strategies to Improve Health Literacy for the People
(16:56) What Happens to Home Office in a Post-Pandemic World
(20:00) Sascha Berger – Recap of 2021
(21:45) Significant closings in the Life Science VC world during the pandemic
(22:57) Lasting Effects of the Capital Flow Towards Life Science
(25:20) Will the Development Speed in the Pharma Industry in 2020/21 be Lasting?
(29:17) The Digital Revolution – Does it Affect the Dealflow of Life Science VCs?
(31:55) Outlook for 2022
(32:25) Conference Plans for 2022
(33:29) Thomas Moser and Tilmann Buerckstuemmer – Aelian Biotechnology
(35:33) Aelian Biotechnology – This was 2021
(36:00) Bit.BioDiscovery – Finding New Cell Types – The Holy Grail of Biology
(37:14) Outsourcing Trend for Pharma and Biotech Companies
(38:00) Trend to Digitalisation
(39:38) Data – Is it More Signal or More Noise?
(41:39) CRISPR - Trends
(42:40) The Golden Age of Biotech
(44:18) What is the Big Goal for The Holy Grail of Biology?
(46:34) Golden Age of Biotech or Bubble Territory?
(47:39) Increasing Health and Financial Literacy for the Common Good of Society
(48:18) Data Security in Gene Editing
(49:42) Paradigm Shift in Data Storage
(54:38) Outlook for 2022 – Aelian Biotech
(57:00) Astrid Wollard and Matthias Tarasiewicz – Recap of 2021
(58:51) Talent Shortage
(01:01:15) Web 2.0 vs. Web 3.0
(01:01:55) Use-Cases in Web 3.0 Beyond Token
(01:02:00) Kimberly Cornfield - Intro
(01:02:30) Research Activities at the UCL in Web 3.0 and Beyond
(01:04:00) European Research & Innovation at the UCL
(01:05:00) Effects of the Brexit on European Collaboration with British Universities
(01:07:00) How Did Collaborations between Universities Change With the Pandemic?
(01:08:29) Outlook for 2022 – Focused Research Areas
(01:10:20) Big Trends in Research in 2021
(01:11:00) Artificial Intelligence, Democracy, and Education
(01:11:48) Astrid Woollard – Potential of Artificial Intelligence
(01:13:00) Matthias Tarasiewicz – AI and Machine Learning in this decade
(01:15:32) Kimberly Cornfield – Horizon Europe 2022

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

This is Part 1 of the 7,5 hours conversations marathon before Christmas with speakers from previous podcast episodes and business partners of the host and co-host of the Podcast.

In this episode, we talk about

Covid19
Cryptocurrencies
Cybersecurity and
Merger & Acquisition

I hope you enjoy the conversation the same way as I did.

Who are the Experts in this episode:

Astrid Woollard
Dusica Lukac
Matthias Tarasiewicz
Irénée Robin

Video to the episode: https://youtu.be/s3R93Dmoy6U

Timestamps:(00:00) Opening

(03:15) Astrid Woollard – Foundation of SMAPE Capital and Blockchain Technology

(04:31) How to Manage 80-100 Opportunities per month

(05:39) Focus of SMAPE Capital

(08:00) What is DAO?

(08:35) Selling of one of the First Copies of the US Constitution for 42.5 Million Dollar

(10:30) Potential of DAO in Fundraising for Startups

(11:30) Astrid’s Outlook for 2022

(13:00) Price Predictions for BTC and ETH for 2022

(14:15) Dusica Lukac”The Transaction Diva” – M&A in 2021

(20:30) M&A in Crypto in 2022

(22:30) Great Transactions in 2022

(24:30) Outlook for 2022

(26:00) Which Sector will Dominate 2022?

(28:15) Matthias Tarasiewicz – Covid 19 and Cybersecurity

(36:30) How to Raise Awareness for the Need of Cybersecurity?

(40:00) Messenger Services like Whatsapp, Telegram or Signal and Cybersecurity

(42:15) How Billionaire Entrepreneurs Influence the Public Opinion about Tech

(44:15) Irénée Robin – Vaccines and Therapeutics against SARS CoV 2

(46:45) Expectations on the development of travel restrictions

(47:30) How Did the Drug Development and Vaccine Space evolve since September 2020?

(48:30) The 3 Legs of a Pandemic Response

(55:15) The Success of Pharma in the Pandemic Response

(58:30) Difference Between Tamiflu and c Antiviral Drugs for the SARS CoV 2 Response

(01:03:40) Matthias Tarasiewicz - Supply Chain Issues as a Result of the Pandemic – Hardware, Chips, Drugs

(01:08:40) Supply Chains in Pharma in 2021

(01:11:45) Open Sourcing Medical Devices

(01:13:00) Why Did the Development of Therapeutics Take Longer Than Vaccines?

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In this episode, I am having a conversation with Sascha Berger, Partner at TVM Capital.

Dr. Sascha Berger is a Partner at TVM Capital, based in Munich, Germany. TVM Capital is one of the pioneer transatlantic Life Science Venture Capital funds with Europe and North America teams. Sascha joined TVM Capital in 2016, helped raise the current $480M fund, and works closely with entrepreneurs and founders to advance promising pharmaceutical assets, MedTech, diagnostic, and digital health technologies to the following value inflection points. Sascha is a passionate VC, a Boston Consulting Group alumnus, and has an academic chemistry and finance background.

TVM Capital is a dedicated life science venture capital firm with Europe and North America teams. Since its inception, TVM Capital has invested in entrepreneurial venture-backed companies. Over several fund generations, TVM Capital’s investment strategy has included a multi-stage investment approach spanning discovery to market-ready companies as well as profitable companies searching for growth capital. The investment focus has always been broad and includes investments in therapeutics, technology platforms, MedTech, and diagnostics.

In this episode, we talk about

How the Life Science Eco-Systems evolved in the US and Europe
TVM Capitals Investment Approach
How to reach out to VCs
And much more...

I hope you enjoy the conversation the same way as I did.

Who is the Expert in the show?

Sascha Berger
TVM Capital

Shownotes: https://lsg2g.substack.com/p/59-a-perspective-on-the-life-scienceVideo to the Episode: https://youtu.be/pQxjm-uv61g Timestamps:00:00) Intro
(02:30) The History of TVM Capital
(05:45) The Development of Life Science Eco-Systems in Europe and North America
(10:35) What Possibilities Do Founders Have Today to Move their Companies Forward – From the Investors Perspective
(13:45) Long Term Investment Models in the Life Science Industry
(17:40) Cultural Differences between North America and Europe
(23:50) How to Create Companies That Become Targets for VCs
(27:10) How Important is the Growth Potential of a Company for TVM?
(29:05) How Much Time do VC Processes Take?
(33:35) When is the Right Time to Reach out to VCs?

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In this episode, I am having a conversation with Bettina Resl, Public Affairs Head Europe Consumer Healthcare at Sanofi.

Bettina Resl joined Sanofi Austria in May 2017 as Country Head Public Affairs & Patient Advocacy.
From April 2020 to June 2021 she was also responsible for corporate communications and finally took over the position of Public Affairs Head Europe Consumer Healthcare at Sanofi on July 1, 2021.

Sanofi is dedicated to supporting people through their health challenges. Sanofi is a global biopharmaceutical company focused on human health, preventing illness with vaccines, provide innovative treatments to fight pain and ease suffering. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

In this episode, we talk about

Collaboration in the Pharmaceutical Industry
The Pharma Value Chain
The Role of Patents
And much more….

I hope you enjoy the conversation the same way I did.

Who is the Expert in the show?

Bettina Resl
Sanofi

Shownotes: https://lsg2g.substack.com/p/58-trends-in-the-pharma-industry

Video to the Episode: https://youtu.be/Jadsxf9DL0w

Timestamps:(00:00) Introduction
(03:40) Introduction Bettina Resl
(04:05) What are the Duties of a Public Affairs Head Europe Consumer Healthcare at Sanofi
(10:50) What Best Practices from the Development of Vaccines and Therapeutics against Sars Cov 2 can be conserved in the Pharma Industry?
(14:50) Will the collaborative spirit of 2020/21 remain in the pharma industry?
(17:33) Personalized Medicine
(22:32) Early Stage Development Quo Vadis?
(26:22) The Future Role of Big Data in Pharma and the Healthcare System
(31:57) Are we at the Dawn of a New Golden Age of Biotech?
(38:38) What is the Future of Early-Stage Development in Life Science in Europe?
(42:00) Success Rates in Early-Stage-Development in Pharma
(44:11) What is the Future of mRNA Technology?
(47:49) Longevity Research – Quo Vadis?
(53:25) The Future of Digitally Enhanced Healthcare Systems
Entry
(59:10) The Future of Diagnostics
(01:03:56) Mental Health in Pharma
(01:08:28) The Future of Patents in the light of a fair global distribution of vaccines and therapies
(01:14:19) What are the 3 biggest bottlenecks in the pharmaceutical industry?
(01:18:00) Final Question: What is the most important event or innovation in the Pharma Industry with the highest impact in the coming 10 years?

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In this episode, I have a conversation with Jaromir Zahradka and we will talk about early-stage investments in DeepTech Life Science companies.

He has 5+ years of C-level experience and has been engaged in 8 Biotech spin-offs. He built a unique network within CE institutions and TTOs and has deep scientific and licensing market expertise with over 20 licensing deals worth more than USD 500m.

Jaromír was a co-founder of i&i Prague, a biotechnology incubator.

In this episode, we will talk about

Early-stage investments in a deep tech company
The complexity of spinning out technology from research organizations and
The venture capital situation in Europe
and much more

I hope you enjoy the conversation the same way I did.

Who is the Expert in the show?

Jaromír Zahrádka
i&i Prague
i&i Biotech Fund
IOCB Tech
IOCB Prague

Shownotes: https://lsg2g.substack.com/p/57-bridging-science-and-businessVideo to the Episode:https://youtu.be/HJ_81X-yqz0 Timestamps:(00:00) Intro

(01:43) Start of The Episode

(02:55) A New Fund In Town – I&I Biotech Fund

(04:40) Investment Area of i&I Biotech Fund

(06:15) How is it to found a life science fund?

(09:12) What are the challenges in raising a life science fund?

(13:25) A Fund is Teamwork

(16:06) The Life Science R&D Eco-System in Prague

(28:45) Top Level Expertise at the IOCB in Prague

(31:09) The Role of Tech Transfer Offices in the Value Chain

(39:31) How to Turn Science Into Business

(55:20) The Role of Capital in Deep Tech Life Science

(01:02:50) The Development of Talent – A Key Success Factor

(01:06:30) The perspective of Long Term Investment Funds

(01:12:15) How Can the European Deep Tech Investment Eco-System Evolve Better?

(01:19:00) Cross-Sector and International Collaborations in Europe

(01:22:30) What is the First Step Towards Turning Science into Products and Businesses?

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In today’s episode, we explore Clinical Development with Ole Dammann, the owner of KFGN, a group of 6 clinical trial sites in Germany, and after joining Pratia, several sites in Eastern Europe.

Ole Dammann is one of the best experts in clinical trial management in the LSG2G Community. Ole is currently working on the digitization of clinical research and the development of new business models.

In this episode, we will talk about

Business Models in the Life Science Industry
Clinical Trial Management
Changes in the Business World in the last three decades
Digital Health Revolution and
Much more

Who is the Expert in the show?

Ole Dammann
CEO of KFGN Group

Shownotes
https://lsg2g.substack.com/p/56-how-to-do-clinical-research-in

Video to the Episode Timestamps:(00:00) Intro
(02:30) Life in Germany in October 2021
(05:50) Foundation of KFGN Group in the 90s
(07:25) Extending the Clinical Network to Eastern Europe
(09:10) How to Start a Collaboration During the Pandemic
(12:15) How were Clinical Trials Organized in the 90s compared to today?
(17:00) Clinical Trials and Big Data
(19:20) The European Funding Gap for Startup and Scaleup Companies
(23:20) Business Models for Clinical Trial Management in the 90s
(28:35) Clinical Trials in Separate Sites – Offering New Solutions to Patients
(30:40) The Effects of Personalized Medicine on the Complexity of Clinical Trial Management
(35:20) Rare Diseases and the Challenges For Clinical Trial Management
(38:30) Personalized Clinical Trial Management – Bring the Sites to the Patients
(41:20) Effects of Wearable Technology on Clinical Trials
(44:15) Wearable Technology and Data Collection for Clinical Trials
(47:45) Making Science and Data Understandable and Relatable
(50:00) Digital Therapeutics
(52:50) Current State of Digital Therapeutics
(53:40) Longevity and Clinical Trials
(55:40) What Makes The Eco-System Around the Stanford University so Unique?
(59:15) What is the True Sense of Business?
(01:01:00) Tesla, Apple, Alphabet, Facebook, Stanford University, Palo Alto Networks – Shaping the Entrepreneurial Bay Area Mindset
(01:03:15) Advantages of the European Mindset
(01:05:00) What is the Right Point in Time for Early-Stage Companies to Involve Clinical Experts?

Podcast Links:
Podcast Website: https://www.lifescienceget2gether.com/Community Partner: https://linktr.ee/lsg2g
Christian Soschner: https://linktr.ee/soschner
LSG2G Twitter: https://twitter.com/LGet2gether
LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
Podcast Episodes: https://pod.link/1493847125
Episodes on YouTube: https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In this conversation, I will talk with Peter Llewellyn-Davies, CEO of Apeiron and President of Biotech Austria about the Future of Life Science Entrepreneurship and Investment in Europe.

Topics we discuss in the show:

The Development of the Life Science Eco-System in Europe
How Family Offices Support Life Science Companies in Europe
How to Translate Science into Business
Does Europe Have a Culture of Success?
And much more...

Who is the Expert in the show?

Peter Llewellyn-Davies
CEO of Apeiron Biologics
President of Biotech Austria

Shownotes:

Video to the Episode

Timestamps:
(00:00) Opening
(01:25) How did the Life Science Ecosystem Evolve?
(03:22) The Biontech Success Story
(04:10) How Did The Private and Publice Sector Evolve in Europe Since 2006?
(05:49) What is Biotech Austria’s Mission?
(07:00) How Many Members Does Biotech Austria Have in 2021?
(09:10) Biotech Success Stories From Austria
(11:40) Vienna, Austria, Local Life-Science-Eco-Systems and Biontech’s Success
(13:45) Why is it a Great Decision to Start a Life Science Company in Austria?
(16:26) Where Do Scientists Get Follow On Funding From?
(18:30) How Helpful is the New European Investment Regulation for Foreign Investors?
(21:00) Fundraising Challenges for Life Science Companies
(24:00) Why Life Science Investments Are Attractive
(25:50) How to Get in Touch With Biotech Austria

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In this conversation, I will talk with Oliver Mavher and Michael Deichsel about Crypto Trading and taxes.
Topics we discuss in the show:The questions that I consider relevant for everybody owning digital assets:

What if someone gets paid in Bitcoin or other Cryptocurrencies? Is that a taxable event?
What if someone invests in those novel digital assets and they gain in value?
Does the location of the wallet or crypto exchange make any difference for taxation? Which tax law is applicable?
What about European ETFs and their offshore counterparts that replicate the price of digital assets?
What about investments in companies that invest in digital assets?
Are there differences between retail investors, investment funds, and other institutional investors?
And many more questions similar to the above

Who are the Tax Experts in this Episode?I am delighted to welcome

Oliver Mavher, KPMG and
Michael Deichsel, KPMG

to find answers to a multiverse of questions around crypto investments and taxes.

Shownotes:

Link

Video

Link

Timestamps:

(00:00) Opening What are the Real Life Tax Consequences of Trading with Cryptocurrencies?

(02:47) Opening Oliver Mavher – Support for Digital Companies in Tax Matters

(08:45) What are Security Token Offerings?

(11:00) Opening Michael Deichsel – Crypto and Taxes

(16:10) What is the Tokenization of the Economy?

(18:15) Smart Contracts

(24:15) What are Digital Assets in Terms of Tax Laws?

(27:00) Bitcoin as Legal Tender in El Salvador?

(29:07) Banking the Unbanked.

(30:55) Cryptocurrencies and the Environment

(34:13) What are crypto assets?

(37:00) What are NFTs?

(39:00) NFT and Taxations in Austria

(45:30) Changes in Tax Laws in Austria

(49:05) Taxable Events when BTC is used for salaries

(54:15) Using Cryptocurrencies for everyday purchases – what are the taxable events?

(56:45) Taxable events when trading cryptocurrencies outside Austria – A case for double taxation treaties?

(01:00:00) Different Cases for Taxation and their Consequences

(01:03:00) Taxation for Companies when holding Digital Assets

(01:07:00) Expected changes to the tax laws

(01:09:00) The difference in Taxation between Crypto Currencies and Digital Assets

(01:13:00) Where to get advice for Crypto Taxation?

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In this conversation, we will talk about the future of the Early-Stage Ecosystem in Europe.

Speaker in the Episode:

Alexander Schwartz joined IST cube in 2018 as a Partner. He has more than 15 years of experience in management consulting, eight of which with McKinsey & Company.

Ingrid Kelly Spillman joined the IST Tech Transfer team in October 2018. Ingrid worked as a patent attorney in and for the pharma industry for more than a decade.

IST cube focuses on startups with a strong background in science and technology, such as academic spin-offs or young deep tech companies.

Topics we discuss in the show:

In this conversation, we discuss:

Ecosystems
Early-Stage Investments
VC Investment Stories
From Science to Business
The IST Ecosystem
and much more…

Shownotes:

Link

Video

Link

Timestamps:
(00:00) Introduction

(02:50) Introduction Alexander

(04:12) Introduction Ingrid

(06:05) How are IST, Twist, and IST Cube linked?

(09:21) The Success Story of IST – from Greenfield Operations to Top 3 in 15 years

(13:20) IST Cube’s Role in the Early-StageCommunity

(16:45) The People behind IST Cube

(19:00) Investment Focus of IST Cube

(21:50) What is the attractive opportunity in early-stage investments?

(26:00) When is the right time to reach out to VCs?

(29:30) How Academic and Business Mindset work Together in Early-Stage Development

(34:45) The Attitude for Fundraising Companies

(38:20) What is the right timing for creating a spin-out company?

(43:14) What deal structures are possible for early-stage companies?

(48:25) Entrepreneurial Expertise in the European Eco-System

(58:50) Startup Business Models in the Early-Stage Investment Eco-System

(01:03:00) How Investors and Start-Ups Work Together to bring positive change to the World

(01:06:00) The IST Cube Eco-System in 2021 – Build Around Collaboration and Open Innovation

(01:09:15) How The Innovation Eco-System in Austria Collaborates to Support Companies to go from Zero to One

(01:12:00) How IST Cube Helps Scientists Making the Transition from Academia to Business

(01:17:00)Ideas for the European Eco-System

(01:20:10) Failure Culture in Europe

(01:23:30) Exit Strategies for Founders and Investors

(01:28:35) Four Attributes Startups Should Have to Fit into VC Models.

(01:32:40) What is the essential first step in the creation of a new company?

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

The industry gains complexity, and I am happy that a speaker from the LSG2G community has dedicated time to speak about the Future of the Food Industry.

Speaker in the Episode: Dr. Caroline E. Heil

Since Jul. 1, 2021, Caroline has been CEO of The New Meat Company AG, a young stock-listed, purpose-driven impact investment company in Berlin focusing on alternative proteins.

Caroline is intrigued by the idea of revolutionizing the food industry, especially everything animal production-related, in an environmentally friendly, healthy, and sustainable way that will allow us to feed +10 billion people in the future.

Before joining TNMC, Caroline worked for EY as a lawyer and part of the global EY Agribusiness Team.

The New Meat Co.

The firm invests in game-changing companies and founders that disrupt the status quo of the meat industry to create nutritious, tasty, and sustainable meat alternatives that are good for everyone – animals, humans, and our planet.

Topics we discuss in the show:

In this conversation, we discuss the Future Of the Food Industry and talk about topics like:

Alternative proteins
Nutraceuticals
Functional food
Reworking the supply chain
3d printing of food
Personalized nutrition
And much more…

Follow Caroline E. Heil and The New Meat Co.:

Caroline Heil on Linkedin
The New Meat Co on Linkedin

Shownotes:
Article on Substack

Timestamps:

00:00 Opening

02:25 The New Meat Company – New Trends in the Food Industry

05:06 The Environmental Footprint of the Foot Industry in 2021

08:08 Sustainability of the Food Industry

10:14 Introduction Caroline Heil

14:36 Innovation in the Meat Industry

19:10 Sustainability of Analog Meat

22:00 The Health Impact of Nutrition

28:35 Solving the Global Distribution of Food with Modern Technology?

34:38 The Hellofresh Case – High-Quality Food at Low Prices

39:57 Consumer Trends in the Food Industry

42:23 Insects as Protein Source?

46:20 Lab-Grown Meat

57:45 How Industry and StartUps Can Evolve Together

01:00:00 Mission Statement of The New Meat Company

01:03:20 What Invention Will Have the Biggest Impact on The Food Industry in This Decade?

01:06:50 3D Printing of Food

01:11:20 Longevity and the Food Industry

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Tech Transfer describes the process to bring scientific inventions from the discovery stage into companies for translational and clinical R&D.

To gain more insights into this area, I invited a tech transfer expert from the LSG2G Community to this conversation.

Speaker in this Episode is Saara Inkinen, Nordic Catalyst.

Dr. Inkinen is a technology transfer and innovation management specialist based in Vienna, Austria. She originally came from Finland and had her first position in the chemical industry already in 2000.

For more details on Dr. Inkinen’s education and professional experience, please have a look at her LinkedIn profile.

The Company - Nordic Catalyst

Nordic Catalyst is a technology transfer and innovation management company founded by Dr. Saara Inkinen in 2018. Nordic Catalyst is located in Austria, and it works with an international client base consisting of both research organizations and companies.

Questions we discuss in the show:

What is Tech Transfer?
Why is it necessary to bring ideas from universities into startups and companies?
Is tech transfer biotech and pharma different from other tech areas?
What challenges solve tech transfer?
How has the environment changed with the pandemic?
And much more…

Follow Saara Inkinen and Nordic Catalyst:

Saara Inkinen on Linkedin
Nordic Catalyst on Linkedin

Shownotes:

Link to Article in the Member & Partner Community

Timestamps:
00:00 Introduction

01:45 What is Tech Transfer

02:30 The Tech Transfer Process

04:05 Tech Transfer – Licensing, IP Sale and Startups

05:00 Tech Transfer with Industrial Partners

07:40 Why is Tech Transfer Necessary?

13:20 Which Challenges Does TTO Face in the Life Science Networked Economy?

16:37 How do different Skillsets Interact in Early Stage Development?

19:35 Advantages and Disadvantages of the Startup Ecosystem for Deep Tech Companies

23:10 How did the Pandemic Change the Environment for Tech Transfer

27:17 How long does it take to turn a scientific idea into a finished product?

30:52 What Challenges Exist in the Early Stage Development Field?

33:40 How Do Business and Science Play Together?

35:00 New Trends in Tech Transfer

37:00 How Connected is the European Early Stage Industry?

38:00 What is the First Step Towards Putting a scientific idea into a product?

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In this conversation, we discuss the development of the European Pharma Eco-System, different business models, and what it takes to lead a company to success.

Today’s speaker is Dimitrios Tzalis.In the 90s, he received a Ph.D. from the University of California, San Diego, a Master of Science in Chemistry from the University of Chicago, and a Master of Science in Biochemistry from Ball State University in Muncie, Indiana USA.

1998 he returned to Germany to found Taros Chemicals GmbH & Co. KG.

Questions we discuss in the show:

When and why did Dimitrios decide to found a novel company?
How did Dimitrios find the Right Business Model?
How did the industry evolve in India and Germany over the last two decades?
How do you see the future of the life science industry globally after the push that it got with Sars Cov 2?
And more…

Timestamps:
00:00 Introduction
04:25 Introduction Dimitrios Tzalis
05:45 How to Start a Life Science Company During the Dot.com Bubble Times
08:15 The Decision to Start a Company Rather Than Applying for a Job
10:15 How did the European Life Science Eco-System Look Like in the 1990s?
12:54 Where to Get Inspiration for Writing a Business Plan?
16:54 The Structure of the Pharmaceutical Industry in the 90s/early 2000s
20:15 The Life Science Economy
22:55 The Different Mindsets to Bringing an Idea to Market
31:05 How to Fund Early-Stage Development Companies
36:30 From Founding a Company in Germany to India
41:10 How Technology Changed Collaboration in the Last Two Decades
44:25 Development of Cultural Similarities and Differences Between India and Germany Since 2000
47:00 Is there a Global Convergence of Business Culture?
52:17 The Pharma Industry in India – 2000-2021
55:20 The Future of the Pharmaceutical Industry in India
57:40 How Are Problems Approached in India vs. Europe?
01:01:20 How Entrepreneurs Approach Problems
01:03:15 Entrepreneurship & Passion
01:06:00 The Role of Passion
01:10:20 The Role of Leadership
01:12:26 Teamplay in Companies
01:14:54 Life Science Business Models
01:20:10 The Private and The Public Life Science World
01:25:00 The Future of the Life Science Industry
01:42:50 The European Culture Around Entrepreneurship
01:50:00 Short-Term Thinking and Long Term Planning
01:54:30 What is the Most Important Advice to First Time Founders

Follow Dimitrios Tzalis and Taros:

Dimitrios Tzalis
Taros

Shownotes:

Video to the Episode
Article to the Episode

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Here is my conversation with Andrea Sommer about the advantages of patents for private deep-tech companies.

Timestamps:
For those who want to listen to specific parts of the episode, here are the timestamps:

00:00 Opening Christian Soschner
02:00 Intro Andrea Sommer – Importance of Patents
03:48 The Role of Patents in Deep Tech Companies – Understanding the Importance of Patent Processes
13:51 What is the right point in time to file a patent application?
15:57 Patent process in Europe
24:25 Patents – A Once in a Lifetime Event or a Process?
35:00 The importance of getting the right information for the first filing
37:10 The Reasons for an FTO Analysis from the Patent Attorney’s Perspective
41:40 When is the right time for an FTO Analysis
46:00 More Details on the Process of FTO Analysis – Better Late than Never?
51:15 How to Implement Patent and FTO Processes into the Organisation
57:27 Patent Infringement
01:02:10 Possibilities of Compulsory Licenses
01:07:15 A Brief History of Patent Laws…
01:09:20 … and The Future Of Patent Laws
01:15:00 The Future of Patents and Licenses
01:23:00 Patents and Sars CoV 2 – Would giving up patent rights by governmental enforcement tackle the right problem?
01:27:40 Tesla put all Patents into the Public Domain 2014 – Does that make sense?
01:33:20 The Role of Patents in Startups
01:40:30 Is there a difference between US Entrepreneurs and their European counterparts?
01:44:00 Perception of Entrepreneurship
01:49:00 How to Collaborate with Big Corporations as an SME
01:53:00 Patents and Investors

Episode Links:
Article to the Episode: https://lsg2g.substack.com/p/marrying-deeptech-with-ip-strategy-7f8
Youtube: https://youtu.be/yjqq6P2eWVc
Andrea Sommer: https://www.linkedin.com/in/dr-andrea-sommer/

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Here is my conversation with Kurt Höller and Joy Cürten from EIT Health about the health tech revolution in Europe and the Rest of the World.

Episode Links:
Article to the Episode: https://lsg2g.substack.com/p/eit-health-and-the-international-514
Youtube: https://youtu.be/OnQrvbgcO8Y
Kurt Höller: https://www.linkedin.com/in/hoeller/
Joy Cürten: https://www.linkedin.com/in/joy-c%C3%BCrten-a8977241/
EIT Health: https://www.linkedin.com/company/eithealth/

Podcast Links:
Podcast Website: https://www.lifescienceget2gether.com/Community Partner: https://linktr.ee/lsg2g
Christian Soschner: https://linktr.ee/soschner
LSG2G Twitter: https://twitter.com/LGet2gether
LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
Podcast Episodes: https://pod.link/1493847125
Episodes on YouTube: https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV

Timestamps:
For those who want to listen to specific parts of the episode, here are the timestamps:

(00:00) Opening Christian Soschner
(04:19) Introduction Joy Cürten
(08:47) Introduction Kurt Höller
(15:08) How Much Funding is Needed to Start an Initiative Like EIT Health
(16:12) The Early Days of EIT Health
(19:31) How Does EIT Operate?
(21:05) Initiatives at EIT Health
(26:33) Classification of Healthtech Companies
(32:53) How did the pandemic shape the health tech sector in Europe?
(50:00) Cultural Differences Between Entrepreneurship in the US and Europe
(58:40) Development of Open Innovation and Communication in Europe
(01:08:00) How the Pandemic changed the European Landscape
(01:15:00) What Policy Changes Would Help the European Healthtech Sector?
(01.21:00) EIC, EIT, and EIF – How The Institutions Work Together with Corporate Investors and VCs

Referenced in the show:
Sachs Forum Basel 2021: https://www.sachsforum.com/21bef-about.html
Weltmarktführer Innovation Day 2021: https://www.weltmarktfuehrer-innovationday.de/, https://www.fau.de/innovator-of-tomorrow-award/
e-Health Investment Forum 2021 https://echalliance.com/event/bhh-is-calling-startups-working-on-ai-in-healthcare/
EHC Digital Health Semifinal 2021 https://eithealth.eventscase.com/EN/catapult_semifinals20214yFN 2022, https://www.4yfn.com/
MedtecLIVE 2022 https://www.medteclive.com/en/exhibitors/participation/start-ups
EIT Health Summit 2022 https://eithealth.eu/event/save-the-date-eit-health-summit-2022/

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Here is my conversation with Sebastien Groyer, Entrepreneur and Venture Capitalist

Episode Links:
Article to the Episode: https://lsg2g.substack.com/p/7-tales-from-20-years-of-deep-tech-42f
Youtube: https://youtu.be/Ni3mEDM7-_c
Sebastien Groyer: https://www.linkedin.com/in/sebastien-groyer-2438548/

Timestamps:
For those who want to listen to specific parts of the episode, here are the timestamps:

00:00 Introduction

02:35 How do VCs view planning in companies?

05:59 How to Approach Investors when Plans Change

11:00 What are Target Companies of VCs?

15:15 Are VCs Going for First Movers or Rather Established Markets?

19:30 How Detailed Should Business Plans be when Pitching to VCs?

23:50 Storytelling – From Rough to Detail

27:15 The Reality of VC Life

34:40 How Often Can You Follow Up with VCs before Ending Up on a Blacklist

38:54 What is the Right Time to Approach VCs?

40:40 How do VCs view companies in Fundraising Mode?

46:10 The Fundraising Process in a Company

48:15 Is the Fundraisngprocess Transactional, or do Relationships matter?

51:00 Fundraising – Similarities and Differences between the US and the European Approach

56:50 Entrepreneurship and Investors – Lifestyle or a Job?

01:00:00 The Role of Money in Different Societies

01:04:00 Why Do VCs Search for Exits?

01:11:00 Valuation Expectations of VCs

01:14:00 It is all about growth

01:19:00 When Does it Make Sense to Reach out to VCs?

01:23:00 Differences in the Value of Information in the B2B and B2C world

01:27:00 The Pros and Cons of Being an Investor or Entrepreneur

01:30:00 Spirituality, Investment, and Entrepreneurship

01:34:30 What is the most important thing to consider when reaching out to VCs?

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Here is my conversation with Wolfgang Kienreich, CBO of Know-Center.

Episode Links:
Article to the Episode: https://lsg2g.substack.com/p/46-an-introduction-to-know-center
Youtube: https://youtu.be/eTU5zROX5E4
Wolfgang Kienreich: https://www.linkedin.com/in/wolfgang-kienreich-8350b899/
Know Center: https://www.linkedin.com/company/know-center/

Timestamps:
For those who want to listen to specific parts of the episode, here are the timestamps:

00:00 Introduction
01:45 What is Fact and What is Fiction in Artificial Intelligence?
05:45 Artificial Intelligence in Autonomous Driving
07:30 AI in Language Translation and Understanding
11:00 AI in Education
12:20 How AI Improves Drug Discovery and Development
15:00 Analyzing Health Data under GDPR
16:55 How Wearable Technology Can Support Scientists to Get More Insights into the Development of Diseases
18:15 European North Star Projects in AI
20:45 Starting Point for SME Entrepreneurs in AI
24:00 The History of the KNOW Center
27:20 Industry Partners of the KNOW Center and Use Cases Developed with them
31:30 How Does AI Affect Labour?
34:05 Innovation Speed and AI
36:00 The Role of AI in Search
41:00 AI and Recommendation Management
43:00 Potential in Assisted Living
44:30 What is a Digital Twin?
47:35 Recommendation to SMEs to Approach KNOW Center

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Here is my conversation with Jama Nateqi, CEO of Symptoma.

Episode Links:
Article to the Episode: https://lsg2g.substack.com/p/45-hidden-secrets-to-successful-entrepreneurship
Youtube: https://youtu.be/VOBc7pfqWOI
Jama Nateqi: https://www.linkedin.com/in/jama-nateqi/
Symptoma: https://www.linkedin.com/company/symptoma/

Timestamps:
For those who want to listen to specific parts of the episode, here are the timestamps:

00:00:00 Kick-Off
00:02:12 Intro Jama Nateqi – Give up your Freedom to gain Freedom
00:03:47 Sleeping Habit
00:04:53 Benefits of Waking Up Early
00:05:43 What Is More Important – Quality or Quantity of Sleep?
00:14:30 Why Making Your Bed Matters
00:17:31 How to Achieve Peak Performance
00:18:25 Lack of Sleep and its Impact on IQ
00:19:20 Symptoma and Working Hours
00:21:00 Meditation
00:30:00 Deep Work & Digital Drugs
00:36:00 Screentime – Modern Technology – Blessing or a Burden?
00:45:00 Does Free Will Exist?
00:53:00 Bad and Good – Yin And Yang
00:56:00 The Power of Habit
01:04:00 The Amazon Case
01:06:30 Never Stop Learning
01:08:00 The Role of Exercising
01:12:30 Health Benefits of Exercising
01:16:00 The Benefits of “Don’t Demand too Much of Yourself.”
01:20:00 New Year’s Resolutions
01:23:00 Setting Goals in the Right Size
01:26:00 The Habits of Setting Daily Goals & Time blocking
01:33:00 Attitude to Failure
01:35:00 About Nutrition
01:39:25 Why conserving willpower is crucial for deep work
01:43:00 Journaling
01:45:00 Meaning of Life & Purpose of Businesses
01:55:00 Finding the Right Team for a Vision
02:06:00 What is Your Biggest Success in Life?
02:10:00 What is the most important habit?

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Here is the conversation with Tero Weckroth, Business Angel and Investment Expert from Finland about Public and Private Investments.

Episode Links:
Article to the Episode: https://lsg2g.substack.com/p/44-private-and-public-investments
Video to the Episode: https://youtu.be/7WDHWOyaPQQ
Tero Weckroth: https://www.linkedin.com/in/tero-weckroth-5b927/
Chessboxing: https://www.nordicchessboxing.com/

Podcast Links:Podcast Website: https://www.lifescienceget2gether.com/Community Partner: https://linktr.ee/lsg2g
Christian Soschner: https://linktr.ee/soschner
LSG2G Twitter: https://twitter.com/LGet2gether
LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
Podcast Episodes: https://pod.link/1493847125
Episodes on YouTube: https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV

Timestamps:
For those who want to listen to specific parts of the episode, here are the timestamps:

(0:00) Opening words
(0:30) Introduction Tero Weckroth
(3:00) Life Science in Finland
(8:30) Life Science Investments for Business Angels
(22:00) Alzheimer Drug Development and Diagnostics – Biogen and Combinostics
(26:40) What is the Right Pricing for Drugs on the Market?
(30:00) Availability of Capital for Early-Stage Drug Development
(33:00) Importance of a Team
(38:00) Public Investments and Crowdfunding
(44:00) Risk Management for Investors
(46:00) Differences between Privat and Public Investment and Crowdfunding
(49:30) Reddit – New Development on the Stock Market
(01:00:00) New Macroeconomic Era?
(01:06:00) Cash, Gold, or Digital Gold?
(01:15:00) Technological Evolvement in the Investment Banking World
(01:20:00) Effects of the Pandemic on Regulations
(01:25:00) Cryptocurrencies - Bitcoin, Cardano, Etherum & co.

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Thomas Moser and Tilmann Buerckstuemmer lead the Austrian Life Science Company Aelian Biotechnology.

Episode Links:
Article to the Episode: https://lsg2g.substack.com/p/gene-editing-the-next-game-changing-d3f
Video to the Episode: https://youtu.be/3bf7ChYUHLE
Aelian Biotechnology: https://aelian.bio/
Thomas Moser: https://www.linkedin.com/in/thomas-moser-79819a5/
Tilmann Buerckstuemmer: https://www.linkedin.com/in/tilmann-burckstummer-19b65949/

Podcast Links:Podcast Website: https://www.lifescienceget2gether.com/ Community Partner: https://linktr.ee/lsg2g
Christian Soschner: https://linktr.ee/soschner
LSG2G Twitter: https://twitter.com/LGet2gether
LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
Podcast Episodes: https://pod.link/1493847125
Episodes on YouTube: https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV
Timestamps:For those who want to listen to specific parts of the episode, here are the timestamps:

(00:00) Introduction
(02:23) Introduction Thomas Moser
(05:45) Introduction Tilmann Bürckstümmer
(08:40) Aelian Biotechnology
(10:20) The Science Behind Aelian
(17:50) Life Science Business Model
(27:00) How to Setup Business Relationships in Life Science
(34:35) Gene Editing - Why Did it Create Such a Hype?
(41:00) History of Gene Editing with Insights Into CRISPR/Cas9
(45:30) Vienna - Part of The CRISPR Community
(47:50) IP of CRISPR
(50:00) CRISPR - Real Life Use Cases
(55:05) CRISPR in Cancer Research
(59:20) Are Genetically Altered Human Beings Possible?
(01:04:20) Genetically Enhanced Human Beings - Reality or SciFi?
(01:08:00) Gene Editing and its Role in Agriculture
(01:12:00) SARS-CoV-2 - What Role Did CRISPR Play in Fighting the Pandemic?
(01:12:20) CRISPR Screen for SARS-CoV-2 - Technology of Aelian Biotechnology
(01:15:00) Drug Discovery for SARS-CoV-2 with CRISPR
(01:18:00) Fundraising for Life Science Companies
(01:27:00) Comparison of the Investment Culture in Europe and the United States
(01:31:00) Major Players in the CRISPR Field
(01:32:00) CRISPR - IP Landscape
(01:44:00) Final Question: Advice for First Time Entrepreneurs

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Have you ever wondered what role the small country Austria - located in the center of Europe - plays in Life Science?

Then listen to the managing directors of LISAvienna, Johannes Sarx, and Philipp Hainzl.

LISAvienna is a joint life science platform operated by Austria Wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry for Digital and Economic Affairs and the City of Vienna, it contributes to the advancement of life sciences in Vienna.

LISAvienna supports innovative biotech, pharmaceutical, medical device, and digital health companies in Vienna that develop and market new products, services, and processes. The platform links these companies with development partners and key customers.

As a central knowledge carrier, LISAvienna provides input for decisions to advance the life sciences in Vienna and contributes to positioning the city of Vienna as one of the leading European innovation centers.

If you want to learn more about the Life Science Hot Spots in the center of Europe, then this episode is for you.

In this talk we discussed the situation of Life Science in Austria and covered topics like

Public Funding
Life Science Conferences
Infrastructure
Access to global talent and
private funding as well as the pharma industry.

Join us for a colloquial chat over Life Science and Entrepreneurship.

Conference in person in fall in Austria as discussed in the Episode:

The European Forum for Industrial Biotechnology and the Bioeconomy (EFIB)will take place in #Vienna this year, and is themed “Delivering the EU Green Deal: Industrial biotechnology into business”. Join the dialogue on how biotech can enable a more circular and sustainable future. As EFIB’s local partner, LISAvienna is looking forward to connecting you to experts in the region. Mark your calendar for October 6-7, 2021 and join us at Austria Center Vienna - Internationales Kongresszentrum.

This is a great opportunity to grow your network.

Learn more about the regional expertise, potential partners and new products and services online. Many of these breakthrough innovations will be showcased at EFIB in Vienna.
Image: acv.at / begehungen.de
https://lnkd.in/euT5eRe

Speaker:
Christian Soschner
Johannes Sarx
Philipp Hainzl

Organizations:
CS Life Science Invest
LISAvienna

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

This episode will discuss what it takes to build companies that develop novel therapies, vaccines, and diagnostics in the pharma industry.

Since the pandemic, everybody has become familiar with the critical elements of pharma product development.

But let’s take a closer look into the value chain of the industry.

What does it take to pick up a technology and bring it to patients?

Questions we will discuss:

Some questions we will focus on:

What strategic approaches do exist for life science companies?
How important is the team in developing a company to an IPO?
Where can scientists find help when they want to start a company?

About Christoph Lengauer (from Third Rock Ventures)

“The most powerful thing about being a part of this industry is having the opportunity to improve the lives of patients and their families.”

Christoph loves the ideation of new company concepts and focuses on the formation, development, and strategy of our portfolio companies. He is an accomplished scientist and drug hunter with the ability to translate that knowledge, insight, and expertise into compelling business strategies. Christoph has contributed to the discovery and development of eight FDA-approved medicines.

Christoph is dedicated to making a dramatic difference in patients’ lives.

About Third Rock Ventures

We discover, launch, and build great companies based on bold ideas that meet at the intersection of science, strategy, business, and medicine – where transformational science meets operational reality – providing the best opportunity to make a dramatic difference in patients’ lives.

Timestamps:
(00:00) Opening

(01:30) Intro Christoph Lengauer

(05:19) Blueprint Medicine – What Does a Company Need for an IPO?

(08:45) How Important is the Team for the Investment Decision?

(10:20) What is the Best Attitude Towards Success?

(13:40) Why are IPOs Important to Companies and Investors?

(16:45) Third Rock Ventures Mission

(18:20) Why is the Listing Place Still Important in 2021?

(20:40) Early Stage Funding – US vs. Europe

(25:40) What is an entrepreneurial mindset?

(30:20) The Third Rock Ventures Investment Approach

(35:25) The Role a Technology Plays in the Investors Decision Process

(40:00) Exit Strategies for Life Science Companies

(44:00) What are Reasonable Valuations in the Life Science Industries Along the Value Chain?

(49:45) What Effect do the Bail Out Programs have on Valuations in the Private Life Science Sector?

(52:50) Success in the Life Science Industry in the last 10 years

(54:30) What Do We Need to Improve in the Industry?

(56:50) Fair Distribution of Medicine

(59:50) Distribution of Medicine – Poverty – Education

(01:02:50) The Future Of Life Science in the next 20 Years

Link to the Video of the Recording:
YouTube

Speaker:Christoph Lengauer
Christian Soschner

Organizations:
CS Life Science Invest
Third Rock Ventures

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In history, most of the time, humans needed to provide everything they needed to make a living for themselves. Trading goods were part of life but didn’t take up most of the world’s population’s time.

Industrialization changed the job profiles, the needs of workers, and the availability of goods.

In this century, many people in the western world have jobs to provide services and get what they need for getting through the day in shops. Since I can think I mostly get my shopping done on Saturday.

It is an event for the whole family, and often I invite friends for the coffee breaks to get a bit of socializing.

In March 2020, the pandemic shifted a lot of commerce towards the internet and trained the western world's population to adopt online shopping.

Whenever such a Black Swan Event happens, the consumer’s expectations shift as a result of such a dramatic experience.

What new expectations will appear once the pandemic is over and consumers come back to real-life shopping more often?

Max Weiland is working on solutions for such challenges with his team since 2014.

About beaconsmind

Founded in 2015 in Switzerland, beaconsmind is a pioneer in location-based marketing (LBM) software for retail chains. beaconsmind helps retailers run successful location-based marketing campaigns.

By fitting stores with Bluetooth beacons that precisely locate and identify customers and integrating its Software Suite, beaconsmind opens a brand-new channel for retailers to interact with their customers, fundamentally transforming the shopping experience. Thanks to its solution, retailers can converge digital and physical shopping and address the convenience gaps.

Consumers increasingly expect the convenience of the online shopping experience at the POS. In that regard, LBM is a proven tool and marketing channel for increasing POS sales productivity by implementing digital features to the in-store purchasing experience.

While LBM is a largely fragmented and budding start-up scene, beaconsmind differentiates in many ways compared to relevant competitors:

unique one-stop-shop featuring hardware and software;
focus on retail with an actionable and plug-and-play solution;
customized beacon solution requiring no maintenance;
one of the first global roll-outs in an emerging industry with Adidas seeking to equip up to 15k POS worldwide with the beaconsmindsolution.

The podcast guests and host will discuss questions like?

Foundation of a novel company
Key Milestones in beaconsmind corporate development
Benefits of an IPO in Europe
beaconsmind solutions
The future of Commerce

Interested?

Link to the Video of the Recording:
YouTube

Speaker:Christian Soschner
Max Weiland

Organizations:
CS Life Science Invest
beaconsmind

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

This podcast episode will discuss the EU’s next framework program for research and innovation, Horizon Europe, and the exciting opportunities this program offers businesses, scientists, and investors. With the launch of the Horizon Europe program just weeks away, we will share insight into the program's novelties, where to start, and tips on how to be successful.

The Podcast Host, guests Kimberly Cornfield and Michael Browne will discuss questions like:

What is new in Horizon Europe? The European Innovation Council, Missions and Clusters – all you need to know
Funding for DeepTech? The opportunities for high-risk/high gain and interdisciplinary research and innovation collaboration
Where, when, and how to apply for Horizon Europe funding? – tips from the experts

We shall address all these questions and discuss the latest priorities in EU research and innovation funding and the importance of collaboration.

Our guests in this episode:

Kimberly Cornfield is Head of European Research and Innovation at University College London (UCL), one of the top-performing universities under the EU’s Horizon 2020 program, having secured ca. €400 million over the last seven years to support its research and innovation activities. To support UCL in upholding its place as one of the leading universities in the next EU research and innovation program, Horizon Europe, and achieving its impact objectives, Kimberly and her team connect scientists and business around EU collaborative funding opportunities and offer a suite of support services to improve the chances of success in obtaining funding and achieving their impact objectives.

Michael Browne is Director and Co-founder at Crowdhelix - an Open Innovation Platform that forges links between an international network of excellent researchers and innovating companies to help deliver pioneering collaborative projects. Michael has worked in the European Research & Innovation space for more than 15 years and is a recognized expert in Framework Programme funding.

Host:
Christian Soschner

Link to the Video of the Recording:

Youtube Video

Be part of our Network:
Subscribe here: Link

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In this podcast episode, we will discuss several different forms of growth and scaling up companies. In the era of the fast-growing unicorns and skyrocketing valuations, we try to disassemble the growth path and see what a founder can do to benefit most of these options.

How to decide if an organic or buy&build model is the right one for me?
Are mergers & acquisitions play-field only for the very mature companies?
When is the time to start with bolt-on acquisitions?
Is fast growth really possible in only an organic way?
We shall address all these questions, look into the latest M&A trends of 2020 and 2021, shed a light on the life science industry, and discuss several real-life cases of buy&build growth models.

As we are excited about the next podcast episode let us just say ‘Hopin' our podcast episode for more.

Dusica Lukac holds an Executive MBA from Carlson Business School, Minnesota, the US and Wirtschaft Universitaet Wien, Vienna, Austria: Entrepreneurial Specialization and Fintech Law and Regulations courses Duke University, US; Private Equity and Venture Capital course Bocconi, Italy.

Traveled to 78 countries, multilingual, fascinated with financial innovation, watercolor painter.

Link to the Video of the Recording:
YouTube

Speaker:Astrid WoollardChristian Soschner
Dusica H. Lukac

Organizations:
CS Life Science Invest
DL Capital Partners Ltd
XenoVC

Be part of our Network:
Subscribe here: Link

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In this podcast episode, we will discuss how blockchain technology is utilized in the energy sector beyond the well-known utility of a payments system, her experiences in entrepreneurship and innovation, including start-up life in Berlin.

Ana Trbovich is the Grid Singularity co-founder & COO and Vice-Chair of the Energy Web Foundation. She serves on UNECE Carbon Neutrality and DENA SET Hub Advisory Boards, and previously acted as an independent board member at the European Institute for Innovation and Technology (EIT), Axa, and the Belgrade Philharmonic, among others. She teaches Entrepreneurship at FEFA, a leading business school in Belgrade, Serbia, where she also served as Dean from 2012 to 2015. She has consulted on good governance, competitiveness, and innovation policy for international organizations, including the EU and the World Bank.

Link to the Video of the Recording:
YouTube

Speaker:Ana TrbovichAstrid WoollardChristian Soschner

Organizations:
CS Life Science Invest
Grid Singularity
Scytale Ventures

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

It was great fun to talk with Walter Stockinger, Co-Founder of Hadean Ventures, about the topic of Life Science Investments.

We covered the following questions:

How do Venture Funds operate?
What do you need to know about approaching VCs?
What is the purpose of a VC?
Why are exits necessary for VCs?
And what exit strategies are relevant?
Why do VCs raise money, and from whom?

Use the opportunity to get your answer directly from a VC.

Link to the Video of the Recording:
YouTube

Speaker:Astrid WoollardChristian Soschner
Walter Stockinger

Organizations:
CS Life Science Invest
Hadean Ventures
Scytale Ventures

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

This one is an episode for the go-getters and never-giveupers.

Astrid and Christian had great fun talking with Essa Saulat, Chief Growth Officer of the Austrian digital health company Symptoma.

Essa is a seasoned entrepreneur and helped many start-ups getting off the ground.

In this episode, he shares his life story of overcoming adversity, keeping moving forward relentlessly, and ultimately changing his world and the worlds of many people he met in his life for the better.

He shares in unambiguous words the most important question every entrepreneur needs to confront frequently.

When you look at the most successful founders and companies globally, they all have clarity and a strong answer to this key question of entrepreneurship.

Enjoy the show.

Link to the Video of the Recording:
YouTube

Speaker:Astrid WoollardChristian Soschner
Essa Saulat

Organizations:
CS Life Science Invest
Scytale Ventures
Symptoma

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Drug Development is a challenging process. It needs profound basic research, translating scientific results into products and moving them towards the market.

Making things more challenging deal structuring is also a b2b business, which means selling products to the pharma industry that completes the product development and brings therapeutics to patients.

How does structuring deals with the pharma industry really work to sign one of those multi-billion dollar contracts?

Sascha Bucher is a Venture Capital expert with tremendous experience in deal structuring with the pharmaceutical industry.

In his career at renowned venture funds and companies like Roivant Sciences, Roche, or UBS, he completed transactions worth more than 10 billion dollars.

To give life science entrepreneurs access to the expertise, network, and funding, he and his team are in the process of founding Forty51 Ventures - a novel venture fund dedicated to closing the Life Science Valley of Death in Central Europe.

Join our conversation and learn more about how to negotiate with the pharmaceutical industry.

Gain more insights into VCs' daily business life with a particular focus on building relationships with BD, R&D, and C-suite executives in the industry.

Link to the Video of the Recording:
YouTube

Speaker:Astrid WoollardChristian Soschner
Sascha Bucher

Organizations:
CS Life Science Invest
Forty51 Ventures
Scytale Ventures

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

For more than 10 years the blockchain technology has shaped our economy. The background technology is mostly invisible for average users like me.

On the front end, cryptocurrency has hit the news. I remember well the highs of Bitcoin in 2017. And recently, Bitcoin is rising again.

But, and this is something I want to learn, what applications do exist that can improve the life science industries? Is there something else in the background that will help us solve the problems we have in drug development, medical devices, diagnostics, and digital health?

These and many more questions will be answered by the experts Paul Kohlhaas and Astrid Woollard.

Join us on this Life Science specific Blockchain update.

Link to the Video of the Recording:
YouTube

Do you prefer reading?
Here is your Transcript ready for purchase in the LSG2G Etsy Shop.

Speaker:Astrid WoollardChristian Soschner
Paul Kohlhaas

Organizations:
CS Life Science Invest
Molecule.to
Scytale Ventures

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

A new year brings new tax rules.

Astrid Woollard and Christian Soschner asked the Tax Experts of KPMG Austria to give an update on the newest regulations in Austria.

We also had a chance to talk about tax advisors and auditors' roles in the start-up economy.

Listen to this episode to learn what's new and when to consult advisors.

If you have questions after listening to the episode, reach out to Michael and Oliver.

For the videophile:
The Video to the Podcast

Resources mentioned in the podcast:
Research Premium and its role in Fundraising
Government and institution measures in response to COVID-19
COVID-19 Tax Info (in German)
Folge #099: Tax Hacks & Fun Stuff aus der Start-up-Beratungspraxis (in German)

Speaker:Astrid Woollard Christian Soschner
Michael Klewan
Oliver Mavher

Organizations:
CS Life Science Invest
KPMG Austria
Scytale Ventures

Show Notes:
00:11:27 Home Office and Taxation
00:14:34 Funding and SMEs
00:17:44 Solvency and Zombie Companies
00:20:54 Cryptocurrency
00:24:41 The Role of Tax Consultants and Auditors in Start-Up Companies
00:31:58 AI in Bookkeeping
00:36:00 Secrets of Auditing in the Start-Up World
00:44:12 Wirecard and Auditing
00:54:40 Tax Deadlines and Tax Breaks in 2021
01:04:14 Research Premium and SAAS
01:26:17 Critical Deadlines in 2021
01:29:00 Tax Loss Carry Backwards
01:34:00 New VC Fund for Start-Ups in Austria
01:38:00 Invitation to Reach Out to Michael and Oliver.

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

What was hot and what not - in Blockchain and Life Science and other Tech Areas the speakers love.

Listen about what was going on in the world in 2020 - besides SARS CoV 2.

Speaker:Albert Missbichler (https://www.linkedin.com/in/albert-missbichler-3a362931/)Astrid Woollard (https://www.linkedin.com/in/astridwoollard/)Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Elisabeth Pfneisl (https://www.linkedin.com/in/elisabeth-pfneisl-81095163/)
Gregory Mannix (https://www.linkedin.com/in/greg-mannix/)
Irina Korschineck (https://www.linkedin.com/in/irina-korschineck-35a40289/)
Jama Nateqi (https://www.linkedin.com/in/jama-nateqi/)
Julia Resch (https://www.linkedin.com/in/julia-resch/)
Kimberly Cornfield (https://www.linkedin.com/in/kimberly-cornfield-55383136/)
Klara Brandstätter (https://www.linkedin.com/in/klara-brandst%C3%A4tter-b6029491/)
Matthias Tarasiewicz (https://www.linkedin.com/in/parasew/)
Michael Browne (https://www.linkedin.com/in/michael-browne-frsa-5a616138/)
Thomas Schirrmann (https://www.linkedin.com/in/thomas-schirrmann-45a64183/)

Organizations:Corat Therapeutics (https://www.linkedin.com/company/corat-therapeutics/)
CS Life Science Invest (https://lnkd.in/eyhWK7H)
Crowdhelix (https://www.linkedin.com/company/crowdhelix/)
Falcon Digital Investment (https://www.linkedin.com/company/falcon-digital-investments/about/)
Fianostics (https://www.fianostics.at/en/home/)
IECT Hermann Hauser (https://www.linkedin.com/company/iect-hermann-hauser)
Ingenetix (https://www.ingenetix.com/en/home/)
Life Science Nation (https://www.linkedin.com/company/life-science-nation/)
RIAT - Research Institute for Future Cryptoeconomics (https://riat.at/)
Symptoma (https://www.linkedin.com/company/symptoma/)
UCL (https://www.linkedin.com/school/university-college-london/)
Vienna Stock Exchange (https://www.linkedin.com/company/wiener-borse-ag/)
Yumab (https://www.linkedin.com/company/yumab-gmbh/)

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

At the beginning of the new millennium, the next technological quantum leap began to emerge, known as the fourth industrial revolution – or Industry 4.0 for short. New technologies permit the development of new business models. In general, a business model describes a company’s business processes to achieve a defined business objective within the context of its social environment. The term sums up visions, ideas, defining features, and design models.

In the context of digitization, intellectual property (IP) is becoming an increasingly important element in a company’s strategy to remain competitive by establishing defensible positions. This importance necessitates systematic and value-driven management of IP. In light of the shift from a production-oriented towards a software-driven economy, finding valuable ideas has become a challenging task. The formation of digitalized eco-systems allows new market entrants to compete with established companies easily. Therefore, understanding how intellectual property rights can protect aspects of such digital business models is desirable.

For the videophile:
The Video to the Podcast

Speaker:Prof. Alexander Wurzer (https://www.linkedin.com/in/profalexanderwurzer/)Astrid Woollard (https://www.linkedin.com/in/astridwoollard/)Christian Soschner (https://www.linkedin.com/in/christiansoschner/)

Organizations:
CS Life Science Invest (https://lnkd.in/eyhWK7H)
Falcon Digital Investment (https://www.linkedin.com/company/falcon-digital-investments/about/)
IP Business Academy (https://www.linkedin.com/company/ipbusinessacademy/)

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

One problem in the digital world is: We cannot feel the interaction.

Prof. Sriram Subramanian is working on solutions for this problem. He has spun out Ultraleap from the University of Bristol. The company translates the research into products for the digital world.

In this episode, I will talk with Prof. Subramanian about real-life applications for his inventions, the importance of touch for well-being, and the potential for the life science industry.

Speaker:Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Sriram Subramanian (https://www.linkedin.com/in/srisub/)

Organizations:
CS Life Science Invest (https://lnkd.in/eyhWK7H)
UCL (https://www.linkedin.com/school/university-college-london/)
Ultraleap (https://www.linkedin.com/company/ultraleap/)

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Let's sit down for a conversation about my favorite topic: Fundraising in the Life Science Industry.

How is it to raise significant financing rounds during a pandemic when the research focus is not related to SARS-CoV-2?

It is my pleasure to welcome Dr. Daniela Marino, CEO and Co-founder of Cutiss AG.

Speaker:Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Daniela Marino (https://www.linkedin.com/in/daniela-marino-3bb35a26/)

Organizations:
CS Life Science Invest (https://lnkd.in/eyhWK7H)
Cutiss AG (https://www.linkedin.com/company/cutiss-ag/)

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In the last episodes, I have talked with investors and decision-makers of the pharmaceutical industry about the importance of having a vision and passion for the life science company.

I want to explore this topic further and ask the life science entrepreneur Christof Goetz to chat with me about finding your vision and passion for your company.

Christof is a Serial Entrepreneur with more than 20 years of experience managing complex business, software, and hardware development projects.

MyMind is a life science company based in Vienna. MyMinds vision is to help people with neurological impairments to live towards their full brain potential with affordable and easy-to-use brain training and assessment technology. MyMind currently focuses on Autism Spectrum Disorders (ASD), whether comorbid with Attention Deficit Hyperactivity Disorder (ADHD), Intellectual Disability (low IQ), Epilepsy, and Anxiety. Subsequently, MyMind will extend to other neurological issues such as dementia or stroke recovery.

Speaker:Christof Goetz (https://www.linkedin.com/in/christofgoetz/)
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)

Organizations:
CS Life Science Invest (https://lnkd.in/eyhWK7H)
My Mind GmbH (https://www.linkedin.com/company/mymindvienna/)

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In this episode, I had the pleasure of talking with two Diagnostics Experts.

Irina Korschinek, CEO of Ingenetix and Albert Missbichler, Business Angel specialized in Diagnostics.

Do you want to know answers to all or one of the following questions?

• What is a PCR test?
• Why is it the gold standard for measuring SARS-Cov2 Infections?
• What does a positive or negative test result say?
• Why do false positives and false negatives exist. Shouldn`t the test have 100% accuracy?
• Why do no yes or no answers exist to a viral infection?
• What makes diagnostics so complex?

Speaker:Albert Missbichler (https://www.linkedin.com/in/albert-missbichler-3a362931/
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Irina Korschinek (https://www.linkedin.com/in/irina-korschineck-35a40289/)

Organizations:
CS Life Science Invest (https://lnkd.in/eyhWK7H)
Ingenetix (https://www.ingenetix.com/en/home/)
Fianostics (https://www.fianostics.at/en/home/)

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Did you know that the successful pipeline of one of the most important pharmaceutical companies in the United States started in Europe, and scientists from Prague played a key role? Did you know that profound expertise in turning deep tech life science into a business, scale it, and go public in the US can be found in Prague since the late 80s of the previous century?

If you want to know which US pharmaceutical companies pipeline started in Prague, then listen to this Episode Number 25. I am delighted to host an exceptional guest from one of the most beautiful cities in Europe. I will talk with Karel Kubias, from i&i in Prague.

Karel studied organic chemistry and photochemistry at TH Merseburg, Germany, and holds an MBA in Healthcare Management (Auburn University program).

He gained his broad professional knowledge and skills during his 24 years in various management positions at multinational chemical and pharmaceutical company Merck KGaA. Between 2006 – 2015, Karel worked in executive positions – first as Managing Director of Merck spol. s r.o.. Prague and then as Regional sales director for the region EEMEA (Eastern Europe, Middle East & Africa) of Merck Millipore division, where he acquired further experience on the international level. He now supports i&i Prague as Director for Partnerships and Strategic Alliances.

i&i Prague is accelerating the proof-of-concept stage of projects in the fields of Medtech, Diagnostics, and Drug discovery. The company focuses on projects in the discovery, pre-seed, or seed phase, projects with excellent innovative potential, which will benefit from the project-launching experience and networking skills developed by IOCB Tech over the last decade. Furthermore, the financial support provided by i&i Prague should significantly increase the appeal and value of a project for further licensees and/ or investors.

Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Karel Kubias (https://www.linkedin.com/in/karelkubias/)

Organizations:
CS Life Science Invest (https://lnkd.in/eyhWK7H)
i&i Prague (https://www.linkedin.com/company/iniprague/)
IOCB Tech (https://www.linkedin.com/company/iocb-tto-s-r-o-/)
IOCB (https://www.linkedin.com/company/iocb-prague/)

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Listen to my inspiring conversation with Vassilis Ragoussis about initiatives that support young scientists to become Entrepreneurs.

We dived deep into the entrepreneurial Life Science Eco-System in Oxford, Europe, and the United States.

If you want to know what the Eco-System in Oxford is doing for young scientist entrepreneurs, this podcast is for you.

Learn more about Oxford University Biotech Society and Oxford Foundry.

Vassilis is an avid networker and a Ph.D. student at the University of Oxford studying Clinical Medicine. His research requires to analyze large amounts of next-generation sequencing data using bioinformatics and computational analysis. In addition, he critically and objectively assesses his findings, validating any discoveries with functional experiments. During his time at Boston University and Oxford University, he competed at the highest level of rowing, dedicating 30+ hours a week to training and competing, gaining a profound understanding and tremendous respect for teamwork, time management, and team leadership. He has a strong interest in venture capital, life science consulting, and medical device innovations.

Speaker:
Christian Soschner
Vassilis Ragoussis

Organizations:
CS Life Science Invest (https://lnkd.in/eyhWK7H)
Oxford Foundry
Oxford University Biotech Society
University of Oxford

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Listen to my conversation with Nicolaj Højer Nielsen about the life of an early-stage investors in Europe.

Nicolaj Højer Nielsen is a serial entrepreneur and business angel who has been building startups since 1999. He focuses on high potential startups and has co-founded and invested in thirteen companies, primarily within IT. He has experience securing funding from all possible sources – friends and family, business angels, VC funds, and public funds. His expertise is based on reviewing thousands of different investment opportunities, and he knows the fundraising process from both sides of the table.

His latest venture is Copenhagen United, an investment fund focusing on providing capital and mentoring for early-stage software companies.

Let`s chat with him about his view on the early-stage investment eco-system in Europe.

Speaker:
Christian Soschner
Nicolaj Højer Nielsen

Companies:
CS Life Science Invest (https://lnkd.in/eyhWK7H)
InProTher Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

We are in the 7th month of the SARS-CoV-2 Pandemic in Europe.

Governments are doing what’s necessary to deal with the situation.

More and more governments are initiating strong measures to control the infection rate with SARS-CoV-2. Israel has announced a second lockdown from September 18 for about three weeks.

There is a lot of coverage of European measures in the local news. Also, a lot of information is published about actions taken in the United States. I rarely read anything about the situation in Asia. Is life back to normal in Asia? How is the risk assessment of the novel Corona Virus in Asian countries?

That‘s why I asked a colleague who lives in Shanghai and is one of the best experts in Life Science and Asia in the world. In this webinar/podcast recording, I will talk with Irénée Robins about these topics.

Born in North-Eastern France in 1971, Irénée Robin has been living in China for almost 20 years. Married with three children, genuinely bicultural, he speaks, reads, and writes Mandarin fluently.

After ten years in the financial services industry with the BNP Paribas group, Irénée started his life sciences career in 2003 by joining Shanghai Cathay Biotech, where he established his first Sino-foreign joint venture with a major German specialty chemicals conglomerate,
leading to the creation of Degussa Cathay Biotechnology in Jining, Shandong Province.

From 2006 to 2011, he worked with the Institut Pasteur of Shanghai, an international research venture established by the Chinese Academy of Sciences, the Shanghai municipal government, and Institut Pasteur. Under his tenure, the institute grew from 40 to 240 researchers, with numerous drug/vaccine discovery programs against life-threatening infectious diseases such as HFMD, HCV, and malaria. His efforts were directed at increasing the institute’s financial resources, notably via expanding CSR programs with multinational corporations and successfully applying to European and international grants.

In 2012, as a Senior Representative for the Biotechnology Innovation Organization (BIO), he organized the “BIO Convention in China” in Shanghai.

From 2013 to early 2019, he was the Chief Marketing Officer for Shanghai Newsummit Biopharma, a subsidiary of Shenzhen-listed Zhejiang Yatai Pharmaceuticals (SHE:002370). He attracted more than 30 Western companies onto the Chinese market during those six years through a vast array of transaction types, from in-licensing to co-development, distribution, and service agreements. He also established 4 Sino-foreign joint ventures in 4 different Chinese cities, including China’s most advanced molecular pathology and next-gen cancer diagnostics lab (Shanghai German JV partner) and a first-in-class IVD development venture based on patients’ immune status markers, the use of NGS platforms. He targeted data mining/deep learning algorithms (Guangzhou – French JV partner).

Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Irénée Robin (https://www.linkedin.com/in/ireneerobin/)

Companies:
CS Life Science Invest (https://www.cslifescienceinvest.com/)
VVR Medical (https://www.linkedin.com/company/vvr-international/)
Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Do you want to know how to approach Pharma?
Do you want to learn what information is needed to partner a life science project with Pharma?
And how long the process takes?

Then this podcast is for you.

Listen to the expertise of Natalia Novac, Director of Emerging Technologies and Innovation, Eli Lilly.

Natalia has profound experience in strategy, corporate, and business development. She had leading roles at Merck and now Eli Lilly.

Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Natalia Novac (https://www.linkedin.com/in/natalia-novac-a3aa7131/)

Companies:
Eli Lilly (https://www.linkedin.com/company/eli-lilly-and-company/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In light of the pandemic, the Life Science Industry is changing. One of the positive developments: The industry is moving faster. The necessity of developing diagnostics, therapeutics, and vaccines against this novel viral threat quickly generates a steep learning curve for all of us.

In this episode, I am talking with Peter Llewellyn-Davies, CEO of Apeiron Biologics, how he and his team have set up a clinical phase 2 trial and a 40 million Euro financing round in less than eight weeks.

Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Peter Llewellyn-Davies (https://www.linkedin.com/in/peterld/)

Companies:
Apeiron Biologics (https://www.linkedin.com/company/apeiron-biologics/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Since the beginning of the SARS-CoV-2 Pandemic, more and more people got interested in the Life Science Industry.

Scientists worldwide have worked together for decades and centuries to solve the world's most severe health problems.

In the last decades, a unique Eco-System of start-ups, investors, industrial partners, and public funding organizations evolved out of this search for finding cures against the world's most complex diseases.

In this episode, you will hear:

How important is building strong relationships?
How does this Life Science Value Eco System function in 2020?
How do companies, investors, and Start-Ups interact with each other?
What roles does the player have?
How do investors life look like?
And how do Start-Ups approach investors?

Speaker:
Bruno Montanari (https://www.linkedin.com/in/bruno-montanari-882559/)
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)

Companies:
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Seroba Life Sciences (https://www.linkedin.com/company/serobalifesciences/)

Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Rumour has it: It takes 10-15 years to bring a new therapy to the patients. Only 1% of all scientific ideas make it to the market - is another statistical fact.

How do those people who made developing novel therapies their mission make money on their way?

In this episode, I have the huge pleasure to chat with Thomas Schirrmann. He has profound experience in starting companies from scratch, walking through the ups and downs of Death Valley, and turn it into a commercial success.

Listen to his insights in creating and developing life science companies.

Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Thomas Schirrmann (https://www.linkedin.com/in/thomas-schirrmann-45a64183/)

Companies:
Corat Therapeutics (https://www.linkedin.com/company/corat-therapeutics/)
CS Life Science Invest (https://www.cslifescienceinvest.com)
Yumab (https://www.linkedin.com/company/yumab-gmbh/)

Do you want to learn more about life science?
Subscribe to our newsletter: https://mailchi.mp/e2467061ef75/lsg2g

Stada
Caring for people’s health as a trusted partner

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

How is it to start a company from scratch, found it and fund it in the US, and get customers like the US Air Force and the Department of Defence.

In this episode, you will hear how Jessica Walsh, Founder, and CEO of RxBandz, a successful woman in life science, did it.

In this episode, listen to Jessica’s stories about how to get into life science out of necessity, how it is to find the right team and develop the team and the project at the same time.

Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Jessica Walsh (https://www.linkedin.com/in/jessica-walsh-3025807/)

Companies:
CS Life Science Invest (https://www.cslifescienceinvest.com/)
RxBandz (https://www.linkedin.com/company/rx-bandz/)

Do you want to learn more about life science?
Subscribe to our newsletter: https://mailchi.mp/e2467061ef75/lsg2g

Fianostics
Super-Sensitive and Easy

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

We are the average of the five people we spent the most time with. Or are we the opposite?

Listen in this podcast episode how Daria Tataj sees it. Daria is THE number one networking expert in Europe.

Daria Tataj is a researcher, Ph.D., keynote speaker, author, and world expert on innovation networks.

After having reached more than 30.000 decision-makers around the world through her work helping companies, governments, and cities to foster innovation through the strategic use of networks,
Daria has now decided to share her knowledge with you in one Program, the Network Thinking Training.

She is also one of the founding board members of the European Institute of Innovation & Technology (https://eit.europa.eu/)

Do you want to get in touch with Daria?

Join her next networking webinar: https://tatajinnovation.com/forhealth/

Special Offer:
As a subscriber to this podcast you get a EUR 100,- discount. Passcode: LSG2G
Partner and member get a 46% discount.

Become a member and send a mail to lsg2g.news@lifescienceget2gether.com for further information

Book:
Get Darias book at Amazon: https://amzn.to/2YJtMy4

Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Daria Tataj (https://www.linkedin.com/in/dariatataj/)

Companies:
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Tataj Innovation (https://tatajinnovation.com/)

Do you want to learn more about life science?
Become a member of the LSG2G Network.

Join today: https://www.lifescienceget2gether.com/registration-membersclub/

Buzzsprout - Let's get your podcast launched!
Start for FREE

The LSG2G Partners
Experts in Life Science

Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.

Support the show (https://lsg2g.substack.com/subscribe?)

Innovation and Entrepreneurship: A Growth Model for Europe Beyond the Crisis

View Details

Everybody comes in touch with the life science industry. Hardly anybody knew about the challenges, and hardships scientists have to overcome to bring a product from the university-level to the market.

Since the outbreak of SARS-CoV-2, more and more people are becoming interested in life science investments. And ask the question: How does that work?

In this episode, I am talking with entrepreneurs and investors from the LSG2G network. How do life science investments work? What are investors looking at? Is the life science industry right for Business Angels? What does it take to bring a product to the market?

All these questions I discussed with the keynote speaker and panelists.

Speaker:
Andreas Grassauer (https://www.linkedin.com/in/andreas-grassauer-048843b2/)
Astrid Woollard (https://www.linkedin.com/in/astridwoollard/)
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Christopher de Souza (https://www.linkedin.com/in/cdesouza1/)
Henriette Lininger (https://www.linkedin.com/in/henriette-lininger-90759615/)
Sara Núñez-Garcia (https://www.linkedin.com/in/sara-n%C3%BA%C3%B1ez-garcia-phd-mba-00141a3/)
Walter Stockinger (https://www.linkedin.com/in/walter-stockinger-dr-13b1a4b/)

Companies:
Broadview Ventures (https://www.linkedin.com/company/broadview-ventures-inc/about/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Hadean Ventures (https://www.linkedin.com/company/hadean-ventures/)
LSG2G (https://www.lifescienceget2gether.com/)
Roivant Sciences (https://roivant.com/)
Scytale Ventures (https://www.linkedin.com/company/scytale-ventures/)
Vienna Stock Exchange (https://www.linkedin.com/company/wiener-borse-ag/)

Do you want to learn more about life science?
Join exclusive future webinars and member-only events: Become a member of the LSG2G Network.

Join today: https://www.lifescienceget2gether.com/registration-membersclub/

F.Trenka - Nature is our remedy
Since 1909.

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

The current pandemic shines a light on deep tech companies. Especially in life science. Did you ask yourself the question: What is necessary to bring a scientific idea from universities into companies and ultimately onto the market?

In this episode, I am talking with Klara Brandstätter and Jasmin Gungör. They are responsible for training, financing, and connecting deep-tech scientists.

What exactly they are doing, you will hear in this episode.

Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Jasmin Güngör (https://www.linkedin.com/in/jasmin-g%C3%BCng%C3%B6r-62111959/)
Klara Brandstätter (https://www.linkedin.com/in/klara-brandst%C3%A4tter-b6029491/)

Companies:
CS Life Science Invest (https://www.cslifescienceinvest.com/)
IECT Summer School (https://www.iect.at/en/i-e-c-t-summer-school-on-entrepreneurship-en/)

Do you enjoy the podcast?
Become a member of the LSG2G Network and join the recording. You will get an individual "member only" invitation and will have a chance to talk with the speakers directly during the recording. The questions will be featured in the podcast.

Do you like this idea? Join today: https://www.lifescienceget2gether.com/registration-membersclub/

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

How to bring scientific life science ideas to patients?

Three key components are needed:

World-class science
World-class development team
Massive public and private funding

In this episode, I am talking with Michael Browne and Kimberly Cornfield on how to solve these three problems.

Reach out to Kimberly and Michael if you want to access their top-notch science networks within Crowdhelix and UCL.

Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Kimberly Cornfield (https://www.linkedin.com/in/kimberly-cornfield-55383136/)
Michael Browne (https://www.linkedin.com/in/michael-browne-frsa-5a616138/)

Companies:
Crowdhelix (https://crowdhelix.com/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)
UCL (https://www.ucl.ac.uk/)

Do you enjoy the podcast?
Become a member of the LSG2G Network and join the recording. You will get a special "member only" invitation. You will have the unique opportunity to talk with the speakers directly in the Q&A - and you will get featured in the podcast episode.

Join the community: https://lnkd.in/ejWEtRf

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

The current pandemic SARS Cov 2 is shining a light on vaccine development. Since December 2019, the novel coronavirus is known amongst scientists. The virus is highly contagious. As a first measure, many governments all over the world have ordered a complete lockdown of the countries.

Some politicians make reverting life back to normal dependent on the existence of medication and/or vaccine. How long does it take to develop a vaccine against this novel coronavirus?

In this episode, the vaccine development expert Ericht Tauber, CEO, and founder of Themis Bioscience, explains what it takes to develop a novel vaccine and also gives an outlook on the timeline.

It was a huge pleasure to be accompanied by Elisabeth Pfneisl, Addendum.org, during the recording of this interview.

Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Elisabeth Pfneisl (https://www.linkedin.com/in/elisabeth-pfneisl-81095163/)
Erich Tauber (https://www.linkedin.com/in/erich-tauber-0ba8a111/)

Companies:
Addendum.org (https://www.addendum.org/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Themis BioScience (https://themisbio.com/)

Do you enjoy the podcast?
Become a member of the LSG2G Network and join the recording. You will get an individual "member only" invitation and will have a chance to talk with the speakers directly in the Q&A. The questions will be featured in the podcast.

Do you like this idea? Join today: https://www.lifescienceget2gether.com/registration-membersclub/

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Digital health is a technology that appeared only a few years ago. Up to now, it was very often overlooked. The current situation is helping digital health to show its full potential. For example, Digital health can be used as a triage system, finding out what kind of illness a patient has with chatbots and telemedicine solutions. Afterward, the patients can be referred to real-life doctors - to the right one.

A solution Symptoma has developed. In this episode, I am talking with the CEO of Symptoma, Jama Nateqi, about the real potential of digital health.

Another novel technology appeared recently - blockchain. Astrid Woollard, Partner at Scytale Ventures, is investing in companies that develop blockchain-based solutions. She has joined us to chat about the leverage blockchain can provide for digital health and the entire healthcare system.

Link to the Video of the Recording:
YouTube

Speaker:
Astrid Woollard (https://www.linkedin.com/in/astridwoollard/)
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Jama Nateqi (https://www.linkedin.com/in/jama-nateqi/)

Companies:
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Scytale Ventures (https://scytale.ventures/)
Symptoma (https://www.symptoma.com/)

Do you enjoy the podcast?
Become a member of the LSG2G Network and join the recording. You will get an individual "member only" invitation and will have a chance to talk with the speakers in the Q&A. The best questions will be featured in the podcast. Do you like this idea? Join today: https://www.lifescienceget2gether.com/registration-membersclub/

The LSG2G Partners
Experts in Life Science

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Viral threats to humankind like the Coronavirus need scientists from all over the world collaborating to solve the problem. People like Saara Inkinen support scientists and universities to transfer their inventions to companies who turn science into products.

These products help patients to overcome illnesses and stay healthy. In this episode you will get some information how Saara helps in that area.

More information:

Nordic Catalyst (https://www.nordiccatalyst.com/)
LSG2G (https://www.lifescienceget2gether.com/)

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

These days there is a lot of discussion about the development of diagnostics, therapeutics, and vaccines against the Coronavirus and its disease COVID 19. Viruses are one threat to the health of human beings, and bacteria are another one. Traditionally, bacterial infections are treated with antibiotics, and recently, some bacteria have developed antibiotic resistance.

The WHO describes that Antibiotic resistance is one of the biggest threats to global health, food security, and development today. (https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance)

Phagomed (https://www.phagomed.com/) is developing a novel approach to treat bacterial infections without antibiotics. How that works, the challenges a company has to face while developing novel drugs, and why not all viruses are evil, you will hear in this episode.

Timestamps:
(00:00) Opening
(02:26) Intro Alexander Belcredi
(03:30) Foundation of Phagomed
(06:45) Phages – An Alternative to Antibiotics
(08:10) The Different Types of Viruses
(09:20) Why Are There Not Sufficient Solutions against Bacterial Infections?
(10:50) Competitive Landscape in the Anti-bacterial Industry
(12:30) Status of Clinical Development of Phage-Based Therapies in April 2020
(14:35) Are there Registered Phage-Based Therapies on the Market in 2020?
(16:30) How Capital Intensive is the Development of Phage-Based Therapies
(18:15) Funding Sources For Early-Stage Companies in Europe
(20:00) How to Prepare for Fundraising?
(23:30) When is the right time to go on the Market for Fundraising?
(25:00) What are the right expectations for fundraising processes? What is the success rate?
(30:45) What was the biggest challenge for Phagomed in Fundraising Phases?
(32:30) Is there a suitable time for Fundraising?
(35:20) How Long Does it Take from Starting a Financing Round to The Closing?
(36:55) Raising a Series A in 2020 – Resulted in an Acquisition in 2021
(37:55) Milestone Planning for a Series A Round
(39:05) European Public Funds to Leverage Private Investments
(42:25) What Advice Would you Give Your Younger Self Who Is at the Beginning of His Journey?

Shownotes @ PodcastNotes:Link

More information:
https://www.phagomed.com/
https://www.lifescienceget2gether.com/
https://linktr.ee/soschner

Video to the episode:
https://youtu.be/YHTR8yMoC3w

Do you want to learn more about life science?
Join exclusive future webinars and member-only events: Become a member of the LSG2G Network.

Join today: https://lsg2g.substack.com/subscribe

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

This week I had the honor to moderate a panel discussion at the RESI conference (https://www.resiconference.com/). It is one of the most important meetings for early-stage investment in the United States. Life Science Nation is the organizer of the event series. Last year in March the RESI conference visited Europe for the first time. The city of choice was Vienna. I invited Dennis Ford and Greg Mannix to visit the Life Science Get2gether #8.

At the RESI conference in Vienna, I had the opportunity to speak at the Panel - how business angels and family offices view seed and Series A rounds? At the time of the Bio US, I again supported the RESI conference as a speaker. This time we were talking about European Tech Hubs.

This year the conference is back in Europe. Well, due to the actual situation with the Corona Virus the conference turned digital. Last Monday we recorded the European tech Hub panel. At the panel, I had the opportunity to speak with 3 speakers about their model and the situation for Investors in Europe.

Institutional life science investors such as VCs or family offices are looking for assets that are de-risked and have data packages that indicate potential efficacy and safety – however, reaching that point takes substantial funding that’s not easy to find. Life science entrepreneurs need novel funding and development solutions that help them overcome this steep funding challenge at the very earliest stage of company formation, typically in years 0-3 of a company’s life. In this RESI panel, the audience can learn about new initiatives that are creating opportunities for life science startups to thrive in Europe.

The speaker:

Jeroen Blokhuis, PhD is the Chief Business Officer of the Pivot Park in the Netherlands. Pivot Park is an 8-year young Dutch Science Park, formally the R&D campus of Organon, that in the past was acquired by Shering-Plough, then acquired by MSD, and then given back to municipality in 2012. The Pivot Park now houses 60+ biotech startups and scale-ups, including Acerta-Pharma.

Dr. Irene Fialka is CEO of INiTS, Vienna’s University Business Incubator (UBI) serving all academic institutions in Vienna. She has a background in genetics and has worked with R&D-based deep-tech startups since 2004. INiTS has been ranked amongst the TOP20 UBIs worldwide since 2013 by UBI Global (ubi-global.com). INiTS’ startups outperform creating jobs, raising funds and finding strategic partners. Some examples are Apeptico, Lexogen, Marinomed (INiTS’ 1st IPO), MedicusAI, mySugr, S-TARget etc. She is co-founder of investorinnen.com (female investing) and Women in Health IT and since 2018 managing partner of healthhubvienna.com, an international acceleration program to drive innovation in healthcare.

Olivier Nosjean is the Research Scientific Director at Servier. A biochemist by training, he has been a drug discovery researcher and manager for 20 years. He established and has been a contributor to a range of public/private partnerships throughout the world, focused on therapeutic innovation and on scientific and technology expertise. Olivier is currently leading the technology innovation strategy and the Program for PhD students and Post-docs at Servier. He is an active contributor to Servier initiatives related to open innovation, entrepreneurship and strategic partnerships. One of his most exciting actions today are dedicated to preparing the opening of a drug discovery incubator along with the new research site of Servier currently under construction.

More information:

linktr.ee/soschner

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Michael Lukesch has recently closed his first financing round for Valanx Biotech. He started right after graduating into his entrepreneurial journey and cleared many obstacles on the way with excellence.

Valanx focuses on a novel approach for protein conjugation. Specific, fast, and cost-effective. The company is operating in lower Austria.

In the most recent episode of beginner's mind, Michael talks about how he brought himself to leap into entrepreneurship, navigating the rollercoaster ride of building a startup, what he learned at top-notch incubation programs like Rebel Bio and early-stage conferences like Biovaria.

More information at

Michael Lukesch (https://www.linkedin.com/in/michaellukesch/)
Valanx (valanx.bio)
linktr.ee/soschner
lifescienceget2gether.com

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Did you ever wonder: Whatever effort you spent with potential clients. The sales figure doesn’t go up. Instead, it is moving down. The more time you spent with potential clients, the less you sell. Well, trying to convince the unconvinceable might be the reason.
In this episode, Christian speaks about the importance of selecting the right approach towards potential customers.

Read the script to this episode at medium (https://medium.com/@christian.soschner/no-sales-that-might-be-the-reason-fe66eae649fa?source=friends_link&sk=21ac770d4dc263b21424493cf5fb9580)

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

How to turn a daily habit into an investment. Some thoughts on savings, investment and making money.

More information:

Linktr.ee/soschner

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

In 2017 I created the Life Science Network LSG2G. This is a brief overview of the history and the next event.

More information at lifescienceget2gether.com

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

There is this thing that some people demand free work. My take on it. Script: https://medium.com/@christian.soschner/a-business-needs-paying-customers-7cb8f1c6e4a3?source=friends_link&sk=299243e18054aa66acb69b02ec31b56d

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Thoughts about money managing skills. Script: https://medium.com/@christian.soschner/lottery-winner-3ced34ee9d48?source=friends_link&sk=230f2f2a4a0193d4dd435cfc5d278872

Support the show (https://lsg2g.substack.com/subscribe?)

View Details

Intro to the Podcast Beginners Mind. Talk about the reasons why to start another podcast.

Link to Script: https://medium.com/@christian.soschner/episode-1-a-beginners-mind-f2dfe9e472a8?sk=e5b8823f8daea67bace179bef2d31079

Support the show (https://lsg2g.substack.com/subscribe?)

Beginner's Mind: Recent Episodes

Christian Soschner

nanotemper #spaceexploration #microgravity #philippbaaske